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Dosimétrie des radiopharmaceutiques en radiothérapie interne 
vectorisée 
  
Resumé  
La médecine nucléaire est une spécialité médicale dont l’une des applications 
est l’étude de la physiologie des organes et du métabolisme de divers types de 
tumeurs. Les produits pharmaceutiques liés à un isotope radioactif (médicament 
radio-pharmaceutique, MRP) sont étudiés en préclinique avant d’être utilisés chez 
l’homme. Les rongeurs sont généralement utilisés pour étudier la bio-cinétique du 
traceur dans un groupe d'organes prédéfinis. L'extrapolation des résultats de ces 
études de l’animal à l'homme permet d'avoir une estimation du comportement des 
MRP et de l’irradiation délivrée en clinique. Trois nouveaux MRP ont été mis au 
point, l'un en France (CHU-Hôpital Purpan) et deux en Uruguay (CUDIM). Deux 
visent à étudier le cerveau et un vise à diagnostiquer le cancer de la prostate. Dans 
ce travail, l'extrapolation des résultats précliniques est présentée, les doses 
absorbées et efficaces sont estimées en utilisant les logiciels OLINDA/EXM V1.0, 
V2.0 et IDAC2.1. Les différences entre les résultats de chaque programme sont 
discutées. 
Au niveau clinique, les protocoles dosimétriques incluent la détermination du 
facteur d'étalonnage, la segmentation, le recalage, l'ajustement des courbes et le 
calcul de la dose absorbée. Dans ce travail, l’étalonnage développé pour un 
SPECT/CT est présenté en utilisant différentes sources d’étalonnage et différentes 
géométries. L’influence de la méthode de reconstruction sur la détermination du 
facteur d’étalonnage et les courbes du facteur de récupération sont présentées. 
Par ailleurs, quatre logiciels commerciaux sont comparés sur la base des 
informations cliniques de deux patients atteints de tumeurs gastro-entéro-
pancréatiques d’origine neuroendocrine et traitées au 177Lu-DOTATATE. Deux cycles 
de traitement pour chaque patient ont été utilisés afin d’estimer les temps de 
résidence des reins, du foie, de la rate, de la moelle osseuse et du corps entier. Le 
calcul des doses absorbées a été initialement réalisé à l'aide de OLINDA/EXM V1.0 
& V2.0, en ajustant la masse de chaque organe/tissu. Dans le cas de la moelle 
osseuse, une nouvelle méthodologie est présentée pour estimer la dose absorbée 
sans qu'il soit nécessaire de procéder à des mesures de corps entier. Il est possible 
de constater que le recalage des images a un impact sur la détermination de la dose 
absorbée. Les résultats sont donc calculés en employant d'un outil permettant de 
recaler indépendamment chaque organe et non pas toute l'image du champ de vue. 
Différents algorithmes de calcul ont été utilisés pour déterminer la dose 
absorbée délivrée aux patients, par exemple le modèle de sphère d’OLINDA/EXM 
V2.0, les méthodes de convolution et le dépôt d’énergie local de PLANET®Onco 
Dose de Dosisoft. Les résultats trouvés avec les différents outils sont comparés et 
discutés. 
 
Mots clés : Dosimétrie, Radiothérapie Interne Vectorisée, Médicine Nucléaire 
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Radiopharmaceutical dosimetry in targeted radionuclide 
therapy 
Abstract 
Nuclear medicine is a medical specialty in which one of whose applications is 
the study of the physiology of organs and the metabolism of various types of 
tumours. Pharmaceuticals labelled with radionuclides (radiopharmaceuticals) are 
studied at pre-clinical level before being used in humans. Rodents are generally used 
to study the biokinetics of tracer in a group of predefined organs. The extrapolation of 
the results of these studies from animals to humans provides an estimate of the 
behaviour of the radiopharmaceuticals and the irradiation delivered clinically. Three 
new radiopharmaceuticals were developed, one in France (CHU-Hôpital Purpan) and 
two in Uruguay (CUDIM). Two aim to study the brain and one aims to diagnose 
prostate cancer. In this work, extrapolation of pharmacokinetics preclinical results to 
the human is presented; absorbed and effective doses are estimated using 
OLINDA/EXM V1.0, V2.0 and IDAC2.1 software. The differences between the results 
of each program are discussed. 
At a clinical level, dosimetric protocols include calibration factor determination, 
segmentation, registration, curve fitting, and calculation of absorbed dose. In this 
work, the calibration developed for a SPECT/CT is presented using different 
calibration sources and different geometries. The influence of the reconstruction 
method in the determination of the calibration factor and the recovery coefficient 
curves are shown.  
In addition, four commercial software are compared based-on clinical 
information of two patients with gastro-entero-pancreatic tumours of neuroendocrine 
origin treated with 177Lu-DOTATATE. Two cycles of treatment for each patient were 
used to estimate residence times for the kidneys, liver, spleen, bone marrow and 
whole body. Calculation of absorbed dose was initially developed using 
OLINDA/EXM V1.0 & V2.0, adjusting the mass of each organ/tissue. In the case of 
the bone marrow, a novel methodology is presented to estimate the absorbed dose 
without the need for whole-body measurements. It can be seen that the registration 
of the images has an impact on the determination of the absorbed dose. The results 
are thus calculated by employing a tool allowing to register independently each organ 
and not all the image of the field of view. 
Different calculation algorithms were used to determine the absorbed dose 
delivered to patients, for example the OLINDA/EXM V2.0 sphere model, convolution 
and local energy deposition methods of PLANET®Onco Dose from Dosisoft. The 
results found with the different tools are compared and discussed. 
 
Keywords: Dosimetry, Targeted Radionuclide Therapy, Nuclear Medicine 
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Introduction générale (FR) 
 
La médecine nucléaire est une spécialité médicale dont les applications, 
essentiellement diagnostiques, permettent l’étude de la physiologie des organes et le 
métabolisme de divers types de tumeurs. La radiothérapie interne vectorisée (RIV) 
est une approche thérapeutique de la Médecine Nucléaire. Le but de la RIV est de 
transporter le radionucléide vers la tumeur. Il faudra donc considérer différents types 
de molécules vectrices, leur affinité pour les tumeurs, différents isotopes radioactifs 
et la manière de lier l’isotope à la molécule vectrice. La RIT possède plusieurs 
catégories, en fonction du type de molécules vectrices utilisées 
(radioimmunothérapie, radiopeptidethérapie), ou selon l’isotope sélectionné (i.e. 
irathérapie).    
L’efficacité du traitement dépendra de nombreux facteurs, dont du type de 
rayonnement. Les radionucléides choisis sont généralement ceux qui ont la propriété 
d'émettre des particules alpha ou bêta, voire Auger, qui ont un parcours réduit dans 
la matière et qui permettent de délivrer une irradiation localisée autour du point 
d’émission. Selon la pénétration de ces particules dans la matière, un effet de feu 
croisé est attendu, dépendant de la portée des radiations et de la taille de la tumeur, 
ce qui permet théoriquement d’augmenter l’efficacité de la thérapie. Pour les 
émetteurs de particules alpha, on peut de plus bénéficier d’un transfert linéique 
d'énergie (TEL) élevé de ce type de particules, qui entraine une augmentation de 
l’efficacité de l’irradiation pour une même énergie délivrée. Enfin, si les isotopes 
possèdent une émission gamma, il sera possible de générer des images permettant 
de suivre le devenir du vecteur radioactif dans le patient.   
La place de la dosimétrie en RIV est en constant débat (Chiesa et al., 2017; 
Flux et al., 2017; Giammarile et al., 2017), entre la nécessité de « documenter » 
l’irradiation délivrée et la possibilité « d’optimiser » le traitement. Son développement 
au niveau dosimétrie clinique est contrasté mais indéniable. L'article 56 
(Optimisation) de la directive 2013/59/Euratom du Conseil (Conseil de l'Union 
européenne 2014), stipule explicitement que "Pour toutes les expositions médicales 
de patients à des fins radiothérapeutiques, les expositions de volumes cibles sont 
planifiées individuellement et leur délivrance est dûment vérifiée en tenant compte 
que les doses aux volumes et tissus non cibles doivent être aussi faibles que 
raisonnablement possible et compatibles avec l'objectif radiothérapeutique de 
l'exposition". 
La méthodologie est disponible – mais implémenté de façon inégale en 
clinique, selon les pays et les centres cliniques. De fait, un bon indicateur du 
développement spectaculaire et récent de la dosimétrie clinique est la mise sur le 
marché de solutions commerciales. Il est désormais possible d’effectuer des 
dosimétries personnalisées, tenant compte de la pharmacocinétique du médicament 
radiopharmeceutique (MRP) et propre à chaque patient et de sa morphologie. 
Pour ce qui concerne la dosimétrie dans un contexte diagnostique, elle est 
essentiellement réalisée lors de la mise au point de nouveaux traceurs, afin de 
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déterminer des ordres de grandeur de la faible l’irradiation délivrée. On parle alors de 
dosimétrie de référence. 
Ce travail de thèse est axé sur la dosimétrie clinique et préclinique des 
radiopharmaceutiques : 
• Nous avons dans un premier temps établi les doses absorbées de 
référence pour trois nouveaux médicaments radiopharmaceutiques à 
visée diagnostique, en extrapolant les données précliniques à l'être 
humain, à l'aide de trois logiciels permettant de comparer les résultats. 
• Par la suite, nous avons étudié quatre solutions dosimétriques 
commerciales, à l'aide d'expériences réalisées sur fantômes et de 
traitement de données cliniques. Pour les 4 solutions commerciales 
étudiées, les similitudes et les différences sont présentées. La 
comparaison s'est avérée difficile, car les différentes solutions 
commerciales proposent des implémentations différentes de la 
dosimétrie clinique, ce qui limite parfois l’évaluation ou la comparaison 
des performances.  
Dans le premier chapitre de ce travail, différentes approches de radiothérapie 
interne vectorisée sont mentionnées. Selon le type de molécule vectrice, on peut les 
diviser en différents groupes :  
• Le cas où l’isotope est également le vecteur (131I, 223Ra), 
• Le cas où le vecteur participe au métabolisme tumoral (mIBG), 
• Les thérapies utilisant des peptides (radiopeptidothérapie, en anglais 
peptide receptor radionuclide therapy ou PRRT),  
• Les thérapies utilisant des anticorps (radioimmunothérapie - RIT),  
• La radiothérapie interne sélective (RIS) : utilise des microsphères 
radioactives (90Y ou 166Ho) placées au contact des cibles tumorales. 
Cette technique est utilisée de plus en plus pour la thérapie des 
tumeurs hépatiques. Il s’agit d'un groupe spécial de thérapies qui 
n'utilisent pas de MRP mais des dispositifs médicaux (DM). Les 
radiologues interventionnels effectuent une évaluation angiographique 
à la recherche du vaisseau qui nourrit les tumeurs, puis placent les 
microsphères au contact des régions à traiter.  
Dans le cas des radiopeptidothérapies, les radionucléides les plus utilisés sont 
l’indium 111 (111In), l’yttrium 90 (90Y) et le lutécium 177 (177Lu). Ils sont liés à un 
peptide, par exemple au DOTATATE et le DOTATOC, qui sont les plus utilisés. 
L’indium a été initialement utilisé parce que des images pouvaient être générées et, 
en même temps, la tumeur pouvait être traitée. Cependant, son efficacité 
thérapeutique s’est avérée bien moindre que celle des autres isotopes. L’yttrium a 
commencé à être utilisé avec succès, mais des toxicités importantes ont été 
rapportées. Par ailleurs, les images qui sont générées par rayonnement de freinage 
sont de qualité réduite. Par conséquent, la quantification n'est pas facile à réaliser. 
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Dans le cas du 177Lu, la réponse thérapeutique est très bonne et des images peuvent 
être réalisées avec suffisamment de qualité pour permettre une bonne estimation 
des doses absorbées. 
Dans le cas des RIT, l'anti-CD20 a été utilisé pendant de nombreuses années 
(mais pas en Europe) avec le produit commercial Bexxar (131I-tositumomab) puis a 
été abandonné. Le Zevalin (90Y-ibritumomab tiuxétan) a été introduit sur le marché 
(Europe et USA). Les deux médicaments ont été utilisés pour le traitement des 
lymphomes. Dans le cas du lymphome non hodgkinien, le 131I-rituximab en 
conjonction avec rituximab, est l'un des anticorps les plus utilisés de nos jours (Gill et 
al., 2017; McQuillan et al., 2015).  
Différents concepts dosimétriques utilisés dans les chapitres suivants de ce 
travail sont introduits. Une attention particulière est portée aux techniques de 
quantification planaire et TEMP qui sont utilisées en dosimétrie clinique, ainsi qu'aux 
techniques de correction des effets qui dégradent les images et limitent la possibilité 
de quantification de l'activité. 
Dans le deuxième chapitre de ce travail, l’étude de trois nouveaux produits 
radiopharmaceutiques diagnostiques est présentée. L’introduction de produits 
radiopharmaceutiques dans l'environnement clinique nécessite au préalable des 
études précliniques (cellulaire et petit animal). Dans ce contexte, différents animaux 
sont utilisés pour établir la biodistribution et la biocinétique : des rongeurs, différents 
types de singes, de chiens et des porcs. L'idée est de rechercher l'animal qui 
présente la plus grande similitude avec l'être humain, du point de vue de la 
physiologie de l'organe étudié. Dans le cas de MRP à usage diagnostic, l’irradiation 
délivrée est faible, mais doit toutefois être évaluée afin de permettre l’obtention de 
l’autorisation de mise sur le marché (AMM). L'extrapolation des résultats de 
pharmacocinétique de l’animal à l'humain permet d’estimer l’irradiation délivrée en 
clinique. 
Un premier MRP a été développé en France (CHU-Hôpital Purpan) et deux 
autres en Uruguay (CUDIM). Deux d'entre eux ont pour objectif d'étudier des 
maladies cérébrales et le dernier de diagnostiquer le cancer de la prostate. Une 
étude dosimétrique basée sur les études précliniques a été réalisée pour ces trois 
radiopharmaceutiques.  
L'étude dosimétrique du MRP développé en France s’est basée sur des 
images TEP/TDM de rats, en déterminant la biodistribution et la biocinétique du 
produit. Nous avons déterminé un modèle biocinétique qui représente les courbes 
d'activité en fonction du temps pour divers organes. Ce modèle biocinétique a été 
utilisé pour déterminer les temps de résidence. Pour les organes dans lesquels ce 
modèle n’était pas adapté, l’intégration de l’activité au cours du temps a été réalisée 
par la méthode des trapèzes. 
Dans le cas des deux MRP développés en Uruguay, l’étude dosimétrique a 
été réalisée en quantifiant l'activité directement à partir des comptages de la 
radioactivité présente dans des échantillons (organes, tissus) prélevés après 
dissection. Dans les 2 cas, l’intégration de l’activité au cours du temps a été réalisée 
par la méthode des trapèzes afin de déterminer les temps de résidence. 
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L'extrapolation des résultats précliniques à l'humain a été réalisée par 
pondération des masses des organes entre les deux espèces. L'un des MRP est 
utilisé pour étudier le cancer de la prostate. Pour ce produit, il est possible de 
déterminer que la voie d'excrétion est urinaire. L'extrapolation des données 
pharmacocinétiques a été réalisée en tenant compte ou non de la vidange de la 
vessie à différents moments après l’injection. Pour les MRP utilisés pour étudier les 
maladies cérébrales, dans un cas la voie d’excrétion est fécale, et dans l’autre c’est 
urinaire (la vidange de la vessie n’a pas été étudié).  
Les modèles dosimétriques de référence proposés par la Commission 
Internationale de Protection Radiologique (CIPR) ont été utilisés pour déterminer les 
masses des organes chez l’homme. Les doses absorbées et efficaces ont été 
estimées à l'aide des trois programmes OLINDA/EXM V1.0, V2.0 et IDAC2.1. Il est 
possible d’expliquer les différences entre les résultats obtenus par des différences 
entre les modèles dosimétriques utilisés, la manière dont le calcul des doses 
absorbées et efficaces est implémenté, et les différents codes utilisés pour le calcul 
des valeurs S. 
Dans le troisième chapitre, la dosimétrie clinique en RIV est étudiée. Les 
différentes étapes de la dosimétrie clinique dans ce contexte incluent la 
détermination du facteur d'étalonnage des systèmes d’imagerie, l’acquisition et la 
reconstruction des images, la segmentation des volumes d’intérêt et leur 
repositionnement sur les différentes images acquises à différents temps, l'ajustement 
des courbes d'activité-temps, la détermination des temps de résidence et le calcul de 
la dose absorbée. Cependant, chacune de ces étapes peut être abordée de 
plusieurs manières. 
Généralement, les protocoles de dosimétrie clinique sont implémentés dans 
des établissements qui disposent de ressources, notamment de personnel 
spécialisé, de l'infrastructure nécessaire et de programmes de calcul permettant de 
déterminer la dose absorbée par un organe ou une tumeur en particulier. 
Malheureusement, les solutions logicielles de dosimétrie clinique étant le plus 
souvent développées localement, elles ne sont généralement pas accessibles à la 
communauté internationale.  
En dehors des solutions académiques, il existe aujourd'hui des programmes 
commerciaux dans lesquels divers protocoles dosimétriques sont disponibles. Par 
exemple, on peut trouver des protocoles planaires, TEMP/ TDM ou hybrides, qui 
exigent un nombre minimum (mais variable !) de points de mesure pour chaque 
patient afin de déterminer les courbes d'activité temps. Certains d'entre eux 
disposent d'outils pour effectuer la reconstruction des images, en utilisant différentes 
méthodes de correction des effets limitent la quantification de l’activité. D'autres ne 
disposent pas de ce type d'outils et leur objectif principal est la détermination de la 
dose absorbée à partir d’images reconstruites. Pour effectuer cette tâche, chaque 
programme établit comment entrer un facteur d'étalonnage (coups/Bq ou équivalent). 
Différents outils de recalage et de segmentation d’images sont généralement 
disponibles. Enfin, certains codes requièrent uniquement le temps de résidence. Le 
calcul de la dose absorbée est alors réalisé sur un autre code spécifique, fourni ou 
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non dans la solution dosimétrique. D'autres, en plus d'estimer les temps de 
residence, peuvent calculer la dose absorbée directement de différentes façons. 
Le facteur d'étalonnage est un paramètre qui doit être entré afin d'estimer 
l'activité à un certain point de mesure. Ce point a été étudié par de nombreux 
groupes de recherche et dépend de différentes géométries des sources utilisées et 
de fantômes, dont les données sont disponibles dans la littérature. Il existe une 
relation entre les paramètres d'acquisition, de reconstruction et de correction des 
images, tant pour l'estimation du facteur d'étalonnage que pour la détermination de 
l'activité chez les patients.  
Dans les études séquentielles, le positionnement du patient est un facteur 
important lors du recalage des différentes structures. Mais dans la pratique clinique, 
il est possible que le positionnement du patient ne soit pas identique à 100% pour 
toutes les études acquises. Les mouvements des organes entre deux images acquis 
à différents temps peuvent se produire en raison de la respiration, le changement de 
position et même au cours de l’acquisition des images, par des mouvements du 
patient. Tous ces aspects affectent la quantification des structures étudiées. Les 
techniques de segmentation et de recalage d'images disponibles aujourd'hui 
permettent de réduire les erreurs introduites dans les études cliniques séquentielles.  
La détermination de la pharmacocinétique du MRP peut se révéler difficile car 
les points (temps) de mesures disponibles sont généralement peu nombreux, entre 
autres du fait de l'état clinique du patient qui ne permet pas toujours d’acquérir des 
images aussi souvent que souhaité. L'ajustement de la courbe activité-temps est 
aussi dépendante de l’algorithme sélectionné – et de la possibilité d’évaluer 
l’incertitude associée au calcul des paramètres pharmacocinétiques. 
Enfin, les différents algorithmes de calcul de la dose absorbée peuvent 
générer des résultats différents, selon le type d’approche considérée lors du calcul. 
Les résultats sont d'abord présentés pour un étalonnage en mode planaire, 
recommandé par GE pour la mise en œuvre de son programme de dosimétrie. Un 
étalonnage TEMP/TDM est également effectué par la suite pour l’ensemble des 
solutions logicielles. De plus, l’étalonnage par TEMP/TDM est présenté où 
différentes sources d'étalonnage et différentes géométries sont considérées, 
différents aspects liés à la méthode de reconstruction, par exemple : le nombre 
d'itérations, les sous-ensembles et les méthodes de correction qui peuvent être 
implémentés. Une variation du facteur d'étalonnage peut être établie en apportant 
des changements à chacun d'eux.  
De plus, les courbes des facteurs de récupération ont été étudiées pour un 
fantôme de sphères avec et sans activité de fond.  
Un artefact connu sous le nom de « Gibbs-like » est représenté dans plusieurs 
géométries (dont les résultats sont disponibles dans les annexes de ce chapitre), ce 
qui est lié à la correction de la réponse du collimateur et à l'augmentation du nombre 
de mises à jour (itérations - sous-ensembles). 
Dans ce travail, la radiopeptidothérapie au 177Lu a été utilisée pour évaluer 
solutions logicielles commerciales de dosimétrie clinique : Dosimetry Toolkit (DTK) 
qui est une application de Xeleris® de GE, Hybrid Dosimetry Module™ (HDM) 
General	introduction	
                                                                                                                              6 
 
d’HERMES, STRATOS qui fait partie de IMALYTICS, la station de travail pour la 
recherche de Phillips et PLANET® Onco Dose (PDOSE) de Dosisoft. 
Afin de valider le facteur d'étalonnage pour HDM, STRATOS et PDOSE, une 
évaluation globale est effectuée pour une géométrie spécifique (fantôme) sur la 
capacité de chaque logiciel à déterminer le temps de résidence, ce critère étant donc 
sélectionné à des fins de comparaison. Un autre critère d'évaluation était la 
détermination de l'activité à chaque point de mesure. Pour le fantôme, une bouteille 
a été remplie d’eau avec une solution de 177Lu. Cette bouteille a été placée à 
l’intérieur d’un autre fantôme, le NEMA 2012/IEC 2008 PET. Cinq points de mesure 
ont été obtenus pour générer une courbe de désintégration radioactive 
représentative du 177Lu. La variation de la position du fantôme a permis d'étudier 
l'influence du recalage rigide d'images séquentielles sur la détermination du temps 
de résidence (dans un cas favorable), pour chaque logiciel et différents facteurs de 
calibration. Les images ont été reconstruites dans HERMES, puis chargées et 
analysées dans HDM, STRATOS et PDOSE. Les flux de travail de chaque solution 
ont été étudiés pour comprendre leurs forces et faiblesses. Sur la base des résultats 
obtenus à partir des temps de résidence et de l'activité pour chaque point de mesure, 
deux facteurs d'étalonnage ont été sélectionnés pour être utilisés dans les 
dosimétries avec les données des patients. 
Dans le quatrième chapitre, les données cliniques de deux patients (un 
homme et une femme) atteints de tumeurs gastro-entéro-pancréatiques d'origine 
neuroendocrinienne traitées au 177Lu-DOTATATE ont été utilisées. Pour chaque 
patient, deux cycles de traitement ont été utilisés pour estimer les temps de 
résidence et les doses absorbées dans les reins, le foie, la rate, la moelle osseuse et 
le corps entier en utilisant les différentes stations de travail dosimétriques/solutions 
logicielles commerciales. L’activité administrée était d’environ 7,2 GBq par cycle pour 
chaque patient. 
Les dosimétries ont été réalisées sur les bases d’acquisitions TEMP/TDM. 
Seuls Xeleris® et HERMES permettent de reconstruire les images. Les images des 
patients ont été reconstruites indépendamment et par différents utilisateurs avec 
Xeleris® et HERMES. Les images reconstruites avec Xeleris® ne sont analysées 
qu’avec DTK, mais les images reconstruites avec HERMES sont chargées et 
analysées avec HDM, STRATOS et PDOSE.  
Dans toutes les stations de travail, la même méthode du recalage des images 
a été utilisée. Dans le cas du recalage d'images, pour DTK, HDM et STRATOS la 
méthode a été appliquée en utilisant l'image entière du champ de vision. Dans le cas 
de PDOSE la méthode appliquée a été optimisée au niveau de chaque organe. Dans 
le cas de DTK la segmentation a été automatique. Pour HDM, STRATOS et PDOSE 
la segmentation manuelle a été utilisée. 
Les méthodes d'ajustement des courbes d'activité - temps implémentées dans 
les logiciels sont différentes, il n'est donc pas possible d'appliquer une méthode 
commune. Nous avons donc utilisé la méthode la plus optimale disponible dans 
chaque solution logicielle. Une seule station de travail dispose d'une méthode 
permettant de valider de manière objective la méthode d’ajustement sélectionnée. 
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En ce qui concerne la méthode de calcul dosimétrique, on constate que pour 
le 177Lu la plus grande contribution à la dose absorbée locale est due à l’émission 
bêta, et que pour tous les organes la contribution gamma lui est en général inférieure 
de deux ordres de grandeur. 
Les doses absorbées ont été estimées à l'aide des outils disponibles dans 
chaque logiciel. Ce calcul est effectué pour le foie, la rate et les reins. Dans le cas de 
DTK et HDM, un calcul est effectué en utilisant OLINDA/EXM V1.0 et V2.0, 
respectivement, puisque les deux logiciels y exportent leurs résultats. De plus, les 
doses sont ajustées en fonction de la masse de chaque organe. Dans le cas du 
PDOSE, on utilise la méthode du dépôt local d'énergie et dans le cas du STRATOS, 
on effectue un calcul par convolution.  Enfin, tous les logiciels peuvent estimer les 
temps de résidence.  
La comparaison des logiciels se fait en utilisant les résultats de la 
segmentation (masse des organes), les temps de résidence et les doses absorbées. 
En tenant compte de l’ajustement par les masses des organes/tissus, les calculs de 
dose absorbée suivent directement les calculs de temps de résidence. 
On voit donc que les masses sont variables d’un patient à l’autre, mais moins 
variables d’un cycle à l’autre et elles dépendent peu de la station de travail utilisée 
pour la segmentation (écart type relatif faible). 
On constate que les temps de résidence sont très variables d’un patient à 
l’autre, d’un facteur supérieur à 10 par exemple entre l’homme et la femme pour le 
foie. Ces facteurs sont également variables d’un cycle à l’autre pour le même patient 
(exemple du temps de résidence au foie pour la patiente), mais somme toute peu 
variable d’une station de travail à l’autre. 
Pour la patiente, la dose absorbée moyenne au foie a diminué de près 50% 
entre les 2 cycles. Pour cet organe, de multiples métastases sont visibles. Il est 
probable que ces lésions captent moins de MRP, ce qui entraîne une diminution de 
la dose absorbée.  Les doses absorbées moyennes pour la rate sont plus élevées 
que pour les reins, justifié par les différences de valeurs S associées à cet organe 
pour le 177Lu. Les résultats de dose absorbée moyenne pour les reins sont du même 
ordre de grandeur que ceux rapportés par Sundlöv (Sundlöv et al. 2017), pour la 
dose absorbée rénale médiane = 4,5Gy/fraction, pour 51 patients (199 cycles de 
traitement). 
Dans le cas de l'estimation de la dose absorbée dans la moelle osseuse et 
conformément au schéma du MIRD, il convient de tenir compte à la fois de l'auto-
absorption et du rayonnement croisé. Dans le cas de l'auto-absorption, l'estimation 
de la dose absorbée peut être donnée au moyen de mesures sanguines ou d'images 
des vertèbres L2 à L4. En principe, les deux méthodes devraient être comparables, 
bien que certains auteurs aient (Beykan et al., 2018) récemment mentionné que ce 
n'était peut-être pas le cas pour le peptide étudié. Dans le cas du rayonnement 
croisé (contribution gamma), la contribution des différents organes sources et du 
corps entier doit être estimée. Pour ces patients, il n'a pas été possible de compter 
sur les mesures de corps entier. Une nouvelle approche qui permet d’estimer la dose 
absorbée sans avoir besoin d’utiliser de mesures du corps entier est présentée. Les 
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résultats obtenus sont comparables à d'autres résultats de la littérature (Forrer et al., 
2009). 
La dernière section du présent document est consacrée à la conclusion 
générale, aux questions encore en suspens et aux perspectives des travaux futurs. 
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General introduction  
 
Nuclear medicine is a medical specialty whose applications, essentially 
diagnostic allow the study of organ physiology and the metabolism of various types of 
tumours. Targeted radionuclide therapies (TRT) is a therapeutic approach to nuclear 
medicine. The purpose of TRT is to transport the radionuclide to the tumor. It will 
therefore be necessary to consider different types of carrier molecules, their affinity 
for tumours, different radioactive isotopes and binding of the isotope to the carrier 
molecule. The TRT can be categorized in many ways, for example, according to the 
type of carrier molecules used (radioimmunotherapy, radiopeptidetherapy), or 
according to the selected isotope. 
The response to treatment depends on many factors, one of them being the 
type of radiation. The radionuclides selection is based on the type of emission- alpha 
or beta particles, or Auger having a reduced path in the material and allowing 
localized irradiation to be delivered around the emission point. Depending on the 
penetration of these particles into the material, a crossfire effect can be expected 
(depending on the radiation range and tumour size), which theoretically increases the 
effectiveness of the therapy. For alpha particle emitters, it is also possible to benefit 
from the high linear energy transfer (LET) of this type of particle thus leading to an 
increase in irradiation efficiency for the same delivered energy. In addition, if the 
isotopes have gamma emission, it will be possible to generate images to monitor the 
fate of the radioactive vector in the patient. 
The place of dosimetry in TRT is a debated issue (Chiesa et al., 2017; Flux et 
al., 2017; Giammarile et al., 2017). Between the need to document the delivered 
irradiation and the possibility to optimize the treatment, the development of clinical 
dosimetry is contrasted but undeniable. Article 56 (Optimization) of Council Directive 
2013/59/Euratom (Council of the European Union 2014) explicitly states that "For all 
medical exposures of patients for radiotherapeutic purposes, exposures of target 
volumes shall be planned individually and their delivery duly verified taking into 
account that doses to non-target volumes and tissues shall be as low as reasonably 
achievable and consistent with the radiotherapeutic objective of exposure". 
The methodology is available - but implemented very differently in clinics 
depending on the countries and clinical centers. Indeed, a good indicator of the 
clinical dosimetry development is availability of commercial solutions in the market 
that has seen spectacular recent developments. It is now possible to perform 
personalized dosimetries, considering the pharmacokinetics of radiopharmaceuticals 
and the morphology of each patient. 
As far as dosimetry in a diagnostic context is concerned, it is mainly carried 
out during the development of new tracers, in order to determine orders of magnitude 
of the (low) irradiation delivered. This is referred to as reference dosimetry. 
This doctoral project focuses on clinical dosimetry of radiopharmaceuticals: 
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• We first established the reference absorbed doses for three new 
diagnostic radiopharmaceuticals by extrapolating the preclinical data to 
humans using the three software packages and comparing the results. 
• Subsequently, we studied four commercial dosimetry solutions, using 
phantom experiments and clinical data processing. For the 4 
commercial solutions studied, similarities and differences are 
presented. The comparison proved difficult as the different commercial 
solutions offer different implementations of clinical dosimetry, which 
sometimes limits the evaluation or comparison of performance.  
In the first chapter of this work, different approaches to vectorized internal 
radiotherapy are mentioned. Depending on the type of carrier molecule, they can be 
divided into different groups:  
• The case where the isotope is also the carrier/vector (131I, 223Ra), 
• The case where the vector participates in tumour metabolism (mIBG), 
• Peptide-based therapies (peptide receptor radionuclide therapy or 
PRRT), 
• Antibody therapies (radioimmunotherapy),  
• Selective internal radiotherapy (STIR): It uses radioactive microspheres 
(90Y or 166Ho) placed in contact with tumor targets. This technique is 
increasingly used for the therapy of hepatic tumours. This is a special 
group of therapies that uses medical devices instead of 
radiopharmaceuticals. Interventional radiologists perform an 
angiographic evaluation in search of the vessel that feeds the tumors, 
and then places the microspheres in contact with the areas to be 
treated. 
In case of PRRT, the most commonly used radionuclides are 111-Indium 
(111In), 90-Yttrium (90Y) and 177-Lutetium (177Lu). They are linked to a peptide, for 
example DOTATATE and DOTATOC (frequently used). 111In was initially used 
because images could be generated and, at the same time, the tumor could be 
treated. However, because of its low efficacy compared to that of therapies using 
other isotopes, it is not in use nowadays. 90Y has had successful start, however 
significant toxicities have been reported. In addition, the images generated by 
bremsstrahlung are of reduced quality. Therefore, quantification is not easy to 
achieve. In the case of 177Lu, the therapeutic response is very good and images can 
be taken with sufficient quality to allow a good estimate of the absorbed doses. 
In the case of radioimmunotherapy, anti-CD20 has been used for many years 
(but not in Europe) with the commercial product Bexxar (131I-tositumomab) and has 
been discontinued. Zevalin (90Y-ibritumomab tiuxetan) has been introduced in the 
market (Europe and USA). Both drugs have been used to treat lymphoma. In the 
case of non-Hodgkin's lymphoma, 131I-rituximab in conjunction with rituximab is one 
of the most commonly used antibodies today (Gill et al., 2017; McQuillan et al., 
2015). 
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An introduction of the different dosimetric concepts that are used in following 
chapters of this work is presented. Particular attention is paid to planar and SPECT 
quantification techniques used in clinical dosimetry, as well as to techniques related 
to correction effects degrading the image quality and limiting the quantification of 
activity. 
In the second chapter of this work, the study of three new diagnostic 
radiopharmaceuticals is presented. The introduction of radiopharmaceuticals into the 
clinical environment requires pre-clinical studies (cellular and small animal). In the 
latter case, different animals are used to establish biodistribution and biokinetics: 
rodents, different types of monkeys, dogs and even pigs can be used. The idea is to 
search for the animal that has the greatest similarity with the human being, from the 
point of view of the physiology of the organ being studied. In the case of diagnostic 
radiopharmaceuticals, the irradiation delivered is low. However, it must be evaluated 
before the product is granted a marketing authorisation (MA). Extrapolation of 
pharmacokinetic results from animal to human allows to estimate the irradiation 
delivered in clinics. 
The first radiopharmaceutical was developed in France (CHU-Hôpital Purpan) 
and the other two in Uruguay (CUDIM). Two of them are used to study brain 
diseases and the last one for diagnosing prostate cancer. A dosimetric study based 
on preclinical studies was performed for these three radiopharmaceuticals.  
The dosimetric study of the radiopharmaceutical developed in France was 
based on PET/CT images of rats, determining the biodistribution and biokinetics of 
the product. A biokinetic model was determined that accurately represents the 
activity curves over time for various organs. This biokinetic model was used to 
determine residence times. For organs in which this model was not suitable, the 
integration of activity over time was performed by the trapezoidal method. 
In the case of the two radiopharmaceuticals developed in Uruguay, the 
dosimetric study was carried out by quantifying the activity directly from the counts of 
radioactivity present in samples (organs, tissues) taken after dissection. In both 
cases, the integration of the activity over time was carried out by the trapezoid 
method in order to determine the residence times. 
Extrapolation of preclinical results to humans was performed by weighing 
organ masses between the two species. One of the radiopharmaceuticals was used 
to study prostate cancer. For this product, it was possible to determine that the 
excretion route is through urine. Extrapolation of pharmacokinetic data was 
performed with or without consideration of emptying bladder at different times after 
injection. For radiopharmaceuticals used to study brain diseases, in one case the 
excretion pathway is faecal, and in the other the quantification of dynamic bladder 
emptying has not been performed. 
The reference dosimetric models proposed by the International Commission 
on Radiological Protection (ICRP) have been used to determine the masses of 
organs in humans. Absorbed and effective doses were estimated using the three 
OLINDA/EXM programs V1.0, V2.0 and IDAC2.1, and it is possible to explain the 
differences between the results obtained by differences between the dosimetric 
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models used, the way in which the calculation of absorbed and effective doses is 
implemented, and the different codes used for the calculation of S-values. 
In the third chapter, clinical dosimetry in TRT was studied. The different steps 
of clinical dosimetry in this context includes the determination of the calibration factor 
of imaging systems, image acquisition and reconstruction, segmentation of volumes 
of interest and their repositioning on different images acquired at different times, 
adjustment of time-activity curves, determination of residence times and calculation 
of absorbed dose. However, each of these steps can be addressed in several ways. 
Generally, clinical dosimetry protocols are implemented in institutions that 
have resources, including specialized personnel, the necessary infrastructure and 
calculation programs to determine the dose absorbed by a particular organ or 
tumour. Unfortunately, since clinical dosimetry software solutions are most often 
developed locally, they are generally not accessible to the international community.  
In addition to academic solutions, there are now commercial programs in 
which various dosimetric protocols are available. For example, the choice of planar, 
SPECT/CT or hybrid protocols, which require a minimum (but variable!) number of 
measurement points for each patient to determine time-activity curves. Some of them 
have tools to perform image reconstruction using different effect correction methods 
thus limiting the quantification of activity while some have their main objective to 
determine the absorbed dose from reconstructed images. To perform these tasks, 
each program determines how to enter a calibration factor (counts/Bq or equivalent). 
Different tools for image registration and segmentation are generally available. 
However, some codes only estimate residence time. The calculation of the absorbed 
dose is then performed on another specific code whether or not provided in the 
dosimetry solution. Others, in addition to estimating residence times, can calculate 
the absorbed dose directly in different ways. 
The calibration factor is a parameter that must be entered in order to estimate 
the activity at a certain measurement point. Many research groups have studied the 
use of different geometries of the sources and the phantoms and this can be found in 
the literature. There is a relationship between the form of image acquisition, 
reconstruction and correction, both for the estimation of the calibration factor and for 
the determination of activity in patients.  
In sequential studies, patient positioning is an important factor when relocating 
different structures. But in clinical practice, it is possible that the patient's positioning 
may not be 100% identical for all acquired studies. Organ movements between two 
images acquired at different times can occur due to breathing, change of position or 
even during image acquisition by patient movements. All these aspects affect the 
quantification of the studied structures. The segmentation and image registration 
techniques available today makes it possible to reduce the errors introduced in 
sequential clinical studies. 
Determining the pharmacokinetics of a radiopharmaceutical can be difficult 
because the available measurement points (time) are generally few, partly because 
of the patient's clinical condition, which does not always allow images to be acquired 
as often as desired. The adjustment of the time-activity curve is also dependent on 
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the algorithm selected and the ability to assess the uncertainty associated with the 
calculation of pharmacokinetic parameters. 
Finally, the different algorithms for calculating the absorbed dose may 
generate different results depending on the type of approach considered in the 
calculation.  
The results are presented for a planar calibration recommended by GE for the 
implementation of its dosimetry program. A SPECT/CT calibration is also performed 
thereafter for all software solutions. In addition, SPECT/CT calibration is presented 
where different calibration sources, geometries and different aspects related to the 
reconstruction method were considered, for example: the number of iterations, 
subsets and correction methods that can be implemented. A variation in the 
calibration factor can be established by changing each of them. 
In this work, 177Lu PRRT was used to evaluate commercial clinical dosimetry 
software solutions: Dosimetry Toolkit (DTK), an application of GE's Xeleris®; Hybrid 
Dosimetry Module™ (HDM) from HERMES; STRATOS, which is part of IMALYTICS; 
the Phillips Research Workstation and PLANET® Onco Dose (PDOSE) from 
Dosisoft.  
In order to validate the calibration factor for HDM, STRATOS and PDOSE, an 
experiment was developed for a specific geometry (phantom) in which the ability of 
each software to determine residence time was evaluated. This criterion was being 
selected for comparison purposes. Another evaluation criterion was the 
determination of activity at each measurement point. For the phantom, a bottle was 
filled with water with a 177Lu solution. The bottle was placed inside another phantom 
the NEMA 2012/IEC 2008 PET. Five measurement points were obtained to generate 
a radioactive decay curve representative of 177Lu. The position of the phantom was 
not always the same, which made it possible to study the influence of rigid 
registration of sequential images on the determination of residence time (in a 
favorable case), for each software and different calibration factors. The images were 
reconstructed in HERMES, then uploaded and analyzed in the HDM, STRATOS and 
PDOSE workflows. In this sense, the workflows of each solution have been studied 
to understand their strengths and weaknesses. Based on the results obtained from 
residence times and activity for each measurement point, two calibration factors were 
selected for use in dosimetries with patient data sets. 
In the fourth chapter, clinical data from two patients (one male and one 
female) with neuroendocrine gastroenteropancreatic tumours treated with 177Lu-
DOTATATE were used. For each patient, two treatment cycles were used to estimate 
residence times and absorbed doses in the kidneys, liver, spleen, bone marrow and 
whole body using the different dosimetric workstations/commercial software 
solutions. The administered activity was approximately 7.2 GBq per cycle for each 
patient. 
Dosimetries were performed on the basis of SPECT/CT acquisitions. Only 
Xeleris® and HERMES can reconstruct images. Patient images were reconstructed 
independently and by different users with Xeleris® and HERMES. Images 
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reconstructed with Xeleris® were only analyzed with DTK, but images reconstructed 
with HERMES were loaded and analyzed with HDM, STRATOS and PDOSE. 
In all workstations, the same method of image registration and segmentation 
was used. In the case of image registration, for DTK, HDM and STRATOS the 
method was applied using the entire image of the field of view. In the case of 
PDOSE, the method applied was optimized for each organ. In the case of DTK the 
segmentation was automatic and for HDM, STRATOS and PDOSE, the manual 
segmentation was used. 
The methods of fitting time-activity curves implemented in the software differ 
which makes it impossible to apply the same method to all. We therefore used the 
best possible method available in each software. Only one workstation has a method 
to objectively validate the selected adjustment method. 
Regarding the dosimetric calculation method, it can be seen that for 177Lu, the 
greatest contribution to the local absorbed dose is due to beta emission and that for 
all organs, the gamma contribution is generally lower by two orders of magnitude. 
The absorbed doses were estimated using the tools available in each software 
package. This calculation is performed for the liver, spleen and kidneys. In the case 
of DTK and HDM, a calculation is performed using OLINDA/EXM V1.0 and V2.0 
respectively, since both software packages export their results to them. In addition, 
doses are adjusted according to the mass of each organ. In the case of PDOSE, the 
local energy deposition method is used and in the case of STRATOS a convolution 
calculation is performed.  In addition, all software can estimate residence times. 
The comparison of workstations is made using the results of segmentation 
(mass of organs), residence times and absorbed doses. Even considering the mass 
adjustment of organs/tissues, absorbed dose calculations directly followed the 
residence time calculations. 
We can therefore see that the masses are variable from one patient to 
another, but less variable from one cycle to another and they depend little on the 
workstation used for segmentation (low relative standard deviation). 
It can be seen that residence times vary greatly from one patient to another 
(factor greater than 10 for example between men and women for the liver). Also, it 
varies from one cycle to another for the same patient (example: residence time in the 
liver for the patient) but overall slightly variable from one workstation to another. 
For the female patient, the average absorbed dose to the liver decreased by 
nearly 50% between the 2 cycles. For this organ, multiple metastases are visible. It is 
likely that these lesions capture less radiopharmaceutical, resulting in a decrease in 
the absorbed dose. The average absorbed doses for the spleen are higher than for 
the kidneys due to the S-value associated with this organ for 177Lu. The mean 
absorbed dose results for the kidneys are of the same order of magnitude as those 
reported by Sundlöv et al. (Sundlöv et al. 2017), for the median absorbed renal dose 
= 4.5 Gy/fraction, for 51 patients (199 treatment cycles). 
Dosimetry was performed on the basis of SPECT/CT acquisitions. Only 
Xeleris® and HERMES can rebuild images. All programs calculate residence times 
and DTK exports its results to OLINDA/EXM V1.0. 
General	introduction	
15 
 
The results are first presented for a planar calibration, recommended by GE 
for the implementation of its dosimetry program. A SPECT/CT calibration is also 
performed thereafter for all software solutions.  
Patient images were reconstructed independently and by different users with 
Xeleris® and HERMES. Images reconstructed with Xeleris® are only analyzed with 
DTK, but images reconstructed with HERMES are analyzed with HDM, STRATOS 
and PDOSE.  
In addition, SPECT/CT calibration is presented where different calibration 
sources and geometries are considered along with different aspects related to the 
reconstruction method, for example: the number of iterations, subsets and correction 
methods. A variation in the calibration factor can be established by making changes 
to each of them.  
In addition, the recovery factor curves were studied for a phantom of spheres 
with and without background activity.  
An artifact known as "Gibbs-like" is represented in several geometries relating 
to corrections of collimator response and increasing number of updates (iterations - 
subsets). 
In order to validate the calibration factor for different commercial software, an 
experiment was performed for a specific geometry (phantom) to assess the ability of 
each software to determine residence time and this criterion was therefore selected 
for comparison purposes. For the phantom, a bottle was filled with water with a 177Lu 
solution. The bottle was placed inside another phantom - the NEMA 2012/IEC 2008 
PET. Five measurement points were obtained to generate a radioactive decay curve 
representing the decay of 177Lu. The position of the phantom was not always the 
same, which made it possible to study the influence of rigid registration of sequential 
images on the determination of residence time (in a favorable case) for each 
software and different calibration factors.  
The workflows of each solution were studied to understand their strengths and 
weaknesses. 
Clinical data from two patients (one male and one female) with 
neuroendocrine gastroenteropancreatic tumours (NETs) treated with 177Lu-
DOTATATE were used. For each patient, two treatment cycles were used to estimate 
residence times and absorbed doses in the kidneys, liver, spleen, bone marrow and 
whole body with different dosimetric workstations/commercial software solutions. The 
administered activity was approximately 7.4 GBq per cycle for each patient. 
In all workstations, the same method of image registration and segmentation 
was used. In the case of image registration, for DTK, HDM and STRATOS, the 
method was applied using the entire image of the field of view. In the case of 
PDOSE, the method applied was optimized for each organ. In all cases, manual 
segmentation was used. 
The methods of fitting time-activity curves implemented in the software were 
different thus making it impossible to apply the same method to all. We therefore 
used the best possible method available in each IT solution. Only one workstation 
has a method to objectively validate the selected adjustment method. 
General	introduction	
                                                                                                                              16 
 
Absorbed doses were estimated using OLINDA/EXM V1.0 and OLINDA/EXM 
V2.0 software. All results were adjusted according to the masses of each 
organ/tissue.   
Comparison parameters were mass of segmented organs, residence time and 
absorbed dose results. Table I.1 shows the performance results for all software. 
In the case of the estimation of absorbed dose in bone marrow and in 
accordance with the MIRD scheme, both the contribution of self-absorption and 
cross-reactivity should be considered. In the case of self-absorption, the estimate of 
the absorbed dose can be given by means of blood measurements or images of the 
vertebrae L2 to L4. In principle, the two methods should be comparable, although 
some authors have recently mentioned (Beykan et al., 2018) that this may not be the 
case for the studied peptide. In the case of cross radiation (gamma contribution), the 
contribution of the different source organs and the whole body must be estimated. 
For these patients, it was not possible to rely on whole body measurements so a new 
approach is presented to estimate the absorbed dose without the need to use whole 
body measurements. The results obtained were comparable to other results in the 
literature (Forrer et al., 2009). 
The last section of this work is devoted to the general conclusion, questions 
that are still pending and the perspectives for future work. 
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1. Therapeutic Nuclear Medicine 
Treatment of cancer can occur by surgical resection and/or using 
chemotherapy and/or external beam radiotherapy (EBRT). In addition, the use of 
radiopharmaceuticals for cancer therapy (targeted radionuclide therapy - TRT) exists, 
albeit restricted to some tumours. Nowadays therapies provided by nuclear medicine 
can be incorporated as regular methods to treat certain types of tumours (therapeutic 
radiopharmaceutical have FDA or EMA approval). The timeline to use either alone or 
a combination of these tools is decided by the group of physicians in charge of a 
given patient treatment. In the case of locoregional tumours, EBRT and/or surgery 
are often used, but in the case of spread disease chemotherapy and TRT can be 
chosen. The goal TRT is to irradiate cancer cells (localized or metastatic tumours) 
while causing minimal toxicity to surrounding normal tissues. 
1.1. Targeted radionuclide radiotherapy (TRT) 
This type of therapy is also called Molecular Radiotherapy (MRT) and is based 
on the use of high-affinity molecules as carriers of radionuclides to tumour cells. 
Radiopharmaceuticals used in this type of therapy are often injected intravenously or 
intracavitary (Gudkov et al., 2015). Following the injection, such drugs go into to 
blood stream, reach the target thanks to the carrier, then damage the tumour thanks 
to the ionizing radiations emitted by the radionuclide. The basis of its success is 
related to the concentration and prolonged retention of the radiopharmaceutical 
within the tumour. Tumour response depends on several factors. Dosimetric factors 
such as radiation range, cumulated absorbed dose, (maximum) absorbed dose rate 
may impact the treatment. Tumour radiosensitivity – considering also bystander 
effect (Ersahin et al., 2011; Gill et al., 2017) is also a parameter that influences the 
success of the therapy.   
In order to choose a radiopharmaceutical product that can be used in TRT, at 
least two different components need to be considered, the radionuclide and the 
targeting vector. The choice of these two components sometimes can be unique due 
to physicochemical properties, pairing this combination to be tailored precisely to 
specific clinical scenario. In terms of the latest aspect, antibodies, antibodies 
fragments and platforms, proteins, peptides and small molecules have been used, 
having great affinity and specificity for the target (Gill et al., 2017; Gudkov et al., 
2015).  
In terms of radionuclides several aspects can be considered, for instance, their 
radioactive decay properties, and how are produced (Gill et al., 2017; Gudkov et al., 
2015). Three types of emissions are preferred, b-particles that can be used for 
irradiation of volumes with multicellular dimensions; a-particles, that are used to 
irradiate volumes with cellular dimensions; and Auger electrons that can irradiate 
volumes with subcellular dimensions. Moreover, if the radionuclides have g-rays’ 
emissions or annihilation photons, those can be used for dual therapeutic and 
diagnostic applications (so-called theragnostic). Considering each type of emission 
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important aspects are the linear transfer energy (LET), their range in tissue and their 
physical half-life.  
For instance, the LET of a-particles varies between 50 – 230 keV/µm, with a 
range in tissue varying between 20 -100 µm. For b-particles the LET is between 0.2 – 
4 keV/µm, with a range in tissue varying between 0.05 – 12 mm. For Auger electrons 
the LET varies between 4 – 26 keV/µm and the range in tissue is less than 20 µm 
(Gill et al., 2017). An illustration of previous characteristics is shown in figure 1.1. 
 
Figure 1.1: Schematic illustration of the range in tissue, at cellular level for a- and b- particles, and 
Auger electrons. Image taken from (Pouget et al., 2011). 
Pouget et al. presents information regarding half-life, type of emission, 
maximum energy range and maximum range in tissue for several radionuclides 
(Pouget et al., 2011). On the other hand, Gudkov et al. shows the method of 
production for other radionuclides (Gudkov et al., 2015). According to the size of the 
tumour, Auger electrons are suitable to target single cells, a-particles are ideal for 
treating small or micro-metastases and blood or bone marrow diseases (short range 
and high energy); finally b-particles are superior for targeting large tumours (long 
range) and even cells without expression of the molecular target will be irradiated 
due to the so-called cross-fire effect (Gill et al., 2017). 
1.1.1. Peptide receptor radionuclide therapy (PRRT) for neuroendocrine 
tumours (NET’s) 
This type of therapy is mostly used in gastroenteropancreatic neuroendocrine 
tumours (GEP-NET) and neuroendocrine tumours (NET’s), also located in the lung, 
where somatostatin (SS) receptor expression is over-expressed (Ersahin et al., 
2011).  Generally, these are slow-growing tumours, but in some instances may 
become very aggressive; additionally, they may be identified when the metastatic 
spread is important. Metastasis can be local or may be located in diverse sites such 
as bone, brain and liver (Bodei et al., 2014).  Moreover, PRRT has been suggested 
as a therapy in the management of pheochromocytoma, paraganglioma, 
neuroblastoma, meningioma, medullary thyroid carcinoma and even in non-iodine 
avid differentiated thyroid cancer (Baum R. P., 2014).  
Inoperable or metastasized progressive well-differentiated NET’s patient are 
candidates to highly effective PRRT treatments, and also the determination of the Ki-
67 tumour proliferation index is essential for patient selection. Moreover, high SS 
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receptor expression of the tumours has to be assured previously to the therapy 
(Baum R. P., 2014; Ezziddin et al., 2011). Initially diagnostic occurred using 
SPECT/CT images after administration of 111In-Octreotide, but PET/CT imaging using 
68Ga-DOTA-peptides is becoming available.  
As previously mentioned in TRT the radiopharmaceutical is a combination of 
two components, the pharmaceutical product and the radionuclide. A general 
configuration of this combination can be seen in figure 1.2. 
 
Figure 1.2: Illustration of a radiolabeled peptide radiopharmaceutical for tumour receptor targeting. 
Image taken from (Baum R. P., 2014). 
Normally a chelator agent is used as a linker for successful radiolabelling of 
the SS analogues, such is the case of the DOTA, that can be used for diagnosis or 
therapy of NETs: DOTATOC ([DOTA0, Tyr3]-octreotide) for diagnosis. For therapy 
DOTATATE ([DOTA0, Tyr3]-octreotate), that presents higher affinity to SS target 
receptor 2 (Baum R. P., 2014).  
The radionuclides used with these chelators have been changing during the 
last two decades; the PRRT was introduced into clinical practice by the group of 
(Krenning et al., 1994) in 1994 using [111In-DTPA0]-octreotide, initially for diagnosis 
and then, by incrementing the injected activity, to treat NET’s. However, 111-Indium 
(111In) is no longer used in practice (Valkema et al., 2002), because therapies using 
other isotopes such as 90-Ytrium (90Y) and later 177-Lutetium (177Lu) have shown 
better outcomes.  
In the case of 90Y, this radionuclide was attractive due to its high energy b 
emissions (maximum energy = 2.28 MeV), with a range penetration in tissue of 11.3 
mm, with a half-life of 64.1 h (Eckerman & Endo, 2008), therefore suitable for large 
tumours. Nonetheless, a drawback of using this radionuclide is associated with the 
lack of gamma emission, and activity quantification by bremsstrahlung imaging is 
very complex (Baum R. P., 2014).  
177Lu is used since 2000 the chelated analogue DOTATATE (Bodei et al., 
2014). Some characteristics of this radionuclide are presented in table 1.1. 
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Table 1.1. Physical characteristics of 177Lu (Eckerman & Endo, 2008; Garkavij et al., 2010; Ljungberg 
et al., 2016). 
Emissions Energy (keV) % b % g 
b- (therapy) 
47.5 12.2  
111.5 9.1 
149.1 78.6 
g (imaging and 
dosimetry) 
112.9  6.17 
208.4 10.36 
249.7 0.21 
321.3 0.22 
Ebmax: 498.3 keV Range in tissue (Ebmax): 2.0 mm Physical half-life: 6.7 days 
 
Kidneys have been identified such a limiting organ in PRRT. This is due to the 
small size of the peptides, that are going to be filtered through glomerular capillaries 
in the kidneys and then reabsorbed and kept in the proximal tubular. Maximum 
tolerable absorbed doses, extrapolated from EBRT are between 23-27 Gy (Baum R. 
P., 2014; Bodei et al., 2014).  
Haematological toxicity can be associated to bone marrow uptake in PRRT. 
However, poor correlation between the development of haematological toxicity and 
mean absorbed dose to bone marrow (Bodei et al., 2008; Forrer et al., 2009) has 
been shown. Moreover, it has been shown that blood-based dosimetry cannot be 
compared with image-based dosimetry approaches (Beykan et al., 2018), due the 
difference in the results obtained from both techniques. Thus, in principle a clear 
absorbed dose-response relationship cannot be based on blood measurements and 
further investigations have to be performed to evaluate patient toxicity using image-
based approaches. On the other hand, haematological toxicity could be associated to 
exposure of the spleen, because the uptake for this organ could be important, 
nevertheless further studies have to be performed to confirm or dismiss this 
hypothesis (Svensson et al., 2016). 
1.1.2. Molecular radionuclide therapy (using 131I) 
One of the oldest therapy treatments can be related to the use of 131I for 
patient with differentiated thyroid cancer (papillary and follicular thyroid cancer) and 
also for benign thyroid pathology such as toxic and non-toxic goitre, hyperfunctioning 
nodules and Graves’ disease.  
Some physical properties of 131-Iodine (131I) (half-life of 8.1 days, maximum 
electron energy of 606 keV with tissue range penetration around 2.3 mm) make it 
suitable as a treatment agent. Also with its four gamma emissions 284 keV (5.8%), 
364 keV (82%), 637 keV (6.5%) and 723 keV(1.7%) images can be created to 
quantify activity using a SPECT/CT (Dewaraja et al., 1998; Pouget et al., 2011). 
Probably the first dosimetric results using this therapy in thyroid cancer 
treatment were reported from Benua et al. in 1962 (Benua et al., 1962). Since then a 
lot of experience has been created around the nuclear medicine societies producing 
several guidelines to treat patients at different clinical stages for both types of thyroid 
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diseases (Cooper et al., 2009; Haugen et al., 2016; Luster et al., 2008; Stokkel et al., 
2010).   
In the case of thyroid cancer, these guidelines take into account multiple 
aspects, since the proper identification of the thyroid cancer, the stage of disease, 
placement of a patient in a particular thyroid treatment scheme; this mean surgery, 
time of activity administration after surgery, their follow-up and further actions in the 
case of disease resistance. Moreover, EBRT can also be considered in some cases.  
These guidelines also consider the preparation of the patient before the 
treatment, for instance, when rhTSH stimulation is used or not, the time of low iodine 
diet and the time avoiding TSH drug. Additionally, these guidelines consider how to 
proceed with patients at different ages, for instance, in the case of children or elderly 
people. However, most of the time the prescribing procedure using 131I is referring to 
administrated activity instead of absorbed dose. Therefore, more efforts must be 
undertaken to provide evidence to the physicians of a relevance of dosimetry for this 
treatment.  
In the case of hyperthyroidism, the case of the European Association of 
Nuclear Medicine (EANM) guidelines recommend prescribing different absorbed 
doses depending on the type of disease. Moreover, the EANM has dosimetry 
guidelines for both diseases targeting organs such as the thyroid itself and the bone 
marrow (Hänscheid et al., 2013; Hindorf et al., 2010; Lassmann et al., 2008). In these 
guidelines, how to calibrate the equipment, analyse patient data and how to estimate 
absorbed dose is described. Moreover, the International Atomic Energy Agency 
(IAEA) has created a report in which radiological protection recommendations are 
given to patients who are receiving these treatments (IAEA, 2009). To generate 
these recommendations, the administrated activity was the criteria used. Hence, 
isolation periods from relatives, co-workers, time to sleep alone and visits from 
children are defined for patients who underwent thyroid cancer (for ablation or 
recurrence) and hyperthyroidism treatments. This comprehensive report also 
considers how to proceed with pregnant patients (or potentially pregnant), under 
breast-feeding and even patient death, thus, how to manage radioactive bodies and 
how-to carry-on an autopsy, are topics also considered. On the other hand, the 
United States Nuclear Regulatory Commission (USNRC) (Howe et al., 2008), in the 
appendix U, considering biokinetics of the 131I into the patient and try to personalize 
these recommendations, created a mathematical model for 131I, that can be 
implemented in a nuclear medicine department. 
In recurrent medullary thyroid carcinoma, radiolabelled somatostatin 
analogues could be used, even though they are less sensitive for diagnosis of distant 
metastases and progressive disease, even comparing 68Ga-DOTATATE with 18F-
Fluorodeoxyglucose (FDG) outcomes (Baum R. P., 2014; Conry et al., 2010). 
In the case of neuroendocrine tumours, 131I-Meta Iodobenzylguanidine (MIBG) 
has been used for the treatment of neuroblastoma, pheochromocytoma, extra cranial 
paraganglioma and gastroenteric neuroendocrine tumours (Ersahin et al., 2011), as 
these tumours arise from the primitive neural crest that express the noradrenaline 
(NA) transporter. The use of this radiopharmaceutical has diminished due to 
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emergence of radiolabelled peptides and non-radioactive targeted therapies, but in 
the case of inoperable tumours it is still an option (Baum R. P., 2014). In 
neuroblastoma, that is mostly a child disease, in most of stage I and II patients the 
best treatment is surgery alone. For stages III and IV the treatment using 131I-MIBG 
can be considered and depending on the case, in stage III chemotherapy is used as 
neoadjuvant prior surgery (Ersahin et al., 2011). Patients eligible for this treatment 
have stable bone marrow reserve and renal function, respectively (Baum R. P., 
2014). Patients treated are normally isolated; receiving the radiopharmaceutical 
product using an infusion pump for 1 to 2 h. Patients should avoid sunlight exposure 
and remain well hydrated. More than 50% of the given activity will be excreted within 
urine during the first 48 h (Ersahin et al., 2011). 
1.1.3. Radioimmunotherapy for antibody-targeted tumours (e.g. non-
Hodgkin lymphomas) 
Lymphomas are among the most radiosensitive tumours. When they are well 
localized EBRT can be a curative method. However, in the case of non-Hodgkin 
lymphoma (NHL) the disease is normally disseminated throughout the body. One 
possible solution to treat the NHL is to use total body irradiation but the major 
drawback is bone marrow aplasia (Baum R. P., 2014). Then the use of radiolabelled 
monoclonal antibodies has been used as another line of treatment of this disease. 
Antibodies are immunoglobulins that can be found in the serum of vertebrates, 
the IgG (immunoglobulin G) is the most common used in clinical practice. This large 
protein is composed of pairs of heavy and light polypeptide chains, showing a “Y”-
shaped structure after they are assembled (Baum R. P., 2014). Illustration of 
antibodies being coupled to different types of drugs or radionuclides can be observed 
in figure 1.3. 
 
Figure 1.3: Illustration of antibody conjugates, in which radio- or drug- conjugates are chemically 
associated by linking them to lysine or by sulfhydryl-linkage chemistry. Image taken from (Baum R. P., 
2014). 
The antibody-radioconjugate, so called-radioimmunotherapeutic agent, 
combine the specificity of antibody affinity for cell-surface proteins with a cytotoxic 
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effect. The advantage of antibody-radioconjugate agents over non-radionuclide 
antibody-drugs is the lack of internalization into cancer cells (Gill et al., 2017).  
Two radiolabelled anti-CD20 murine monoclonal antibodies have been used to 
treat lymphomas, the 131I-tositumomab (Bexxar) and 90Y-ibritumomab tiuxetan 
(Zevalin) (Ersahin et al., 2011). Both differs from 131I-rituximab, which has been used 
as a first-line treatment for patients with NHL in conjunction with rituximab (McQuillan 
et al., 2015). Bexxar was withdrawn from the market in 2014. On the other hand, 
Zevalin has been used in combination with chemotherapy in both indolent and 
aggressive NHL (Gill et al., 2017). Rizzieri (Rizzieri, 2016) discuss the continuing 
clinical research in NHL patients using Zevalin. 
Gill et al. (Gill et al., 2017) mentioned that a-particles are starting to be used to 
treat leukaemia in combination with the humanized anti-CD33, using 213-Bismuth 
(213Bi)- and 225-Actinium (225Ac)-lintuzumab; however, clinical trials are still on-going 
(Finn et al., 2017; Jurcic et al., 2016; Rosenblat et al., 2010). On the other hand, b-
particles (177Lu and 90Y) have been used with J591 to treat prostate cancer. In part IX 
of Baum’s book (Baum R.P., 2014) there are several sections dedicated to the use of 
antibodies to treat different types of cancer.  
1.1.4. Others 
Refractory metastatic bone pain is caused by skeletal metastases from 
advanced cancers such as prostate, breast, lung, thyroid and kidney cancer. The first 
two types of cancers can be associated with more than 80% of bone metastases 
(Ersahin et al., 2011). Treatments using 89Sr, 153Sm and 186Re have been addressed 
by the EANM which has proposed a specific guideline (Bodei, Lam, et al., 2008).  
177Lu-labelled prostate-specific membrane antigen (PSMA) has been used for 
metastatic castrate-resistant prostate cancer treatment (Baum R. P., 2014; Gill et al., 
2017). Using a-emitters such as 213Bi (Wild et al., 2011) and 225Ac (Kratochwil et al., 
2016) labelled to PSMA has also been proposed to be used with patients not 
responding to the therapy using 177Lu. Also for the same type of disease 223Ra 
(radium-223 dichloride) has been used (Hoskin et al., 2014; Nilsson, 2016) and got 
the EMA and FDA approval. 
Selective internal radiation therapy (SIRT) groups special therapies that do not 
use radiopharmaceuticals but radioactive medical devices (like brachytherapy), 
placed near tumours (usually in the liver) by the physician, by intra-arterial 
administration. Two types of products can be found in the market made of resin (SIR-
Spheres®, Sirtex Medical Europe, Bonn, Germany) and made of glass 
(TheraSphere®, MDS Nordion, Toronto, Canada) (Baum R. P., 2014), both products 
use 90Y as radionuclide to treat the lesions and images can be generate using the 
bremsstrahlung emission using PET/CT systems (Giammarile et al., 2011; Carlier et 
al., 2013; Lhommel et al., 2010).  
Microspheres of 166Ho are also been studied (Seppenwoolde et al., 2005).  
Dosimetry studies can be performed for radiopharmaceutical products, used 
either for diagnostic or therapeutic purposes. 
Chapter	1:	Theoretical	framework	
25 
 
2. Radiopharmaceutical dosimetry in diagnostic and 
therapy 
The medical decision in order to treat a patient will depend on many aspects, 
such tumours and the organs at risk. 
According to the article 56.1, of the Council Directive 2013/59/Euratom (The 
Council of the European Union, 2014), “For all medical exposure of patients for 
radiotherapeutic purposes, exposures of target volumes shall be individually planned 
and their delivery appropriately verified taking into account that doses to non-target 
volumes and tissues shall be as low as reasonably achievable and consistent with 
the intended radiotherapeutic purpose of the exposure”. In the article 56.6, the same 
document mentioned “Member States shall ensure that in the case of a patient 
undergoing treatment or diagnosis with radionuclides, the practitioner or the 
undertaking, as specified by Member States, provides the patient or their 
representative with information on the risks of ionizing radiation and appropriate 
instructions with a view to restricting doses to persons in contact with the patient as 
far as reasonably achievable. For therapeutic procedures these shall be written 
instructions.” Moreover, in the definitions of Chapter 4 (81), the Directive explicitly 
mentions that "radiotherapeutic" means pertaining to radiotherapy, including nuclear 
medicine for therapeutic purposes.  
From these articles, one can contend that patient-specific dosimetry is a right 
when a patient is benefiting from a therapeutic treatment involving ionising radiations. 
Therefore, all possible efforts should be done in order to implement dosimetry and 
provide accurate results. 
In the case of fixed activity administration, dosimetry can be used to document 
the therapeutic procedure, in order to generate an objective index (efficacy or 
toxicity) to relate to the outcome. For example it may be necessary to give a 
therapeutic activity to a patient that afterwards will receive an external radiation 
therapy treatment as is described by Hobbs et al. (Hobbs et al., 2011). Therefore as 
suggested by the SNMMI (Silberstein et al., 2012) the dosimetry calculation are 
especially important to avoid potential damage to certain organs/tissues. Dosimetry 
will not impact the nuclear medicine therapeutic procedure itself (i.e. activity will not 
be modulated) but will participate to the planning of subsequent external beam 
radiotherapy. 
Dosimetry may also help to modulate the therapeutic activity, which means 
that depending on the dosimetric results the physician will prescribe more or less 
activity. This participates to “personalized medicine”, where every patient is given 
what he or she needs. This can be implemented depending on the needs, in two 
particular time-scenarios:  
a) when the therapy consists in only one cycle of treatment (or for repeated 
cycles that are separated in time so that they can be considered as single 
treatment)  
b) when cycles of treatment are repeated and close enough so that the results 
obtained on one cycle can be used to plan subsequent cycles. 
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For the first scenario, patient may follow a preparation process (indicated by 
the medical staff). Then, a tracer amount of activity will be administered to the patient 
to proceed with the dosimetry measurements. In the case of thyroid cancer cell, a 
saturation effect, called stunning is well known (Coakley, 1998; Lees et al., 2002; 
Sisson et al., 2006), then tracer activities as low as 30 MBq can be used to perform a 
pretherapeutic dosimetric study. In the case of benign thyroid diseases the EANM 
has proposed this method (Hänscheid et al., 2013) using a tracer activity about 2 
MBq. The therapeutic activity will be therefore administrated after the dosimetric 
procedure. The second scenario will estimate absorbed doses to certain organ at risk 
for the first therapy cycle. Under the assumption that organs at risk will have same 
biokinetics among all treatment cycles, a dosimetric extrapolation can be done in 
order to calculate the activity that can safely be administered for subsequent cycles. 
This administration scheme could be implemented for PRRT patients. 
However nowadays patients receive the same therapeutic administration (constant 
activity) for each cycle of treatment (7.4 GBq per cycle, four cycles of treatment 
maximum).  
Yet, Beykan et al. (Beykan et al., 2018) shown that the adjustment of the 
therapeutic activity between cycles can be done for PRRT patients treated with 
Lutathera using high administrated activities. Sundlöv et al. demonstrated that, due to 
inter-patient variability, most patients may benefit of more cycles of treatment (under 
the fixed activity/cycle paradigm) because one of the main organs at risk (the 
kidneys) was not reaching the maximum tolerable absorbed dose after four cycles. 
For most patients, the absorbed dose to the kidneys was more or less the same for 
each cycle of treatment. Conversely, for some other patients, due to intra-patient 
variability, the absorbed dose for each cycle of treatment was very different. While 
variable, these results all conclude to the relevance of patient-specific dosimetry in a 
context of therapeutic optimisation (Sundlöv et al., 2017). 
Clinical dosimetry is an evolving area in which different patient pathologies are 
addressed and the treatment is optimized during the time due to new equipment, new 
radiopharmaceuticals, more professional staff, software availability (to acquire, to 
reconstruct, to correct images), new regulations, etc.  
Probably these are the reasons to find in the literature several acquisition 
protocols, from whole-body planar images (Cremonesi et al., 2006; Mirzaei et al., 
2013; Schuchardt et al., 2013; Svensson et al., 2016) to SPECT/CT images 
(Beauregard et al., 2011; Hänscheid et al., 2018; Ilan et al., 2015; Sanders et al., 
2015) and passing by a combination of them, called the hybrid method (using one or 
two SPECT/CT) (Bailey et al., 2015; Brolin et al., 2015; Garkavij et al., 2010; 
Guerriero et al., 2013; Sandström et al., 2010).  
In fact, implementing clinical dosimetry in practice is quite a demanding task. 
This is why different dosimetric approaches have been proposed, using mostly 
academic software as research tools, even though commercial software is becoming 
increasingly available. 
The most famous radiopharmaceutical calculation scheme was proposed by 
the MIRD committee. 
Chapter	1:	Theoretical	framework	
27 
 
3. MIRD schema for absorbed dose determination  
This committee is part of the Society of Nuclear Medicine & Molecular Imaging 
(SNMMI). It develops standard methods, models, assumptions, and mathematical 
schemas for assessing internal dosimetry from administrated radiopharmaceuticals.  
By checking their web site, one can verify that The Medical Internal Radiation 
Dose (MIRD) Committee started its publications in 1968 with the MIRD Pamphlet No. 
1: Schema for absorbed-dose calculation for biologically distributed radionuclides. 
This first document was revised in 1975 and further publications in 1988 and 1991 
containing examples. In 2009, the MIRD Pamphlet No. 21 (Bolch et al., 2009) 
proposed a new nomenclature, intended to conciliate MIRD and ICRP terminology. 
Even though the initial objective of the MIRD committee was to propose means to 
compute absorbed doses, several publications are intended to address the 
complexity of nuclear medicine imaging quantification. In 1999 the MIRD Pamphlet 
No. 16 (Siegel et al., 1999) showed how to proceed with quantification using planar 
images. In the same year the MIRD No. 17 (Bolch et al., 1999) showed how to 
perform dosimetric calculation for non-uniform activity distributions at voxel level. In  
2012 the MIRD Pamphlet No. 23 (Dewaraja et al., 2012) addressed the quantification 
of SPECT images aiming for patient-specific 3D-dosimetry. In 2016 the MIRD 
Pamphlet No. 26 (Ljungberg et al., 2016) was a joint document between the EANM 
and MIRD Committee and addressed SPECT quantification for 177Lu.     
3.1. Absorbed dose definition  
Taking into consideration information from MIRD Pamphlet 21, the absorbed 
dose rate (J kg-1 s-1) for a target tissue 𝑟" can be expressed as in equation 1.1 
 ?̇?(𝑟", 𝑡) =*𝐴(𝑟,, 𝑡)-. 𝑆(𝑟" ← 𝑟,, 𝑡) 1.1 
Where 𝐴(𝑟,, 𝑡) is the time-dependent activity of the radiopharmaceutical 
product in the source tissue 𝑟,, and 𝑆(𝑟" ← 𝑟,, 𝑡) in known as the S-value which is a 
quantity representing the mean absorbed dose rate to a target tissue 𝑟" at time t after 
administration per unit activity present in source tissue 𝑟,. The S-values are 
estimated using computational models considering age, sex, organs mass (and 
composition), total-body mass and height (Menzel et al., 2009).  
The mean absorbed dose for target tissue 𝑟" can be estimated by integration 
of equation 1.1 over a period of time 𝑇2 (which normaly is defined as infinity), as is 
expressed in equation 1.2 
 𝐷(𝑟", 𝑇2) = 3 ?̇?(𝑟", 𝑡)"45 𝑑𝑡 =*3 𝐴(𝑟,, 𝑡)	𝑆(𝑟" ← 𝑟,, 𝑡)"45-. 𝑑𝑡 1.2 
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Two additional quantities are used for radiation protection purposes in 
diagnostic procedures in nuclear medicine. These are the equivalent dose, HT, and 
the effective dose, E. These parameters are mandatory when a new diagnostic 
radiopharmaceutical is incorporated in the market. It is therefore required to 
determine reference dosimetric values for each new diagnostic radiopharmaceutical. 
These dosimetric quantities are intended to give account of the detriment induced by 
stochastic effects of radiations only. Therefore, they cannot be used in the context of 
therapeutic nuclear medicine procedures where deterministic effects are 
preponderant. 
According to MIRD Pamphlet 21, the equivalent dose, in units of sievert (Sv = 
J*kg-1), can be defined as in equation 1.3: 
 H"(𝑟", 𝑇2) = 	*𝑤:𝐷:(𝑟", 𝑇2):  1.3 
Where wR is the radiation-weighting factor for radiation type R, and 𝐷:(𝑟", 𝑇2) 
is the contribution of radiation type R to the mean absorbed dose in target tissue 𝑟".  
Table 1.2 provides radiation-weighting factors according to ICRP-103 
recommendations. 
 
Table 1.2. Radiation-weighting factors from ICRP-103 (ICRP, 2007). 
Radiation type WR 
Photons, electrons and muons 1 
Protons and charged pions 2 
Alpha particules, fission fragments, heavy 
ions 20 
Neutrons A continuous curve as a function of 
neutron energy 
 
The effective dose, also in units of sievert, considers the tissue-weighting 
factor, wT, for a target tissue 𝑟". Moreover, the condition ∑ 𝑤"" = 1	has to be fulfilled. 
According to ICRP 103, this quantity can be defined as in equation 1.4: 
 E = 	*𝑤"" >𝐻(𝑟", 𝑇2)@ABC + 𝐻(𝑟", 𝑇2)EC@ABC2 G 1.4 
The previous equation gives the effective dose to a reference person. Table 
1.3 shows tissue weighting factor according ICRP-103. 
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Table 1.3. Tissue weighting factors (wT) from ICRP-103 (ICRP, 2007). 
Tissue wT *𝒘𝑻𝑻  
Red bone-marrow, colon, lung, stomach, breast, remainder 
tissues£ 0.12 0.72 
Gonads 0.08 0.08 
Bladder, oesophagus, liver, thyroid 0.04 0.16 
Bone surface, brain, salivary glands, skin 0.01 0.04 
£Remainder tissues (14 in total): adrenals, extra-thoracic region, gall bladder, heart, kidneys, 
lymphatic nodes, muscle, oral mucosa, pancreas, prostate, small intestine, thymus, uterus/cervix. 
 
Figure 1.4 shows a schematic representation of the effective dose 
determination for a reference person. 
 
Figure 1.4: Estimation of effective dose by sex averaging. Image taken from (Menzel et al., 2009). 
3.2. Biokinetics assessment  
3.2.1. Time-integrated activity and residence time 
The bio-kinetics of a radiopharmaceutical can be described knowing the 
relationship of the activity (or number of counts) per time point. By plotting this 
relationship among all pairs (time, activity) a time activity curve (TAC) can be 
generated. Figure 1.5 shows a theoretical representation of a TAC. Estimating the 
area under the TAC will produce the time-integrated activity (TIA), which was also 
known as cumulated activity, in units (Bq.s). Essentially this is a measure of the total 
number of disintegrations occurring in an organ source containing the 
radiopharmaceutical (Cherry et al., 2012).   
Looking at first coefficient of equation 1.1, the TIA can be expressed as 
follows: 
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 𝐴J(𝑟,, 𝑇2) = 3 𝐴(𝑟,, 𝑡)"45 𝑑𝑡 1.5 
Where 𝑇2 is defined as the dose-integration period. 
 
 
 
Figure 1.5: hypothetical description of time-activity curve for radioactivity in a source organ, also 
showing that the area under the curve is the time-integrated activity. Image taken from (Cherry et al., 
2012). 
Normally, the TAC can be mathematically described as the sum of exponential 
functions, as it is shown in equation 1.6:  
 𝐴J(𝑟,, 𝑇2) 	=*𝐴K𝑒MNOPQKRS  1.6 
As equation 1.5 shown, TIA will be generated as the integration of equation 
1.6, in a general scenario 
 𝐴J(𝑟,, 𝑇2) 	=*𝐴K𝜆KQKRS  1.7 
Some organs sources will express a mono-exponential behaviour; other may 
express bi- or tri-exponential behaviour. 
For mono-exponential behaviour, 𝐴J(𝑟,, 𝑇2) 	= UVNV 1.8 
 
For bi-exponential behaviour, 𝐴J(𝑟,, 𝑇2) 	= UVNV + UWNW 1.9 
 
The 𝐴K term is associated with the initial injected to a patient, and 𝜆K is known 
as the decay constant, which considers the biological and physical decay of the 
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product in the organ source. Hence, the effective decay constant 𝜆CEE can be 
expressed as: 
 𝜆CEE 	= 	 BQ(X)"VWYZZ = 𝑙𝑛(2) ∗	^ S"VW_O`ab"VWcde.f 1.10 
The term 𝑇VWCEE is the effective half-life and 𝑇VWgKhB, 𝑇VWijk, are the biological and 
physical half-lives, respectively.  
The time-integrated activity coefficient (TIAC) 𝑎m(𝑟,, 𝑇2), given in units of time 
(i.e. seconds) can be obtained dividing equation 1.5 by the administrated activity Ao 
(IAEA, 2014). These coefficients were named as residence times, 𝜏, in MIRD Primer 
(Loevinger et al., 1991).   
3.3. S-Values  
The S-value is associated to the radionuclide and the model used, which 
means that they take into account the geometry and composition of both the source 
and the target. Therefore, this quantity can be expressed as in equation 1.11 
 𝑆(𝑟" ← 𝑟,, 𝑡) = 1𝑀(𝑟", 𝑡)	*𝐸K𝑌K𝜙(𝑟" ← 𝑟,, 𝐸K, 𝑡)K= 1𝑀(𝑟", 𝑡)	*ΔK𝜙(𝑟" ← 𝑟,, 𝐸K , 𝑡)K  1.11 
Where 𝐸K is the mean energy of the ith nuclear transition, 𝑌K is the number of ith 
nuclear transition per nuclear transformation. 𝜙(𝑟" ← 𝑟,, 𝐸K, 𝑡) is the absorbed fraction, 
which is the fraction of radiation energy emitted 𝐸K	within the source tissue 𝑟, that is 
absorbed in the target tissue 𝑟" , at the time t. 
From equation 1.11 it is important to highlight that the term associated to the 
organ mass is dependent on time. This is a concept that normally is not considered 
for the TIAC estimations, because normally organ mass is seen as a constant value 
among all time point measurements, however, this quantity may change due to organ 
movements, patient respiration movement and patient movement. 
On the other hand, in the same equation, the absorbed fraction is a quantity 
depending on energy and organ mass. This is especially important at small scale 
(cell or small animal dosimetry). 
From the absorbed fraction, the specific absorbed fraction can be defined in 
equation 1.12 as follows: 
 Φ(𝑟" ← 𝑟,, 𝑡) = 𝜙(𝑟" ← 𝑟,, 𝐸K, 𝑡)𝑀(𝑟", 𝑡) 	 1.12 
The first step in direction of patient-specific dosimetry is the accurate 
determination of patient-specific pharmacokinetics. Then, assuming that part is dealt 
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correctly, the absorbed dose calculation itself is not trivial. There are two possibilities 
to address that aspect for clinical dosimetry purposes. 
4. Types of dosimetry 
4.1. Reference dosimetry (Model-based dosimetry) 
This type of dosimetry is implemented for new radiopharmaceutical during the 
course of their development. Reference dosimetry is meant to document the 
irradiation delivered by standard diagnostic procedures. Reference models are used 
to allow the comparison between different diagnostic radiopharmaceuticals. Keeping 
the dosimetric model constant allows for a fair comparison of the dosimetric 
properties of different radiopharmaceuticals. In that context, and for the production of 
reference dosimetric data such as presented in ICRP-128 reports (ICRP, 2015), 
averaged pharmacokinetics obtained on groups of healthy volunteers, patients or 
even sometime extrapolated from animals are entered in reference dosimetric 
models to provide an order of magnitude of the (low) irradiation delivered during 
diagnostic procedures.  
Reference dosimetry is opposed to patient-specific dosimetry.  
4.1.1. Computational reference models for organ/structures-based 
dosimetry  
The MIRD Pamphlet 21 was proposed for the standardization of the 
nomenclature used in dosimetric calculations was considered between MIRD and 
ICRP.  
The historical development of both institutions was trying to address most of 
the time the same problems from different point of views. In the case of ICRP, since 
1928 their goal was to create publications and recommendations that nowadays 
became the basis of world´s regulatory codes and regulations on radiological safety. 
As a summary, from the nuclear medicine point of view, the ICRP has been 
generating recommendations. 
The first recommendation is related to digital models and dosimetric models of 
biological systems in order to have a human representation (from babies to adults). 
The latest ICRP publication regarding digital model dosimetric results is the ICRP-
133 (ICRP, 2016). This document replaces publications 30 and 68 (ICRP, 1979, 
1980, 1981, 1988, 1994b). This publication provides the technical basis for SAFs 
relevant to internalized radionuclide activity in the organs of Reference Adult Male 
and Reference Adult Female as defined in Publications 89 and 110 (ICRP, 2002, 
2009). SAFs are given for uniform distributions of mono-energetic photons, electrons, 
alpha particles, and fission-spectrum neutrons over a range of relevant energies. 
Electron SAFs include both collision and radioactive components of energy 
deposition.  
In terms of dosimetric models of biological systems, this document considers 
the bone and bone marrow, gastrointestinal tract, respiratory system, skeletal model 
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and the alimentary tract model. McParland (McParland, 2010) shows an overview of 
several of these biological systems. For instance, the respiratory system according to 
ICRP (30 and 66) and MIRD Report 18, gastrointestinal tract according to ICRP (30 
and 100), the kidney according to MIRD Pamphlet 19, urinary bladder considering a 
dynamic urinary model, head and brain according to MIRD Pamphlet 15, cardiac wall 
and contents according to MIRD Pamphlet 13, bone and red bone marrow, peritoneal 
cavity, tumours, prostate and rectum.  
Second recommendation, the ICRP-128 (ICRP, 2015), provides a 
compendium of current information relating to irradiation of patients, including 
biokinetic models, biokinetic data, dose coefficients for organ and tissue absorbed 
doses, and effective dose for major radiopharmaceuticals based on the radiation 
protection guidance given in Publication 60 (ICRP, 1991). These data were mainly 
compiled from Publications 53, 80, and 106 (ICRP, 1987, 1998, 2008), and related 
amendments and corrections. This report also includes new information for 82Rb-
chloride, iodide (123I, 124I, 125I, and 131I) and 123I labelled 2-carbomethoxy 3-(4-
iodophenyl)-N-(3-fluoropropyl) nortropane (FPCIT). 
Third recommendation, to define quantities that are going to be associated to 
stochastic effects, and could be used for diagnostic purposes and never be applied in 
a therapeutic context. In the ICRP-103 (2007), several recommendations were 
updated such as the radiation and tissue weighting factors, in the quantities 
equivalent and effective dose and update the radiation detriment. Also, some 
recommendations were maintained for instance, the current individual dose limits for 
effective dose and equivalent dose from all regulated sources in planned exposure 
situations.  
Finally, the ICRP also referenced nuclear decay data (available in ICRP-107 
(2008)).  
Regarding the MIRD committee, several publications are available, the MIRD 
Pamphlet´s provide the scientific overview of a particular nuclear medicine 
application whereas the MIRD dose estimate, provides dosimetric data specific for a 
given radiopharmaceutical (McParland, 2010). 
4.1.2. Anthropomorphic models  
The use of digital models that can represent the human body or organs has 
been subject of development for several decades by different research groups. 
These representations are created because it is not practical perform direct 
measurements of radiation inside the human body using detectors.  
The reference man concept was introduced by the ICRP-23 (ICRP, 1975), 
representing in detail the anatomy, composition and physiology of a “Caucasian 
male” between 20 and 30 years old, with 70kg body mass and 1.7 m. Nowadays, the 
reference man and woman are available in the ICRP-110 with 73 kg body mass and 
1.76 m height. For the woman 60 kg body mass and 1.63 m height. The reference 
man and woman were created using digital models, also named computational 
anthropomorphic models. 
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Using Monte Carlo simulations, or other calculation means and digital models, 
the S-value (previously defined) can be calculated for a specific isotope, source-
target relation and digital model. One example in nuclear medicine is to estimate the 
absorbed dose from one organ “source” to other organs “targets”. By grouping the S-
values, databases can be created to easy estimate the mean absorbed dose from 
the TIAC. There are software available in the market that include these data bases, 
for instance OLINDA/EXM (Stabin et al., 2005) and IDAC (Andersson et al., 2017).  
Digital models can be grouped in three: the stylized, the tomographic or 
voxelized and hybrid (for instance BREP models); the last combines features from 
the stylized and voxelized models. This division is based on their topological 
characteristics and mathematical approach to represent a structure. 
4.1.2.1. Stylized (mathematical) models  
These phantoms represent the morphology of the organ by using simple 
geometrical structures also called primitives, for example; cuboids, prims, pyramids, 
cones, cylinders, ellipsoids and spheres (McParland, 2010). Advance primitives can 
be B-splines lines or non-uniform rational B-splines (NURBS) or polygon mesh (Xu & 
Eckerman, 2009). To create these geometrical structures a solid-geometry modelling 
method called constructive solid geometry (CSG) is used. With CSG a solid object 
can be created using Boolean operators combining the primitives, which are easily 
described by quadric equations (Xu & Eckerman, 2009). As an example, a lung in 
which one section has been removed can be defined using a Boolean operation by 
subtracting one ellipsoid from the other. The quadric equations that may represent 
this example are presented in equation 1.13. 
 𝐸𝑙𝑙𝑖𝑝𝑠𝑜𝑖𝑑	𝐴:	 z𝑥 − 8.55 X +  𝑦7.5X + z𝑧 − 43.524 X 	≤ 1, 𝑧 ≥ 43.5 1.13 𝐸𝑙𝑙𝑖𝑝𝑠𝑜𝑖𝑑	𝐵:	 z𝑥 − 2.55 X +  𝑦7.5X + z𝑧 − 43.524 X 	≥ 1, 𝑖𝑓	𝑦 < 0 
 
An illustration of the previous operation can be seen in figure 1.6A, where the 
lung is presented before and after the Boolean operation. These types of surface 
equations are accepted by Monte Carlo Codes. However, looking at these images, 
they are not very realistic in terms of geometry. These types of phantoms are also 
called “mathematical” phantoms. The same lung can be represented using the CSG 
modelling technique as an assembly of 3D cuboids, as it can be seen in figure 1.6B. 
Looking at this image, the boundary of the lung in a voxel phantom is defined by 
uneven steps instead of smooth surface, therefore the anatomical fidelity depends on 
the voxel size and this can be an issue for small organ/tissues such as eye lens and 
bone marrow (Xu & Eckerman, 2009).  
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Figure 1.6: A) A stylized lung model using the CSG-type method before and after Boolean operation is 
performed. B) A CSG-type method including rigid voxels with an anatomical detail dependent on the 
voxel size. Images from (Xu & Eckerman, 2009). 
The first digital models were created by Fisher–Snyder (Fisher & Snyder, 
1966) in the 1960s. They were designed using CSG modelling techniques using 
elliptical cylinders and cones. In 1969, Snyder et al. created the first heterogeneous 
model, this model was composed of a skeleton, a pair of lungs; and the remainder 
(soft tissue) (Snyder et al., 1969). The representation of the organs was crude, as the 
simple equations captured only the most general description of the position and 
geometry of each organ (Xu & Eckerman, 2009). In 1978, Snyder et al. published an 
improved version of the heterogeneous model, including spheres; ellipsoids; cones, 
tori, and subsections of such objects (Snyder et al., 1978). It was described in three 
sections; an elliptical cylinder, containing arms, torso and hips, then, a truncated 
elliptical cone representing the legs and feet, and finally, an elliptical cylinder to 
represent the head and neck (Zaidi & Xu, 2007). In figure 1.7 representation of the 
Snyder et al. digital model can be seen (Snyder et al., 1978).  
 
 
 
 
 
 
 
 
A B 
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Figure 1.7: Stylized models. A) Exterior view of the adult male. B) Skeleton and internal organs. C) 
Anterior view of the principal organs. Image A and C from (Snyder et al., 1978). Image C) from (Zaidi 
& Xu, 2007) 
 
 
A B 
C 
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4.1.2.2. Voxel (digital) models  
Anatomical realistic representation of the human body was possible until 
tomographic images and computer capacity became available in the 80’s. CT and 
MRI allow visualizing the internal structures of the body in three dimensions. Due to 
powerful computers, both types of images could be stored in versatile digital formats. 
These characteristics helped to create the so-called voxel- or tomographic phantoms. 
In terms of solid-geometry modelling techniques, a voxel is a basic CSG primitive.  
The creation of these models where very challenging for several reasons: 
images from the whole-body were necessary from live subjects or cadavers, then, 
the identification of organs and tissues had to be made, which is really important for 
dosimetric calculations. The amount of data was potentially too big for a computer’s 
memory to handle and finally, having created the model, radiation transport had to be 
done for various types of radiation, however at the time computing capabilities were 
limited (Zaidi & Xu, 2007). 
On the other hand, tomographic models are fundamentally different from the 
stylized ones, because the 3D tomographic representation is the displaying of 
multiple two-dimensional pixel maps. This type of models contains a huge amount of 
voxels grouped to represent different tissues or organs (Xu & Eckerman, 2009). One 
limiting factor using this type of models is the size of the voxel, as was shown in 
figure 1.6B. Depending on the tissue or structure the voxel size is important; for 
instance, in the case of defining the bladder walls, or the inner parts of the kidneys, 
voxels have to be sufficiently small to give account of the geometry (Marcatili et al., 
2014), otherwise a hybrid calculation scheme must be implemented. In order to gain 
the battle to the limited spatial sampling, the Visible Human Project (VHP) (Spitzer & 
Whitlock, 1998) produced anatomically similar CT, MRI and cross-sectional colour 
photographs, creating voxel sizes of 0.33x0.33x1 mm3 for the male and 
0.33x0.33x0.33 mm3 for the female.  
One of the first groups developing these models, in the early 80’s, was at the 
GSF (German National Research Centre for Environment and Health, Gesellschaft 
für Strahlenforschung) creating a model series with a range of anatomical 
characteristic (Becker et al., 2007; Fill et al., 2004; Petoussi-Henss et al., 2001; 
Williams et al., 1986; Zankl et al., 1988; Zankl et al., 2005; Zankl et al., 2002) trying 
to cover the majority of man and woman anatomies. Figure 1.8 shows one set of 
women models created by this group. 
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Figure 1.8: Images from Helga, Donna and Irene, from (Fill et al., 2004). 
Efforts in this way were developed by Zubal et al. creating the VoxelMan 
(Zubal et al., 1994). Moreover, Kramer et al. developed the models called, Male Adult 
voXel (MAX) (Kramer et al., 2003) and the Female Adult voXel (FAX) (Kramer et al., 
2004) which were adjusted according to the ICRP-89 body heights and organ 
masses and trying to be compatible with the ICRP-89 voxel models. Finally, the ICRP 
modified the voxel models (Golem and Laura) to create their own voxel models in the 
ICRP-110 and these are consistent with reference anatomical physiological 
parameters defined in the ICRP-89. In table 1.4 some characteristics of the adult 
male and female reference computational phantoms can be seen. In figures 1.9 and 
1.10 illustrations from ICRP computational adult models can be seen.   
 
Table 1.4. Main characteristic of the adult male and female reference computational models from 
ICRP-110 (ICRP, 2008). 
Characteristics Male Female 
Height (m)  1.76 1.63 
Mass (kg) 73.0 60.0 
Number of tissue voxels 1,946,375 3,866,020 
Slice thickness (voxel height, mm)  8.0 4.84 
Voxel in-plane resolution (mm) 2.137 1.775 
Voxel volume (mm3) 36.54 15.25 
Number of columns 254 299 
Number of rows 127 137 
Number of slices 220(+2)* 346(+2)* 
*Additional slices of skin at the top and bottom 
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Figure 1.9: Different views of the adult female (AF) model from ICRP-110 (ICRP, 2008). Images 
created at CRCT using ImageJ. 
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Figure 1.10: Different views of the adult male (AM) model from ICRP-110 (ICRP, 2008). Images 
created at CRCT using ImageJ. 
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4.1.2.3. BREP (hybrid) models  
The boundary representation (BREP) is other general method of solid-
geometry modelling, including two types of information: the topological and the 
geometric. Topological information provides relationships among vertices, edges, 
faces and also its orientations. With NURBS very smoothed surfaces can be 
generated; then exterior part of an object can be created. For example, the faces can 
be represented as polygons defined using coordinates values. BREP is much flexible 
because a richer set of operations tools are available (e.g. extrusion, chamfering, 
blending, drafting, shelling, and tweaking) (Xu & Eckerman, 2009). Also, BREP is 
ideal for surface deformation, which might be necessary for organ size adjustment 
and for organ motion correction, then comparing to voxel-based models, BREP allow 
the construction of models close to the real patient anatomy. One of the first 
implementation of BREP-based models was the Cardiac-Torso (NCAT) model, 
create by Segars et al. (Segars et al., 2001; Segars & Tsui, 2002) using NURBS 
using information from the Visible Human Project taking into account CT image data 
sets. The NCAT was created to replace the stylized mathematical cardiac torso 
model (MCAT) developed by Snyder et al. taking information from the MIRD-5 
(Snyder et al., 1969). Organ shapes in the NCAT model are more realistic than those 
from the MCAT model, also the NCAT is more flexible because it considers the 
cardiac and the respiratory motion (Lee et al., 2007). 
Other example from BREP-models is the series of model representing a 
pregnant woman and her foetus at different stages of gestations, this work was 
developed by Xu et al. at the Rensselaer Polytechnic Institute (RPI) in the United 
States (Xu et al., 2007). In this work pregnant women were defined by polygonal 
meshes from three sets of data: a nonpregnant female, a 7-month pregnant woman, 
and a mesh model of the foetus. The organs were adjusted in mesh format. Figure 
1.11 shows the finalized models that were created by this group and were exported 
to the Monte Carlo code MCNPX. 
 
Figure 1.11: Finalized RPI-P models. (a) rendering of 3D models of pregnant female RPI-P3, -P6 and 
–P9. (b) rendering of the voxelized RPI-P9 model before translated into the MCNPX, (c) a direct 
MNCPX geometry plot showing a cross-section view of the 3 mm voxel model of the RPI-P9 
implemented for MC radiation transport calculations. Images from (Xu et al., 2007). 
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As it was shown in figure 1.11, these models were voxelized to be 
implemented in Monte Carlo simulation codes. Therefore, in order to voxelize the 
NURBS smooth models, the surfaces have to be transferred back to polygonal 
meshes (see figure 1.12). 
 
Figure 1.12: Example of voxelization process starting with (A) the original voxel model of the left lung, 
(B) its polygon mesh model, (C) its NURBS surface model and (D) and (E) voxelized models of the left 
lung at two different isotropic voxel resolutions (2 mm and 1 mm, respectively). Image from (Lee et al., 
2007). 
Moreover, using a triangular mesh approach a pair of adult male and female 
models were created, called RPI adult male and female (Hegenbart et al., 2008; Xu 
et al., 2008), which were carefully adjusted to match the ICRP-89 reference values 
for more than 70 organs, 45 bones and muscles.  
For dosimetric purposes, small animal models have also been developed. 
4.1.3. Small animal models 
Nowadays the increasing number of radiopharmaceuticals in the market has 
developed technological platforms to acquire animal images of different sizes. For 
example, looking at Mediso Medical Imaging Systems website 
(http://www.mediso.com), the image modalities available, for pre-clinical studies, are 
hybrid including SPECT/CT/PET, SPECT/CT, PET/CT, SPECT/MRI, PET/MRI. Then, 
animal dosimetry may have two different global objectives, one is related to the 
absorbed dose estimations to animal tissues and, second the extrapolation of bio-
kinetics results to humans. In case of the first objective, using images can be very 
challenging, due to logistics, setting the equipment, animal conditions, etc.  
In order to help with the dosimetric estimations animal models can be an 
option. As was presented for anthropomorphic models, the development started with 
stylized models, then, passing to voxelized models and, finally, today hybrid 
(NURBS) models such as ROBY and MOBY are available. Figure 1.13 shows real 
size images from these two models.           
The development of small animal models started years later comparing with 
the anthropomorphic models. One of the first studies was from Hui (Hui et al., 1994) 
which developed a stylized model, based-on athymic nude mice for radio-
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immunotherapy calculating organ self-doses for 90Y. This was the first murine 
phantom used exclusively for internal absorbed dose using antibodies labelled with 
this isotope. Most of the organs were modelled such as ellipsoids, the skeleton was 
modelled by the femur, the bone and marrow were represented by concentric 
cylinders and a spherical tumour was also included (McParland, 2010).  
 
 
Figure 1.13: Unmodified images from ROBY and MOBY, showing their real size. (Keenan et al., 2010; 
Segars & Tsui, 2007) 
Muthuswamy et al. complemented the model developed by Hui et al. 
developing a model of marrow applied for 131I, 186Re and 90Y (Muthuswamy et al., 
1998). Some other authors have created more stylized models, for instance, mouse 
models were created by Flynn et al. (Flynn et al., 2001), Hindorf et al. (Hindorf et al., 
2004) and a model of Wistar rat was created by Konijnenberg et al. (Konijnenberg et 
al., 2004). In the case of Hindorf et al. (Hindorf et al., 2004) they treated the model in 
a voxel format. In figure 1.14 images from Konijnenberg et al. and Hindorf et al. 
models can be seen. 
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Figure 1.14: Stylized models examples of two different rodents: A) Hindorf et al. (Hindorf et al., 2004), 
B) Konijnenberg et al. (Konijnenberg et al., 2004).  
 
Other voxelized models have been created using high-spatial resolution MRI 
and CT studies (Bitar et al., 2007; Dogdas et al., 2007). For example, Kolbert et al. 
used MRI of a female athymic mouse representing realistic models of the kidneys, 
spleen and liver (Kolbert et al., 2003). Stabin et al. used micro-CT images of a mouse 
and rat to estimated SAFs for photon and electron sources (Stabin et al., 2006).  
In the case of hybrid models, Segars et al. implement NURBS using MRM 
create a murine model including respiratory and cardiac motion (Segars et al., 2004). 
From this initial work, Segars et al. manage to develop more the models as they are 
presented in figure 1.13 (Segars & Tsui, 2007). 
4.2. Adjusted model-based dosimetry 
Since not every centre has the possibility to compute the absorbed dose 
specifically for a given patient morphology, a workaround consists in adjusting 
reference dosimetric data to give account the morphology of the patient.  
A first order correction consists in adjusting S values by the mass ratio 
between patient and reference model source organ mass (or volume). This in strictly 
true only for non-penetrating radiations (i.e. alpha and beta emissions at the scale of 
human organs/tissues), but provides reasonable results in most situations (Divoli et 
al., 2009). 
When the organ mass is adjusted, the S-value is modified according to the 
radionuclide emission (Divoli et al., 2009; Grimes et al., 2012; HERMES Medical 
Solutions, 2016; Petoussi-Henss et al., 2007). Equation 1.14 shows the linear-scaling 
applied to organ mass for non-penetrating radiation   
 
A B 
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𝑆(𝑟, ← 𝑟,)iAPKCQP = 	𝑆(𝑟, ← 𝑟,)-CEC-CQC 	𝑚,-CEC-CQC𝑚,iAPKCQP 	 1.14 
A correction for the gamma contribution to self-irradiation according to 
equation 1.15 is integrated in OLINDA, but most often can be considered as a 
second order correction 
 𝑆(𝑟, ← 𝑟,)iAPKCQP = 	𝑆(𝑟, ← 𝑟,)-CEC-CQC 	𝑚,-CEC-CQC𝑚,iAPKCQP X/ 1.15 
The correction for cross irradiation is usually considered as not necessary – 
and by all means would be difficult to implement. Petoussi-Henss (Petoussi-Henss et 
al., 2007) mentioned that correction by mass is unnecessary even when the source 
and target are close to each other. Moreover, they concluded that another descriptor 
(related to geometry) for patient-specific scaling of reference S-values should be 
found. 
As a conclusion, adjusting S values from a reference model to a given patient 
geometry is a fast way to personalise dosimetry.  
4.3. Full patient-specific dosimetry 
In the case of fully-specific patient dosimetry all aspects related to clinical 
dosimetry have to be patient specific, not only pharmacokinetics determination but 
also absorbed dose calculation. This will necessitate computing capabilities from the 
nuclear medicine centre. However, academic and commercial solutions are 
increasingly available to deal with the many aspects making available dosimetric 
workflows. 
5. Implementing clinical dosimetry 
5.1. Dosimetric workflow/chain  
The dosimetric workflow or dosimetric chain is related with the phases that are 
associated to treat all images and data in a multi-SPECT/CT or PET/CT scenario, in 
which the aim is to calculate the absorbed dose for a specific organ/tissue. Usually 
this workflow is associated to a particular philosophy in which data are acquired and 
treated. There is software that has been created for this purpose, some from 
academic or hospital institutions, other from commercial companies. In figure 1.15 an 
illustration of the clinical dosimetric workflow is presented. 
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Figure 1.15: Clinical dosimetric workflow scheme. Created by Manuel Bardiès. Used with his 
permission. 
Depending on the available software, there are several steps to treat patient 
data. Hence, six different phases are considered as follows: 
1. Image acquisition for calibration: In principle this acquisition should be done 
using the same protocol used for patient imaging. Normally a test-object (also 
called phantom) is used for that purpose. In the literature there are different 
investigations to address this problem for different radionuclides. The objective 
is to calculate the calibration factor, which is going to relate the number of 
counts within the image per voxel with the quantified activity per voxel. 
2. Patient image acquisition: This image covers one section of the patient body, 
where critical organs and/or tumours are present. Depending on the 
dosimetric protocol, several sections can be obtained for the same time point 
measurement. Normally several times point measurements are needed. 
3. Reconstructions and corrections: In a 3D scenario when reconstructions are 
performed corrections are also implemented; hence, counts per voxel are 
going to be generated. Using the calibration factor, activity per voxel can be 
determined instead of counts per voxel, if is necessary. 
4. Registration and segmentation: Due to several patient images acquisition, a 
registration process is necessary to create a reference space among all data 
sets, some software use Whole-FOV registration; few use organ-based 
registration. Normally one data set is used to be the reference against the 
other data sets, to match/fit two images. Segmentation is a procedure in which 
a ROI or VOI is generated with the aim to be characterize the biokinetics 
within.  
5. TAC and TIA assessment: Having the same reference for all time points and 
ROI/VOI segmented, generating time-activity curves for each structure occurs 
to calculate the TIA as it is expressed in equation 1.5. There are several 
options to integrate these curves.  
6. Absorbed dose calculation: There are several ways to calculate absorbed 
dose, at the end of this chapter some approaches are addressed, for instance, 
the analytical, local energy deposition, dose point kernel, dose voxel kernels, 
Monte Carlo and tabular approaches. All these possibilities will produce 
different types of outputs, average absorbed dose, absorbed dose maps and 
voxel-based absorbed dose in which absorbed dose volume histogram can be 
generated. Knowing radiobiological information, some other parameters can 
be estimated. 
Calibration 
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TAC fit and Ã
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5.2. Activity quantification  
Before TIA estimations can occur, activity quantification has to be determined 
for a particular ROI/VOI/structure. As previously mentioned in section 2, there are 
three possibilities to acquire patient data images, using gamma-cameras. The three 
of them are going to be implemented depending on the clinical requirements and the 
techno/methodological capabilities of each nuclear medicine department. Evidently 
there are negatives and positives aspects in each quantification approach.  
5.2.1. Patient planar imaging  
Nowadays, most nuclear medicine department have a single- or dual-head 
imaging system. These systems can be used to image one section of the patient-
body or the patient whole-body. Static, dynamic images or whole-body images can 
be acquired with these systems. Also, in the case of whole-body images an auto-
contour can be activated to generate images as close as possible of the patient.  
According to MIRD Pamphlet 16, “this method will be greatest for 
radiopharmaceuticals distributed in a single region or isolated regions that do not 
overlap (non superimposed) in the planar projection”. Figure 1.16 shows an 
illustration to introduce the quantification scenario.    
 
Figure 1.16:  A source region containing activity “A”, which is embedded in a medium of overall 
thickness “h” and which contains no activity. Image taken from (McParland, 2010). 
 
In McParland (McParland, 2010), the conjugate view approach is explained 
more in-depth. In this example, an object with thickness 𝜏 is placed at depth 𝛿. Here 
assumption of no activity in the medium surrounding the object is considered, and 
also the medium and the object have same physical properties and no scatter is 
presented. A differential slice of activity dA, with thickness dr is placed at distance r. 
Then, this differential of activity is expressed as: 
 𝑑𝐴 = 𝐶U𝑑𝑡 1.16 
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The amount of activity per unit thickness in the object is: 
 
 𝐶U = 	 U  1.17 
The rate of photons detected from this differential thickness in the anterior and 
posterior views are: 
 
Anterior 
𝑑X𝑁U𝑑𝑡	𝑑𝑟 = 𝜅	𝐶U𝑒M- ⟹	𝑑𝑁U𝑑𝑡 = 	𝜅	𝐶U 3 𝑒M-𝑑𝑟b  
 
1.18 
Posterior 
𝑑X𝑁𝑑𝑡	𝑑𝑟 = 𝜅	𝐶U𝑒M- ⟹	𝑑𝑁𝑑𝑡 = 	𝜅	𝐶U 3 𝑒M-𝑑𝑟jMjMM  1.19 
 
Where 𝜅 is the planar calibration factor of the gamma-camera system, 𝜇 is the 
linear attenuation coefficient. Then the geometric mean of the two count rates is: 
 z𝑑𝑁𝑑𝑡 Ch@ = 	𝑑𝑁U𝑑𝑡 	𝑑𝑁𝑑𝑡 = 	𝜅	𝐴	 sinh	¤𝜇𝜏 2¥ ¦¤𝜇𝜏 2¥ ¦ 	§ℌ 1.20 
The attenuation of the emitted photons (ℌ) through the entire thickness of the 
medium is given by: 
 ℌ = 	𝑒M©j 1.21 
Finally, for the object, the activity can be expressed as follows: 
 𝐴 =	 1𝜅§ℌz𝑑𝑁𝑑𝑡 Ch@ 	^ ¤𝜇𝜏 2¥ ¦sinh	¤𝜇𝜏 2¥ ¦f = 	 1𝜅§ℌz𝑑𝑁𝑑𝑡 Ch@ 𝜉 1.22 
Where 𝜉 is called the self-attenuation factor of the activity contained in the 
object.  
Now, considering a scenario in which many overlaying source regions are 
presented, such as the case illustrated in figure 1.17, the activity for a source region 
jth 𝐴«, is given by the general expression: 
 𝐴« = 	 1𝜅§ℌz𝑑𝑁𝑑𝑡 Ch@ ¬ 𝜇«𝜏« 2¥ sinh	 𝜇«𝜏« 2¥ ­ 1.23 
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Figure 1.17: Illustration of surrounding medium containing two different activities A1 and A3. Image 
taken from (McParland, 2010). 
 
The cases showed in the figures 1.16 and 1.17 are ideal, most of the time 
patient images are degraded by different physical effects, for example, dead time, 
background, organ overlapping, scatter and attenuation.  
5.2.1.1. Dead time correction 
This correction must be done when high-count rates are present. This 
phenomenon can be easily seen when scanning a patient after few hours of 
administration of a high amount the radiopharmaceutical (A0 > 3700 MBq, i.e. for 
131I). Figure 1.18 illustrates the effect of counting losses from a high activity source 
placed in air and placed behind 10 cm of water, also in the same figure shows the 
“ideal” performance of a gamma camera. In the case of the scatter medium, less 
count are observed within the energy window used to perform the measurement. 
This is due to the scatter photons associated with the Compton effect that occurred 
and then, with the corresponding lost of energy for those photons. 
 
Figure 1.18: Effect on counting losses in the presence of a high activity source. Counting losses effect 
when the source is in air and the source is behind 10 cm of water. Image taken from (Cherry et al., 
2012). 
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According to Sharp et al. because the gamma camera is a paralyzable 
system, a second event occurring within the dead time due to the first event will not 
be recorded but will also initiate a pile-up effect. This means that not only will be 
recorded counting rate be less than the true counting rate but that, at high sample 
activities, the recorded counting rate will begin to decrease (Sharp et al., 2005). 
If 𝜏 is the system dead time, the observed counting rate Ro is related to the 
true counting rate Rt, in a paralyzable system is as follows: 
 𝑅h = 𝑅P𝑒M:¯ 1.24 
According to Cherry (Cherry et al., 2012) the observed counting rate rises to a 
maximum value given by: 
 𝑅h = 1(𝑒 ∙ 𝜏) 1.25 
Moreover, Cherry et al. proposed a method to determine the dead time 𝜏, 
called “the two-source method” (Cherry et al., 2012), in which two sources with 
similar activities are used, for which the dead time losses are expected between 10% 
and 20%. First step is to place source 1 to establish its the count rate R1. Then 
without moving source 1, source 2 is place at certain distance from source 1, then 
establishing the count rate of the two sources together R12. Then source 1 is 
removed without disturbing source 2 and recording the count rate of source 2, R2.  
Figure 1.19 illustrates the followed steps to carry-on with this procedure. For a 
paralyzable system, the dead time 𝜏 is given in seconds by: 
 𝜏	 ≈ 	 ² 2𝑅SX(𝑅S + 𝑅X)X³ 𝑙𝑛 >(𝑅S + 𝑅X)𝑅SX G 1.26 
 
 
Figure 1.19: Illustration of the steps followed to determining dead time losses by the two sources 
method. Image taken from (Cherry et al., 2012). 
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5.2.1.2. Background correction 
Considering figure 1.17 but now assuming an homogeneous background 
source activity surrounding the source object, the background contribution in each 
view (detector) can be corrected.  
The conventional background correction would be to generated a VOI close to 
A2 and subtract the counts in this VOI to A2 counts, the definition of this VOI is very 
difficult because care must be taken to avoid hot or cold areas, moreover, according 
to MIRD Pamphlet 16, this VOI does not consider the portion of the background 
equivalent to the source region volume and may underestimate the source region 
activity due to oversubtraction of background.   
Therefore, the fraction “F” of geometric mean counts that originates from A2 
alone is: 
𝐹 =	µ¶1 − ¬𝑑𝑁·𝑑𝑡 𝑑𝑁U𝑑𝑡¸ ­1 − 𝜏ℎº	¶¬
𝑑𝑁·𝑑𝑡 𝑑𝑁𝑑𝑡¸ ­1 − 𝜏ℎº»
S/X
 1.27 
Where ¼½¾¼P  is the count rate through the patient from a region adjacent to the 
object with equal area. Considering one patient 𝜏 and ℎ thickness could be measured 
from NM lateral views or using CT information. 
5.2.1.3. Organ overlapping correction 
Organ overlapping can occurs for some organs or tumours, and this is the 
major drawback for planar quantification. For instance, right kidney and liver are 
frequently partially superimposed on planar images. Stabin et al. suggested two 
methods to solve this problem (Stabin, 2008). One option for pairs organs, such as 
kidneys and lungs, is to quantify the activity in one of the organs in which there is no 
overlap, then double the number of counts obtained in this organ to estimate the 
counts in the two organs.  
The second approximation: is to draw an ROI over the organ region in scans 
where there is overlap, count the number of pixels and record the count per pixel, 
then use a ROI from another image in which there is no overlap; record the number 
of pixel from this new image, then multiply the count rate per pixel from the first 
image by the number of pixels in the second image. 
5.2.1.4. Scatter correction 
This correction can be implemented mostly considering two different factors, 
first the image acquisition itself, depending on the number of energy windows used to 
generate the images, and second, the processing software used to perform the 
correction.  
This correction must be applied to determine the amount of scatter photons 
included into the main energy window at its contribution to the total amount of counts 
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within this energy window. The scatter counts will degrade the quality of the acquired 
image and it will affect the quantification. In figure 1.20 an example of the scatter 
photons within the photo-peak and the additional energy window. The multiple order 
of scatter photons can be seen in this figure due to the Monte Carlo simulation.  
 
 
Figure 1.20: Total energy spectrum of a 99mTc and its Monte Carlo simulation. Energy window 
positioning and multiple order of scattering. Image taken from (Ichihara et al., 1993). 
Chapter 7 from Zaidi (Zaidi, 2006) addressed implicit and explicit scatter 
corrections methods, few of these methods are mentioned in the MIRD Pamphlet 16. 
According to McParland (McParland, 2010) scatter correction can be divided into four 
categories, an explanation of the first two is going to be addressed due to their 
implementation in clinical practice: 
• Photon energy discrimination or analysis (Buvat et al., 1994; Buvat et 
al.,1995; Ichihara et al., 1993; Ogawa et al., 1991) 
• The build-up factor (Raymond & Siegel, 1984) 
• Factor analysis (Mas et al., 1990) 
• Convolution/subtraction methods analysis (Axelsson et al., 1984; Willowson 
et al., 2008) 
 
• Photon energy discrimination or analysis  
In the case of the photon energy discrimination or analysis, corrections can be 
implemented by using one, two or more energy windows additionally to the main 
photo-peak energy window. Hence, one can estimate either the complete energy 
spectrum of scatter counts, or at least the integral of that spectrum from the lower-
energy cut-off of the photo-peak window to the upper-energy cut-off of that window, 
subtraction of the scattered counts, pixel by pixel, is still the goal (Zaidi, 2006).  
The dual-energy window (DEW), using just one energy window below the 
main, both with the same width. An assumption is made, considering that the number 
of scattered photons in the “low energy” window is proportional to the number of 
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scattered photons in the main energy window. The number of primary photons is 
given by: 
 𝐶i-K@A-k = 𝐶"hPAB − 𝜅 ∙ 𝐶,APPC-  1.28 
Where κ is a constant value, found to be 0.5 for 99mTc (Koral et al., 1988; 
Oppenheim, 1984). 
The Triple Energy Window (TEW) method employs two energy windows close 
to the main energy window. One of the first articles showing its applicability in nuclear 
medicine was from Ogawa et al. in which they were performing scatter correction 
under different phantom-objects configurations and using Monte Carlo simulations 
(Ogawa et al., 1991). The number of scattered photons can be determined as 
follows: 
 𝐶,APPC- ≅ 	 z𝐶BCEP𝑊, + 𝐶:KjP𝑊,  ∙ 𝑊@2  1.29 
Where 𝐶BCEP and 𝐶:KjP  are the acquired count from the two energy windows 𝑊,	placed above and under the main energy window 𝑊@ . Then the amount of scatter 
counts can be estimated from the trapezoidal region having a left height of ÂaYZ¯Ã. , a 
right height of ÂÄOÅd¯Ã. , and a base of 𝑊@ . Figure 1.21 also shows an illustration of this 
trapezoidal correction. 
 
 
 
Figure 1.21: Location and width of the energy windows. The counts of primary photons in the main 
energy window are estimated as a trapezoidal using the photons of the other two energy windows.  
Image taken from (Ogawa et al., 1991). 
Therefore, using the result from 1.31, the count of primary photons is given by: 
 𝐶i-K@A-k = 𝐶"hPAB − 𝐶,APPC-  1.30 
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• The build-up factor 
This method considers no activity in a scatter medium, as can be seen in 
figure 1.22. To introduce to this method, first the pseudo-extrapolation number 
method (PNM), mentioned at MIRD Pamphlet 16, is considered. The PNM take into 
account the effect of the scatter radiation with a scatter medium as a function of 
depth. Initially a straight line is expected from the simple narrow beam geometry (𝒯 =𝐼 𝐼5¥ = 𝑒M©P), but because scatter is present in the transmission measurements, a 
“shoulder” on the semi log plot can be seen, therefore the straight line in the semi log 
plot can be expressed as follows: 
 𝒯 = 𝑛𝑒M©P 1.31 
The shoulder is a manifestation of the increased scatter photons from the 
activity close to the collimator, n is the pseudo-extrapolation number.  
 
 
Figure 1.22: Experimental measured transmission curve in a tissue equivalent medium using a 67Ga 
source with a medium-energy collimator, showing pseudo-extrapolation number n. Image taken from 
(Siegel et al., 1999). 
The build-up factor method depends on the radionuclide, collimator type, 
energy window, measurement geometry, source size, and it may depend also on the 
source depth and source thickness. The build-up factor can be depth-dependent 
(DDBF) or depth-independent (DIBF). 
According to MIRD Pamphlet 16, the DDBF is defined as the factor by which 
the transmission measurement is made across the patient. Then, an iterative 
calculation procedure is used involving the solution of the set of simultaneous 
equations representing the conjugate-view count rate pairs. Assuming initially source 
thickness 𝜏 = 0. The conjugate-view count rate can be expressed as follows: 
 
Anterior 
𝑑𝑁U𝑑𝑡 = 𝑑𝑁5ÈÂ2𝑑𝑡 𝐵ÈÂ2𝑒M 
 
1.32 
Posterior 𝑑𝑁𝑑𝑡 = 𝑑𝑁5ÈÂ2𝑑𝑡 𝐵jMÈÂ2𝑒M(jM) 1.33 
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Where ¼½ÉÊË4¼P  is the count rate measured in air at the source-collimator distance 
(SCD); 𝐵¼ÈÂ2  is the measured buildup factor for a SCD and for the source at a depth 
“d” in a scattering and attenuation medium, 𝑢 is the narrow-beam linear attenuation 
coefficient. Considering 𝜏 ≠ 0, the previous equation can be expressed as follows: 
 
Anterior 
𝑑𝑁U𝑑𝑡 = 𝑑𝑁5ÈÂ2𝑑𝑡 𝐵ÈÂ2𝑒M 
 
1.34 
Posterior 
𝑑𝑁𝑑𝑡 = 𝑑𝑁5ÈÂ2𝑑𝑡 𝐵jMÈÂ2𝑒M(jM)𝑒M© ^𝑠𝑖𝑛ℎ¤𝜇𝜏 2¥ ¦𝜇𝜏 f 1.35 
 
Because of the contribution of scatter to the broad geometry is inherent to NM 
images, photon attenuation is not purely exponential, as shown in 1.31. This was 
considered by Siegel et al. presenting equation 1.31 (Siegel et al., 1985), 
parameterized  the transmission as a function of depth 𝛿 as: 
 𝒯 = 1 −	¤1 − 𝑒M©¦Q 1.36 
Then, the build-up factor for an infinite depth (which means, large 𝛿), is equal 
to 𝐵Î. Therefore equation 1.36 can be written as follows: 
 𝒯 = 1 −	¤1 − 𝑒M©¦ÏÐ 1.37 
Then, equations 1.34 and 1.35 can be written as follows: 
 
Anterior 
𝑑𝑁U𝑑𝑡 = 𝑑𝑁5ÈÂ2𝑑𝑡 1 −	¤1 − 𝑒M©¦ÏÐ𝑒M© ^𝑠𝑖𝑛ℎ¤𝜇𝜏 2¥ ¦𝜇𝜏 f 
 
1.38 
Posterior 
𝑑𝑁𝑑𝑡 = 𝑑𝑁5ÈÂ2𝑑𝑡 1 −	¤1 − 𝑒M©(jM)¦ÏÐ 𝑒M© ^𝑠𝑖𝑛ℎ¤𝜇𝜏 2¥ ¦𝜇𝜏 f 1.39 
 
The depth-independent build-up factor, is independent of source size and 
depth for a given settings, an in this case is associate to 𝐵Î. 
5.2.1.5. Attenuation correction (Transmission method) 
In this conjugate view scenario, the attenuation correction can be done by 
using a transmission factor, similar to the one presented in equation 1.21. In order to 
generate this factor, a transmission scan is required, sometimes using a 57Co sheet 
source, or flood phantoms (using 99mTc or ideally the isotope used for emission 
image acquisitions). Specific devices have also been presented (Lenta et al., 2000), 
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but not integrated in commercial systems. The CT scout can also be used (Minarik et 
al., 2005).  
For a given ROI (or Whole-Body) the transmission factor ℌ can be expressed 
as follows: 
 
ℌ = 	 Ñ𝑑𝑁𝑑𝑡 Ò:ÓÔ,			hg«CPÑ𝑑𝑁𝑑𝑡 Ò:ÓÔ,QhMhg«CP  1.40 
In a whole-body scan, same bed speed must be applied for both scans.   
When using a different isotope for transmission than for emission images, a 
correction must be applied due to differences in linear attenuation coefficients 
between radionuclides. In this case, the transmission factor can be scaled, as 
presented in equation 1.41: 
 ℌ =	𝑒 ©©ÕYÖ.×ØYÙBQ(ℌÕYÖ.×ØYÙ) 1.41 
Where 𝜇 is the linear attenuation coefficient associated to the injected 
radionuclide (considering broad beam geometry), 𝜇ÚCA,-C¼  and ℌÚCA,-C¼ are the 
attenuation coefficient and the transmission factor of the radionuclide used for the 
transmission scan, respectively. Hence, these two parameters have to be known and 
measured in advance. 
5.2.2. Patient SPECT/CT imaging   
Tomoscintigraphic imaging avoids the overlap between different organs or 
structures. SPECT/CT imaging is a complex and non-standardized image acquisition 
technique and in this section some of the aspects involving image generation are 
covered. Depending on the administrated activity, dead time effect can be also 
present even before the image reconstruction process. 
5.2.2.1. Dead time correction 
In the case of SPECT acquisitions, dead time effects have been studied for 
several radionuclides. According to MIRD Pamphlet 26, in the case of 177Lu because 
of the low yield of g-photons emitted the impact of dead time on SPECT images is 
limited, even for high activities. However, it may be present when scans are obtained 
shortly after the therapeutic injection. This effect also is related to the number of 
energy windows used (which means more photons are detected), the collimator type 
and the amount of administrated activity to the patient. 
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5.2.2.2. Image reconstruction 
Projections are generated from images acquired at different angles, when the 
gamma camera is in rotation around one source or a patient. The reconstruction is 
the process in which 2D projections are converted in a 3D source distribution. Using 
this technique overlapping structures in planar images can be seen properly 
distributed in 3D image. 
From the IAEA book (IAEA, 2014) (chapter 13) and Zaidi (Zaidi, 2006) 
(chapters 3 and 4) the reconstruction techniques are presented in more details. 
Generally, each projection is associated to one angle, its signal information is 
recorded in a form of a 2D matrix. In cartesian coordinates data can be converted to 
polar coordinates, generating a new representation of the data called sinogram. A 
representation of an object source can be seen from the projections (cartesian 
coordinates) and from the sinogram (polar coordinates) points of view can be 
observed in figure 1.23. 
 
  
Figure 1.23: Illustration of an object representation in A: cartesian coordinates, B: Polar coordinates. 
Images taken from (Cherry et al., 2012).   
Therefore, the position of the object (the projection profile) in figure 1.23 can 
be mathematically described as: 𝑟 = 𝑥 cos𝜙 + 𝑦 sin 𝜙 Cartesian 
coordinates 1.42 𝑠 = 𝑥cos𝜙− 𝑦sin𝜙	 Polar coordinates 
 
From this example the generation of a reconstructed image can occurred, 
because the projection profile can be back projected, and recorded in an image 
matrix (from 64x64 to 1024x1024 pixels), as can be observed in figure 1.24A where 
only one projection profiles was back projected.  
In figure 1.24B the effect of adding projection profiles and back projected can 
be noticed. Increasing the number of projection profiles that are back projected, the 
approximation to the real object is improved. 
 
A B 
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Figure 1.24: Illustration of back projection process. A: One projection profile is back projected. B: the 
effect of increasing projection profiles. Images taken from (Cherry et al., 2012).   
 
Mathematically, the back projection of N profiles can be described as follows: 
 𝑓Ý(𝑥, 𝑦) = 	 1𝑁*𝑝(𝑥	𝑐𝑜𝑠𝜙K + 𝑦 sin 𝜙K , 𝜙K)½KRS  1.43 
Where 𝑓Ý(𝑥, 𝑦) denotes an approximation to the true activity distribution, 𝑓(𝑥, 𝑦), 𝜙K is the ith projection angle and 𝑝(𝑟, 𝜙K) is the projection profile. In figure 
1.24B, an artefact is created increasing the number projection profiles that are back 
projected, the object cannot be seen clearly, it is blurred. To correct this blur artefact, 
the filtered back projection process has been developed.   
5.2.2.2.1. Filtered back projection (FBP) 
The filtered back projection implies the use of a filter in order to decrease the 
blurring artefact. One simple approximation that can be applied to the source activity 
in figure 1.24, is to use a profile from a reconstructed image of a point-source, that is 
taken from finely sampled data decreasing in proportion to “1/r”, where “r” is the 
distance from the centre of the point-source location.  
Mathematically, this process can be expressed as follows: 
 
B 
A 
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𝑓Ý(𝑥, 𝑦) = 	𝑓(𝑥, 𝑦) 	∗ 	1𝑟  1.44 
Where “∗” denotes a convolution process. This process is easily processed 
expressing all functions in Fourier transforms. Cherry et al. provides the basis on how 
to perform this process under the spatial frequencies space (Cherry et al., 2012). The 
approximation “1/r” in the spatial frequencies space is known as “ramp filter”. Then, 
after performing the convolution, equation 1.44 can be expressed as follows: 
 𝑓(𝑥, 𝑦) = 	 1𝑁*𝑝Ý(𝑥	𝑐𝑜𝑠𝜙K + 𝑦 sin 𝜙K , 𝜙K)½KRS  1.45 
Where 𝑓(𝑥, 𝑦)	is the true source object activity distribution corrected by the 
convolution process and 𝑝Ý(𝑟, 𝜙K) is the projection profile considering the ramp filter, 
which provides the filtered back projected profile. Figure 1.25 shows the effect of the 
filtered back projection process using a similar example that it was used in figure 
1.24B. 
 
	
Figure 1.25: Illustration of filtered back projection process implemented with data from figure 1.25B. 
Images taken from (Cherry et al., 2012).   
5.2.2.2.2. Iterative reconstruction 
As an improvement of the FBP reconstruction technique, the iterative 
algorithm was developed to deal with the streak artefacts created in the back 
projection process. These artefacts are present specially when many “hot” sources 
are in the image.  
Using this reconstruction technique, the “best” estimation of the activity 
distribution can be found, using some criterion that measures the goodness of the fit 
between two images: the reconstructed image and the measured image; thus, the 
reconstruction technique use a mathematical algorithms to find the optimal solution, 
minimizing differences between these two images, in successive approximations. 
 According to Zaidi (Zaidi, 2006) the iterative process begins with an initial 
estimate of the object count distribution. Provided a suitable model of the emission 
and detection physics is incorporated, the projections that would arise from this initial 
object can be estimated (by forward projection): this effectively an estimate of what 
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the detector would measure given the initial object; normally this estimate of 
projections will differ from the actual measured projections, then, the difference 
between estimated and measured projection can be seed to modify the original 
estimate of the object by use of suitable additive of multiplicative corrections at each 
point (usually via back projection). Thus, the adjusted object becomes the starting 
point for a second iteration. The process will continuous in a feedback loop until a 
final solution is reached. This process previously described can be seen in figure 
1.26.  
 
Figure 1. 26:  Illustration of iterative reconstruction procedure. Images taken from (Cherry et al., 2012).   
 
According to Cherry et al. (Cherry et al., 2012) the two basic components of 
iterative reconstruction algorithms are: the method for comparing the estimated and 
the actual images and the method by which the image is updated on the basis of this 
comparison. Then, the goal of the iterative reconstruction is to produce convergence 
of the estimated image towards the true image as rapidly and accurate as possible. 
The iterative algorithm normally takes into account factor for specific 
characteristics of the gamma camera, for instance, the collimator, its system 
geometry, system spatial resolution, noise characteristics, attenuation and object 
scatter. 
Mathematically, the iterative reconstruction algorithm can be expressed as 
follows: 
 𝑝K = 	*𝑎K«𝑓««  1.46 
Where 𝑝K is the equivalent discrete set of projection pixel values, for counts 
originating from the object voxel activiy concentration 𝑓« . This essentially defines the 
probability of detecting an emitted photon, originating from location j, at any particular 
position, I, on the detector. 𝑎K« is the transition or system matrix. 
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As it is mentioned in chapter 4 from Zaidi (Zaidi, 2006), one reconstruction 
algorithms used is the Maximum Likelihood-Expectation Maximization (ML-EM), 
which involves two steps: first the expected projections are calculated by forward 
projection using the appropriate system matrix, based on the estimate of the activity 
distribution from the previous iteration. Second, the current estimate is updated so as 
to maximise the likelihood, achieved by multiplication of the previous estimate by the 
back projection of the ratio of measured over estimated projections. Mathematically 
this is described as follows: 
 𝑓«QCß = 𝑓«hB¼∑ 𝑎B«B *𝑎K« 𝑝K∑ 𝑎Kà𝑓àhB¼àK  1.47 
To ordered subsets expectation maximization (OS-EM) method use a subset 
of projections for updating rather than comparison of all estimated and measured 
projections. For OS-EM one iteration is normally considered the use of all data one; 
consequently, use of only part of the data during the update process is termed a sub-
iteration. The process is very similar to that presented in equation 1.47, the only 
difference being the use of subsets, Sn, where	𝑛	 ∈ 𝑁, the total number of projections 
divided by the total number of projections per subset, mathematically expressed as: 
 𝑓«QCß = 𝑓«hB¼∑ 𝑎K«K∈Èâ * 𝑎K« 𝑝K∑ 𝑎Kà𝑓àhB¼àK∈Èâ  1.48 
5.2.2.3. Collimator detector response correction 
This is a really complex topic, fortunately most of the reconstruction algorithms 
include this correction. The collimator-detector response (CDR) in a nuclear medicine 
image system refers to the image generated from a point source of activity. The 
shape of the CDR is the primary factor determining the image resolution in SPECT 
(Zaidi, 2006).  
According to the MIRD Pamphlet 23, the CDR has four components: the 
intrinsic response of the detector and three related to the collimator response 
(geometric, septal penetration and scatter). The intrinsic response is well modelled 
as a Gaussian function. The geometric response of the collimator can be calculated 
theoretically and is also often approximated as a Gaussian function as well, with a 
FWHM that is linear function of source-to-collimator distance. The last two 
components of the collimator response cannot be determined as the geometric 
response and both have to be determined by Monte Carlo simulations (which are 
normally performed to fully determine the CDR). The use of this correction method 
helps to reduce the partial volume effect, but is not full compensated. 
In fact, chapter 5 from Zaidi (Zaidi, 2006) explains in detail all these different 
components and how to compensate them. According to MIRD Pamphlet 26, the 
reconstruction algorithms, which include this correction, will modify the distribution of 
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counts in the image but do not change their total number. Also, this correction will 
generate changes in noise texture, so image will appear smoother; moreover, it 
decreases the resolution-induced spill-out of counts from hot regions. This correction 
depends on the signal-to-n ratio, noise levels in the data, camera orbit, and the 
number of iterations. The drawback on this compensation is the generation of Gibss-
like artefacts. 
5.2.2.4. Scatter correction 
Scatter corrections mentioned in section 5.2.1.4 can also be applied in SPECT 
images, this correction can be considered in some cases into the iterative 
reconstruction algorithm.  
5.2.2.5. Attenuation correction  
To address this problem in SPECT, Chang (Chang, 1978) proposed an 
analytical method assuming homogeneous density and using a fixed linear 
attenuation coefficient to correct it; this method is applied after reconstruction, taking 
into account each pixel of the image, however, this technique is assuming a constant 
attenuation coefficient. The attenuation coefficient can be derived from narrow- or 
broad-beam geometries. This method is not used nowadays, because of the hybrid 
SPECT/CT technology available in the nuclear medicine departments. Nonetheless, 
this method can be used with this hybrid system is not available.  
The impact of this attenuation correction method can be seen in figure 1.23. 
 
   
Figure 1.27: Effect of Chang attenuation correction on SPECT images of a 20-cm diameter cylinder 
containing a uniform concentration of 99mTc. No attenuation correction effect, narrow-beam geometry 
coefficient and broad-beam geometry coefficient can be seen. Images taken from (Cherry et al., 
2012).   
Due to the heterogeneity in tissue composition in the human body, the 
estimation of an accurate and patient-specific attenuation map for nonuniform 
attenuation compensation is necessary. This map is a voxel-by-voxel representation 
of the linear attenuation coefficients at the SPECT photon energy. Generally these 
maps have lower noise, better spatial resolution, better contrast and are faster and 
easier to acquire (Dewaraja et al., 2012; IAEA, 2014).  
The attenuation map is described by the matrix of CT numbers associated with 
each pixel in a tomographic slice, generated by a CT scanner. The CT number can 
be defined as it is shown in equation 1.49: 
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𝐶𝑇# =	 𝜇𝜇äWÓ − 1 ∙ 1000 1.49 
Where 𝜇 is the linear attenuation coefficient of the medium and 𝜇äWÓ is the 
linear attenuation coefficient of water. CT number units are Hounsfield Units (HU). 
Because linear attenuation coefficients are energy-dependent, the CT 
numbers at the x-ray energy must be scaled to the energy of the SPECT isotope. In 
the case of low-Z materials, a single scaling factor can be used to convert from x-ray 
energies to SPECT photon energies. For high-Z materials a bilinear scaling is more 
convenient. According to the American Association of Physicists in Medicine (AAPM) 
(Mutic et al., 2003) these relationships are typically scanner dependent.  
Brown et al. derived bilinear functions, using emission sources of different 
radionuclides and trying to perform narrow-beam geometry to find the linear 
attenuation coefficients for several materials (Brown et al., 2008). The International 
Atomic Energy Agency (IAEA) in their book dedicated to Nuclear Medicine teachers 
and students (IAEA, 2014) proposed to generated the attenuation map 𝜇(ℎ) taking 
into account the attenuation coefficients for water and bone as follows (ℎ = 
Hounsfield units): 
 𝜇(ℎ) = 1000 + ℎ1000 𝜇ßAPC-  𝐟𝐨𝐫	𝐡 ≤ 𝟎 
1.50 𝜇(ℎ) = 𝜇ßAPC- + ℎℎghQC (𝜇ghQC − 𝜇ßAPC-) 𝐟𝐨𝐫	𝟎 < 𝐡 < 𝐡𝐛𝐨𝐧𝐞 𝜇(ℎ) = ℎℎghQC 𝜇ghQC 𝐟𝐨𝐫	𝐡 > 𝐡𝐛𝐨𝐧𝐞 
Another approach in similar terms is proposed by McParland (McParland, 
2010), knowing linear attenuation coefficients for a particular energy emission and 
kVp, for particular tissue (bone, water): 
 𝜇PK,C,C@ = 𝜇ßAPC-1000 	 ∙ 𝐶𝑇# 𝐟𝐨𝐫	𝐂𝐓# ≤ 𝟎 
1.51 𝜇PK,C,C@ = 	𝜇äWÓ,ð@ + 𝜇äWÓ,àñi  𝜇ÏhQC,ð@ − 𝜇äWÓ,ð@𝜇ÏhQC,àñi − 𝜇äWÓ,àñi ∙ 𝐶𝑇# 𝐟𝐨𝐫	𝟎 < 𝐂𝐓# < 𝐡𝐛𝐨𝐧𝐞 
5.2.2.5.1. CT calibration curve 
According to the AAPM, this is a curve in which the CT numbers are 
corresponding to the mean linear attenuation coefficients of the material in each 
voxel. These calculations rely on relative physical or electron density, information 
contained in the CT images. For a hybrid SPECT/CT system, the CT part of the 
software has tools to report the mean CT numbers for the region of interest in a CT 
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image. To generate this curve an electron density phantom is used, which normally 
consists of a water-equivalent material with holes, in order to hold interchangeable 
rods made of various tissue and water simulating materials. The sizes of the density 
phantom vary depending on the manufacturer, but normally are available with Head 
and Body inserts, the number of rods varies, also depending company.  
5.2.2.6. Partial volume effect correction  
According to the MIRD Pamphlet 23 this effect starts to appear in small 
structures with dimensions less than 3 x FWHM of the reconstructed image. The 
objects show smaller concentration of activity than they actually do. Nonetheless, it 
can also affect the activity determination at the edge of larger objects because of 
count spill-on and spill-out. The same MIRD Pamphlet mentioned different forms to 
reduce or try to correct for this effect: 
• To determine the ratio of the apparent concentration to true concentration; 
this ratio is called the recovery coefficient factor (RCF). Then applying this 
factor to correct for the partial-volume underestimation of the activity 
concentration in small objects. To estimate the RCF, phantom measurements 
of simple geometric structures are ideal. For instance, using spheres varying 
in size. However, this method depends on several aspects such as, shape of 
the object, its position in the image, and object-to-background contrast.   
• Applying the collimator response correction function in the iterative 
reconstruction model. Nevertheless, this does not produce a full recovery of 
the activity concentration. 
• Using Monte Carlo simulations that generate an accurate characterization of 
the imaging system. 
5.2.2.7. Calibration factor 
This factor is a key aspect that needs to be considered for absolute 
quantification. The calibration factor can be derived from the sensitivity of the 
SPECT/CT system. Normally the sensitivity is given in units of cps/MBq and it is 
obtained by imaging a known activity for a certain period of time.  
According to MIRD Pamphlet 23, the more reliable calibration measurement is 
a SPECT acquisition with a source geometry that better approximates the scatter and 
attenuation properties in patient imaging, such as a tank of uniform activity or hot 
spheres in uniform background activity, thereby reducing the effects of imperfect 
compensation”. Moreover, acquisition, reconstruction and target definition in the 
calibration study should be performed in the same manner as in the patient study.  
Generally, the calibration factor can be obtained from planar and SPECT/CT 
acquisitions. According to Zhao et al. the variation in calibration factor results 
obtained by different experimental geometries (including planar acquisitions) is less 
than 10% in the case of 177Lu (Zhao et al., 2018). Thus, a SPECT/CT calibration 
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factor may be obtained from SPECT/CT acquisitions and planar sensitivity 
verification can be obtained to verify system stability before patient image acquisition. 
5.2.3. Patient planar imaging + patient SPECT/CT imaging (hybrid 
method) 
Planar quantification can be considered as less accurate than SPECT, but 
combining it with SPECT/CT information it can overcome this lack of accuracy. This 
technique implements the whole-body acquisition and the adjustment of the activity 
(or TIA) using one or two SPECT/CT. The SPECT/CT will adjust the planar results. 
The adjustment considers the ratio of the activity measurements from the same 
organ of interest. This technique assumes same biokinetics behaviour between the 
2D and 3D data for the same organ.  
In clinical practice this methodology can be implemented to reduce the time of 
the patient in the nuclear medicine department, because planar whole-body 
acquisitions are less time consuming than SPECT/CT acquisitions.  
5.3. Segmentation  
In order to identify and quantify the information gathered from the images, 
regions of interest must be precisely delineated and separated out for further 
processing. Segmentation is the name of this process (Zaidi, 2006). Then, all 
subsequent interpretation tasks like feature extraction, object recognition, and 
classification depend largely on the quality of the segmentation output. The level to 
which the segmentation is carried out depends on the problem to solve. 
Segmentation should stop when the regions of interest are generated. Thus, one of 
the main challenges of segmentation is to accurately delineate the organ or structure 
and separate it out from the rest of the data sets. 
According to Zaidi (Zaidi, 2006), the segmentation process can be defined as 
follows: 
a) ò𝑅K =ÂKRS 𝐼 
1.52 
b) 𝑅K is the connected region, 𝑖 = 1, 2,… , 𝐶 
c) 𝑅Kô𝑅« = ∅	∀𝑖, 𝑗, 𝑖 ≠ 𝑗 
d) 𝑃	(𝑅K) = true for 𝑖 = 1, 2, … , 𝐶 
e) 𝑃	¤𝑅K ⋃𝑅«¦ = false for 𝑖 ≠ 𝑗 
 
Where P () is a uniform (homogeneity) predicate, C is the number of regions 
“R”. Each region is homogeneous and the union of two non-adjacent regions is 
homogeneous. The conditions defined in 1.55 are explained as follows: 
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a) indicates that the segmentation must be complete, then every pixel must be 
in the region 
b) requires that points in a region must be connected 
c) indicates that the regions must be disjoint 
d) deals with the properties that must be satisfied by the pixels in a segmented 
region 
e) indicates that regions Ri and Rj are different in the sense of predicate P(). 
Removing the constraint that regions must be connected, then the regions are 
called pixel classification and the regions themselves are named classes, this is 
important when disconnected regions belonging to the same tissue class need to be 
identified. Labelling is the process of assigning identification to each region or class 
and can be performed separately from segmentation (Pham et al., 1998). There are 
several segmentation approaches that can be implemented: 
5.3.1. Thresholding 
With this approach a scalar image is generated by binary partitioning of the 
image intensities. The aim of the thresholding is to determine an intensity value in 
order to separate the desired regions. Then by grouping all pixels with intensity 
greater than the threshold, one region is created and the rest of pixels will be 
associated to other regions (Pham et al., 1998).  If only one threshold is used, the 
process is called global thresholding. If there are several thresholds partitioning the 
image in multiple sub-regions, then the process is called local thresholding (Zaidi, 
2006). One limitation of this process is that typically does not consider the spatial 
characteristics of an image, and is sensitive to noise and inhomogeneities.   
5.3.2. Region growing 
The goal is to connect regions of pixels with similar grey values, growing 
uniformly using a seed point that is manually selected by the operator. 
Disadvantages of this approach are related to the manual interaction to obtain the 
seed point, also it can be sensitive to noise (Pham et al., 1998). 
5.3.3. Classifiers 
Classifier methods are pattern recognition that deals with association of 
regions linked to several tissues, thus called labelling (Zaidi, 2006). A feature space 
is the range space of any function of the image that can be related to the image 
intensities themselves or a gradient at a given pixel. This approach is also known as 
supervised methods because requires training data that are manually segmented 
and the used as references for automatically segmenting new data. Standard 
classifiers require that the structures to be segmented possess distinct quantifiable 
features. Disadvantages to this approach is that they generally do not perform any 
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spatial modelling, and also require manual interaction for obtaining training data 
(Pham et al., 1998).  
5.3.4. Clustering 
These algorithms essentially perform the same function as classifiers but 
avoid the training phase, and therefore are known as unsupervised methods. These 
methods iterate between segmenting the image and characterizing the properties of 
each region. However, they do require an initial segmentation. As the classifier 
methods, there are no incorporation of spatial modelling and then are sensitive to 
noise and intensity inhomogeneities (Pham et al., 1998). 
5.3.5. Edge detection 
The edge of a region is characterized by the abrupt change in grey level of 
intensity values when there is an intersection with another region. This approach has 
more advantages with images with good contrast. Since edges are local features, 
they are determined based on local information (Zaidi, 2006).    
5.3.6. Markov random field model 
Thresholding and clustering showed disadvantages regarding noise and 
intensity inhomogeneities, the Markov random field model (MRF) is not a 
segmentation method but a statistical model that considers spatial interactions 
between neighbouring and nearby pixels. Thus, the random nature of the noise and 
any texture in the image are taking into account by the MRF (Zaidi, 2006). This type 
of models can be incorporated into clustering segmentation algorithms; hence the 
segmented region is obtained by maximizing a posteriori probability of the 
segmentation given the image data using iterative methods. The disadvantage of this 
method is linked to the selection of the parameters to control the strength of the 
spatial interactions (Pham et al., 1998). 
5.3.7. Artificial neural networks 
The goal of this method is to emulate some aspects of the human information 
processing and to have the output in real time (Zaidi, 2006). The artificial neural 
networks (ANN) are massively networks of processing elements or nodes simulating 
biological learning. Each node is capable of performing elementary processors. To 
learn the ANN adapts weights assigned to the connections between nodes (Pham et 
al., 1998). The massive connectionist architecture usually makes the system robust 
while the parallel processing enables the system to produce output in real time (Zaidi, 
2006). They are used as classifiers, where the weights are determined using training 
data, also it can be used as unsupervised clustering method as well as deformable 
models. Spatial information can be incorporated into its classification procedures.  
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5.3.8. Deformable models  
These models are curves, surfaces or solids defined with an image, also they 
deform under the influence of internal and external forces. Delineation of an object 
boundary can be generated using a closed curve or surface placed near the desired 
boundary and then allowed to undergo an iterative relaxation process. External 
forces are usually derived from the image to drive the curve towards the desired 
feature of interest. Internal forces are calculated from within the curve to keep it 
smooth throughout the deformation (Zaidi, 2006).  
5.4. Registration  
Registration consist in geometric transformations assessment in order to relate 
two image series, one is a moving dataset and one stationary dataset (Brock et al., 
2017). This process can be associated to the nature of the registration or the nature 
of the transformation. The nature of the registration can be based on extrinsic or 
intrinsic methods. The first ones use foreign objects into the image space, and the 
latest are based on information extracted from the patient (Maintz & Viergever, 
1998). In the case of intrinsic methods, the registration can be based on a limited set 
of identified salient points (landmarks), on the alignment of segmented binary 
structures, or directly on measures computed from the image grey values, called 
voxel-property based (without prior data reduction by the segmentation). Landmarks 
can be points located in the patient anatomy, that can be identified interactively by 
the user, or points that can be associated with a geometric property of the anatomy. 
In principle this registration is versatile because it can be applied to any image, also 
these methods are mostly used to find rigid or affine transformations (Maintz & 
Viergever, 1998). 
Segmentation-based methods, these can be rigid-model based, where 
anatomically the same structures are extracted from both images to be registered 
and used as sole input for the alignment procedure. When the extracted structures 
from one image is elastically deformed to fit the second image, this method can be 
deformable-model based (Maintz & Viergever, 1998). 
Finally, the voxel-property based methods, two approaches can be used: to 
reduce the image grey content to a representative set of scalars and orientation and 
to use the full image content throughout the registration process (Maintz & Viergever, 
1998). Regarding the nature of the transformation, there are four possibilities, rigid, 
affine, projective and curved (elastic). The transformation is called rigid, when only 
translations and rotations are allowed. If the transformation maps parallel lines onto 
parallel lines it is called affined. If it maps lines onto lines, then is called projective. If 
it maps lines onto curves, it is called elastic. 
A composition of more than one transformation can be categorized as a single 
transformation of more complex ones.  Zaidi (Zaidi, 2006) and Maintz (Maintz & 
Viergever, 1998) expressed the transformed coordinates as follows: 
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ú𝑥Ý𝑦Ý𝑧Ý1 û = ú
𝑎SS 𝑎SX 𝑎S ∆𝑥𝑎XS 𝑎XX 𝑎X ∆𝑦𝑎S 𝑎X 𝑎 ∆𝑧0 0 0 1 û ¶
𝑥S𝑦X𝑧1 º 1.53 
Where ∆𝑡 = 	 [∆𝑥, ∆𝑦, ∆𝑧]" is an arbitrary translation vector, aij is the rotation 
matrix defined as follows: 𝑎K« = 𝑎KàS 	𝑎àBX 	𝑎B«  
1.54 
𝑎S = ÿ1 0 00 cos𝜃S − sin 𝜃S0 sin 𝜃S cos𝜃S " 
𝑎X = ÿ cos 𝜃X 0 sin 𝜃X0 1 0−sin 𝜃X 0 cos𝜃X" 
𝑎 = ÿcos𝜃 − sin𝜃 0sin 𝜃 cos 𝜃 00 0 1" 
 
Where 𝑎𝒊 rotates the image around the axis “i” by an angle 𝜃K. 
5.4.1. Rigid  
A rigid or affine 3-D transformation can be described as a single constant 
matrix equation as follows: 𝑥KÝ = 𝑎K«𝑥« 1.55 
 
Where 𝑥«	and 𝑥KÝ are the old and new coordinate vectors respectively. In the 
case of affine transformation, 𝑎K« is unrestricted.  
5.4.2. Elastic 
In the case of elastic transformations these constant matrices cannot be used. 
Generally, in these cases, the transformation is represented in terms of a local vector 
displacement (disparity) field, or as a polynomial transformation in terms of the old 
coordinates. Until this point all different steps associate to the dosimetric workflow 
have been covered. Last step of this chain is the absorbed-dose calculation. 
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5.5. Absorbed-dose calculation approaches 
In reference dosimetry, the absorbed dose can be calculated using S-values 
from a reference model.  
In TRT, the objective is to assess patient-specific dosimetry. Patients are 
different from reference models in terms of total-body weight and size, organs 
masses, etc. Also, depending on the emission that is within the source, the radiation 
transport algorithm implemented for absorbed dose calculation may differ. Therefore, 
considerations regarding the size of the source and targets vs. radiation range are 
key aspects for the selection of absorbed dose calculation algorithms.  
TRT patient data sets are represented in 2D (pixel maps) or 3D (voxel maps) 
images in which the provided information will vary according to the biokinetics of the 
radiopharmaceutical product inside an organ.  
Such a general case, one can considers of homogenous medium with a 
volume V, also for simplicity only g-emissions uniformly distributed in V are taken into 
account. The absorbed dose a given point will depends on its the distance. Figure 
1.28 illustrated the case in these conditions are presented.  
 
 
Figure 1.28:  Illustration to show how to estimate the absorbed dose due to g-emissions at point P 
within a homogeneous, uniformly radioactive object V. Image from (Attix, 2004). 
 
In this case two hypothesis can be made, one, the volume V is surrounded by 
an identical medium, infinite, homogeneous and non-radioactive. Two, volume V is 
surrounding by air (which is not going to be considered). The three points, p, p’ and 
p’’ are points of interests considering volumes dv, dv’ and dv’’. If the volume has a 
mean effective attenuation coefficient µ and considering 𝑒M©- as the fraction of g-
emissions escaping from V in the direction “r” from p, the value of absorbed fraction 
in polar coordinates can be expressed as in (Attix, 2004):  𝜙(𝑝′ ← 𝑝) = 	 14𝜋3 3 (1 − 𝑒M©-)X&'R5&(R5 	𝑠𝑖𝑛𝜃	𝑑𝜃𝑑𝛽 1.56 
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One case, in which photons might not have an influence in the absorbed dose 
result, is when the size of the volume is reduced, for instance, at cellular level. In this 
case the absorbed dose is going to be related to the integration of particle stopping 
powers. Then, the absorbed fraction in this case can be expressed as follows: 
 𝜙(𝑝′ ← 𝑝,𝐸K) = 	3 𝜓iÝ←i(𝑥)Î5 1𝐸K 𝑑𝐸𝑑𝑋	,-(ðO)M· 	𝑑𝑥 1.57 
Where 𝜓iÝ←i(𝑥) is the geometric reduction factor, 𝐸K is the initial energy of the 
ith particle, ¼ð¼-	.-(ðO)M· is the stopping power evaluated at 𝑋(𝐸K) − 𝑥 , 𝑋(𝐸K) is the range 
of a particle of energy 𝐸K , after passing a distance 𝑥 through the medium. The 
geometric factor is the mean probability that a randomly directed vector of length 𝑥 
starting from a random point within 𝑝 ends within 𝑝′. Its value depends on source and 
target geometries (Goddu et al., 1994). 
The calculation of absorbed doses in a patient data set can done using 
different approaches. 
5.5.1. Local energy deposition approach 
This method allows calculating the beta contribution to the 3D dose distribution 
by multiplying the time-integrated activity in the voxel for a unique dosimetric factor. 
Here, all kinetic energy released from b-particles are considered as non-penetrating 
radiation; hence, all energy deposition is within the voxel. The dosimetric factor, for a 
continuous beta spectrum, is calculated as the coefficient of the mean beta energy 
emitted per decay and the voxel mass, as follows (Pacilio et al., 2015):   
 𝑆/ð2 = 𝐸'@CAQ𝑚𝑎𝑠𝑠0h·CB 1.58 
An application of this method was proposed by Pasciak et al. for selective 
internal radiation therapy (SIRT) (Pasciak et al., 2014). Here, the absorbed dose at 
organ-level 𝐷Ag,(𝐺𝑦) can be estimated as follows: 
 𝐷Ag,(𝐺𝑦) = 𝐸Ag,(𝐽)𝑚(𝑘𝑔) = 𝐸h@  𝐽𝑚𝑙𝜌h-AQ z𝑘𝑔𝑚𝑙 1.59 
Where Ecom is the committed total energy released per unit volume, Eabs is the 
energy absorbed, r is the density and “m” is the mass of the segmented volume. 
Then, Ecom can be estimated as follows: 
 𝐸h@ z 𝐽𝑚𝑙 = 𝐴5 z𝐵𝑞𝑚𝑙 ∗ 𝐸A0 ∗ 3 𝑒MNP𝑑𝑡Î5 = 𝐴5𝜆 	∗ 𝐸A0 1.60 
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Where Eavg and l are the average energy release per decay and the decay 
constant for the radionuclide, respectively. 
5.5.2. Dose point kernel (DPK) approach  
According to Bardiès et al. DPK can be defined as the radial distribution of 
absorbed dose around an isotropic point source in an infinite homogeneous 
propagation medium (Bardiès et al., 2003).  The superposition concept is implicit in 
this approach. Any source volume can be broken down into a set of point sources, 
and the determination of dose distribution around point sources allows non-point 
sources to be treated by suitable summation (Bardiès et al., 2003). 
In an analytic way to express the dose point kernel, Giap et al. show for 131I its 
two contributions (Giap et al., 1995), from penetrating and non-penetration emissions 
as follows: 
 𝑘(𝑟) = 	𝑘7(𝑟) +	𝑘'(𝑟) 1.61 
In the case of 𝑘7(𝑟), considering the inverse square, attenuation, and scatter 
build-up effects, the same authors expressed 𝑘7(𝑟)	as shown in equation 1.62: 
 𝑘7(𝑟) = 𝑐*𝑛K𝐸K ²¤𝜇CQ 𝜌¥ ¦ 14𝜋𝑟X 𝑒M©-𝐵CQ(𝜇𝑟)³½8K  1.62 
Where c = 1.60x10-8g cGy MeV-1, 𝑁7 is the total number of photons emitted 
per disintegration, 𝑛K is the number of the ith gamma radiation emitted per 
disintegration, 𝐸K is the mean energy of the ith gamma radiation (MeV), 𝜇CQ is the 
linear photon energy-absorption coefficient (cm-1) at energy 𝐸K, 𝜇is the linear photon 
attenuation coefficient for the same energy, 𝜌 is the density of the medium (g*cm-3), 
and 𝐵CQ is the energy absorption build-up factor at the distance 𝜇𝑟. 
Bardiès (Bardiès & Myers, 1990) expressed the 𝑘'(𝑟), such as “scaled point 
kernel”, as it is presented in equation 1.63: 
 𝑘'(𝑟) = 𝐹(𝑥 𝑟5, 𝐸5⁄ ) = 	4𝜋𝜌𝑥X𝑟5Φ(𝑥, 𝐸5) 1.63 
Where 𝜌 is the density of the medium, r0 is the continuous slowing down 
approximation (CSDA) range at energy E0 and Φ(𝑥, 𝐸5) is the specific absorbed 
fraction. The CSDA is associated to the stopping power for the same energy range. 
Using the DPK expressed in equation 1.61, the absorbed dose can be 
estimated, using the inverse Fourier transform of the convolution result from the TIA 
Fourier transform and the kernel Fourier transform, as follows:  
 𝐷(𝑟", 𝑇2) = 𝐹MS Ñ𝐹 𝐴J(𝑟,, 𝑇2) ∗ 𝐹(𝑘)Ò 1.64 
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A drawback using this approach is related to the homogeneous medium in 
which is used. To overcome this limitation the following approach can be used. 
5.5.3. Dose voxel kernel approach 
The methodology implemented for organ-based dosimetry, can be 
extrapolated to the voxel level, which are contained within the organ, then, explicitly 
non-uniform distribution of activity within target organs can be considered.  From 
MIRD Pamphlet 17, the absorbed dose be applied in a three-dimensional array 
summation to assess the absorbed dose to a given target voxel k from N surrounding 
source voxels h (including absorbed dose contributions from the target voxel itself, 
h=0) (Bolch et al., 1999): 
 𝐷:(𝑣𝑜𝑥𝑒𝑙à) = 	*𝐴J0h·CBd ∙ 𝑆(𝑣𝑜𝑥𝑒𝑙à ← 𝑣𝑜𝑥𝑒𝑙j)½jR5  1.65 
From equation 1.67, the Dose voxel kernel (DVK) can be generated using 
Monte Carlo simulation of voxel geometries; the radionuclide source will be placed at 
the centre of the voxel, and the absorbed dose will be estimated in surrounding 
voxels. The mathematical convolution of pre-calculated DVKs with TIA maps 
provides the absorbed dose distribution of the studied structure. The evaluation of 
equation 1.67 for all target voxels in the VOI can be made by the calculation of 
isodose contours and absorbed dose volume histograms (DVH) within the same 
region. 
In order to perform the mathematical convolution, the DVK sampling must 
match image voxel size, otherwise resampling may be possible as published by 
Dieudonné et al. (Dieudonne et al., 2010) and Fernandez et al. (Fernández et al., 
2013). Hence DVK must be generated for each radionuclide of interest and for any 
possible sampling. This is not an easy task, due to the variety of voxels size available 
for clinical and pre-clinical applications.   
Aside of the work of Bolch in MIRD Pamphlet 17, Lanconelli et al. (Lanconelli 
et al., 2012) and Amato et al. (Amato et al., 2013) have published DVK or voxel S-
value (VSV) for several radionuclides, for different voxel sizes.  
DVK or VSV can be expressed as follows: 
 𝑆(𝑣𝑜𝑥𝑒𝑙à ← 𝑣𝑜𝑥𝑒𝑙j) = 	*∆K ∙ 	𝜙(𝑣𝑜𝑥𝑒𝑙à ← 𝑣𝑜𝑥𝑒𝑙j)𝑚0h·CB<K  1.66 
Where ∆K is the mean energy of the emission particle i per nuclear transition, 𝜙(𝑣𝑜𝑥𝑒𝑙à ← 𝑣𝑜𝑥𝑒𝑙j) is the absorbed fraction to target voxel k per emission of 
radiation particle i from within source voxel h, and 𝑚0h·CB<  is the mass of tissue within 
target voxel k.  
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As was shown by Dieudonné et al. (Dieudonné et al., 2013), the dose voxel 
kernel in a certain group of voxels considering its density variation 𝐷:(𝑣𝑜𝑥𝑒𝑙à,𝜌à) can 
be expressed as in equation 1.67: 
 𝐷:(𝑣𝑜𝑥𝑒𝑙à,𝜌à) = 	𝐷:(𝑣𝑜𝑥𝑒𝑙à) 	× 𝜌𝜌à 1.67 
Where r is the material density implemented in the Monte Carlo simulation of 
the non-corrected kernel. Also taking into account ideas from Schneider et al. 
(Schneider et al., 2000) information from CT images can be incorporated to correct 
for tissue density variation for this approach. 
5.5.4. Monte Carlo Approach  
This method is considered the most accurate to estimate absorbed doses at 
any scale. Monte Carlo simulation considers the explicit radiation transport within 
heterogeneous media using random numbers. The SPECT image will provides the 
radioactivity information and hence its heterogeneity distribution within a VOI. Still, 
the best scenario will provide activity in each voxel, assuming that activity (or TIA) is 
uniform in each voxel. This image represents an emission probability map for the 
definition of voxel sources in the Monte Carlo simulation. CT images contain the 
anatomical information and are going to be associated with density tissue 
characteristics for each voxel. The MC codes have available different physics list to 
consider all physical interactions of all emission within each voxel. For each 
simulated particle its movement and interactions within each voxel are going to be 
recorded and tracked, providing the absorbed dose deposited in each voxel. 
These codes are used for the estimation of S-values in pre-clinical (cellular 
and small animal) or clinical dosimetry, or for patient-specific 3D dosimetry: Fluka 
(Botta et al., 2013), GATE (Mauxion et al., 2013; Sarrut et al., 2014), MINERVA 
(Lehmann et al., 2005), MCNP (Bitar et al., 2007; Boutaleb et al., 2009) can be cited. 
Some of them qualify as treatment planning systems, like the Dose-Planning method 
(Dewaraja et al., 2005), the 3D-RD (Hobbs et al., 2009), Raydose (Marcatili et al., 
2013), and others. Another way to apply MC codes, is to estimate the energy rate 
deposited per voxel per time point and calculate the absorbed dose rate per voxel, by 
dividing it by the voxel mass. Finally, the absorbed dose rate per voxel can be 
integrated and DVH can be created if needed. 
5.5.5. Tabular approach 
Different platforms have databases containing S-values results, for a 
combination of source-target organs, for a different radionuclide, for a specific 
anthropomorphic model. These S values can in turn be calculated using local energy 
deposition, or convolution, or MC approaches. The first software containing such 
information was called MIRDOSE (M G Stabin, 1996), which was developed by the 
Radiation Internal Dose Information Center (RIDIC) at the Oak Ridge National 
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Laboratory in 1980s. Three versions were created, allowing more than 200 
radionuclides and 10 anthropomorphic models in the latest version (McParland, 
2010). The second software developed was OLINDA/EXM, this version included 
more than 800 radionuclides, more anthropomorphic models, for instance the 
pregnant women, spherical tumours and 4 specific organ/tissue models such as the 
prostate gland, the peritoneal cavity, the kidneys and a model of head and brain. This 
version also included a menu to perform curve fitting.  
Nowadays the second version of OLINDA/EXM is distributed by HERMES 
Medical Solutions (https://www.hermesmedical.com/). In principle both versions of 
OLINDA can be used for model (reference) dosimetry. These two software fulfil most 
of the requirements of ICRP to perform reference dosimetry. They can also be used 
for patient-specific dosimetry (adjusted model-based dosimetry) because patient 
organ masses can be introduced to modify reference S values. 
In 2017, the “Internal Dose Assessed by Computer (IDAC-Dose2.1) 
(Andersson et al., 2017) was released to the community, this software fulfil all ICRP 
requirements for reference dosimetry, but only considers the two adult models from 
ICRP 110.  
Another code use in radiation safety is “Activity and internal dose estimates” 
(AIDE) (Bertelli et al., 2008), which incorporates both in vivo biodistribution and in 
vitro assay data. With this software the biokinetic models can be edited. 
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6. Discussion and position of the doctoral project 
The objective of clinical dosimetry is the determination of the absorbed dose 
within the patient, both for tumours and normal (critical) organs/tissues. Several steps 
have to be considered to assess this quantity. The dosimetric workflow described in 
this chapter tries to summarize those steps; each of them has their own background, 
their own theory, and multiple possibilities have been considered in the literature to 
address them in an optimal way.  
The absorbed dose is obtained for radiopharmaceutical that can be used for 
diagnostic or therapeutic purposes. The dosimetric workflow to implement will not be 
the same for these two types of clinical applications. Different studies have to be 
done in order to introduce a diagnostic radiopharmaceutical in clinical practice. These 
studies initially occur at cellular and/or preclinical level. In the case of preclinical 
studies, initial biokinetics is established. Then, extrapolating the results from the 
preclinical level to humans is necessary to estimate the absorbed dose that could be 
delivered to human subjects.  
In this doctoral project three diagnostic radiopharmaceuticals were studied by 
determining the biokinetics for several organs, based on organ harvesting or using 
images, and extrapolating the animal results to the human, before proceeding to an 
absorbed dose calculation using reference dosimetric model data. 
A possible marker of clinical dosimetry spread in nuclear medicine 
departments is the growing availability of dosimetric software. Few years ago, 
academic institutions and/or some hospitals were the only ones having the 
capabilities to perform clinical dosimetry. Unfortunately, the majority of academic 
software is not available to the community, and may suffer from lack of validation and 
continuous support. Nowadays, commercial workstations are becoming increasingly 
available to the Nuclear Medicine departments, allowing the possibility to perform 
dosimetric studies. However, the features and characteristics of these packages 
must be externally reviewed.  
In this doctoral project four commercial solutions were compared using 
phantom experiments and clinical datasets. The way to perform this comparison was 
challenging because even though some commercial solutions proceed similarly in 
some steps of the dosimetric workflow, for other steps their approaches are different. 
For these four workstation similarities and differences are presented.  
The dosimetric chain was first validated by performing phantom experiments 
and using the TIAC as a point of comparison. As a further step in the case of two 
patients treated with 177Lu-DOTATATE, TIAC, organ masses and absorbed doses 
were used as indexes of comparison between the different software. Having these 
results and using references from the literature or other tools from the same 
workstations, absorbed dose comparisons were performed for a subset of 
tissues/organs. Recommendations were derived regarding how to perform the 
evaluation of a dosimetric workstation. 
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1. Introduction  
Regulations for new pharmaceuticals demand biodistribution and biokinetic 
studies in animal, prior evaluation in humans. Same pathway has to be followed by 
new radiopharmaceuticals (McParland, 2010). In that case, it is also required to 
provide an estimation of the irradiation potentially delivered in the human. This is 
obtained by extrapolation of pharmacokinetics data from the animal to the human. 
Hence, animals such as different types of monkeys, mice, rats, dogs or small pigs 
have been subject of investigation. Ideally the choice of the animal is based on a 
previous knowledge regarding the physiology of the animal compared to humans (the 
behavior of the radiopharmaceutical should be reasonably similar in the 2 species). 
However, this is not always the case, due to the financial cost associated to housing 
of the animals with respect to ethics requirements (McParland, 2010).  
Depending on research laboratory facilities, biodistribution and biokinetics 
studies can be obtained from quantitative nuclear medicine (NM) imaging (SPECT, 
PET, or SPECT/CT or PET/CT or PET/MR), or by dissection of the small animal and 
counting of the radioactivity present in animal tissues. Both techniques have their 
own advantages/disadvantages, and require calibration of the equipment used to 
measure activity and different corrections factors.  
For instance, in terms of advantages/disadvantages, in the case of the NM 
images less animals can be used, dynamic and/or many static acquisitions can be 
used to see the biokinetics followed by establishing the biodistribution of the 
radiopharmaceutical. Conversely, animals should be under anesthesia throughout, 
therefore depending on the organ studied, anesthesia could be an issue to consider. 
Other environmental aspects should also be considered such as the bed 
temperature. Also, animal movements can be an issue if the anesthesia does not 
work properly. 
In the case of dissection, anesthesia is not an issue and normally animals are 
housed in special cages where environmental conditions are ideal. However, issues 
with this technique are related to the number of animals used per time point 
measurement (minimum 3) and the dissection technique that only provides for a 
time-point per animal: it is therefore not possible to perform longitudinal studies.            
Three different radiopharmaceuticals were developed at two different research 
centers, at the “Centre Hospitalier Universitaire (CHU) Hôpital Purpan” in Toulouse, 
France and the “Centro Uruguayo de Imagenología Molecular (CUDIM)” in 
Montevideo, Uruguay. The aim of both centers was to assess the biodistribution of 
the products using small animals and then extrapolate the biokinetics results to 
humans. Finally, the “Centre de Recherches en Cancerologie de Toulouse (CRCT)” 
has collaboration agreements with both centers to do the absorbed and effective 
doses assessment. 
At CHU-Hôpital Purpan [18F]FNM (Fluoroethylnormemantine) was developed 
to better understand neurodegenerative diseases (Salabert et al., 2015). They 
explained that this product is derived from memantine, which targets the open 
channel of the NMDA receptor (GluN) (Salabert et al., 2018). These receptors are 
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present in case of neurodegeneration, where neurotoxicity is induced by a massive 
influx of calcium following excessive activation of GluN. The [18F]FNM crosses the 
blood-brain barrier and its distribution within the brain has been found to correlate 
well with the location of GluN. These receptors are also present in Alzheimer’s 
disease; hence, in principle this radiopharmaceutical is a good candidate for human 
use in order to study neurological and psychiatric diseases. This product was 
assessed in rats using PET/CT images (Salabert et al., 2018). 
At CUDIM the first radiopharmaceutical developed was [11C]SAM (S-adenosyl 
Methionine) which is a potential agent that can be used in the diagnosis of 
aggressive prostate cancer. Zoppolo et al. (Zoppolo et al., 2017) explained that the 
overexpression of glycine N-methyltransferase (GNMT EC 2.1.1.20) could be present 
during prostate cancer progression. This enzyme is involved in the methylation 
catalysis of glycine to produce sarcosine using S-adenosyl methionine (SAM or 
AdoMet) as a substrate. As a result, the increased levels of GNMT cause an 
accumulation of sarcosine. It is important to note that this metabolite plays an 
intermediary role in cancer invasion and aggressiveness. The aim of CUDIM was to 
create a new PET tracer to improve sensitivity and specificity for primary prostate 
cancer detection in patients where biochemical failure is crucial. The synthesis of this 
product was studied and reported (Zoppolo et al., 2017).  
The second product successfully synthesized is the [18F]SRF-101 (SR101 N-
(3-[18F]Fluoropropyl) sulphonamide) which is a Sulforhodamine 101 (SR101) 
derivative (Kreimerman et al., 2017). Kreimerman et al. explained that this product 
has been reported as a specific marker of astroglia in the neocortex of rodents in vivo 
(Kreimerman et al., 2018). The astroglia is affected in the early stages of different 
neurologic diseases, and reactive astrocytes contribute to neuroinflammation at later 
stages. The CUDIM was focused on reactive astrocytosis in Alzheimer’s disease. 
Both products derived from CUDIM were assessed in mice using organ harvesting. 
In this chapter, these three radiopharmaceuticals are addressed from the 
dosimetric point of view. In order to do so, biodistribution and biokinetics of the 
products have to be established and extrapolated from animal to human. Then, the 
Organ level internal dose assessment code (OLINDA) V1.0 (Stabin et al., 2005) is 
generally used for estimation of absorbed and effective doses, and can be 
considered as gold standard. Nowadays, OLINDA/EXM V2.0 (Stabin & Farmer, 
2012; Stabin & Siegel, 2018) a new version is commercially available. A new 
software, based-on recent ICPR recommendations, called IDAC 2.1 (Andersson et 
al., 2017) can also be used for same purposes.  
We estimated the absorbed and effective doses using the three software and 
compared the results. We tried to understand the differences between the results 
provided by the different codes, in regards of the reference models and the manner 
in which dosimetric quantities are estimated. Finally, the extrapolated results to 
humans can be compared with data using radiopharmaceutical products in 
voluntaries or patients. Chapter 3 addressed calibration process in a SPECT/CT 
system, this procedure is necessary previous the quantification of activity from 
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patients and/or volunteers. An example of quantification process given dosimetric 
results is presented in chapter 4. 
2. Material and Methods  
2.1. Image data acquisition for [18F]FNM based-on animal 
images and percentage of injected activity estimation 
This study was conducted under protocols approved by French animal Ethics 
Committee (n°2016021711398144). Three Sprague Dawley female rats were 
anesthetized with 55 mg/kg of pentobarbital and a CT scan was performed. 
Intravenous injections of 67.8 ± 10 MBq of [18F]FNM in the tail were performed at the 
beginning of PET acquisition. Acquisition was performed in list mode on PET/CT and 
lasted 70 min. PET list mode data were used to create 16 3D-sinograms such as 
dynamic histograms (3*10 s; 5*30 s; 4*105 s; 2*600 s; 2*1200 s). For reconstruction: 
the image size was 256*300, 6 iterations, 16 subsets were used and also 2 mm 
FWHM Gaussian filter. All dynamic images were automatically corrected for 
radioactive decay during acquisition following manufacturer software settings. 
Following the reconstruction, the CT images were spatially aligned to match the PET 
images. In addition to being reconstructed into a single image, the CT data was used 
for attenuation correction of PET images. 
Processing of reconstructed images was performed with an in-house software 
(Tensaouti et al., 2008). Organs were identified and 3D volumes of interest (VOIs) 
were manually drawn on the CT in the center of each organ. This identification was 
carried out by an expert in animal image segmentation. All VOIs were transferred to 
dynamic PET images and the non-decay corrected mean time activity curves (TACs) 
were extracted for each target organ.  
Eight VOIs were selected: brain, heart, lung, spleen, kidney, stomach, liver 
and whole body. For each rat, an average of three measurements of the same region 
of interest was done in order to obtain the values of activity as a function of time for 
each organ. In the case of the heart and the stomach, we assumed that VOI 
measurements were from the contents. After sacrificing the rats, the mass of the 
organs was obtained. 
A mathematical model was used to fit time-activity data. Measured time points 
were t = 0.17, 0.33, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.75, 6.5, 8.25, 10.0, 20.0, 30.0, 50.0 
and 70.0 min corresponding to the 16 image datasets acquired. The mathematical 
model (Equation 2.1) takes into account the uptake and the clearance phases of the 
radiopharmaceutical for each organ (McParland, 2010).  
 𝑓(𝑡) = 	𝑎 ∗ (𝑒MgP − 𝑒MP) 2.1 
 
Integration of the fitting the model took place in order to estimate the 
cumulated activity, and hence, the residence time. For some organs, the fitting model 
did not match experimental data, especially for heart, lungs and brain. For these 
particular cases, fitting was carried out by segments, using two or three data points 
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(and respectively a first or second-degree polynomial). From the last experimental 
data time point, mono-exponential decay (considering only physical decay) was 
assumed. To consider the contribution from the whole body, a remainder of the body 
was estimated. This means for each rat, all organs were summed and then 
subtracted from the whole body. 
2.2. Percentage of injected activity for [11C]SAM and 
[18F]SFR101 based-on organ harvesting  
The animal experimentation protocol for both radiopharmaceuticals was 
designed in accordance with institutional, national and international guidelines for the 
use of research animals. It was approved by the Ethical Committee of CUDIM (No. 
14012202) in agreement with national regulations: national law on animal 
experimentation No. 18.611, Commission of Ethics for Animal Studies (CEUA) and 
National Commission of Experimentation with Animals (CNEA). 
A solution of [11C]SAM (7.7-36.0 MBq, 100-200 µL) was injected intravenously 
(IV) in male Swiss mice group (15-16 weeks old, 32.9-38.8 g) via the tail vein. Mice 
were sacrificed by cervical dislocation at 10, 30 and 70 min after injection (n=3 in the 
first two time points, and n=2 in the last one). Different organ and tissue samples 
were considered (blood, liver and gallbladder, heart, lungs, spleen, kidneys, muscles, 
bones, stomach, gastrointestinal tract, carcass, bladder+urine) because not all of 
them were “extracted”.  
In the case of [18F]SRF101, male healthy black C57BL6J mice were injected 
IV with 1.5-35.5 MBq (100-250 µL) into the caudal tail vein and were sacrificed by 
cervical dislocation at 14, 33, 65 and 110 min after injection (n=3 in the first three 
time points, and n=2 in the last one). Organs removed were (lung, heart, spleen, 
liver, kidneys, muscle, bone, stomach, intestines, carcass, bladder and brain). Then 
these organs weighed (except stomach, intestines and bladder). Blood was also 
collected. Total urine volume was collected during the bio-distribution period and 
removed from the bladder after sacrifice, and its activity was measured. For the 
heart, we considered that measured activity came from the heart wall. In the case of 
the gastrointestinal tract and urinary bladder, we considered that measured activity 
came from their contents. 
Using a gamma counter (3” x 3” well type NaI(Tl) solid scintillation detector 
coupled to a multichannel analyser ORTEC), the total number of counts per second 
(cps) were measured for each organ for both radiopharmaceuticals. To obtain the 
activity presented in each organ, a calibration factor is needed. This parameter is 
associated to the response of the detector for a known amount of activity. In our 
study this parameter was not available. However, we developed a methodology to 
establish it by knowing the total amount of counts per second (cps) and the total 
activity injected (MBq) to the small animal. This methodology is described as follows: 
• Three different times were recorded: injection time (tinj), sacrifice time (tsac) and 
organ/tissue measuring time (tmes).  
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• A geometric correction factor was applied to obtain the corrected counts per 
second for background and geometry ¤𝑐𝑝𝑠gà,Ch¦PRP>Y..  
• Each organ measurement ¤𝑐𝑝𝑠gà,Ch¦PRP>Y.	was decay corrected between the 
injection and the measured time to compare the injected activity (Ainj) to the sum of 
counts:  
 𝐴KQ« =* ¤𝑐𝑝𝑠gà,Ch¦PRP>Y. ∗ 𝑒N∆Ph-AQ =* ¤𝑐𝑝𝑠gà,Ch¦PRP>Y. ∗ 𝑒N(P>Y.MPOâ?)h-AQ  2.2 
 
• In addition, each organ measurement ¤𝑐𝑝𝑠gà,Ch¦PRP>Y.	was decay corrected 
between the sacrifice and measurement time: 
 𝑐𝑝𝑠,Ah-AQ = ¤𝑐𝑝𝑠gà,Ch¦PRP>Y. ∗ 𝑒N∆P = ¤𝑐𝑝𝑠gà,Ch¦PRP>Y. ∗ 𝑒N(P>Y.MP.Ö@) 2.3 
      
• The percentage of injected activity ¤%𝐴KQ«¦POh-AQ	for each organ/tissue at one 
particular time can therefore be expressed as shown in equation 2.4: 
 ¤%𝐴KQ«¦POh-AQ = ¤𝑐𝑝𝑠gà,Ch¦PRP>Y. ∗ 𝑒N(P>Y.MP.Ö@)∑ ¤𝑐𝑝𝑠gà,Ch¦PRP>Y. ∗ 𝑒N(P>Y.MPOâ?)h-AQ ∗ 100 2.4 
 
• The average percentage of injected activity for each organ ¤%𝐴BQC¦PDh-AQEEEEEEEEEEEEEEEEE	was also 
estimated for each mouse time group.  
• To take into account the contribution from the whole body, a remainder of the body 
was estimated, that means summing all organs and subtracting them to the whole 
body for each rat. 
Physical half-lives of 109.77 min for 18F and 20.39 min for 11C were used 
according to the MIRD Radionuclide Data and Decay Schemes (Eckerman & Endo, 
2008). 
2.3. Residence time calculation 
As previously mentioned, in the case of [18F]FNM bio-kinetics of some organs 
followed the fitting model. Then, integration took place to estimate the residence 
time. For some other organs, as well as in the case of [11C]SAM and [18F]SRF101, 
the procedure in order to estimate the residence times was as follows: an assumption 
of no activity at t=0 min was considered. Normalized non-decay corrected time 
activity curves were generated for each organ.  
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For the three radiopharmaceuticals normalized cumulated activity for humans 
was calculated using mass scaling between mice/rats and humans for the whole 
body and different organs. McParland (McParland, 2010) described the estimation of 
the normalised cumulated activity for humans. Based on this information, the 
normalized cumulated activity for humans can be re-written as shown in equation 2.5: 
 𝐴JÓ-AQ,ä@AQ = z𝑚UQK@AB𝑚ä@AQÃÏ ∗ z𝑚ä@AQ𝑚UQK@ABÓ- ∗ 𝐴JÓ-AQ,UQK@AB  2.5 
 
To perform dosimetric extrapolations for humans, two versions of OLINDA are 
available. OLINDA/EXM V1.0 and OLINDA/EXM V2.0 provide information regarding 
human organ mass and consider different anthropomorphic dosimetric models: 
OLINDA/EXM V1.0 considers the Cristy and Eckerman mathematical models (Cristy 
& Eckerman, 1987) based on ICRP-23 recommendations (ICRP, 1975), whereas 
OLINDA/EXM V2.0 considers voxel-based models (Stabin et al., 2008) based on 
ICRP-89 recommendations.  
The extrapolation of pharmaco-kinetic (PK) results from animal to human 
requires that for each source organ/tissue identified on the animal, an explicit 
counterpart exists in the human model. For example both OLINDA’s versions provide 
information regarding human bladder content mass or human intestine content mass. 
This means that bladder, intestines and their contents can be dealt with as explicit 
sources.  
In addition, current dosimetric codes explicitly separate male and female 
absorbed dose calculation by using reference human male and female models. This 
means that the extrapolation from animal to human (equation 2.5) must be done by 
considering the masses of organs/tissues of the different models, but from a unique 
rodent dataset. 
Due to the bio-distribution of [11C]SAM and [18F]SRF101 radiopharmaceuticals 
in mice, three considerations were made: 
a) For [11C]SAM, it was assumed that no bladder voiding may lead to an 
overestimation of the irradiation delivered by the bladder content. Therefore, 
estimation of residence times was performed, by extrapolating data with and without 
bladder voiding.  The remainder of the body residence time took into account blood, 
muscles, bones and carcass.  
b) For [18F]SRF101 and [11C]SAM the residence time for each section of the 
intestines used in the models was estimated by assigning the residence time 
proportionally to the mass of each section;  
c) In the case of [18F]SRF101, the bladder voiding consideration was not 
addressed. 
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2.4. Absorbed dose estimations 
Residence times obtained after mass scaling are used to calculate the 
absorbed doses using both versions of OLINDA/EXM. Since OLINDA/EXM V2.0 
could be used for reference dosimetry of new radiopharmaceuticals (as it was used 
OLINDA/EXM V1.0 in the past), a decision was taken in order to compare it against 
IDAC 2.1. In order to carry-on this comparison, the residence times obtained after 
mass scaling using human models from OLINDA/EXM V2.0 are entered into IDAC 
2.1 (for the same organ sources). In terms of human models IDAC 2.1 used 
reference from ICRP-110. 
Since we had no specific assessment of male/female pharmacokinetics from 
animal experiments, the gender specific estimate was obtained during the 
extrapolation phase, by scaling differently the same animal pharmacokinetics.  
As previously mentioned, OLINDA/EXM V1.0 and OLINDA/EXM V2.0 provide 
information regarding human organ mass and consider different anthropomorphic 
dosimetric models: OLINDA/EXM V1.0 considers the Cristy and Eckerman 
mathematical models (Cristy & Eckerman, 1987) based on ICRP-23 
recommendations (ICRP, 1975), whereas OLINDA/EXM V2.0 considers voxel-based 
models (Stabin et al., 2008) based on ICRP-89 recommendations. 
For absorbed dose estimation, the S-value is a key factor that is needed. As it 
was defined in chapter 1, S-value is obtained from the estimation of specific 
absorbed fractions (SAF). In the case of OLINDA/EXM V1.0 SAF were estimated 
using ALGAMP Monte Carlo code (Ryman et al., 1987). In the case of OLINDA/EXM 
V2.0 GEANT4 was used and in the case of IDAC 2.1 EGS4 was used. For effective 
dose calculation, OLINDA/EXM V1.0 and OLINDA/EXM V2.0 follow 
recommendations from ICRP-60 (ICRP, 1991) and ICRP-103 (ICRP, 2007), 
respectively. IDAC 2.1 fulfil with ICPR-133 recommendations and also provide results 
considering ICRP-60 recommendations. 
3. Results  
3.1. Residence times and absorbed dose estimations for 
[18F]FNM  
In figure 2.1 the same cross-sectional evolution of [18F]FNM biodistribution 
(LUT is the same for all images) is appreciated. Also, uptake within the retina and 
pituitary Px (schiffer atlas) was also observed for all animals.  
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Figure 2.1: Left: Whole body biodistribution of [18F]FNM after injection of 60 MBq in tail vein. Rigth: 
Arrow shows uptake in pituitary PX. Figure from Salabert et al. (Salabert et al., 2018), with permission 
from authors. 
 
In table 2.1, results for cumulated activity and residence times for the three 
rats can be observed. In average, organs with highest residence times are kidneys, 
liver, lungs and whole body. In the case of Rat 3, measurement of the stomach 
contents was not available and therefore the average result considered 2 animals 
only. 
Table 2.1. Summary of results for cumulative activity and residence times (T) for each rat. 
Organ Rat 1, Ao = 61.63 MBq Rat 2, Ao = 18.00 MBq Rat 3, Ao = 111.00 MBq Average A (Bq.min) T (h) A (Bq.min) T (h) A (Bq.min) T (h) T (h) 
Brain 2.09E+07 5.64E-03 4.01E+06 3.71E-03 6.30E+07 9.46E-03 6.27E-03 
Heart 1.62E+07 4.37E-03 3.50E+06 3.24E-03 4.57E+07 6.87E-03 4.83E-03 
Kidneys 1.67E+08 4.51E-02 4.54E+07 4.20E-02 3.02E+08 4.54E-02 4.42E-02 
Liver 1.68E+08 4.55E-02 6.35E+07 5.88E-02 3.80E+08 5.71E-02 5.38E-02 
Lungs 3.90E+07 1.06E-02 9.71E+06 8.99E-03 1.09E+08 1.64E-02 1.20E-02 
Spleen 1.48E+07 3.99E-03 1.18E+06 1.09E-03 7.38E+07 1.11E-02 5.39E-03 
Stomach 2.25E+07 6.09E-03 8.89E+06 8.23E-03 - - 7.16E-03 
Remainder - 7.05E-01 - 2.81E-01 - 9.42E-01 6.43E-01 
Whole 
body 3.05E+09 8.26E-01 4.40E+08 4.07E-01 7.25E+09 1.09E+00 7.74E-01 
 
In table 2.2, organ masses for male and female dosimetric models and rats 
used for mass scaling can be seen. From this table it can be seen that differences in 
masses between human models and measured rat organs are between two or three 
orders of magnitude. The residence times used in OLINDA/EXM V2.0 after mass 
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scaling are also exhibited. For both human models, the highest residence times are 
brain, kidneys, liver, lungs and spleen. 
In the appendix, a table showing organ masses for different dosimetric 
human’s and animal models can be seen. When OLINDA/EXM V1.0 is used similar 
results are observed.  
 
Table 2.2. Organ masses for male/female dosimetric models and rats used for mass scaling. 
Moreover, residence times T used in OLINDA/EXM V2.0 after mass scaling. 
Organ Mmale (g) Mfemale (g) Mrat (g) Tmale (h) Tfemale (h) 
Brain 1450 1300 1.99 2.07E-02 2.25E-02 
Heart contents 510 370 1.22 9.12E-03 8.05E-03 
Kidney 310 275.5 2.61 2.37E-02 2.56E-02 
Liver 1800 1400 8.20 5.34E-02 5.05E-02 
Lung 1200 950 1.65 3.94E-02 3.80E-02 
Spleen 150 130 0.65 5.62E-03 5.93E-03 
Stomach contents 250 230 1.34 6.04E-03 6.76E-03 
Remainder 67330 55344.5 312.34 6.26E-01 6.26E-01 
Whole body 73000 60000 330 - - 
 
In figure 2.2, looking at the right-up section of the figure, the uptake in the 
remainder is higher than other organs. Liver and kidneys also exhibit higher uptake. 
TACs show a rapid decrease in cardiac uptake, which could be due to a rapid blood 
clearance. Looking at the right-down section of the figure, uptake of different organs 
is observed without the remainder contribution, and the uptake in spleen, stomach, 
brain and lungs was weak. The kidney seems to be the significant clearance 
pathway. Uptake in the lung was very fast and remained high. Uptake in the liver, 
spleen and stomach seem to be more gradual. In the left section of the figure a 
sagittal whole-body PET-CT view of a sprague dawley rat can be seen. 
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Figure 2.2: Left: Sagittal whole-body PET-CT of a sprague dawley rat. Right-up: Percentage of 
injected activity for each organ after an intravenous injection of [18F]FNM, for rat 1 (Ao= 61.63 MBq), 
with the remainder. Right-down: Percentage of injected activity for each organ after an intravenous 
injection of [18F]FNM, for rat 1, without the remainder. Figure from Salabert et al. (Salabert et al., 
2018), with permission from authors. 
 
Table 2.3 shows results for the absorbed dose coefficients (ADC) and the 
contribution to the effective dose factor (CEDF) per organ, for both adult models from 
OLINDA/EXM V2.0. As was expected, kidneys present the highest absorbed dose, 
probably because this organ can be associated with the clearance pathway of the 
radiopharmaceutical. Other organs showing high-absorbed dose for both adult 
models are adrenals, stomach wall, heart wall, liver, lungs and spleen.  
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Table 2.3. Absorbed dose coefficients (ADC) and contribution to the effective dose factor (CEDF) 
results for adult male and female models from OLINDA/EXM V2.0. 
Organ 
Male Female 
ADC 
(mGy/MBq) 
CEDF 
(mSv/MBq) 
ADC 
(mGy/MBq) 
CEDF 
(mSv/MBq) 
Adrenals 6.12E-03 5.65E-05 7.33E-03 6.77E-05 
Brain 4.05E-03 4.05E-05 4.93E-03 4.93E-05 
Breast - - 3.53E-03 4.24E-04 
Esophagus 4.20E-03 1.68E-04 4.83E-03 1.93E-04 
Eyes 2.91E-03 - 3.62E-03 - 
Gallbladder Wall 5.35E-03 4.94E-05 5.78E-03 5.34E-05 
Left colon 4.21E-03 2.04E-04 5.08E-03 2.47E-04 
Small Intestine 4.08E-03 3.77E-05 4.65E-03 4.29E-05 
Stomach Wall 6.51E-03 7.82E-04 7.84E-03 9.41E-04 
Right colon 4.21E-03 2.04E-04 5.01E-03 2.43E-04 
Rectum 3.75E-03 8.63E-05 4.57E-03 1.05E-04 
Heart Wall 6.04E-03 5.57E-05 7.18E-03 6.62E-05 
Kidneys 1.63E-02 1.51E-04 1.97E-02 1.81E-04 
Liver 8.77E-03 3.51E-04 1.06E-02 4.22E-04 
Lungs 7.55E-03 9.06E-04 9.14E-03 1.10E-03 
Ovaries - - 4.66E-03 1.86E-04 
Pancreas 4.73E-03 4.37E-05 5.97E-03 5.51E-05 
Prostate 3.75E-03 1.73E-05 - - 
Salivary Glands 3.37E-03 3.37E-05 3.84E-03 3.84E-05 
Red Marrow 3.36E-03 4.04E-04 4.09E-03 4.90E-04 
Osteogenic Cells 2.96E-03 2.96E-05 3.49E-03 3.49E-05 
Spleen 9.25E-03 8.54E-05 1.15E-02 1.06E-04 
Testes 3.06E-03 1.22E-04 - - 
Thymus 3.90E-03 3.60E-05 4.94E-03 4.56E-05 
Thyroid 3.62E-03 1.45E-04 4.08E-03 1.63E-04 
Urinary Bladder Wall 3.68E-03 1.47E-04 3.78E-03 1.51E-04 
Uterus - - 4.61E-03 2.13E-05 
Total Body 3.52E-03 - 4.46E-03 - 
Total effective dose (mSv/MBq) - 4.16E-03 - 5.43E-03 
 
 
Table 2.4 shows results of ADC and effective dose results, considering ICRP-
60 and ICRP-103, for adult male and female models from IDAC 2.1. In both cases, 
organs exhibiting high-absorbed doses are adrenals, alveolar-interstitial, bronchioles, 
heart wall, kidneys, liver, lungs and spleen. The ADCs results for the female model 
are higher than the male model, which is due the difference in organ masses in each 
model. 
To estimate the effective dose in OLINDA/EXM V2.0, all contributions from the 
organs were added. The results are 4.16x10-3 mSv/MBq and 5.43x10-3 mSv/MBq for 
male and female models, respectively. This would correspond to effective doses of 
1.46 mSv (male) and 1.90 mSv (female) for a realistic administrated activity of 350 
MBq.   
On the other hand, for IDAC 2.1, effective doses are almost the same for both 
models, 5.03x10-3 mSv/MBq and 5.02 x10-3 mSv/MBq for male and female model, 
respectively. This would correspond to effective doses of 1.76 mSv for both models, 
for the same administrative activity. In the case of ICRP-60 recommendations the 
effective dose for male model is 4.63x10-3 mSv/MBq and for the female model is 
5.63x10-3 mSv/MBq. 
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Table 2.4. Absorbed dose coefficients (ADC) for adult male and female models from IDAC 2.1. 
Target organ 
From male bio-kinetics From female bio-kinetics 
ADC male 
(mGy/MBq) 
ADC female 
(mGy/MBq) 
ADC male 
(mGy/MBq) 
ADC female 
(mGy/MBq) 
Adipose/residual tissue 3.21E-03 3.68E-03 3.21E-03 3.68E-03 
Adrenals 6.00E-03 6.92E-03 6.09E-03 6.94E-03 
Alveolar-interstitial 8.63E-03 1.05E-02 8.40E-03 1.02E-02 
Brain 3.88E-03 4.31E-03 4.15E-03 4.61E-03 
Breast 3.13E-03 3.92E-03 3.11E-03 3.89E-03 
Bronchi bound 5.15E-03 6.40E-03 5.05E-03 6.26E-03 
Bronchi sequestered 5.14E-03 6.39E-03 5.04E-03 6.24E-03 
Bronchioles 8.69E-03 1.05E-02 8.45E-03 1.02E-02 
Colon Wall 3.42E-03 3.83E-03 3.43E-03 3.84E-03 
Endosteum  
(bone surface) 3.53E-03 4.07E-03 3.54E-03 4.08E-03 
ET región 2.26E-03 2.78E-03 2.29E-03 2.81E-03 
ET1 basal cells 1.46E-03 2.08E-03 1.47E-03 2.09E-03 
ET2 basal cells 2.26E-03 2.78E-03 2.29E-03 2.81E-03 
Eye lenses 2.26E-03 2.67E-03 2.29E-03 2.69E-03 
Gallbladder wall 5.65E-03 6.92E-03 5.53E-03 6.83E-03 
Heart Wall 6.84E-03 8.54E-03 6.36E-03 7.91E-03 
Kidneys 1.27E-02 1.50E-02 1.35E-02 1.59E-02 
Left colon wall 3.37E-03 3.73E-03 3.39E-03 3.74E-03 
Liver 7.22E-03 8.86E-03 6.95E-03 8.53E-03 
Lung 7.49E-03 9.16E-03 7.30E-03 8.91E-03 
Lymphatic nodes 3.90E-03 4.67E-03 3.89E-03 4.66E-03 
Lymph nodes in ET region 3.34E-03 4.21E-03 3.34E-03 4.21E-03 
Lymph nodes in sys 3.91E-03 4.66E-03 3.90E-03 4.65E-03 
Lymph nodes in thoracic 
region 4.38E-03 5.24E-03 4.31E-03 5.16E-03 
Muscle 3.22E-03 3.94E-03 3.22E-03 3.94E-03 
Oesophagus 4.26E-03 4.98E-03 4.19E-03 4.90E-03 
Oral mucosa 3.08E-03 3.61E-03 3.09E-03 3.62E-03 
Ovaries - 4.51E-03 - 4.51E-03 
Pancreas 4.78E-03 5.70E-03 4.77E-03 5.74E-03 
Pituitary gland 3.51E-03 4.16E-03 3.63E-03 4.28E-03 
Prostate 3.71E-03 - 3.71E-03 - 
Recto-sigmoid colon wall 3.15E-03 3.87E-03 3.15E-03 3.87E-03 
Red (active) bone marrow 4.06E-03 4.68E-03 4.05E-03 4.66E-03 
Right colon wall 3.61E-03 3.91E-03 3.60E-03 3.92E-03 
Salivary glands 2.89E-03 3.59E-03 2.90E-03 3.60E-03 
Skin 2.45E-03 2.92E-03 2.45E-03 2.91E-03 
Small intestine wall 3.39E-03 4.10E-03 3.40E-03 4.12E-03 
Spleen 7.11E-03 8.51E-03 7.37E-03 8.83E-03 
Stomach wall 5.73E-03 6.59E-03 5.92E-03 6.80E-03 
Testes 3.11E-03 - 3.11E-03 - 
Thymus 3.86E-03 4.74E-03 3.81E-03 4.68E-03 
Thyroid 3.33E-03 3.94E-03 3.31E-03 3.92E-03 
Tongue 2.28E-03 2.49E-03 2.29E-03 2.50E-03 
Tonsils 3.33E-03 3.73E-03 3.37E-03 3.76E-03 
Ureters 4.19E-03 5.01E-03 4.21E-03 5.03E-03 
Urinary bladder wall 3.46E-03 3.81E-03 3.46E-03 3.81E-03 
Uterus/cervix - 4.37E-03 - 4.37E-03 
Effective dose 60 
[mSv/MBq] 4.63E-03 5.63E-03 4.64E-03 5.63E-03 
Effective dose 103 
[mSv/MBq] 4.58E-03 - - 5.07E-03 
 
 
In table 2.5 a summary of the effective dose factor results can be seen for 
[18F]FNM, considering the three software. For both models, results are in the same 
order of magnitude. In the case of female model, the effective dose factors are higher 
than the male model. For the female model, results from both versions of OLINDA 
are comparable to the results obtained using ICRP-60 (IDAC 2.1), but are higher 
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comparing with ICRP-103 (IDAC 2.1). For male model, results from OLINDA/EXM 
V1.0 and ICRP-60 (IDAC 2.1) are almost the same and higher than OLINDA/EXM 
V2.0, and the values from ICRP-103 (IDAC 2.1) are similar to the others. 
 
Table 2.5. Summary of effective dose factor results (mSv/MBq) for [18F]FNM. 
OLINDA/EXM V1.0 OLINDA/EXM V2.0 
IDAC 2.1 
ICRP-60 
 ICRP-103 
Male Female Male Female Male Female Reference person 
4.65E-03 5.73E-03 4.16E-03 5.43E-03 4.63E-03 5.63E-03 4.83E-03 
 
3.2. Residence times and absorbed dose estimations for 
[11C]SAM 
The variations of the average of percentages of injected activity for all organs 
for each mice time group are shown in Figure 2.3.A. The difference between the 
organs with the highest average percentage of injected activity was approximately 
12.44% at t=10 min (bladder+urine and carcass). The excretion of radioactive 
material was observed in the bladder+urine compartment. Depending on the transit 
of this radioactive material through the kidneys compartment, high-absorbed doses 
may be expected. 
The average percentage of injected activity without the contribution of the 
bladder+urine is provided in Figure 2.3.B. From this figure at t=10 min kidneys are 
the organs with highest activity, which is in agreement with previous studies on rats 
(Ishiwata et al., 1986; Tolvanen et al., 2010). In another article, Ishiwata et al. 
described a high uptake in the kidneys and a rapid blood clearance for the same 
tracer in mice and rats bearing tumour cells (Ishiwata et al., 1988). Other organs with 
high activity uptakes were the liver-gallbladder, blood and intestines. The variations 
of the average percentages of injected activity in the bladder+urine compartment with 
and without bladder voiding are provided in Figure 2.3.C.  
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Figure 2.3: Average percentage of administrated activity per organ for [11C]SAM per mice time group. 
A: All measured organs; B: all organs except bladder+urine and carcass; C: bladder+urine 
compartment with and without bladder voiding.  Figure adapted from (Zoppolo et al., 2018), with 
permission from authors. 
 
 
 
 
 
 
 
A 
B 
C 
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The residence time in hours for mice organs is shown in Table 2.6, 
bladder+urine, kidneys and carcass had high values. The highest value was 
observed for the remainder when the bladder+urine without bladder voiding was 
considered. The difference between bladder+urine residence time with and without 
bladder voiding is about 2.5 times. 
 
Table 2.6. Residence times (T) for each mice organ using [11C]SAM. 
Organ Residence time (h) 
Blood 7.14E-03 
Liver-Gallbladder 8.53E-03 
Heart wall 4.22E-04 
Lungs 1.40E-03 
Spleen 3.43E-04 
Kidneys 3.03E-02 
Muscle 1.27E-03 
Bones 4.20E-04 
Stomach contents 1.24E-03 
Intestines contents 7.65E-03 
Carcass 9.06E-02 
Bladder contents without bladder 
voiding 2.36E-01 
Bladder contents with bladder 
voiding 9.49E-02 
Remainder  9.94E-02[a] 
[a] Remainder is the sum of blood, muscles, bones and carcass. 
 
 
Mass values for the male dosimetric model from OLINDA/EXM V2.0 are 
shown in Table 2.7, along with the S-factors for different organs, considering only 
self-irradiation. The difference in mass between human model and measured mice 
organs is between two to four orders of magnitude. This table also shows the 
residence times for the human model. These figures were used in OLINDA/EXM 
V2.0 to estimate the absorbed and effective dose. The highest residence time values 
for the male dosimetric model were for the remainder, bladder+urine and kidneys. 
The difference between bladder+urine residence time with and without bladder 
voiding is about 2.5 times. 
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Table 2.7. Organ mass values, for male model and mouse, used for mass scaling. Residence 
times used in OLINDA/EXM V2.0. 
 
Organ Mmale (g) S-factor
[a] 
(mGy/MBq.s) Mmouse (g) Tmale(h) 
Heart Wall 330 2.11E-4 0.1400 ± 0.010 5.03E-04 
Kidneys 310 2.36E-4 0.4746 ± 0.047 1.00E-02 
Liver+Gallbladder 1858 --- 1.8355 ± 0.203 4.36E-03 
Liver 1800 4.91E-5 --- 4.22E-03 
Gallbladder contents 58 6.65E-4[b] --- 1.36E-04 
Lungs 1200 5.72E-5 0.2018 ± 0.012 4.20E-03 
Spleen 150 4.77E-4 0.1109 ± 0.015 2.34E-04 
Stomach contents 250 1.62E-4[b] 0.1000[c] 1.57E-03 
Intestines contents 650 --- 3.3000[c] 7.61E-04 
Left colon contents (LLI) 75 4.49E-4[b] --- 8.78E-4 
Small intestine contents 
(SI) 350 1.05E-4
[b] --- 4.10E-4 
Right colon contents (ULI)  150 2.46E-4[b]  1.76E-4 
Rectum contents 75 4.65E-4[b] --- 8.78E-4 
Bladder contents without 
Bladder Voiding 211 1.91E-4
[b] 0.1000[c] 2.52E-01 
Bladder contents with 
Bladder Voiding 211 1.91E-4
[b] 0.1000[c] 1.01E-01 
Remainder 68031 --- 30.7023 1.11E-01[d] 
Whole Body 73000 1.65E-6 36.8650 ± 2.010 ----- 
Whole body mass for mice group at 10 min (g) 37.3633 ± 1.906 
Whole body mass for mice group at 30 min (g) 37.0567 ± 1.285 
Whole body mass for mice group at 70 min (g) 35.8300 ± 4.158 
[a] S-factor refers to self-irradiation; [b] S-factor for gallbladder wall, stomach wall, LLI 
wall, SI wall, ULI wall, rectum wall and urinary bladder wall, considering their contents 
as a source; [c] Mouse stomach, intestines and bladder contents masses taken from 
OLINDA/EXM V2.0; [d] Remainder considers blood, muscles, bones and carcass. 
 
 
Table 2.8 shows the results for absorbed and effective dose estimations with 
and without bladder voiding using OLINDA/EXM V2.0. The total absorbed dose 
varies between 1.6 to 2.5 times for organs close to the bladder content (small 
intestine, rectum, prostate and testes), indicating the importance of taking bladder 
voiding into account. In addition, it is important to note the difference in the total 
absorbed dose to the urinary bladder wall, which is about 2.48 times. For organs far 
from the bladder contents compartment, the values of the total absorbed dose were 
in the same order of magnitude. Regarding the mean effective dose, its ratio was 
about 2.1 times for the same situations.  
From OLINDA/EXM V2.0, for kidneys, when bladder voiding is considered, the 
ADC is 9.00x10-3 mGy/MBq, and without considering bladder voiding, this coefficient 
is 9.21x10-3 mGy/MBq.  
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Table 2.8. Absorbed dose coefficients (ADC) and contribution to effective dose factor 
(CEDF) results for adult male model from OLINDA/EXM V2.0, with and without bladder 
voiding consideration. 
  Without Bladder voiding With Bladder voiding 
Target Organ ADC (mGy/MBq) 
CEDF 
(mSv/MBq) 
ADC 
(mGy/MBq) 
CEDF 
(mSv/MBq) 
Adrenals 1.85E-03 1.71E-05 1.70E-03 1.57E-05 
Brain 6.27E-04 6.27E-06 6.27E-04 6.27E-06 
Esophagus 8.61E-04 3.44E-05 8.26E-04 3.30E-05 
Eyes 6.37E-04 - 6.30E-04 - 
Gallbladder Wall 1.46E-03 1.35E-05 1.32E-03 1.22E-05 
Left Colon 2.93E-03 1.42E-04 2.57E-03 1.24E-04 
Small Intestine 2.60E-03 2.40E-05 1.65E-03 1.53E-05 
Stomach Wall 1.81E-03 2.17E-04 1.75E-03 2.10E-04 
Right Colon 1.69E-03 8.17E-05 1.27E-03 6.17E-05 
Rectum 8.03E-03 1.85E-04 4.57E-03 1.05E-04 
Heart Wall 8.93E-04 8.24E-06 8.61E-04 7.95E-06 
Kidneys 9.21E-03 8.50E-05 9.00E-03 8.31E-05 
Liver 1.25E-03 4.99E-05 1.17E-03 4.67E-05 
Lungs 1.23E-03 1.48E-04 1.21E-03 1.45E-04 
Pancreas 1.17E-03 1.08E-05 1.06E-03 9.81E-06 
Prostate 9.32E-03 4.30E-05 4.23E-03 1.96E-05 
Salivary Glands 7.08E-04 7.08E-06 7.07E-04 7.07E-06 
Red Marrow 1.68E-03 2.01E-04 1.08E-03 1.30E-04 
Osteogenic Cells 1.09E-03 1.09E-05 7.77E-04 7.77E-06 
Spleen 1.12E-03 1.03E-05 1.05E-03 9.66E-06 
Testes 2.66E-03 1.06E-04 1.47E-03 5.88E-05 
Thymus 7.75E-04 7.15E-06 7.62E-04 7.03E-06 
Thyroid 7.49E-04 3.00E-05 7.41E-04 2.96E-05 
Urinary 
BladderWall 
1.74E-01 6.96E-03 7.02E-02 2.81E-03 
Total Body 2.22E-03 - 1.36E-03 - 
Total Effective 
Dose (mSv/MBq) 
- 8.40E-03 - 3.96E-03 
 
 
Table 2.9 shows similar results as in table 2.8, but using IDAC 2.1. For small 
intestine, rectum, prostate, testes, ureters and urinary bladder wall similar differences 
for ADCs can be seen for OLINDA/EXM V2.  
According to ICRP-103 the mean effective dose must be estimated for male 
and female reference models, but this radiopharmaceutical will be used for male 
patients. Consequently, another quantity should be used instead of effective dose, in 
the case of radiopharmaceuticals used only for male or female patients. Taking into 
account this idea, in a publication from Giussani et al. (Giussani et al., 2012), a 
quantity called “risk-weighted absorbed dose coefficient” was reported, using 
information from ICRP-60. Following this idea and applying ICRP-103 
recommendations, in table 2.8, a contribution to the effective dose factor is calculated 
to find the “risk-weighted effective dose coefficient” (RWEDC) with and without 
bladder voiding, which is almost a factor of two for these situations.   
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Table 2.9. Absorbed dose coefficients (ADC) for adult male model using IDAC 2.1. Risk-
weighted effective dose coefficient (RWEDC) using information from ICRP-103. 
Target organ 
Without Bladder voiding With Bladder voiding 
ADC 
(mGy/MBq) 
RWEDC 
(mSv/MBq) 
ADC 
(mGy/MBq) 
RWEDC 
(mSv/MBq) 
Adipose/residual tissue 1.72E-03 - 1.12E-03 - 
Adrenals 1.73E-03 - 1.65E-03 - 
Alveolar-interstitial 1.44E-03 - 1.43E-03 - 
Brain 6.42E-04 6.42E-06 6.41E-04 6.41E-06 
Breast 6.70E-04 8.04E-05 6.53E-04 7.84E-05 
Bronchi bound 9.58E-04 - 9.41E-04 - 
Bronchi sequestered 9.56E-04 - 9.39E-04 - 
Bronchioles 1.46E-03 - 1.44E-03 - 
Colon Wall 3.04E-03 3.65E-04 1.73E-03 2.08E-04 
Endosteum 
(bone surface) 1.61E-03 1.61E-05 1.11E-03 1.11E-05 
ET región 4.25E-04 - 4.23E-04 - 
ET1 basal cells 2.85E-04 - 2.84E-04 - 
ET2 basal cells 4.25E-04 - 4.24E-04 - 
Eye lenses 4.66E-04 - 4.66E-04 - 
Gallbladder wall 1.25E-03 - 1.14E-03 - 
Heart Wall 8.46E-04 - 8.21E-04 - 
Kidneys 6.79E-03 - 6.65E-03 - 
Left colon wall 1.21E-03 - 1.02E-03 - 
Liver 1.09E-03 4.36E-05 1.03E-03 4.12E-05 
Lung 1.29E-03 1.55E-04 1.27E-03 1.52E-04 
Lymphatic nodes 2.96E-03 - 1.68E-03 - 
Lymph nodes in ET region 7.20E-04 - 7.18E-04 - 
Lymph nodes in sys 3.38E-03 - 1.85E-03 - 
Lymph nodes in thoracic 
Region 8.27E-04 - 8.17E-04 - 
Muscle 1.43E-03 - 9.96E-04 - 
Oesophagus 7.79E-04 3.12E-05 7.61E-04 3.04E-05 
Oral mucosa 6.60E-04 - 6.58E-04 - 
Ovaries - - - - 
Pancreas 1.23E-03 - 1.09E-03 - 
Pituitary gland 6.71E-04 - 6.71E-04 - 
Prostate 1.76E-02 - 7.52E-03 - 
Recto-sigmoid colon wall 1.00E-02 - 4.57E-03 - 
Red (active) bone marrow 2.33E-03 2.80E-04 1.45E-03 1.74E-04 
Right colon wall 1.38E-03 - 1.02E-03 - 
Salivary glands 6.28E-04 6.28E-06 6.27E-04 6.27E-06 
Skin 8.15E-04 8.15E-06 6.48E-04 6.48E-06 
Small intestine wall 3.69E-03 - 1.95E-03 - 
Spleen 9.13E-04 - 8.64E-04 - 
Stomach wall 1.70E-03 2.04E-04 1.63E-03 1.96E-04 
Testes 1.73E-03 1.38E-04 1.10E-03 8.80E-05 
Thymus 7.58E-04 - 7.50E-04 - 
Thyroid 6.83E-04 2.73E-05 6.78E-04 2.71E-05 
Tongue 4.52E-04 - 4.50E-04 - 
Tonsils 6.92E-04 - 6.91E-04 - 
Ureters 5.28E-03 - 2.70E-03 - 
Urinary bladder wall 5.83E-02 2.33E-03 2.38E-02 9.52E-04 
Uterus/cervix - - - - 
Remainder 3.10E-03 3.72E-04 2.01E-03 2.42E-04 
Effective dose 60 [mSv/MBq] 4.52E-03 - 2.36E-03 - 
Risk-weighted effective dose 
103 [mSv/MBq] - 4.06E-3 - 2.22E-03 
 
The mean effective doses using OLINDA/EXM V2.0 are 8.40x10-3 mSv/MBq 
and 3.96x10-3 mSv/MBq without and with the bladder voiding, respectively. According 
to CUDIM protocols, the injected activity of this product will be between 4-6 MBq/kg, 
which is between 292–438 MBq for a 73 kg patient. Without bladder voiding, the 
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mean effective dose range is between 2.45–3.68 mSv, and with bladder voiding, the 
effective dose ranged from 1.16–1.73 mSv.  
Using information from IDAC 2.1, the risk-weighted effective dose would be 
4.06 x10-3 mSv/MBq and 2.22 x10-3 mSv/MBq without and with the bladder voiding 
consideration, respectively. Without bladder voiding, the mean effective dose range 
is between 1.19–1.78 mSv, and with bladder voiding, the effective dose ranged from 
0.65–0.97 mSv, for the same injected activities. Considering ICRP-60 
recommendations, the effective dose would be 4.52 x10-3 mSv/MBq and 2.36 x10-3 
mSv/MBq without and with the bladder voiding consideration, respectively. This 
would correspond to mean effective doses ranging from 1.32-1.98 mSv and 0.69-
1.03 mSv without and with the bladder voiding consideration, respectively. 
In table 2.10 effective dose factor results can be seen, with and without 
bladder voiding consideration. Without bladder voiding consideration, both OLINDAs 
version results are higher than those values obtained with IDAC 2.1. In the case of 
OLINDA/EXM V2.0 the result can be twice of the values from IDAC 2.1. The same 
effect occurs with bladder voiding consideration. 
 
Table 2.10. Summary of effective dose factor results (mSv/MBq) for [11C]SAM, in the case of male 
model with and without bladder voiding considerations. 
OLINDA/EXM V1.0 OLINDA/EXM V2.0 IDAC 2.1(RWEDC) ICRP-60 ICRP-103 
With Without With Without With Without With Without 
3.32E-03 6.82E-03 3.96E-03 8.40E-03 2.36E-03 4.52E-03 2.22E-03 4.06E-03 
 
 
In table 2.11 the percentage of relative difference (PRD) for the absorbed dose 
coefficients (ADC) between IDAC 2.1 (used as reference) and OLINDA/EXM V2.0. 
The first difference to highlight between the two software is the amount of target 
organs used, IDAC 2.1 complies with ICRP recommendations in those terms. 
Second for left colon wall differences are higher than 140% and urinary bladder wall 
more than 190%. Other organs exhibit differences higher than ± 20% are: 
endosteum, eye lens, kidneys, prostate, red bone marrow, right colon, small 
intestine, spleen and testes.     
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Table 2.11. Percentage of relative difference (PRD) for the absorbed dose coefficients 
(ADC) between IDAC 2.1 (used as reference) and OLINDA/EXM V2.0 for [11C]SAM. 
Target organ PRD with bladder voiding 
PRD without bladder 
voiding 
Adipose/residual tissue --- --- 
Adrenals 3,03 6,94 
Alveolar-interstitial --- --- 
Brain -2,18 -2,34 
Breast --- --- 
Bronchi bound --- --- 
Bronchi sequestered --- --- 
Bronchioles --- --- 
Colon wall --- --- 
Endosteum (bone surface) -30,00 -32,30 
ET region --- --- 
ET1 basal cells --- --- 
ET2 basal cells --- --- 
Eye lenses 35,19 36,70 
Gallbladder wall 15,79 16,80 
Heart wall 4,87 5,56 
Kidneys 35,34 35,64 
Left colon wall 151,96 142,15 
Liver 13,59 14,68 
Lung -4,72 -4,65 
Lymphatic nodes --- --- 
Lymph nodes in ET region --- --- 
Lymph nodes in sys --- --- 
Lymph nodes in thoracic region --- --- 
Muscle --- --- 
Oesophagus 8,54 10,53 
Oral mucosa --- --- 
Ovaries --- --- 
Pancreas -2,75 -4,88 
Pituitary gland --- --- 
Prostate -43,75 -47,05 
Recto-sigmoid colon wall 0,00 -19,70 
Red (active) bone marrow -25,52 -27,90 
Right colon wall 24,51 22,46 
Salivary glands 12,76 12,74 
Skin --- --- 
Small intestine wall -15,38 -29,54 
Spleen 21,53 22,67 
Stomach wall 7,36 6,47 
Testes 33,64 53,76 
Thymus 1,60 2,24 
Thyroid 9,29 9,66 
Tongue --- --- 
Tonsils --- --- 
Ureters --- --- 
Urinary bladder wall 194,96 198,46 
Uterus/cervix --- --- 
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3.3. Residence times and absorbed dose estimations for 
[18F]SFR101 
Figure 2.4.A. shows the variations in the averages of percentages of injected 
activity per mice group for all organs. High uptake can be observed in the intestines 
and liver, demonstrating the clearance pathway of this radiopharmaceutical. The 
uptake for the other organs is little, as it can be observed in figure 2.4.B. 
The residence times for each mice organ and the mass values considered for 
mass scaling are described in Table 2.12. As it is expected, the highest residence 
time is for the intestines. The remainder, liver, kidneys, carcass and stomach showed 
high values as well.  
 
 
 
 
Figure 2.4: Percentage of administrated activity per mice time group for [18F]SFR101. A: all measured 
organs. B: all organs except intestines. Figure adapted from (Kreimerman et al., 2018), also with 
permission from authors. 
 
 
 
 
 
 
 
 
A 
B 
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Table 2.12. Residence times (T) for each organ for [18F]SFR101 in mice. Average measure of 
the mice organ masses used for the mass scaling process for some organs. Mass average and 
standard deviation for each mice group. 
Organ Residence time (h) Organ mass (g) 
Blood 3.11E-03 --- 
Brain 1.37E-04 0.4090 ± 0.0731 
Liver 1.16E-01 1.8596 ± 0.2463 
Heart wall 9.52E-05 0.1646 ± 0.0286 
Lungs 9.75E-04 0.2193 ± 0.0319 
Spleen 5.48E-05 0.0963 ± 0.0285 
Kidneys 1.29E-02 0.4204 ± 0.0425 
Muscles 2.63E-04 --- 
Bones 2.18E-04 --- 
Stomach contents 1.77E-02 0.1000[a] 
Intestines 1.69E+00 3.3000[a] 
Bladder contents 7.65E-03 0.1000[a] 
Carcass 3.11E-02 --- 
Remainder  3.47E-02 28.2063[b] 
Whole body mass --- 34.8755 ± 3.4749 
Whole body mass for mice group 14 min (g) 32.02 ± 3.47 
Whole body mass for mice group 33 min (g) 37.52 ± 3.13 
Whole body mass for mice group 65 min (g) 33.67 ± 2.34 
Whole body mass for mice group 110 min (g) 37.00 ± 2.69 
[a] Mice intestines, stomach and bladder contents masses taken from OLINDA/EXM V2.0; 
[b] Remainder takes into account the blood, muscles, bones and carcass.  
 
 
The mass values used for the male and female dosimetric models of 
OLINDA/EXM V2.0 and the self-irradiation S-factor for each organ are included in 
Table 2.13. As was observed in the previous cases, the differences in mass between 
human dosimetric models and measured mice organs are between two or four orders 
of magnitude. 
 
Table 2.13. Mass values used for mass scaling and self-irradiation S-factor for each organ, 
taken from male/female models available in OLINDA/EXM V2.0. 
Organ mmale (g) S-factor 
[a] 
(mGy/MBq-s) mfemale (g) 
S-factor [a] 
(mGy/MBq-s) 
Brain 1450 4.44E-05 1300 4.89E-05 
Heart wall 330 1.42E-04 250 1.86E-04 
Kidneys 310 1.64E-04 275.5 1.82E-04 
Intestines contents 650[c] --- 600[c] --- 
Left colon contents (LLI) 75 2.95E-04[b] 80 2.77E-04[b] 
Small intestine contents (SI) 350 7.17E-05[b] 280 8.71E-05[b] 
Right colon contents (ULI) 150 1.68E-04[b] 160 1.57E-04[b] 
Rectum contents 75 3.10E-04[b] 80 3.00E-04[b] 
Liver 1800 3.62E-05 1400 4.53E-05 
Lungs 1200 3.90E-05 950 4.80E-05 
Spleen 150 3.29E-04 130 3.76E-04 
Stomach contents 250[c] 1.15E-04[b] 230[c] 1.26E-04[b] 
Bladder contents 211[c] 1.35E-04[b] 160[c] 1.56E-04[b] 
Remainder 66649 1.29E-06 54704.5 1.57E-06 
Whole body 73000 --- 60000 --- 
[a] S-factor refers to self-irradiation; [b] S-factor for LLI wall, SI wall, ULI wall, rectum wall, 
stomach wall and urinary bladder wall, considering their contents as a source; [c] 
Intestines, stomach and urinary bladder contents masses taken from OLINDA/EXM V2.0;  
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Human residence times used in OLINDA/EXM V2.0 after mass scaling are 
shown in Table 2.14. The highest values are for the remainder, intestines and 
stomach contents and liver, for both dosimetric models. 
 
Table 2.14. Residence times (T) used for dosimetric estimations in OLINDA/EXM V2.0. 
Organ Tmale(h) Tfemale(h) 
Brain 2.31E-04 2.52E-04 
Heart wall 9.12E-05 8.41E-05 
Kidneys 4.56E-03 4.93E-03 
Intestines contents 1.59E-01 1.79E-01 
Left colon contents (LLI) 1.84E-02 2.39E-02 
Small intestine contents (SI) 8.56E-02 8.35E-02 
Right colon contents (ULI) 3.67E-02 4.77E-02 
Rectum contents 1.84E-02 2.39E-02 
Liver 5.37E-02 5.08E-02 
Lungs 2.55E-03 2.46E-03 
Spleen 4.07E-05 4.30E-05 
Stomach contents 2.11E-02 2.36E-02 
Bladder contents 7.72E-03 7.12E-03 
Remainder  3.91E-02[a] 3.91E-02[a] 
[a] Remainder considers the blood, muscles, bones and carcass. 
 
The absorbed and effective doses estimated by OLINDA/EXM V2.0 are shown 
in table 2.15. The highest ADCs values are for the different sections of the wall 
intestines (left colon, small intestine, right colon and rectum). For the male dosimetric 
model, other organs exhibiting a high ADCs, for instance, gallbladder wall, kidneys, 
liver, pancreas and urinary bladder wall. For the female dosimetric model, the uterus 
also exhibits high ADC in addition to the mentioned organs. The mean effective 
doses according to OLINDA/EXM V2.0 were 5.26x10-3 mSv/MBq and 6.51x10-3 
mSv/MBq for the male and female dosimetric models, respectively. When an 
administered activity of 350 MBq is injected to a patient (according to CUDIM 
protocols), it would correspond to 1.44 mSv and 2.28 mSv for male and female 
dosimetric models, respectively. 
The absorbed and effective doses estimated by IDAC 2.1 are shown in table 
2.16. For both dosimetric models the highest ADCs values are for the different 
sections of the wall intestines (left colon, small intestine, right colon and rectum), 
gallbladder wall, kidneys, liver and pancreas. Then for IDAC 2.1, the effective doses 
are 3.12x10-3 mSv/MBq and 3.59x10-3 mSv/MBq for male and female models 
respectively (for a reference person 3.36x10-3 mSv/MBq). This would correspond to 
effective doses of 1.18 mSv and 1.28 mSv, for male and female models respectively, 
for the same administrated activity (for a reference person 1.18 mSv). In the case of 
ICRP-60 recommendations the effective dose for male model varies between 2.91 
x10-3 mSv/MBq and 3.17 x10-3 mSv/MBq and for the female model varies between 
3.75x10-3 mSv/MBq and 4.08x10-3 mSv/MBq. 
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Table 2.15. Absorbed dose coefficients (ADC) and contribution to the effective dose factor 
(CEDF) results for adult male and female models from OLINDA/EXM V2.0. 
Target organ 
Male Female 
ADC 
(mGy/MBq) 
CEDF 
(mSv/MBq) 
ADC 
(mGy/MBq) 
CEDF 
(mSv/MBq) 
Adrenals 3.23E-03 2.98E-05 3.23E-03 2.98E-05 
Brain 9.94E-05 9.94E-07 1.22E-04 1.22E-06 
Breast --- --- 5.57E-04 6.69E-05 
Oesophagus 1.34E-03 5.37E-05 1.31E-03 5.25E-05 
Eyes 1.84E-04 --- 2.22E-04 --- 
Gallbladder Wall 4.29E-03 3.96E-05 4.64E-03 4.28E-05 
Left colon 2.26E-02 1.10E-03 2.65E-02 1.28E-03 
Small Intestine 2.40E-02 2.21E-04 2.83E-02 2.61E-04 
Stomach Wall 1.00E-02 1.20E-03 1.25E-02 1.50E-03 
Right colon 2.41E-02 1.17E-03 2.91E-02 1.41E-03 
Rectum 2.21E-02 5.09E-04 2.74E-02 6.30E-04 
Heart Wall 1.45E-03 1.34E-05 1.08E-03 1.00E-05 
Kidneys 4.50E-03 4.15E-05 5.58E-03 5.15E-05 
Liver 7.98E-03 3.19E-04 9.43E-03 3.77E-04 
Lungs 1.24E-03 1.49E-04 1.33E-03 1.59E-04 
Ovaries --- --- 2.94E-03 1.18E-04 
Pancreas 4.58E-03 4.23E-05 4.32E-03 3.99E-05 
Prostate 1.94E-03 8.98E-06 - - 
Salivary Glands 2.31E-04 2.31E-06 2.62E-04 2.62E-06 
Red Marrow 9.00E-04 1.08E-04 1.22E-03 1.47E-04 
Osteogenic Cells 6.11E-04 6.11E-06 7.54E-04 7.54E-06 
Spleen 1.54E-03 1.42E-05 2.58E-03 2.38E-05 
Testes 3.76E-04 1.50E-05 --- --- 
Thymus 5.97E-04 5.51E-06 6.41E-04 5.92E-06 
Thyroid 3.65E-04 1.46E-05 4.00E-04 1.60E-05 
Urinary Bladder Wall 4.89E-03 1.96E-04 6.31E-03 2.52E-04 
Uterus --- --- 4.81E-03 2.22E-05 
Total Body 1.18E-03 --- 1.87E-03 --- 
Effective dose 
(mSv/MBq) --- 5.26E-03 --- 6.51E-03 
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Table 2.16. Absorbed dose coefficients (ADC) for adult male and female models using IDAC 2.1. 
Target organ 
From male bio-kinetics From female bio-kinetics 
Male ADC 
(mGy/MBq) 
Female ADC 
(mGy/MBq) 
Male ADC 
(mGy/MBq) 
Female ADC 
(mGy/MBq) 
Adipose/residual tissue 1.03E-03 8.86E-04 1.10E-03 9.47E-04 
Adrenals 3.21E-03 3.84E-03 3.30E-03 3.86E-03 
Alveolar-interstitial 1.36E-03 1.39E-03 1.37E-03 1.38E-03 
Brain 9.46E-05 1.04E-04 9.84E-05 1.08E-04 
Breast 9.07E-04 7.04E-04 9.39E-04 7.06E-04 
Bronchi bound 1.03E-03 8.77E-04 1.05E-03 8.75E-04 
Bronchi sequestered 1.03E-03 8.77E-04 1.05E-03 8.74E-04 
Bronchioles 1.36E-03 1.39E-03 1.37E-03 1.38E-03 
Colon Wall 5.99E-03 6.54E-03 7.07E-03 7.85E-03 
Endosteum 
(bone surface) 6.18E-04 8.72E-04 6.48E-04 9.25E-04 
ET región 1.68E-04 2.01E-04 1.70E-04 2.02E-04 
ET1 basal cells 1.23E-04 1.58E-04 1.25E-04 1.59E-04 
ET2 basal cells 1.68E-04 2.01E-04 1.70E-04 2.02E-04 
Eye lenses 1.48E-04 1.85E-04 1.48E-04 1.86E-04 
Gallbladder wall 5.69E-03 5.13E-03 6.02E-03 5.09E-03 
Heart Wall 1.55E-03 1.34E-03 1.60E-03 1.35E-03 
Kidneys 4.95E-03 5.61E-03 5.25E-03 5.92E-03 
Left colon wall 6.01E-03 5.82E-03 6.86E-03 6.90E-03 
Liver 6.80E-03 7.85E-03 6.71E-03 7.58E-03 
Lung 1.25E-03 1.22E-03 1.26E-03 1.21E-03 
Lymphatic nodes 2.05E-03 2.38E-03 2.18E-03 2.55E-03 
Lymph nodes in ET region 2.76E-04 3.23E-04 2.79E-04 3.23E-04 
Lymph nodes in sys 2.35E-03 2.75E-03 2.51E-03 2.94E-03 
Lymph nodes in thoracic 
region 6.32E-04 6.07E-04 6.42E-04 6.04E-04 
Muscle 6.35E-04 8.77E-04 6.73E-04 9.40E-04 
Oesophagus 1.20E-03 1.09E-03 1.23E-03 1.09E-03 
Oral mucosa 2.32E-04 2.70E-04 2.34E-04 2.71E-04 
Ovaries --- 3.28E-03 --- 3.61E-03 
Pancreas 6.03E-03 5.85E-03 6.30E-03 5.98E-03 
Pituitary gland 1.64E-04 2.09E-04 1.67E-04 2.10E-04 
Prostate 1.10E-03 --- 1.13E-03 --- 
Recto-sigmoid colon wall 4.32E-03 6.21E-03 5.33E-03 7.39E-03 
Red (active) bone marrow 1.20E-03 1.63E-03 1.26E-03 1.73E-03 
Right colon wall 6.81E-03 7.41E-03 8.14E-03 9.04E-03 
Salivary glands 2.16E-04 2.55E-04 2.18E-04 2.56E-04 
Skin 4.21E-04 5.03E-04 4.44E-04 5.28E-04 
Small intestine wall 7.93E-03 9.59E-03 8.08E-03 9.86E-03 
Spleen 2.04E-03 2.34E-03 2.18E-03 2.47E-03 
Stomach wall 1.00E-02 1.01E-02 1.10E-02 1.09E-02 
Testes 2.94E-04 0.00E+00 3.03E-04 0.00E+00 
Thymus 5.06E-04 5.24E-04 5.14E-04 5.23E-04 
Thyroid 3.51E-04 3.61E-04 3.56E-04 3.61E-04 
Tongue 1.85E-04 2.00E-04 1.87E-04 2.01E-04 
Tonsils 2.13E-04 2.62E-04 2.15E-04 2.62E-04 
Ureters 3.25E-03 4.29E-03 3.41E-03 4.64E-03 
Urinary bladder wall 2.39E-03 3.86E-03 2.42E-03 4.01E-03 
Uterus/cervix --- 4.01E-03 --- 4.40E-03 
Effective dose 60 
[mSv/MBq] 2.91E-03 3.75E-03 3.17E-03 4.08E-03 
Risk-weighted effective 
dose 103 [mSv/MBq] 3.12E-03 - - 3.59E-03 
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In table 2.17 effective dose factor results are presented. For both models, for 
both versions of OLINDA results are higher than those values obtained with IDAC 
2.1. For female model, results are higher that male model for all software. For this 
model, for both versions of OLINDA results are almost twice those results obtained 
using IDAC 2.1. The same effect occurs for male model. 
 
Table 2.17. Summary of effective dose factor results (mSv/MBq) for [18F]SFR-101. 
OLINDA/EXM V1.0 OLINDA/EXM V2.0 IDAC 2.1 ICRP-60 ICRP-103 
Male Female Male Female Male Female Reference person 
6.55E-03 8.77E-03 5.26E-03 6.51E-03 2.91E-03 4.08E-03 3.36E-03 
 
4. Discussion  
In this chapter, three different radiopharmaceuticals were studied from the 
dosimetric point of view. Also, the biodistribution of these products were established 
by using images or by dissection of the animals. Most of the time, the preferred 
animals to study these products are among mammalians species, because they 
approximate well the human response. Hence, by knowing the biodistribution in the 
animal, pharmacokinetics assessment can take place by using empirical approaches, 
considering the body surface area (BSA), rates of metabolism and allometric 
approaches, which are relative mass scaling between organ masses and whole-body 
masses. However, there are aspects that need to be considered in order to quantify 
the activity accurately as possible independently of the chosen method to study the 
bio-kinetics of the radiopharmaceutical. For instance: 
4.1. Scaling to human’s method and differences in organs sizes  
McParland (McParland, 2010) discussed different scaling methods. One of the 
simplest approaches is to consider the same pharmacokinetics between humans and 
animals. Depending on the chosen animals some differences cannot be neglected, 
for instance, a) the rat does not have gallbladder, and therefore, the liver behaviour is 
not the same; b) organ sizes, the weight of the rat testes can be higher comparing to 
a reference man. Consequently, assuming no specificity, the testicular uptake is 
higher than expected, with a subsequent overestimation of testicular absorbed dose 
in man; c) the metabolism rate between species will typically differ.  
Conversely, assuming same pharmacokinetics between different species, the 
pharmacokinetics result can be scaled with the organ mass as a fraction of the total 
body mass. Tolvanen et al. (Tolvanen et al., 2010) mentioned that due to the faster 
physiology of rodents, the absorbed and effective doses extrapolated from mice may 
be lower than in data obtained directly from humans. In particular, there are 
qualitative differences in liver metabolism between species that can introduce bias in 
the results. Beykan et al. (Beykan et al., 2016) highlighted that pig models studies 
are more suitable than small animals (mice/rats) due to the similarity in physical 
properties and biodistribution compared to human physiology. Moreover, Kranz et al. 
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(Kranz, Sattler, Wüst, et al., 2016) concluded that the extrapolation of preclinical data 
obtained from studies in small animals (primates (Macaca fascicularis), rats, squirrels 
monkeys, piglets or rabbits), either by organ harvesting or PET images, would result 
in an underestimation of the human effective dose due to limitations in allometric 
scaling and species-specific target expression. 
Avila-Rodriguez et al. (Avila-Rodriguez et al., 2017) examined [64Cu]CuCl2 in 
healthy rats and human volunteers. Initially they performed MicroPET imaging 
(Manrique-Arias et al., 2016) to rats and then extrapolation to human was carried out 
by mass scaling. When they compared the extrapolated data with images from 
human volunteers, they found discrepancies in the results due to differences in sizes 
between species, metabolic rate and in assumptions in the dose calculations.  
Also Beykan et al. (Beykan et al., 2016) and McParland (McParland, 2010)  
mentioned that sources of errors due to the allometric approach can be introduced 
because scaling increases or decreases the values of residence times, and 
consequently, the same effect will be present on absorbed doses. In our results, 
residence times suffer these variations, for instance, for brain and lung, for [18F]FNM 
and [18F]SFR-101, an increment occurs ranging between 1.8 to 3.4 times. For the 
three products, these results depend on the dosimetric model used, reduction in 
kidneys occurs between 0.34 to 0.57 times and in liver between 0.46 to 0.99 times. 
4.2. Gender of the animals  
The ideal would be to have the pharmacokinetic of male and female animals, 
but the number of animals must be kept minimum, due to ethical and financial 
reasons. Consequently, in our studies one gender was used to assess the products.  
Since we had no specific assessment of male/female pharmacokinetics from animal 
experiments, the gender specific estimate was obtained during the extrapolation 
phase, by scaling differently the same animal pharmacokinetics. This is clearly a bias 
that would require further studies. 
4.3. Half-life of the radionuclide and measured time points  
Our study considered two isotopes with short half-lives; furthermore, 11C has a 
shorter half-life than 18F. Hence, regarding data acquisition and/or measuring times 
McParland (McParland, 2010) provided two recommendations: a) include data 
measurements between 2 and 5 min to determine the uptake of the 
radiopharmaceutical and b) the last point measurement should be at t=4*T1/2p (four 
times the physical half-life). 
For [11C]SAM Ishiwata et al. reported an increase in 11C concentration until 10 
min after injection in rats (Ishiwata et al., 1986) but they started measurements 
before 5 min. Bearing in mind that our measurements began at t=10 min in the 
current study to reduce the number of animals. On the other hand, for this product, 
last measure data time point was near to the criterion given by McParland 
Chapter	2:	Dosimetry	for	new	radiopharmaceuticals	
115 
 
(McParland, 2010). In case of both products with 18F, it was really difficult to follow 
the recommendation for the last data time point. 
On one hand, for the organ harvesting studies the number of animals were 
kept as low as possible, trying to keep financial cost as minimum as possible, but 
also to be representative enough in terms of time point measurements. On the other 
hand, for [18F]FNM the issue was not the number of animals, but how to keep the rats 
under anaesthesia to acquire images at late time points. This was the main reason to 
stop image acquisition at 70 min. 
4.4. Calibration of the equipment used to quantify activity  
4.4.1. PET/CT units  
It is well known that issues such as acquisition settings, reconstruction 
parameters, attenuation/scatter/partial volume effect may impact the quantification. 
Corrections have been studied and optimization can be done in each step if 
necessary. Other important aspect to consider is how to obtain the calibration factor 
for the system. This is linked to the previous steps and for small animal imaging it’s 
also critical due to the small structures present, due to the possibility of errors 
induced by the partial volume effect. In our study, image registration and 
segmentation took place using validated software called Sysiphe (Ducassou et al., 
2013; Ken et al., 2015; Salabert et al., 2017; Tensaouti et al., 2018) developed in 
Toulouse, which was available at the moment of this study and was used by a well-
trained professional. 
4.4.2. Well counters 
Well counters are used most of the time following a dissection. This procedure 
can be highly user-dependent; therefore, activity loss can happen. Measuring 
settings (centre of the channel of measure and energy width) were similar for both 
isotopes due to the g-emission. Background corrections were performed before 
measurement. Volume corrections were considered due to the difference in the 
dissected organs, therefore, CUDIM has a reference volume to compare with, and 
from it the correction took place. This correction is very important to be taken into 
account as great errors can happen in terms of quantification. Finally, time of 
measurements was kept constant. 
4.5. Applied fitting method  
Depending on the number of data time points, bi-exponential analysis can be 
done, as it was the case of some organs for [18F]FNM. However, when is not 
possible, the trapezoidal method is normally used.  Guerriero et al. (Guerriero et al., 
2013), mentioned an overestimation of time-integrated activities using the trapezoidal 
method (also considering physical decay from the last point measurement) compared 
to those generated by bi-exponential or other methods. However, in the case of 
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[11C]SAM and [18F]SFR-101, the time-integrated activity curves of the different 
organs did not show an exponential behaviour. Therefore, the best way to estimate 
the cumulated activity was by applying the trapezoidal method. To evaluate the best 
fit, the Pearson correlation coefficient (R2) was used (being > 0.98 in all cases) for 
the linear functions. In our case Mathematica (Mathematica, 2015) was used 
applying non-linear fitting for some organs when [18F]FNM was employed. For the 
other products, Mathematica was used to assess the linear fitting in the trapezoidal 
method. In the case of Boschi et al. (Boschi et al., 2016a) and other authors (Beykan 
et al., 2016; Boschi et al., 2016b; Herrmann et al., 2015; Schottelius et al., 2017; 
Weineisen et al., 2015) for dosimetric analysis and calculations using NUKFIT, which 
may have advantages over Mathematica, because this software can incorporate the 
systematic error in activity determination, and error propagation also can be taken 
into account. Finally, we assumed no activity at t= 0 h, therefore between this time 
and the first data time point, we assumed a line to join the two points (forming a 
triangle). For each organ we could assume different approaches, but this is time 
consuming and depending on the organ the impact would be low. Some software, 
such as the fitting module from Dosisoft (Gardin et al., 2017), allows the user to 
choose between three options to create the fitting from t=0h to the first data time 
point, but entering data is not possible within this module. 
4.6. Reference model used  
Differences between OLINDA/EXM V1.0, V2.0 and IDAC 2.1 are the following: 
4.6.1. Organ geometries, composition and masses  
The human models (stylised) from Cristy and Eckerman are used in 
OLINDA/EXM V1.0. These models were created considering anatomical information 
from ICRP-23, in terms of organ mass and composition. In case of OLINDA/EXM 
V2.0, non-uniform rational B-splines (NURBS) body and organ models were scaled 
and shaped to fulfil the ICRP-89 values, in terms of organ mass and its composition. 
This means that human models considered in OLINDA/EXM V2.0 are not the same 
as those presented in ICRP-110, but most characteristics are similar. However, 
organ shapes and positions within the human models may vary from the ICRP-110. 
In IDAC 2.1, the ICRP-110 human models (voxelized) are used. 
4.6.2. S-value estimation  
In OLINDA/EXM V1.0, the absorbed fraction (AF) is considered = 1 for alpha 
and beta emissions when the source region is the same as the target region. Hence, 
a linear mass scaling can be performed in order to adjust the AF to a particular organ 
mass value. Also, in this case AF = 0 when the source region is different from the 
target region for the same emissions. In the case of photons, AF≠1, because cross-
irradiation will occur from the source region to the target region. Then, if mass 
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adjustment is needed, the AF can be adjusted with the cube root of the new organ 
mass. 
In OLINDA/EXM V2.0 and IDAC 2.1, the AF was estimated using MC codes. 
In the case of OLINDA/EXM V2.0, GEANT4 was used for SAF estimations. In the 
case of IDAC 2.1 references from ICRP-133 were used using EGS4. 
4.6.3. Radiation and tissue weight factors employed and effective dose 
estimation 
OLINDA versions do not strictly follow ICRP recommendations for the 
estimations of effective dose. Conversely, IDAC 2.1 strictly complies with ICRP 
recommendations, for both effective dose estimations under ICRP-60 and ICRP-103.  
In the case of OLINDA/EXM V1.0 / ICRP-60, some organs are missing, for 
example, oesophagus. The colon is divided in two sections, the Lower Large 
Intestine (LLI) is part of colon and the Upper Large Intestine (ULI) is part of the 
remainder. For gonads a value is assigned for ovaries and not for testes, only when 
they are considered as a source. Also, in the case of the estimation of the remainder, 
there are some ICRP-60 recommendations not followed in OLINDA/EXM. For 
gallbladder, heart wall and testes there is no weighting tissue factor assigned, 
meaning that they do not contribute to the effective dose.  
In the case of OLINDA/EXM V2.0 / ICRP-103, some organs are missing, for 
instance skin, breast for adult male. Weighting tissue factor for ovaries, testes, 
prostate and ureters are different comparing to ICRP-103 recommendations. For the 
remainder, four organs are not taken into account, extrathoracic region (ET), 
lymphatic tissue (Lymph), muscle and oral-mucosa (O-mucosa). 
In terms of radiation weighting factor, for alpha emissions, OLINDA/EXM V1.0 
and V2.0 consider a value of 5 (Feinendegen & McClure, 1997), instead of 20 as is 
recommended by ICRP-103. This is to give account of deterministic effects, but 
certainly deviates from ICRP concepts. 
In the case of [18F]FNM results from table 2.5 are lower than those observed in 
other 18F-PET tracers used in neurology. For example, [18F] DPA714 is around 17.2 
µSv/MBq (Arlicot et al., 2012), [18F]FEDDA is around 36 µSv/MBq (Takano et al., 
2011) and the [18F] amyloid tracer flutemetamol, is around 25-30 µSv/MBq (Koole et 
al., 2009). This may be associated to the fast clearance of the radiopharmaceutical 
through the kidneys. On the other hand, comparing results between OLINDA/EXM 
V1.0 and IDAC 2.1 (ICRP-60), these are very similar even though the mean effective 
doses from IDAC 2.1 were obtained using a different mass scaling and different 
dosimetric models.  
Moreover, comparing OLINDA/EXM V2.0 with IDAC 2.1 (ICRP-103), mean 
effective dose values are in the same order of magnitude, but with OLINDA/EXM 
V2.0 some organs are not considered. Moreover, in IDAC 2.1 the mean effective 
dose for the reference person are from averaging male and female models results.  
In the case of [11C]SAM, as described by Ishiwata et al. and Tolvanen et al. in 
rats (Ishiwata et al., 1986; Tolvanen et al., 2010), the highest total absorbed dose is 
for the kidneys as it was in our case. Tolvanen et al. (Tolvanen et al., 2010) reported 
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effective dose values varying from 3.2x10-3 to 1.41x10-2 mSv/MBq for 11C-
radiopharmaceuticals in humans, and the current results are comparable to those 
figures.  
Moreover, looking at table 2.10, results for OLINDA/EXM V1.0 and IDAC 2.1 
(ICRP-60) are in the same order of magnitude, but some differences can be 
highlighted. First, the organ mass for the bladder contents is almost twice higher in 
IDAC 2.1 than OLINDA/EXM V1.0. In OLINDA/EXM V1.0, the SAF for the urinary 
bladder wall due to the bladder contents irradiation is estimated as 0.5xbladder 
contents mass. However, in IDAC 2.1 the SAF is estimated from MC simulations. 
Also, there are differences regarding the estimation of the remainder and the 
contribution of the intestines (especially the large intestine) to the mean effective 
dose.  
Also, comparing results between OLINDA/EXM V2.0 and IDAC 2.1 (ICRP-
103) in table 2.11 the percentage of relative difference for the ADC, with and without 
bladder voiding. For left colon wall and urinary bladder wall, these values are almost 
200%, which means that the model generated in OLINDA/EXM V2.0 has an impact 
on the absorbed dose calculation. Hence, for hollow organs, which mean the ones 
having no-contents, may also be important in absorbed dose calculations. Moreover, 
other organs exhibit percentage of relative differences more than 30% are the 
endosteum, eyes lens, kidneys, prostate and testes. In the case of kidneys, prostate 
and testes are close to the bladder, and then irradiation should be important. Finally, 
tissue weighting factors, the way in which the remainder is estimated, and the organs 
used to compute the mean effective dose are not exactly the same between the two 
software.  
In the case of [18F]SFR-101, values of mean effective dose in table 2.17 are 
lower but comparable to different radiopharmaceuticals previously published: 12.1 
µSv/MBq for [18F]-Flubatine (Kranz et al., 2016);  6.23 µSv/MBq for [18F]-PMSA [27]; 
25 µSv/MBq for [18F]-Tetrafluoroborate (Marti-Climent et al., 2015); 19 µSv/MBq for 
[18F]-VAT (Karimi et al., 2015); 21 µSv/MBq for [18F]-Fluspidine [28], 20 µGy/MBq for 
[18F]-SFE (Waterhouse et al., 2006); and 20 µGy/MBq for [18F]-FPS [29]. The 
differences between the two versions of OLINDA/EXM and IDAC 2.1 that were 
mentioned before for [11C]SAM, apply here also. For [18F]SFR-101, the highest 
residence times were for intestines. Therefore, the greatest percentages of relative 
differences can be seen for the intestine’s walls, again showing that contents are 
important to be considered as source. 
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5. Conclusions 
In this chapter biodistribution and bio-kinetics for three radiopharmaceuticals 
have been shown. These data were obtained from small animals (rats and mice). For 
the three products extrapolations to humans was carried out. This procedure was 
performed by allometric scaling of the normalised cumulated activity by using mass 
organ information from ICRP-23 and ICRP-89. The extrapolated results to humans 
were assessed using three software. OLINDA/EXM V1.0 is nowadays the gold 
standard in this field. However, its new version is in the market as well as IDAC 2.1, 
which can be used for same purposes, claiming the fulfilment of ICRP-103 
recommendations. Main characteristics between the software have been addressed 
in order to explain differences in their results. Despite the differences in the methods 
used to assess dosimetric estimations, the current data provide a reasonable basis 
for evaluating human dosimetry, that can be better-established in human subjects, to 
verify or to compare the obtained results at a pre-clinical level. 
As a future work, we are expecting to perform dosimetry for healthy volunteers 
and patients for the three radiopharmaceuticals studied in this chapter. At the 
moment the final approval of the national/local ethics committees and the revision of 
the clinical protocols proposed by each research centre are under study.    
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1. Introduction  
Gamma camera calibration is a key factor for quantitative imaging, and 
therefore participates to the dosimetric chain. SPECT/CT systems from different 
manufacturers  have been studied to derive calibration procedures (Beauregard et al. 
2011; de Nijs et al., 2014; Sandström al., 2010). For 177Lu, several publications can 
be found showing acquisition protocols to perform calibration. In tables 3.1 and 3.2, a 
resume of the protocols used to achieve this goal is shown. As can be seen, the 
comparison between calibration procedures can be a difficult task. 
Table 3.1 shows differences in crystal thickness (3/8”, 5/8”, 1”), collimator type 
(LEHR, LEGP, MELP, MEGP), acquisition time (20 s, 30 s, 40 s, 45 s, 60 s), number 
of projections (60, 64, 120, 128), number of energy windows per photo-peak (113 
keV @ 20%, 208 keV @ 20%, 208 keV @ 15%), the matrix size (generally 128x128 
is used but there is one study also showing results with 256x256) (Sanders et al. 
2015), acquisition orbit (frequently is auto-contouring, but circular orbits have been 
used with a fixed radius of 25cm) (de Nijs et al., 2014; Robinson et al. 2016), and 
pixel size (in the majority of the cases it varies from 4.4 mm to 4.8 mm). In the same 
table regarding the reconstruction process, in most of the cases OSEM was used. de 
Nijs et al. (de Nijs et al., 2014) and Sanders et al. (Sanders et al., 2015) have 
explored the influence of the combination in iterations and subsets. In most of 
publications, TEW (Ichiharaet al., 1993; Ogawa et al., 1991) is used as scatter 
correction method. However, de Nijs et al. (de Nijs et al., 2014) compared different 
scatter corrections methods, for instance, the effective scatter source estimation 
(ESSE) (Kadrmas et al. 1998), DEW (Jaszczak et al. 1984), TEW (Ogawa et al., 
1991), downscatter correction (de Nijs et al. 2010), combined scatter and 
downscatter correction (de Nijs & Svarer, 2007), and dual-photopeak window ( 
Ljungberg et al. 1994). Other corrections can also be seen in the same table for 
example, collimator-detector response, pre- and post-filtering, recovery coefficient 
and dead time. 
Table 3.2 presents differences in the CT acquisition protocols (kV and mAs 
applied), the calibration procedure, the registration and segmentation procedures, 
absorbed dose results, residence times estimations, phantoms used for calibration, 
sensitivity units and sensitivity results. This shows that, to date, there is not 
standardized procedure to acquire, reconstruct, register and segment 
phantom/patient data. However, Wevrett et al. (Wevrett et al., 2017) proposed a 
calibration protocol for quantitative imaging for molecular radiotherapy dosimetry. 
Although they did not address all possible corrections that could be implemented, 
they suggested clearly how to perform the calibration of the SPECT/CT system. In 
addition, the MIRD committee has produced extensive and comprehensive 
documents to address quantitative planar (Siegel et al., 1999) and SPECT (Dewaraja 
et al., 2012) imaging.  
Following the quantitative imaging general principles presented in Dewaraja et 
al. (Dewaraja et al., 2012), in 2016 the EANM and MIRD (Ljungberg et al., 2016) 
generated guidelines for quantitative 177Lu-SPECT; illustrating the results of Monte 
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Carlo simulations, phantoms experiments and examples of patients protocols used in 
clinic. The importance of this effort from EANM/MIRD is related to the review of the 
literature regarding some of the effects degrading images for quantitative SPECT 
with this isotope specifically. Moreover, in this work the information is very rich as it 
provides a series of recommendations to estimate activity accurately. Tran-Gia and 
Lassmann (Tran-Gia & Lassmann, 2017) created a 3D realistic 2-compartment 
kidney phantom, to study partial volume correction methods on quantitative 
SPECT/CT imaging for 177Lu, using two commercially available reconstruction 
methods. They mentioned that in sphere-like objects, the central voxels are far away 
from the object edges and, therefore, are largely unaffected by partial volume errors. 
In contrast, in complex structures such as renal cortex, most voxels are close to one 
of the object edges, thus, affecting these voxels by partial volume errors. Moreover, 
they showed an example where Gibbs ringing occurs after certain number of 
iterations, without post-filtering, for the two reconstruction methods evaluated.  
 
In this work four commercial workstation were studied, GE Dosimetry Toolkit 
(DTK), Hermes Hybrid dosimetry Module™ (HDM), Philips STRATOS and Dosisoft 
PLANET® Onco Dose (PDOSE). The calibration factor used in each workstation and 
the units in which this parameter is expressed may differ. An overview of these 
software is presented as follows: 
• DTK is an application from the GE Xeleris® workstation, that is working in 
Windows. The user can upload either serial Anterior-Posterior WB scans; serial 
Anterior-Posterior WBs and one SPECT (or SPECT/CT) study, or 3 serial 
SPECT (or SPECT/CT) studies. DTK requires two steps: first the “preparation for 
dosimetry toolkit” is used for the reconstruction of SPECT/CT raw data and the 
definition of a reference for later registration of the CT scans; second, the 
“Dosimetry toolkit” is used to segment different organs, to create time activity 
curves and to fit them by a mono-exponential, in order to calculate residence 
times for each organ. Finally the residence times can be exported to 
OLINDA/EXM V1.0 (Stabin et al., 2005). A calibration method is proposed by this 
company based-on planar measurements, estimating the calibration factor in 
units of cps/MBq. 
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• In the case of the Hermes workstation, reconstruction can be performed. This 
workstation also contains HDM version 1.0, which has been used with 177Lu-
DOTATATE patient data (Hippeläinen et al., 2016). Patient data can be used 
under different scenarios, for example, either a minimum of 3 serial Anterior-
Posterior WBs; or 3 serial Anterior-Posterior WBs and one SPECT (or SPECT/CT 
study) or 3 serial SPECT (or SPECT/CT studies). A calibration method is 
proposed based on a uniformly filled cylindrical phantom. HDM requires a 
calibration factor in MBq/counts obtained from SPECT/CT acquisitions. Fitting can 
be done using mono-exponential or bi-exponential approaches. By knowing the 
injected activity and injection time, the residence times can be estimated in HDM 
and its results can be exported to OLINDA/EXM V2.0 (Stabin & Farmer, 2012). 
• STRATOS is a software which part of Phillips IMALYTICS research workstation 
(3.2, Rev 6289(64)), reconstructions cannot be performed and no calibration 
method is suggested. This software can be used only with 3D SPECT/CT data. A 
relationship between the number of counts and intensity can be established by 
setting the number of counts equal to the level of intensity in the NM image. The 
calibration factor is therefore expressed in Bq/Intensity. Fitting can be done voxel 
by voxel using the trapezoidal method, and also considering a mono-exponential 
decay from last measure time point. Absorbed doses are calculated by convolution 
at the voxel level. DVHs can be generated. STRATOS has been used by some 
authors, for instance for comparison with an internally-developed software (Grassi 
et al., 2015), to OLINDA/EXM and GATE Monte Carlo code (Marcatili et al., 2015).  
• PDOSE (version 3.1.1RC-2018-03-16), from DOSISOFT works only with 
SPECT/CT acquisitions and no calibration method is suggested by this company, 
also operates on Linux (7.3.1611, CentOS7-64bits). The calibration factor can be 
expressed in units of Bq/counts, but other options are available. PDOSE allows 
the usage of different calibration factors, thus, the user can vary acquisition time. 
Fitting can be done by different approaches, for instance, using the trapezoidal 
method, mono-exponential, bi- or tri-exponentials. PDOSE can calculate the mean 
absorbed doses by considering both organ-based and voxel-based approaches. 
PDOSE can estimate the mean absorbed dose by convolution (Dieudonne et al., 
2011, 2013; Dieudonne et al., 2010) and assuming local energy deposition 
(Pasciak et al., 2014). This software have been used for other applications, for 
instance in PET/CT for radiotherapy purposes (Desbordes et al., 2017; Desbordes 
et al., 2014; Vera et al., 2013) and in the treatment of liver cancers with 90Y 
microspheres (Gardin et al., 2017).   
In summary, DTK and HDM are able to perform image reconstruction. 
However, they propose only model-based dosimetry at the organ level. STRATOS 
performs dosimetry at the voxel level. PDOSE can do both. DTK, being part of 
Xeleris®, is a medical device that can be used in a clinical context. HDM and PDOSE 
are both aiming for that (PDOSE got the CE marking during this work). STRATOS is 
and will remain a research tool. 
In this chapter the calibration of a SPECT/CT system using different source 
geometries is presented. The calibration factor was determined for several 
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reconstructions to show the influence of the reconstruction method on the 
determination of this parameter. Recovery coefficient results were obtained from 
phantom studies. A phantom study was performed to test the calibration factor 
chosen in several workstations.  
In this chapter two main objective are addressed: 
1. To calibrate a SPECT/CT. 
a. To generate the CT calibration curve. 
b. To determine the sensitivity of the system. 
i. Planar sensitivity. 
ii. SPECT sensitivity. 
c. To determine the calibration factor. 
d. To generate the recovery coefficient curve. 
2. To test the performance of three commercial workstations using phantom data 
sets by: 
a. Estimating the activity for a phantom configuration. 
b. Assessing the dosimetric workflow to calculate residence times.  
2. Materials and Methods  
Phantom experiments were carried out at the Institut régional du cancer de 
Montpellier (ICM) in the Nuclear Medicine Department, using a SPECT/CT unit GE-
Discovery NM/CT 670, 9.5 mm crystal thickness. All activity measurements were 
done in an accurate activimeter calibrated for 177Lu measurements. Projections were 
acquired, reconstructed and analyzed independently at the ICM and the Centre de 
Recherches en Cancérologie de Toulouse (CRCT). All activity measurements were 
done in an accurate activimeter calibrated for 177Lu measurements.  
At ICM images were reconstructed using Dosimetry Toolkit®. At CRCT 
reconstruction was performed using HybridRecon-Oncology version_1.3_Dicom 
(HROD) from Hermes without using the SPECT Standard Uptake Value (SUV) 
(Kangasmaa et al., 2016) option.   
2.1. CT calibration curve  
To correct for the attenuation effect, a CT calibration curve was generated 
using the Catphan 500 phantom. This phantom can be also used in the quality 
assurance program. In figure 3.1 a representation of a slice of the phantom can be 
observed, showing materials such as teflon, LDPE, acrylic, etc. In table 3.3, 
information regarding data from the Catphan500 inserts can be seen. The phantom 
was placed in the SPECT/CT and CT acquisition protocol was as follows: 140 kV, 
mA was set in auto, matrix size 512x512, noise index 6.4, slice thickness 5 mm, pitch 
1.375 and standard reconstruction filter.  
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Table 3.3. Information regarding data from the Catphan 500. 
Material Density (g/cm3) Other information 
µ (cm-1) at  
80 keV from 
ICM 
µ (cm-1) at 
80 keV 
from NIST 
Hounsfield 
units (HU) 
Air   0  -972.21 
H2O 1  0.184 0.184 0 
Polystyrene 0.96 – 1.04  0.180 0.183 -35.37 
LDPE 0.910 – 0.940 
Low density 
polyethylene (LDPE) 0.167 0.170 -78.12 
Acrylic 1.18 Poly(methyl methacrylate (PMMA) 0.207 0.208 133.06 
Teflon 2.2 Polytetrafluoroethylene (PTFE) 0.342 0.367 910.1 
 
The effective energy associated at 140 kV is 80 keV. The same information to 
generate the calibration curve was used for reconstruction purposes in HROD and 
Xeleris®. The ICM provided information for the linear attenuation coefficient and its 
associate Hounsfield Units (HU). This information is needed in HROD to perform the 
attenuation correction in the reconstruction process. This information is required at 
140 keV, and HROD automatically converts to the energy of the isotope (in this case 
177Lu). Hermes provides a software called, “CT-based attenuation map calibration-
Hybrid Recon™”, to estimate the equations associated to these parameters (Hermes 
Medical Solutions, 2014).  
Linear attenuation coefficients at 80 keV were compared to those from 
National Institute of Standards and Technology (https://www.nist.gov/) (NIST). Linear 
attenuation coefficients at 100 keV and 150 keV were extracted from this database in 
order to estimate the respective values at 140 keV, using a first-degree polynomial 
approximation, because the attenuation coefficient is not provided at this energy.  
 
 
Figure 3.1: CTP404 module with slice width, sensitometry and pixel size. 
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2.2. Data acquisition for sensitivity determination  
2.2.1. Planar sensitivity tests  
At the ICM the sensitivity factor (cps/MBq) was determined from planar 
images, this was requirement by DTK. The estimation of the planar sensitivity 
occurred using a spherical source at different source-to-collimator distances. The 
acquisition protocol was as follows: matrix size 128x128, zoom=1, two energy 
windows were used, the principal centered at 208 keV with 20% of energy window 
width, a secondary energy window, centered at 177 keV with 10% of energy window 
width, acquisition time 5 min, medium energy general-purpose (MEGP) collimator. 
Figure 3.2 shows the energy windows set-up generated by the gamma camera. The 
activity in the source was 75.88 MBq. Images were generated at different source-to-
collimator distances (d=8 cm, 13 cm, 18 cm) using a fillable sphere (external 
diameter 33.27 mm) placed in air. 
 
	
Figure 3.2: Energy spectrum of 177Lu acquired on SPECT/CT unit GE-Discovery NM/CT 670. The 
main energy window was set at 208 keV @ 20%, the secondary energy window was set at 177 keV @ 
10%. Images provided by ICM nuclear medicine department. 
For each distance, planar sensitivities were estimated from geometric mean 
images using ImageJ (Schneider et al. 2012): a) using one ROI covering the whole 
image, b) drawing a circular ROI 4 and 10 pixels in diameter, which were centered on 
the maximal pixel counts. Moreover, using results from ImageJ planar sensitivity 
variation with distance for the two collimators and the geometric mean (without 
scatter correction) were plotted for the same distances.  
2.2.2. SPECT sensitivity tests 
To estimate the SPECT sensitivity different options were addressed in terms 
of phantom configuration, acquisition time and reconstruction. Table 3.4 shows 
different characteristics for each phantom configuration along with acquisition and 
reconstruction parameters. Phantom configurations 3 and 4 were used to partially 
replicate the procedure implemented in the MetroMRT European project (Wevrett et 
al., 2017). Figure 3.3 shows phantom set-up for each configuration. Phantom 
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configurations showed in table 3.4 are going to be used in the following sections. At 
ICM the only configuration analyzed was configuration 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter	3:	SPECT/CT	calibration	and	workstation’s	evaluation	
133 
 
A		
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Figure 3.3: A. Spherical source placed at the centre of an empty cylindrical phantom. B. Placement of 
spherical source at the centre of an empty cylindrical phantom in the SPECT/CT. C. Placement of 
spherical source in the centre of a cylindrical phantom filled with water in the SPECT/CT. D. 
Placement in the SPECT/CT of the NEMA 2012/IEC 2008 phantom filled with water (no background 
activity) and containing a fillable bottle (500ml). Images provided by ICM nuclear medicine 
department. 
 
SPECT acquisitions were as follows: one FOV covering the whole phantom, 
60 projections in total, zoom 1, matrix size 128x128, using two energy windows one 
centered at 208 keV at 20% and one at 177 keV at 10%, parallel-hole medium 
energy general purpose (MEGP) collimator, step & shoot, and body auto-contour. CT 
acquisition protocol was as follows: 120 kV, mA was set in auto, matrix size 512x512, 
noise index 6.4, slice thickness 5 mm, pitch 1.375 and standard reconstruction filter. 
2.3. SPECT data reconstruction  
Reconstructions at CRCT were as follows: for phantom configurations 1 and 2, 
OSEM (Hudson & Larkin, 1994) (6i, 10ss) was used; for phantom configurations 3 
and 4, several OSEM combinations were used, varying between number of iterations 
(4, 6, 8, 16, 32) and subsets (5, 10). Gaussian post-filter was set at 0.0, 0.11 and 
1.00 cm. 
For all phantom configurations, different correction methods available were 
applied, such as attenuation, collimator-detector response and Monte Carlo Scatter 
Modelling (MCSM) (Sohlberg et al., 2008). In order to apply the MCSM, a 
modification of the DICOM header from the original images took place using the 
Dicom Editor Tool 3.2.6 (DVTk Library 3.1.9, www.dvtk.org) because the MCSM 
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works with the main energy windows.  
As described by other authors (Hippeläinen et al., 2016; Sohlberg et al., 2008), 
the CT attenuation map, when using HROD, was generated using a bilinear 
conversion from HU to linear attenuation coefficient values and the collimator 
correction was based on the Gaussian convolution. Then, the projection data was 
loaded with the attenuation map into the HROD Reconstruction Module. The 
attenuation map was resampled to correct size/energy, this resampling was 
performed automatically by the workstation (Hermes Medical Solutions, 2015). 
At the ICM the configuration 1 was reconstructed as follows: OSEM (6i, 10ss), 
using all corrections methods available (scatter, attenuation and collimator-detector 
response correction) and using Gaussian post-filter set at 0.11 cm. 
2.4. Segmentation and image analysis for SPECT sensitivity  
Using the Hybrid Viewer Multi (HVM) version 2.7 from Hermes, for configurations 
3 and 4, a VOI was generated on the CT image creating a spherical volume. The 
diameter of the generated sphere was 3.13 cm in order to have a volume of 16 ml. In 
order to place the center of the generated VOI, the biggest diameter of the spherical 
volume in the CT image was chosen, and correct positioning was assessed visually. 
The volume created on the CT image was copied to the NM reconstructed images. 
On average, the generated volume on the NM reconstructed images for the empty 
phantom was 15.88 ml and for the water-filled phantom was 16.51 ml.    
Manual segmentation of the bottle was not easy to perform using HVM, 
because of the bottle wall thickness. Therefore, for configuration 1, an automatic 
segmentation was used by absolute thresholding in the NM signal. Hence, by using 
different percentages (23% and 24%) relative to the maximum number of counts 
within the VOI, the automatic segmentation tool was tested.  
For phantom configuration 4, with all correction methods were tested, with 
gaussian post-filter set at 0.0, 0.11 and 1.0 cm.  Line-profiles crossing the sphere 
source were generated using ImageJ (Schneider et al., 2012), for the same slice of 
the phantom, for each NM reconstructed image. For every image, the same position 
in the “y-axis” was used in order to draw the profiles. Gray values in these profiles 
are related to the number of counts present in each voxel of the line. 
2.5. Calibration factor determination  
The calibration factor was found as the inverse of the system volumetric 
sensitivity. As described by Sanders et al. (Sanders et al., 2015), the system’s 
volumetric sensitivity, expressed in (cps/ml)/(MBq/ml), is estimated as follows: 
 𝑆 = 𝑐@C,𝜏AF × 	𝐶h × 𝑒𝑥𝑝 −𝑙𝑛(2)× Δ𝑡ΤS X¥  3.1 
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Where 𝑐@C, is the number of counts in the generated VOI, 𝜏AF is the 
acquisition duration (i.e., time per projection multiplied by the total number of 
projections), 𝐶h is the prepared activity concentration, Δ𝑡 is the time between the 
source activity preparation and the SPECT/CT acquisition, and ΤS X¥ is the physical 
half-life of the radionuclide. This expression of the calibration factor was also used by 
Marin et al. (Marin et al., 2017). 
For all configurations, average of respective volumetric sensitivities were 
estimated, as it is recommended by Wevrett et al. (Wevrett et al., 2017): with 
Gaussian post-filtering set at 0.0, 0.11 and 1.0 cm, this was done for:  all corrections 
methods used in the reconstruction algorithm; using only attenuation + collimator 
response correction and using only attenuation. 
These figures were used directly into three different workstations, Hermes, 
PDOSE and STRATOS. For the three workstations the same calibration factor can 
be used with the appropriate units (activity/counts). Also, in the case of STRATOS 
the intensity of the displayed image can be associated with the number of counts in 
the NM image. For each configuration, the calibration factor was found by multiplying 
the estimated volumetric sensitivity by the acquisition time. 
Finally, these results were helpful for the evaluation of the residence times 
when a phantom with a cylindrical source was used as it is explained in the next 
section. 
2.6. Recovery coefficients determination   
In order to determinate the recovery coefficient, two experiments were carried 
out using two cylindrical phantoms (Jaszczak, 6.4 L) one filled with background 
activity and another without background activity, using two sets of 6 fillable spherical 
sources (16, 8, 4, 2, 1, 0.5 ml). The volumetric activity used with each source was 
0.54 MBq/ml. The volumetric activity used such as background was 0.07 MBq/ml.  
Acquisition protocol was as follows: one FOV covering the whole phantom, 60 
projections in total, 120 seconds per projection, zoom 1, matrix size 128x128, using 
two energy windows one centred at 208 keV at 20% and one at 177 keV at 10%, 
MEGP collimator, step & shoot and body auto-contour. The CT acquisition protocol 
was 120 kV, mA was set in auto, matrix size 512x512, noise index 6.4, slice 
thickness 5 mm, pitch 1.375 and standard reconstruction filter.   
VOI’s were created in the CT image for each sphere and then copied in the 
NM images. In the case of the phantom with background activity, spheres of same 
volumes in the background region were create and these figures were subtracted 
from the values obtained from the counts in each sphere. All image analysis occurred 
with HVM. 
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2.7. Assessment on three commercial workstations  
The dosimetric workflow implemented in each work station not only considered 
the determination of activity at a given time point from a calibration factor, but also 
how different time points were integrated to provide for cumulated activity/residence 
time before absorbed dose calculation. Therefore, we decided to test the whole chain 
of processing on phantom experiments. We performed SPECT/CT acquisitions of 
phantom configuration 2, imaged at approximately 2.5, 25, 48, 146 and 165 h. The 
phantom placement was not exactly the same between the different time point 
measurements, in order to assess the (rigid) registration tools provided by each 
workstation. This configuration was used, because the source can mimic one kidney. 
As only physical decay of the radionuclide occurred during the experiments, the 
residence time for 177Lu should be equal to 230.15h (230.15h =Ñ SBQX ∗ ΤS X¥ ijk,Ò). 
2.7.1. Activity determination  
In collaboration with Montpellier we decided to perform an initial evaluation using 
the calibration factor resulting from the OSEM reconstruction, with 6 iterations, 10 
subsets, using all corrections methods and Gaussian post-filter at 0.11 cm. Then, 
uploading reconstructed images from the previous phantom in Hermes, PDOSE and 
STRATOS, an estimation of the activity at each time point and associated relative 
difference was found.  
The dosimetry workflow using HDM was as follows: automatic registration by 
conducting a rigid registration (translation) taking as reference the first SPECT/CT 
was performed; the software synchronized two SPECT/CT series at the time. The 
VOIs were created using the automatic segmentation tool, as mentioned before. A 
mono-exponential fit was applied, and integration from t=0 to infinity was done to find 
the residence time. 
In the case of PDOSE the workflow was as follows: segmentation was carried 
out manually on the reference CT slices. This software also synchronized two 
SPECT/CT series at the time. Rigid registration was performed taking as reference 
the first SPECT/CT. PDOSE has many fitting options available but we decided to use 
mono-exponential fitting. Integration from t=0 to infinity was done to find the 
residence time, by knowing the initial activity, also PRD was found. 
In the case of STRATOS, automatic rigid registration was performed by rigid 
registration, between each NM study and the first CT study (which was taken as a 
reference). Segmentation was carried out manually on the reference CT slices. Here 
fitting was carried out by segments applying the trapezoidal method, and from the 
last data point, extrapolation to infinity, assuming mono-exponential decay (called tail 
integration) and considering physical half-life only. To estimate the residence time, 
the software performed integration of each segment automatically and also PRD was 
found.     
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2.7.2. Residence times evaluation and phantom validation 
The VOI of the bottle was generated using automatic segmentation, based on 
absolute thresholding, in HDM. Hence, two different percentages (23% and 24%) 
relative to the maximum number of counts within the VOI, were generated. The 
segmented VOI’s were copied to the other SPECT/CT data points. Fitting was 
applied by using a mono-exponential function. Finally residence times were 
calculated for each calibration factor, from phantom configurations 1 to 4. The 
approach described in the previous section was implemented in STRATOS and 
PDOSE. The relative difference is calculated between the theoretical and estimated 
residence times for all software. 
3. Results  
3.1. CT calibration curve  
In table 3.5 results for linear attenuation coefficient and HU are presented. The 
values from GE and NIST at 80 keV are similar for the majority of the materials. Only 
5 materials were chosen for this analysis. In the case of Polystyrene results were not 
similar, therefore we did not use this material to generate our calibration curve. 
In figure 3.4, calibration curve results using the software provided by Hermes 
can be seen, showing the bilinear fitting. In figure 3.4.A, coefficients for the slope and 
intercept of the two equations are shown. In figure 3.4.B, an image of how these 
coefficients were introduced in HROD to perform the reconstruction is presented. 
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Table 3.5. Linear attenuation coefficient and HU results for the CT calibration curve. 
Material 
Linear attenuation coefficient µ (cm-1) 
GE 80 keV NIST 80 keV 
NIST  
100 keV 
NIST  
140 keV 
NIST  
150 keV 
H2O 0.1837 0.1837 0.1707 0.1545 0.1505 
POLYSTYRENE (PS) 0.18 0.1829 0.1721 0.1572 0.1535 
L-POLYETHYLENE 
(LDPE) 0.167 0.1695 0.1599 0.1461 0.1427 
Polymethylmethacrylate 
(PMMA) 0.207 0.2084 0.1953 0.1777 0.1733 
Polytetrafluoroethylene 
(PTFE), r=2,25 0.342 0.3672 0.3375 0.3033 0.2948 
Material 
Hounsfield units (# CT) 
GE 80 keV NIST 80 keV 
NIST  
100 keV 
NIST  
140 keV 
NIST  
150 keV 
H2O 0.000 0.000 0.000 0.000 0.000 
POLYSTYRENE (PS) -35.75 -4.63 8.46 17.34 19.85 
L-POLYETHYLENE 
(LDPE) -78.12 -77.09 -63.46 -54.59 -52.08 
Polymethylmethacrylate 
(PMMA) 133.06 134.29 143.99 149.65 151.26 
Polytetrafluoroethylene 
(PTFE), r=2,25 910.1 998.91 977.15 962.60 958.47 
CT calibration curve used in HU-fit software (from HERMES) 
Material Hounsfield units (# CT) Linear attenuation coefficient µ (cm-1) 
Air -972.21 0.000 
L-POLYETHYLENE (LDPE) -54.60 0.146 
H2O 0.00 0.155 
Polymethylmethacrylate (PMMA) 149.65 0.178 
Polytetrafluoroethylene (PTFE), r=2,25 962.60 0.303 
 
  
Figure 3.4: Results from bilinear fitting using software provided by HERMES. A: coefficients generated 
for the two linear equations. B: Attenuation correction menu from HROD. 
A B 
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3.2. Sensitivity determination results  
3.2.1. Planar sensitivity test results  
In terms of planar sensitivity, figure 3.5 shows sensitivity results for detector and 
the geometric mean (GM) of both results when the measured ROI size increases 
(from 4 to 10 pixels). This figure shows that for the same distance, sensitivity 
increases with ROI size. Moreover, as the source–to–collimator distance increases, 
the sensitivity decreases for the same measured ROI. The relative difference (taking 
18 cm data as reference) in GM sensitivity varies from 14.50% to 4.80%, between 4- 
and 10-pixels ROI measured size, for 8 cm and 18 cm.       
 
 
Figure 3.5: Planar sensitivity variation in air, for a matrix size of 128x128, for different source–to–
collimator distance for GE-Discovery NM/CT 670, for each gamma camera detector and for the 
geometric mean (GM) for different ROI sizes. D: GM sensitivity results for different source–to–
collimator distance. 
3.2.2. SPECT sensitivity test results  
3.2.2.1. Spherical source geometry  
Table 3.6 shows results for sensitivity factors from phantom configurations 3 
and 4 and its average for different reconstructions. Sensitivity results for 0.0 and 0.11 
cm are similar, variation occurs after the second significant number. Then from now 
and towards, without post-filter results are the same for 0.0 and 0.11cm. For the 
same post-filter, as the number of iterations increases, the sensitivity increases. For 
the same number of iterations and subsets, without post-filter, sensitivity values for 
the source placed inside the empty phantom are higher than the results for the 
source placed in the phantom containing water.  
The absolute difference between sensitivity values for the source placed inside 
the phantoms (in air and containing water) varies from 0.55 to 0.73 cps/MBq without 
post-filtering, and in the when post-filter is set to 1cm, these differences decreases 
varying from 0.04 to 0.28 cps/MBq. For all the cases, the post-filtering effect on 
sensitivity results is important because the values can be reduced up to 1.98 
cps/MBq.  
On the other hand, considering all correction methods applied within OSEM 
and non-post-filter, sensitivity varies from 9.32 to 10.41 cps/MBq (average 9.91 
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cps/MBq); for Gaussian post-filter = 1.0 cm, sensitivity varies from 7.61 to 7.90 
cps/MBq (average 7.76 cps/MBq).  
 
Table 3.6. Sensitivity results for spherical source centered either in an empty phantom or in a phantom 
filled with water using attenuation, scatter and collimator response corrections within OSEM and 
Gaussian post-filter. 
Id Gaussian post- filter (cm) Iterations Subsets 
Sensitivity (cps/MBq) 
Empty 
phantom 
Phantom filled 
with Water Average±s 
1 Without post-filter 
4 5 
9.32 9.04 9.18±0.20 
2 1 7.61 7.63 7.62±0.01 
3 Without post-filter 
4 10 
9.69 9.38 9.54±0.22 
4 1 7.72 7.79 7.76±0.05 
5 Without post-filter 
6 10 
9.84 9.51 9.68±0.24 
6 1 7.72 7.79 7.76±0.05 
7 Without post-filter 
8 10 
9.95 9.59 9.77±0.25 
8 1 7.73 7.81 7.77±.0.06 
9 Without post-filter 
16 10 
10.22 9.83 10.03±0.27 
10 1 7.74 7.86 7.80±0.08 
11 Without post-filter 
32 10 
10.41 10.05 10.23±0.26 
12 1 7.76 7.90 7.83±0.01 
 
In the appendix of this chapter figures A.1 and A.2 show an artifact that may 
be associate to the use of the collimator-response-correction, this is known as Gibbs-
like artifact.  
3.2.2.2. Cylindrical source geometry 
Table 3.7 shows results for the sensitivity factors obtained with configurations 
1 and 2. Different activities and different acquisition times were used. In both cases, 
as expected, segmentation produces different volumes depending on the modality. 
With threshold set at 23 and 24%, volumes close to the real source distribution are 
generated. However, regardless the threshold, the sensitivity values are very similar, 
for two different initial activities and acquisition times. For the two activities and two 
thresholds used, sensitivities vary between 10.10 and 10.21 cps/MBq. Moreover, 
comparing these results with the ones of 3 and 4 configurations (considering the 
variation in source geometry), sensitivity results are in the same order of magnitude 
and comparable to those values generated when non-post-filter was used. 
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Table 3.7. Sensitivity results for activity placed in a bottle (to mimic a kidney) placed into a phantom 
filled with water, using a reconstructed image with OSEM (6i, 10ss) +AC+S+CR+non-GPF. 
Activity in the bottle NM volume (ml) CT volume (ml) 
Initial activity 
(MBq) 
Sensitivity 
(cps/MBq) 
Threshold curve 23 % 497.90 505.11 A1=535.44 10.10 Threshold curve 24 % 493.33 500.88 10.15 
Threshold curve 23 % 494.88 504.39 A0=272.80 10.18 Threshold curve 24 % 491.61 499.55 10.21 
 
3.2.2.3. Recovery coefficient results  
Figure 3.6 shows the recovery coefficient results using a phantom with and 
without background activity, when non-Gaussian post-filter is used. In both cases, 
images were reconstructed using OSEM, applying all correction methods. As the 
number of updates increase, the recovery coefficient increase. In the case figure 
3.6.A., for spheres volumes 2 and 4 ml, as the number of updates increase, the 
recovery coefficient increases reaching more than 100% (for 320 updates). For 
spheres volumes between 8 and 16 ml, the same effect is observed, as the number 
of updates increase, the recovery coefficient also increases, but for these spheres 
reaching values less than 100%. Similar tendency occurs in the presence of 
background activity (figure 3.6.B.), for the 2 ml sphere the variation in the recovery 
coefficient is between 23% and 68%; for the 4 ml sphere the variation is between 
45% and 87%, for 8 ml sphere the variation is between 56% and 77% and for the 16 
ml sphere is between 69% and 81%, from 20 to 320 updates, respectively. From both 
figures, an overestimation in the recovery coefficient occurs for spheres of 2 and 4 
ml, as the number of updates increases. 
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Figure 3.6: Recovery coefficient for OSEM reconstructed images of a phantom using attenuation, 
collimator response and scatter corrections, without Gaussian post-filter. A: without background 
activity. B: with background activity. 
3.2.3. Phantom evaluation on three commercially available workstations  
3.2.3.1. Activity determination 
Looking at the results in table 3.8, good results in terms of the activity 
estimation and residence times can be seen for HDM and PDOSE, less so for 
STRATOS. In the case of HDM the relative difference (%) in activity varies from -
7.02% to -3.80% and for the residence time results the relative difference (%) is 
4.44%. For PDOSE the relative difference (%) varies from -2.20% to 3.20% and -
3.54% in activity and residence times, respectively. In the case of STRATOS the 
percentage of relative difference varies from -61.22% to 5.70% and -50.52% in 
activity and residence times, respectively. 
 
 
 
 
 
 
 
 
A 
B 
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Table 3.8. Activity estimation for each software for reconstruction OSEM (6i,10ss) +A+S+CR+Non-
Gaussian post-filter. 
DT (hours) Activity (MBq) Relative difference (%) 
Residence 
time (h) 
Relative 
difference (%) Software Theory Estimation 
2.50 529.80 550.62 -3,93 
241.93 4.44 HDM 
24.97 480.53 499.73 -4,00 
49.05 432.78 463.17 -7,02 
146.28 283.66 297.51 -4,88 
168.70 257.33 267.11 -3,80 
2.50 529.80 546.72 3,20 
222.00 -3.54 PDOSE 
24.97 480.53 480.75 0,05 
49.05 432.78 432.86 0,02 
146.28 283.66 283.18 -0,17 
168.70 257.33 251.72 -2,20 
2.50 529.80 560.00 5.70 
114.00 -50.52 STRATOS 
24.97 480.53 390.00 -18.84 
49.05 432.78 350.00 -19.13 
146.28 283.66 110.00 -61.22 
168.70 257.33 100.00 -61.14 
 
Figures 3.7.A and 3.7.B show the positioning and placement variation of the 
phantom using HDM and PDose for each time point measurement, after the 
registration process. These images are not possible to extract from STRATOS. In the 
case of HDM and PDOSE results regarding the mono-exponential fit can be seen. 
STRATOS does not provide this information. PDOSE provides a tool to verify the 
goodness of the fit by using the Spearman coefficient, while the other software do not 
provide such tools for this evaluation. 
Figure 3.7. (C, D, E) shows mono-exponential fit results for HDM, PDOSE, 
and STRATOS. With HDM and PDOSE, the point measurements almost fit a mono-
exponential function. However, with STRATOS, the point measurements are fitted by 
the trapezoidal method. 
3.2.3.2. Residence time evaluation and phantom validation   
Tables 3.9, 3.10 and 3.11 used the average sensitivity values from tables 3.6 
and 3.7 and show results for relative difference (%) between the theoretical 
residence time and the estimated residence time using HDV, STRATOS, and 
PDOSE.  
In case of table 3.9, for the two thresholds applied, as the sensitivity values 
increases, the percentage of error decreases. For sensitivity values obtained without 
post-filter (same Id), the relative differences (%) are lower than 5%, as it can be seen 
for sensitivity values varying from 9.78 to 10.23 cps/MBq. For these reconstructions a 
Gibbslike artifact can be observed (see appendix chapter 3). Moreover, for sensitivity 
values obtained using a Gaussian post-filter at 1.0 cm, the percentage of relative 
difference varies from 29.90 to 33.74%.  
In table 3.10, percentage of relative difference are lower than 1% when the 
calibration factors are coming from the sensitivity values obtained using the same 
source configuration. In this case Gibbslike artifacts are less important because the 
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reconstruction was carried out using 60 updates (see appendix chapter 3). 
In table 3.11, for STRATOS, the relative difference (%) results vary from -
44.48 to -50.52% and -28.79 to -38.45%, for non-post-filter and post-filter at 1.0 cm, 
respectively. For PDOSE these figures vary from -8.58 to 1.83% and 19.31 to 
22.67%, for non-post-filter and post-filter at 1.0 cm, respectively. 
 
	
	
	
C: Fraction of injected activity and 
Mono-exponential fitting by HDM 
	
D: Time activity curve for the generated 
volumes and trapezoidal fitting by 
STRATOS 
	
E: Time activity curve for the generated 
volume and Mono-exponential fitting by 
PDose 
Figure 3.7: A: Axial view of phantom placement after registration process using HDM and B: PDOSE. 
 
 
 
 
 
B 
A 
B 
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Table 3.9. Percentage of relative difference (PRD) results for residence time estimations entering into 
HDM sensitivities values from table 3.6. 
Id Average Sensitivity (cps/MBq) 
PRD in residence times 
Segmentation threshold applied 
23% 24% 
1 9.18 11.02 10.77 
2 7.62 33.74 33.45 
3 9.54 6.91 6.67 
4 7.76 31.45 31.16 
5 9.68 5.12 5.35 
6 7.76 31.37 31.09 
7 9.77 4.07 4.29 
8 7.77 30.87 31.16 
9 10.03 1.51 1.73 
10 7.80 30.35 30.63 
11 10.23 -0.56 -0.35 
12 7.83 29.90 30.19 
 
Table 3.10. Percentage of relative difference (PRD) results for residence time estimations entering 
into HDM sensitivities values from table 3.7. 
Sensitivity (cps/MBq) 
PRD in residence times 
Segmentation threshold applied 
23% 24% 
10.10 0.95 0.73 
10.15 0.38 0.16 
10.21 0.11 -0.11 
10.18 -0.19 -0.41 
 
Table 3.11. Percentage of relative difference (PRD) results for residence time estimations entering into 
STRATOS and PDose sensitivities values from table 3.6. 
Id Average Sensitivity (cps/MBq) 
PRD in residence times for 
STRATOS 
PRD in residence times for 
PDose 
1 9.18 -48.10 1.83 
2 7.62 -34.83 22.67 
3 9.54 -50.52 -2.20 
4 7.76 -33.62 20.32 
5 9.68 -48.10 -3.54 
6 7.76 -31.20 20.32 
7 9.77 -46.86 -4.55 
8 7.77 -38.45 20.32 
9 10.03 -44.48 -6.90 
10 7.80 -28.79 19.65 
11 10.23 -49.31 -8.58 
12 7.83 -38.45 19.31 
 
From the previous results, the calibration factor providing the best residence 
times are for reconstructions using OSEM (6 or 8 iterations, 10 subsets), with all 
corrections and gaussian post-filter set at 0.0 cm, for all workstations except for 
STRATOS. Higher number of updates provided good results as well, but Gibbs-like 
artifacts are presented. 
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4. Discussion  
In table 3.1, an overview of different SPECT acquisitions protocols was 
presented. Most publications used gamma cameras with the same crystal thickness 
and the same collimator type. Therefore, one should expect similar results because 
intrinsic and extrinsic sensitivities should be close. Our SPECT/CT was from GE, 
therefore, our acquisition protocol was very similar those using this SPECT/CT 
system. Energy windows selected in our studies were similar to the majority of the 
references and chosen according to the recommendations from Ljungberg 
(Ljungberg et al., 2016).  
Four out of five of GE SPECT/CT systems used 60 projections in total, with more 
than 40 seconds per projection. On the other hand, for the three references using 
Siemens SPECT/CT systems the number of projections was variable, and times per 
projection were equal to or lower than 40 seconds. Also, two out of three reference 
used different acquisition times for calibration and patient acquisition. The Phillips 
SPECT/CT system was used with 128 projections and 30 seconds per projection.  
For acquisition, the preferred matrix size was 128x128 matrix size. The preferred 
acquisition mode was step&shoot rather than continuous. Auto-contouring was 
preferred because most reconstruction algorithms contains the collimator response 
correction. From these references an acquisition protocol can be drafted. 
In terms of reconstruction, two out of nine references used reconstruction 
software different from that of the manufacturer. The reconstruction algorithm chosen 
was OSEM. In terms of number of iterations and subsets, references using Phillips 
and Siemens systems there were not seem to be a clear relation, but for GE systems 
4 or 8 iterations, with 8 or 10 subsets where chosen.           
In terms of SPECT corrections, all references cited used attenuation 
correction. For scatter, one reference used different methods, one used DEW, one 
used a Monte Carlo Simulation approach, two used TEW, two used ESSE and two 
did not mentioned their selected approach. For collimator response, three out of nine 
references did not mention if they used any. For dead time, one out of nine took this 
correction into account. According to MIRD recommendation (Ljungberg et al., 2016), 
for scans acquired shortly after injection time, dead time may have little effect on the 
overall absorbed dose calculation. For partial volume effect correction, three 
publications clearly mentioned that they did not use any, and in two there was no 
mention of its use. Six out of nine reference used recovery coefficients to correct this 
effect.  
Our reconstruction method was based-on HROD considering all corrections 
available in this workstation. We did not perform any dead time correction because 
for the calibration process we did not used high activity.  
The SUV option in the HROD module from Hermes allows the comparison of 
SPECT sensitivity results with other workstations. However, at the time of performing 
this study, this option was not available.  
Regarding calibration factors presented in the same table, some of the authors 
have used them with similar units cps/kBq (de Nijs et al., 2014) and cpm/kBq 
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(Sanders et al., 2015) or identical units as those presented in this work, cps/MBq. In 
the majority of cases, cylinders were preferred as phantom geometries to contain 
several inserts that were used as a calibration source. Cylinders, spheres and bottles 
inserts were chosen as source geometry. In planar studies petri dishes were 
preferred. 
4.1. CT calibration curve  
Most of the SPECT/CT systems can use the information regarding this CT 
calibration directly by following manufacturer recommendations. Hermes is an 
independent workstation to perform reconstructions. The determination of the CT 
calibration curve was a challenge, because we were using the results at 80 keV, from 
the measurements using the Catphan phantom, to establish the bilinear equations at 
140 keV. Using information from NIST our results for water are slightly higher 
compared to those reported by Brown (Brown et al., 2008). Knowing this difference 
all reconstructions were performed in the same way, for phantom calibrations and 
patient data, therefore creating a systematic bias.  
Brown et al. has investigated how to obtain these relationships using different 
radionuclides and slabs of different materials by creating a narrow beam geometry 
and measuring directly in the gamma camera (Brown et al., 2008). At 140 keV, for 
water, they reported a linear attenuation coefficient of 0.149 cm-1. They reported 
differences for all measured material in less than 2% at this energy, comparing to 
NIST. Our results at 140 keV are slightly higher than those reported by the same 
group.  
McParland (McParland, 2010) developed an interesting methodology to create 
this curve (see chapter 1), nevertheless, by using the linear attenuation coefficient 
information for bone, from the emissions photons and the CT component, these data 
was not available, hence we could not test this approach. 
4.2. Sensitivity determination  
4.2.1. Planar sensitivity  
Barquero et al. has shown planar sensitivity results for a Siemens e-cam 
system (Barquero et al., 2017). Their results are for 131I from measurements and 
Monte Carlo simulations using SIMIND. They showed sensitivity increases with size 
(ROI) for any distance, and decreases with distance for any size. Similar results were 
seen using ImageJ at CRCT. Using XelerisTM at ICM and creating a circular ROI to 
cover the source distribution, insignificant variation of sensitivity was observed for all 
distances. 
Uribe et al. (Uribe et al., 2017) and Zhao et al. (Zhao et al., 2018) have 
performed studies using a point source in air, in both cases TEW corrections were 
applied. In both cases they used a collimator-to-source distance between 25 and 
30cm. They concluded that camera sensitivity does not depend on the source-
collimator distance although increase in recorded counts may occur due to septal 
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penetration if sources are placed very close to the collimator. The previous 
conclusion can be confirmed by looking at figure 3.5. 
In our case scatter correction was not performed, because we did not found an 
agreement in the value of “k” that is necessary to be applied with the Dual Energy 
Window (DEW), for instance, de Nijs et al. (de Nijs et al., 2014) mentioned that 
further studies should be perform with patient data, because “k” values may differ 
from the ones that they studied (k= 0.5, 0.8, 0.9). Then, our planar sensitivity results 
are higher than expected because DEW was not performed. However, if DEW was 
performed, results should be comparable, because the scatter counts from a 
spherical source in air are not high.    
4.2.2. SPECT sensitivity  
4.2.2.1. Spherical source – Gibbslike artifacts  
From table 3.6, as expected, when the number of updates increases, the 
counts will increase and then converge to a certain level; this phenomenon is present 
under OSEM reconstructions. For both phantom configurations (3 and 4), sensitivity 
results are very similar but not equal. On the other hand, the impact on reconstructed 
images due to the post-filtering (1.0 cm) is very important, therefore it may be 
necessary to perform two different reconstructions, one for clinicians (for patient 
reports) and one for physicists (for quantification procedures).  
Considering phantom model and the source placement, in the work of Wevrett 
et al. (Wevrett et al., 2017), different phantom configurations were used in order to 
determine the calibration factor for a specific equipment. They recommended to use 
the mean value of the sensitivity obtained from three configurations, which are the 
source centrally in air, source centrally in a phantom filled with water and source with 
an offset in a phantom filled with water. They also mentioned that adding resolution 
recovery reduces the variation in the calibration factor by 50% or more, depending on 
the camera system but maintains the geometry dependence, with the overestimation 
of the calibration factor increasing with distance from the centre of the phantom. We 
did not perform the offset configuration because we were satisfied with the obtained 
results with the source centered in air and in a phantom with water.  
In terms of Gibbslike artifacts, according to Ljungberg et al. (Ljungberg et al., 
2016), using collimator response correction can benefit NM images in several ways. 
For instance, it can modify the distribution of counts in the image without changing 
their total number. Therefore, the quantification in the field of view should not be 
affected. Also, it decreases the resolution-induced spill-out of counts from hot 
regions. However, it may create Gibbslike artifacts in the vicinity of sharp boundaries. 
This phenomenon is presented in our reconstructed images, especially in phantoms 
where no background activity and no post-filtering were employed (figures in 
appendix of chapter 3). Also, when post-filtering is used this phenomenon is highly 
reduced and it only starts to appear at 320 updates. However, in clinical practice 
these situations will not be seen, because background activity will be within the 
patient, surrounding different VOI’s. We did not study deeply this effect in the 
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background:spheres ratio activity. In our case, an activity ratio of 8:1 was employed 
and this effect is still present at 160 updates.  
A decision was taken in terms of the reconstruction, considering only using 
OSEM 6 iteration and 10 subsets. Gibbslike artifacts may be reduced at this number 
of updates, without Gaussian post-filter. The speed of reconstruction was fast, then 
optimal for clinical implementation.  
4.2.2.2. Cylindrical source 
In table 3.7, sensitivity results for different source geometry can be seen. 
Using the threshold at 24% generated a CT volume close to the real source volume. 
The bottle was segmented automatically considering that it was not easy to do it 
manually, due to the thickness of the bottle wall. Moreover, source and phantom 
were filled with water increasing the difficulty to segment volumes correctly. By using 
the automatic segmentation tool same volumes were generated, in a reproducible 
way. However, when manual segmentation was performed volumes close to 500 ml 
were generated.  
The sensitivity results presented in this table were obtained using two initial 
activities; results vary from 10.10 and 10.21 cps/MBq (average 10.18 cps/MBq). 
These results are 1.01 cps/MBq higher than sensitivity results of reconstruction Id #5 
from table 3.6. This insignificant difference can be associated to difference in source 
geometry, phantom model (cylindrical vs elliptical), and acquisition time.  
Considering source geometry (sphere vs bottle), less partial volume effect may 
be expected for the bottle source geometry than the sphere source geometry due to 
the difference in diameter size, therefore better results in terms of sensitivity should 
be expected. 
Robinson et al. (Robinson et al., 2016) used a large cylinder phantom to 
determine whole-body sensitivity but their conclusions are related with the TEW 
scatter correction and they do not use collimator response correction in their work. 
Dewaraja et al. (Dewaraja et al., 2012) proposed to have calibration factors based-on 
the studied volume. Tran-Gia and Lassmann (Tran-Gia & Lassmann, 2017), created 
a 3D realistic 2-compartment kidney phantom. They considered the effect of source 
geometry and its placement, observed Gibbslike artifacts, and partial volume effect. 
Zhao et al. (Zhao et al., 2018) mentioned that its calibration factor value corresponds 
purely to the camera efficiency for given radioisotope, collimator and energy window 
settings. It does not depend on the camera and image resolution, the size and shape 
of the imaged object, the signal-to-background ratio and other factors. 
The HROD user’s manual (Hermes Medical Solutions, 2015), presents an in-
house study using an Jaszczak phantom filled with water and 99mTc. The acquisition 
was performed using a Siemens® Symbia-T SPECT/CT, with LEHR collimators. 
They explain the reconstructing procedure and they draw spherical ROIs of 3.0cm in 
diameter in 5 different locations. They find good activity concentration results; 
however, they did not used the whole Jaszczak phantom filled water as source 
geometry to perform the calibration itself. 
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For calibration purposes it may be important to consider a bigger geometry 
source, such as the whole Jaszczak phantom (without the inner structures) at least to 
reduce partial volume effect. But in the case of quality control, in order to check the 
stability of the gamma camera for 177Lu, a planar acquisition of a point source in air 
can be implemented in clinical practice. 
Regarding the calibration factor estimation, acquisition time will not have an 
impact on our results, at least for HDM, STRATOS and PDOSE, because for these 
workstations calibration factor it is not time dependent. This is not true in the case of 
DTK.  
SPECT sensitivity results (cps/MBq) for 177Lu obtained after reconstruction 
with HROD, Marin et al. (Marin et al., 2017), Uribe et al. (Uribe et al., 2017) and Zhao 
et al. (Zhao et al., 2018) showed similar results using another gamma camera type. 
4.2.3. Recovery coefficients  
Marin et al., used a similar phantom configuration and similar set of spheres, 
different SPECT/CT (Symbia TruePoint T), different reconstruction algorithm (Syngo 
MI Applications 8.5) and different collimator type - medium energy, low penetration 
collimator (MELP), In their results as the number of updates increases, the recovery 
coefficient increases for different Gaussian post-filters, for two different sphere sizes. 
Their recovery coefficient values are comparable to our results using a Gaussian 
post-filter set at 1.0 cm. It is important to notice the behavior of the recovery 
coefficient when non-Gaussian post-filter was applied for spheres between 2 and 4 
ml, showing an overestimation of the real activity in the sources. Nonetheless, for the 
same spheres with Gaussian post-filter this overestimation is reduced up to 38% and 
50%, respectively; this is due to the smoothing of counts generated when the post-
filter is applied. The overestimation effect, for these two spheres, increases as the 
number of updates increases. When Gaussian post-filter at 1.0 cm is applied our 
results are similar to those presented by Marin et al. (Marin et al., 2017) for an 
equivalent number of updates. In our case, the recovery coefficient results are just to 
benchmark the SPECT/CT, because in our clinical implementation (see chapter 4) 
the segmented volumes are bigger than 70 ml, then the recovery coefficient should 
be 1 (or very close). 
According to Dewaraja et al. (Dewaraja et al., 2012), in iterative 
reconstruction, using the distance-dependent collimator-detector response function 
will reduce partial-volume effects but complete resolution recovery will not take place. 
Therefore, this correction should be applied for some small structures. 
4.2.4. Phantom evaluation on three commercially available workstations  
To evaluate (part of) the dosimetric chain, rather than just activity 
quantification, we evaluated the residence times in HDM, PDOSE, and STRATOS. 
One idea was to check the registration process in a multi-SPECT/CT scenario, 
especially considering the misplacement of the phantom. Obviously, the phantom 
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being rigid, this is an oversimplified use of registration algorithms implemented in the 
workstations. In real patient acquisitions the situation would be much worse, due to 
patient placement, internal organs movements, related or not to respiratory motion. 
Looking at figure 3.7.A and 3.7.B, using HDM and PDOSE, the phantom positioning 
can be visually assessed after registration (for instance, in the axial view); with 
STRATOS, the registration cannot be checked in a similar way.  
4.2.4.1. Activity determination  
The initial idea was to compare the three workstations according to the 
reconstruction method, to measure the activity at each time point for each 
workstation and to estimate the residence time. 
From our results in table 3.8, HDM performed similarly as PDOSE, showing 
that the registration method was able to see the variations in phantom positioning. 
The variations in segmentation for both software are not very important, because at 
each time point the PRD is less than ±10%, and in the case of PDOSE the PRD are 
less than ± 3.3%. In the case of STRATOS, for the first three data points the activity 
estimation was good, reaching PRD values less than ± 20%. For the last two data 
points the phantom position varied, hence the activity estimation was not good. Most 
probably the error in quantification is associated to the registration method, in which 
only one CT (reference CT) is used to register all NM data points. From this 
experience, it could be advisable to perform the registration using CT data only.    
4.2.4.2. Residence time evaluation 
For each average sensitivity, a calibration factor was estimated in order to be 
used in each software. Looking at table 3.9 for calibrations factors derived from 
reconstructions with non-Gaussian post-filter, PRDs are lower than 11.02%, for the 
two segmentation thresholds applied. In fact, when average sensitivity is close to 10 
cps/MBq, the relative difference (%) between the theoretical and estimated residence 
time is close to 0%. Relative differences (%) derived from reconstructions using post-
filter 1.0 cm are the worst for the tested calibrations factors. These results confirm 
that one set of reconstructed images with non-Gaussian post-filter must be used for 
quantification. From this table, the sensitivity factors 9.68 or 9.77 cps/MBq, should be 
chosen for quantification purposes. 
In the case of results from table 3.10, calibration factors come from 
sensitivities values close to 10 cps/MBq, therefore percentage of relative differences 
are lower than 1%.  
Table 3.11 the percentage of relative differences using STRATOS and 
PDOSE can be observed. When using PDOSE similar tendency as HDM can be 
observed. The best results are obtained with non-Gaussian post-filter. However, this 
occurs for the sensitivities lower than 10 cps/MBq. In this case, the segmentation 
process was manual, generating a source volume of 492 ml, very close to the real 
volume in the bottle. With this software the goodness of the fitting can be evaluated 
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quantitatively and qualitatively by using the Spearman’s coefficient. Nevertheless, no 
explanation has been found to the opposite behavior of HDM and PDose.   
On the other side, table 3.11 shows percentage of relative differences using 
STRATOS, for this software no trend in the results can be seen for any of the 
calibration factors used.  
Comparing HDM and PDOSE, both performed similarly in terms of residence 
time and activity estimations, as shown in table 3.8. Both show the final registration 
result and the user can evaluate qualitatively its performance. On the other hand, 
HDM shows the highest percentage of relative difference (7%) in activity estimation 
(for time point at 49h), this effect can be seen also in figure 3.7.C.  
STRATOS could not recognize the phantom misplacements, therefore, 
registration process between the first CT and the others NM images may generate 
great variations in the estimated activity for each measured time point (and voxel per 
voxel); hence, estimation of residence time for 177Lu will not be optimal. Our version 
of the software does not provide manual registration option; hence, we applied the 
same automatic registration algorithm, but it was not possible to obtain the same 
registration parameters results when reprocessing phantom data. These results can 
be confirmed by looking at table 3.8, in which the highest percentages of relative 
differences in activity were seen when the positioning of the phantom varied 
importantly, creating a bias in residence time estimation. 
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5. Conclusions  
As could be seen, calibration procedure is a complex process that is far from 
being standardized. This is reflected in the different dosimetric software. 
CT calibration curve, planar and SPECT sensitivity factors were estimated and 
established for a SPECT/CT system at the ICM. 
In this study, two phantom models using different source geometries were 
used. One important effect degrading image quality is the partial volume effect, but 
using collimator-response correction (and recovery coefficients) this phenomenon 
could be reduced in small structures. Nevertheless, this correction can generate 
Gibbslike artifacts.  
Although there are several publications regarding 177Lu, further investigations 
should be done to assess Gibbslike artifacts in clinical practice, especially when high 
numbers of updates are used with OSEM reconstruction algorithm.  
One possible solution to avoid PVE artifacts is to use big sources for the 
calibration process and to use point sources for quality control purposes (to assess 
the constancy of the detector). 
In the case of HDM and PDOSE, preliminary results show best calibration 
factors derived from sensitivity values close to 10 cps/MBq. For STRATOS it was not 
possible to obtain a calibration factor.  
HDM and STRATOS allow using one calibration factor only. PDOSE allows 
more than one calibration factor (if the user needed). This option should be managed 
carefully in clinical routine as there is no built-in verification process (i.e. sanity check 
of entered values). 
We presented an indirect validation method to assess the dosimetric chain in 
three workstations. This method was implemented by finding the theoretical 
residence time in a phantom study (considering phantom displacements). From 
residence time results assessed in a phantom study, HDM and PDOSE performed 
similarly and STRATOS shows a bias that may be associated to the registration 
process (even in simple situations as that of a rigid phantom).  
Having established the best reconstruction set-up, its associated calibration 
factor and validated three workstations, clinical patient data can be processed and 
analyzed. Moreover, dosimetric results can be obtained for segmented structures.  
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1. Introduction  
Lutetium 177 (177Lu) is a good candidate for targeted radionuclide therapy, due 
to the possibility of reliable labeling on biomolecules used for tumour targeting and its 
decay characteristics (Ljungberg et al., 2016). It has been used for example in 
peptide receptor radionuclide therapy (PRRT). The agent 177Lu-DOTA-octreotate 
enables the targeting of somatostatin receptors (SSTR) expressed at the surface of 
neuroendocrine tumours (NET) (Kashyap et al., 2014).  
PRRT has been used for several years proving to be safe, efficient and well-
tolerated to treat patients with NETs (Bodei et al., 2011; Strosberg et al., 2017). 
Lutathera (177Lu-labelled DOTATATE) has recently received EMA and FDA approval, 
with an administration scheme of 4 cycles of fixed (7.4 GBq) activity. This has 
triggered a debate within the nuclear medicine community regarding the relevance of 
advocating “one-size-fits-all” approaches in the personalized medicine era (Chiesa et 
al., 2017; Flux et al., 2017; Giammarile et al., 2017). Regardless of the obvious clash 
between the Euratom Directive and EMA decision (one EU body enforcing patient-
specific dosimetry whereas another one de facto limits its implementation), 
publications have demonstrated the added value of dosimetry in a context of PRRT 
with 177Lu.  
Treatment optimization can be based on the evaluation of absorbed doses 
delivered to critical organs (kidneys, red or active bone marrow) or tumours 
(Bergsma et al., 2016; Garske-Román et al., 2018; Astrid Gosewisch et al., 2018; 
Sundlöv et al., 2017; Valkema et al., 2005).  
Different approaches to clinical dosimetry have been proposed. They are 
based on whole body (WB) planar images (Cremonesi, et al. 2006; Mirzaei, et al., 
2013; Schuchardt, et al., 2013; Svensson et al., 2016), SPECT/CT images 
(Beauregard, et al., 2011; Hänscheid, et al., 2018; Ilan et al., 2015; Sanders, et al., 
2015) or hybrid methods combining WB planar images with one or two SPECT/CT 
(Bailey et al., 2015; Brolin, et al., 2015; Garkavij et al., 2010; Guerriero et al., 2013; 
Sandström, et al., 2010). Comparison between planar and SPECT activity 
quantification treating NET patients has shown an overestimation of kidney activity 
using planar methods, due to overlapping of high activity areas (Garkavij et al., 
2010). 
Up to recently, there was no dosimetry software in commercial nuclear 
medicine workstations. Therefore academic/research institutions/hospitals developed 
ad hoc dosimetric software. Among these software are: DOSIMG (Tagesson, et al., 
1996), MABDOSE (Johnson, et al., 1999), DOSE3D (Clairand, et al., 1999), RMDP 
(Guy, et al., 2003), VoxelDose (Gardin et al., 2003), MrVoxel (McKay, 2003), 3D-ID 
(Sgouros et al., 2004), LundADose (Sjögreen et al., 2005), OEDIPE (Chiavassa et 
al., 2006), MINERVA (Lehmann et al., 2005), 3D-RD (Prideaux et al., 2007), 
RAYDOSE (Marcatili et al., 2013), VIDA (Kost et al., 2015) and NUKDOS (Kletting et 
al., 2015).  
Beyond these efforts, commercial packages are arriving on the market, 
providing solutions that include different modules for dealing with raw data or 
Chapter	4:	Patient	data	evaluation	on	commercial	workstations	
159 
 
uploading reconstructed DICOM images, allowing registration and segmentation 
processes, data fitting and absorbed dose estimations/reporting, i.e. addressing the 
different steps of the dosimetric workflow. Figure 4.1 shows a scheme of the 
dosimetric workflow. 
 
 
Figure 4.1: Clinical dosimetric workflow scheme. Created by Manuel Bardiès. Used with his 
permission. 
 
In this chapter four commercial software are compared based-on clinical data 
from two patients with gastroenteropancreatic tumours of neuroendocrine origin 
treated with 177Lu-DOTATATE. Two cycles of treatment for each patient were used to 
estimate residence times for the kidneys, liver, spleen, bone marrow and whole body.  
In the case of the bone marrow, a new methodology is presented to estimate 
the absorbed dose without the need for whole-body measurements.  
It can be seen that the registration of the images has an impact on the 
determination of the absorbed dose. The results are therefore calculated by 
employing an approach that involves independent registration of each volume of 
interest in the images.  
Different calculation algorithms were used to determine the absorbed dose 
delivered to patients.  
Several objectives are addressed to assess the reliability of four commercial 
workstations using patient data sets: 
c. To calculate residence times for liver, spleen and kidneys. 
d. To estimate the absorbed doses for the previous organs. 
e. To estimate the absorbed dose to red bone marrow when whole body 
measurements were not performed. 
 
2. Materials and Methods  
All measurements and treatments were carried out at the Institut régional du 
Cancer de Montpellier (ICM) in the Nuclear Medicine Department, using a GE-
Discovery NM/CT 670 SPECT/CT, 9.5 mm crystal thickness. One set of projections 
was acquired and was reconstructed and analyzed at the ICM and the Centre de 
Recherches en Cancérologie de Toulouse (CRCT). All activity measurements were 
done in an accurate activimeter calibrated for 177Lu measurements.  
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At CRCT reconstruction was performed using HybridRecon-Oncology 
version_1.3_Dicom (HROD) from Hermes without using the SPECT Standard Uptake 
Value (SUV) (Kangasmaa, et al., 2016) option. At ICM images were reconstructed 
using Dosimetry Toolkit®, which is an application of the commercial workstation 
Xeleris®. A general overview of the four software was introduced in chapter 3. 
2.1. Patient characteristics 
Two patients (one male, one female) who benefited from PRRT with 177Lu 
were considered in this study. Table 4.1 shows some characteristic of these patients. 
Each patient received four cycles of therapy, with an interval of approximately 8 
weeks.  
 
Table 4.1. Characteristics of patients treated with 177Lu-DOTATATE for PRRT. 
 Treatment cycle for female patient Treatment cycle for male patient First Second First Second 
Injected activity 7176.7 7239.4 7207.2 7188.2 
Age (years) 82 59 
Weight (kg) 
Height (cm) 
57 
153 
79 
180 
Primary tumor Pancreas NET Small intestine NET 
Metastasis Liver Mesentery, liver 
 
2.1.1. Patient data acquisition and reconstruction  
Using same equipment described in chapter 3, SPECT/CT images were 
acquired at 4, 24, 72 and 192 h. In one FOV, pelvic and thoracic regions were 
acquired using 60 projections in total, 45 s per projection, zoom 1, matrix size 
128x128, using two energy windows (one centered at 208 keV at 20% and one at 
177 keV at 10%), parallel-hole medium energy general purpose (MEGP) collimator 
and body auto-contour were used. The CT acquisition protocol was 120 kV, mA was 
set in auto, matrix size 512x512, noise index 6.4, slice thickness 5 mm, pitch 1.375 
and standard reconstruction filter. For each patient and for each time point 
measurement, one set of images was generated.  
At ICM transversal slices were reconstructed using “preparation for dosimetry 
Toolkit application”, this includes manufacturer corrections such as scatter, CT-based 
attenuation, collimator-detector response and uses the two energy windows for 
scatter correction.  
At CRCT the reconstruction was performed with Hermes HybridRecon-
Oncology version_1.3_Dicom (HROD) using the main energy window only and 
applying manufacturer corrections (Monte Carlo-based scatter correction (Sohlberg, 
et al., 2008), CT-based attenuation correction (Hippeläinen, et al., 2016), the 
attenuation map was resampled to correct size/energy (this resampling was 
performed automatically by the workstation), collimator-detector response correction. 
The SPECT standard uptake value (SUV) option (Kangasmaa et al., 2016) was not 
available at the time of this study. Both centers reconstructed images using OSEM 
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(6i, 10ss), and using a gaussian post-filter set at 0.11cm.  
The reconstructed data generated at the ICM was uploaded in DTK from 
Xeleris®. Reconstructed data from HROD was uploaded in PLANET® Onco Dose 
(PDOSE) from DOSISOFT (version 3.1.1 RC-2018-03-16), STRATOS from Phillips 
(Imalytics 3.2, Rev 6289(64)) and Hybrid Dosimetry Module™ (HDM) from Hermes 
(Version 1.0).  
2.1.2. Residence times and absorbed dose comparisons    
The selected organs for this study were the liver, spleen and kidneys. 
Sandström (Sandström et al., 2010) in their study mentioned that most patients had a 
large number of metastases within the liver which made it virtually impossible to 
correct adequately for normal liver weight, then we decided to combine the whole 
normal liver and the tumors in one VOI, which may be wrong from a clinical point of 
view but does not limit the analysis of the dosimetric workstations. 
2.1.2.1. GE Healthcare Dosimetry Toolkit® (DTK)  
Automatic registration occurred by conducting a rigid registration between 
each CT scan and the first CT scan. The reconstruction results were uploaded in the 
“Dosimetry toolkit” application. Kidneys, liver and spleen organs were automatically 
segmented using the first CT and NM images. They were then subsequently 
replicated to the other time point measurements. The SPECT/CT calibration factor 
was used to find the activity per organ at each time point. Fitting was performed 
using a mono-exponential function. By integrating all fitted data, the software 
estimated the residence times per organ and it exported the results to OLINDA/EXM 
V1.0 to calculate the mean absorbed dose.  
2.1.2.2. Hermes Hybrid Dosimetry Module™ (HDM)  
Automatic rigid registration (translation and rotation) was performed taking the 
first SPECT/CT as a reference; the software synchronized two SPECT/CT series at a 
time. Segmentation was carried out manually on CT slices by creating ROI’s for each 
organ. The software automatically created each ROI from the CT on the NM matrix. 
Segmented organs were copied to the following SPECT/CT series, keeping the 
volume constant. If the generated ROI’s did not match the position in axial plane of 
the SPECT/CT series, manual ROI’s replacement was performed. The calibration 
factor was entered in units of MBq/counts, with information regarding date; time of 
injection and injected activity. Extrapolation before the first data point was done by 
creating a horizontal line from t=0 to the first data point (constant activity). Then from 
the first to the last time point curve fitting was done assuming bi-exponential decay 
using the Levenburg-Marquardt algorithm (Mirzaei et al., 2013). From the last time 
point measurement to infinity, mono-exponential decay was assumed considering 
only physical half-life. By integrating all fitted data, the software estimated the 
residence time. Fitting was assessed visually because the software does not provide 
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a tool to evaluate the goodness of the fit. Results were exported to OLINDA/EXM 
V2.0 to estimate mean absorbed dose, with first order mass correction. 
2.1.2.3. DOSISOFT PLANET®Onco Dose (PDOSE)  
Segmentation was carried out manually on the CT slices of the reference CT 
in order to create a VOI for each structure. The software automatically created the 
VOI from the CT on the NM matrix. By using the segmented structure an automatic 
registration was done organ-by-organ. Rigid registration was performed taking the 
first SPECT/CT series as a reference; the software synchronizes two SPECT/CT 
series at a time. Registered images were saved in a new space, called “registered 
space”. After the registration process was done, rigid propagation of the structure 
occurred in the registered space. In this case the generated volume was kept 
constant among all images in the registered space. The calibration factor was 
included at this stage in units of Bq/counts, with the date and injection time 
information. Within the different available fitting options (mono-, bi- or tri-exponential, 
or using the trapezoid method assuming mono-exponential decay from the last data 
point) the best possibility was chosen according to the Spearman coefficient. By 
integrating fitted data the software calculated cumulated activity or mean absorbed 
doses. Using the known injected activity, residence times were also estimated. 
Absorbed dose is estimated by using the local energy deposition method. 
2.1.2.4. STRATOS by Phillips 
Information regarding the calibration factor (in units of Bq/intensity), date and 
time of injection and injected activity were entered. Automatic rigid registration was 
performed between the NM study of each day and the first CT study, which was 
taken as a reference. Segmentation was carried out manually on CT slices of the 
reference CT by creating VOI’s for each organ. The NM images generated by HROD 
had voxel sizes of 4.42 x 4.42 x 4.42 mm3. STRATOS generates cumulated activity 
maps with this voxel size, meaning that no resampling was necessary. Fitting was 
performed at the voxel level, assuming a straight line between zero and the first time 
point; then trapezoid method was applied between the rests of time points. From last 
time point mono-exponential decay (called “tail integration”) was employed 
considering only physical half-life. Voxel S-values in STRATOS are provided for the 
previous dimensions. The cumulated activity is calculated voxel by voxel. The 3D 
cumulated activity maps were then convolved with a pre-calculated water dose voxel 
kernels (DVKs) to obtain a 3D absorbed dose map. Knowing the injected activity, 
residence times can be calculated (Marcatili, et al., 2015).  
2.1.3. Absorbed dose comparisons  
Because DTK export results to OLINDA/EXM V1.0 and HDM export results to 
OLINDA/EXM V2.0, a decision was taken in order to estimate the mean absorbed 
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doses (corrected by organ mass) using each version of the OLINDA (using residence 
times). 
For all software, all organ masses were estimated using density values from 
GATE MC code (Jan, 2004). For liver and spleen this value was 1.06 g*cm-3 and for 
kidneys was 1.05 g*cm-3. Also, to allow comparison with OLINDA, the mean 
absorbed dose to kidneys was performed weighting the left/right results by each 
kidney mass. 
Aside of model-based absorbed dose calculation using S-values tables, other 
approaches are provided within the workstations. In the case of STRATOS mean 
absorbed dose is calculated by a convolution method. In the case of PDOSE, local 
energy deposition method (LDM) is available. 
2.1.3.1. Local energy deposition (LDM) method 
In the case of LDM, this methodology was derived from an image-based 
dosimetry approach developed for radioembolization with resin microspheres. The 
methodology employed by Dosisoft was described in section 5.5.1 from chapter 1.  
The general MIRD equation gives: 
 𝐷:(à←j) = 	𝐴Jj*𝑛KK 𝐸K ϕK(𝑘 ← ℎ)𝑚à  4.1 
 
Where 𝐴Jj is the cumulated activity for an organ source, 𝐸K is the mean energy 
of the ith nuclear transition; 𝑛K is the number of ith nuclear transition per nuclear 
transformation. ϕK(𝑘 ← ℎ) is the absorbed fraction, which is the fraction of radiation 
energy emitted 𝐸K	within the source tissue ℎ that is absorbed in the target tissue 𝑘. 
Finally, 𝑚à is the mass of the organ target. When ϕK(ℎ ← ℎ)=1 (for non-penetrating 
radiation), all emitted energy can be considered as locally absorbed. 
The equation 4.1 becomes: 
 𝐷:(j←j) = 𝐴Jj ∆𝑚j 4.2 
 
 
Where ∆ (in J. Bq-1.s-1) is the emitted energy per decay for the isotope. If LED 
conditions are met, the equation can easily be transposed to voxel-based dosimetry. 
With PDOSE, the average absorbed dose rate will be estimated for each time 
point measurement. Then integrating over time, the average absorbed dose can be 
estimated.  
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2.1.4. Absorbed dose estimation for red bone marrow  
According to Medical Internal Radiation Dose Committee (MIRD) scheme, Red 
Marrow (RM) absorbed doses can be estimated by summing the contributions of self- 
(contribution from RM to RM) and cross-irradiation (from organ sources to RM and 
from remainder of the body (RB) to RM) (Ferrer et al., 2010), as it is shown in 
equation 4.5. 
 𝐷:Ú = 𝐴J:Ú 	× 	 𝑆(:Ú←:Ú) +*𝐴Jjj × 	𝑆(:Ú←j) + 𝐴J:Ï 	× 	 𝑆(:Ú←:Ï) 4.5 
 
Where 𝐴J:Ú, 𝐴Jj and 𝐴J:Ï are the cumulated activities in red marrow, other 
organs and the remainder, respectively. 𝑆(:Ú←:Ú), 𝑆(:Ú←j) and 𝑆(:Ú←:Ï) are S-values 
associated to the previous source-target structures, those values can be found in 
OLINDA/EXM V2.0.  
Manual segmentation of trabecular L2-L4 vertebrae is performed following 
recommendations from Pacilio (Pacilio et al., 2014), also manual segmentation of the 
thoraco-abdominal (TH-AB-FOV) region is performed. In both cases the objective is 
to estimate the volume of each structure. For these two regions residence times are 
calculated, which means, we also applied rigid registration and rigid propagation as it 
was performed for the previous cases. Figure 4.2 shows examples of the performed 
segmentation. 
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Figure 4.2: Example of segmentation (sagital and lateral views) of L2-L4 trabecular vertebrae and the 
thoraco-abdominal region in female patient. 
 
Using residence time results for liver, spleen and kidneys from section 2.1.2.3, 
estimation the remainder of the body (RB) residence time can be obtained by 
summing all other residence times associated to each organs source (liver, kidneys, 
spleen and L2-L4 trabecular vertebrae) and subtracting them from the TH-AB-FOV 
residence time.  
Quantification of RM is possible by using information provided from L2-L4 
trabecular vertebrae, several authors have implemented this quantification (Ferrer et 
al., 2010; Pacilio et al., 2014; Shen et al., 2002). The volume of L2-L4 trabecular 
vertebrae for a female and male reference were 49 ml and 70 ml (Pacilio et al., 
2014), respectively.  Then, the L2-L4 trabecular vertebrae residence time previously 
found is scaled; thus, the remainder residence time is corrected by this new 
estimation. 
On the other hand, S-value 𝑆(:Ú←:Ú) is also scaled, by the ratio 
reference:patient volume of the trabecular vertebrae. Hence, 𝐷:Ú is estimated 
according to equation 4.6. 
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𝐷:Ú = 𝐴J:Ú 	× 	 𝑆(:Ú←:Ú) = 	𝐴J/WM/I0.067 	× 	^𝑆(:Ú←:Ú) × 	𝑉P-Ag	/WM/I-CE@AQ𝑉P-Ag	/WM/IiAPKCQP f 4.6 
 
The images of the patients were focussed in the thoraco-abdominal (TH-AB-
FOV) region and whole-body measurements were not performed. Then, the activity 
determination of the remainder of the body only on acquisitions SPECT is 
challenging, because whole-body (WB)-SPECT was not performed.  
The previous residence time of the remainder of the body is relative to the TH-
AB-FOV, then an approximation to the real patient WB is proposed by the estimation 
of the ratio between the volume of TH-AB-FOV:WB on both patients, and the same 
ratio estimation is calculated for the ICRP-110 models, for validation purposes.  
The WB volume of patients is calculated from their mass, assuming a density 
of 1.01g/cm3, whereas the FOV volume of the patients is extracted from images (see 
figure 4.3.B).  
For the models, the WB volume was known; and we extracted the FOV 
volume by dividing each model between: upper-part (with arms), FOV and lower-part. 
Figure 4.3.A, shows how this division occurred in the model.  
Equation 4.7 shows how the ratios for the volume between patient and models 
are estimated. 
 𝑅@h¼CB = 	 ñLMNOPQRSñTP 	, 𝑅iAPKCQP = 	 ñLMNOPQRSñTP  4.7 
 
Then, if the ratio between the model/patient volumes is similar, the cumulated 
activity of the remainder of the body is scaled as can be seen in equation 4.8 
 𝐴J:Ï,ABC¼ = UUÄPNQRS:cÖ¯OYâ¯   4.8 
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Figure 4.3: Estimation of ratio between the volume of TH-AB-FOV:WB for patient and model. A) 
Division of ICRP-110 RCP-AM model. B) Section of the TH-AB-FOV of a patient. Own creation. 
Patient image provided by ICM nuclear medicine department. 
 
Finally, 𝑆(:Ú←:Ï) is scaled according the ratio between the reference/patient 
mass, according to Traino (Traino, et al., 2007) and Woodard (Woodard, 1984). Then 
the last term of equation 4.5, can be expressed as it is shown in equation 4.9 
 
 𝐷:Ú←:Ï = 𝐴J:Ï,ABC¼ 	× 	 𝑆(:Ú←:Ï),ABC¼ = 𝐴J:ÏMVÓñ𝑅iAPKCQP × 𝑆(:Ú←:Ï) × 	𝑚-CEC-CC𝑚iAPKCQP  4.9 
 
3. Results  
To estimate the residence times in each workstation the calibration factors 
applied were as follows: for DTK 5.67 cps/MBq, for HERMES 38.3E-06 MBq/counts, 
for STRATOS 38.3 Bq/intensity and PDOSE 38.3 Bq/counts. The calibration factors 
for Hermes, STRATOS and PDOSE were estimated considering the patients were 
acquired 60 projections in total, 45 seconds per projection. This is equivalent to 9.68 
cps/MBq. 
3.1. Residence times determination and absorbed dose results 
Figure 4.4, shows an example of segmentation of the studied organs, for male 
(MP) and female (FP) patients, in both cases using PDOSE. Images are from the 
reference SPECT/CT time point measurement. In the case of the FP, it’s important to 
look at the metastasis within the liver. In the case of the MP, it’s important to notice 
water within the stomach. 
 
A B 
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Figure 4.4: Axial slices showing segmented organs in the reference CT, using PDOSE workstation. A, 
B: female patient first treatment cycle, C, D: male patient first treatment cycle. For female patient E: 
liver, F: spleen, G: right kidney, H: left kidney. Own creation. Patient image provided by ICM nuclear 
medicine department. 
 
Table 4.2 shows the obtained results for average residence time and average 
organ mass (± standard deviation) among all workstations. 
 
Table 4.2. Results for average residence time (T) and average organ mass among all workstations. 
Organ mass  
(g) 
Treatment cycle for female patient Treatment cycle for male patient 
First Second First Second 
Liver 1624.8±43.6 1552.9±68.6 1338.8±87.9 1299.4±11.3 
Spleen 105.9±6.0 106.5±7.8 243.2±8.7 251.6±7.8 
Kidneys 273.7±3.8 275.4±15.1 437.0±44.0 442.3±41.8 
Residence times 
(h) 
Treatment cycle for female patient Treatment cycle for male patient 
First Second First Second 
Liver 42.9±3.2 23.7±1.8 2.7±0.6 3.0±0.3 
Spleen 0.7±0.1 0.9±0.1 1.5±0.2 2.1±0.1 
Kidneys 1.5±0.2 1.7±0.2 1.6±0.2 1.7±0.5 
 
From table 4.2, among all workstations organ mass estimation varies less than 
10% for all organs except for kidneys for MP. The relative standard deviation 
(standard deviation/mean) between organ mass obtained from different workstations 
is <6.7% for each cycle. On average equal to 5.0% (all results pooled). In the case of 
A 
B 
C D 
E F 
G H 
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MP the relative standard deviation for the kidneys, for both cycles of treatment is 
10%. Detail results can be observed in the appendix of this chapter. 
As a reference, for OLINDA/EXM V1.0 female and male models the liver mass 
is 1400g and 1910g, for spleen 150g and 183g, for kidneys 275g and 299g, 
respectively. For OLINDA/EXM V2.0 female and male models the liver mass is 
1400g and 1800g, for spleen 130g and 150g, for kidneys 275.5g and 310g, 
respectively. For IDAC 2.1 female and male models the liver mass is 1810g and 
2360g, for spleen 187g and 228g, for kidneys 357g and 422g, respectively.  
Among all workstation, in the case of residence times, its standard deviation 
variation is less than 15% for all organs. In the case of spleen this variation tends to 
be higher than the other organs. In the case of the female patient, the average 
residence time for liver decreased by almost 50% from the first cycle to the second. 
The relative standard deviation between residence times obtained from different 
workstation is <17% for each cycle, and on average equal to 13.3% (all results 
pooled). However, in some situations the relative standard deviation can be quite 
high (i.e. MP, cycle 2 and kidneys: 31.5%), a variation largely induced by large 
discrepancies of the residence times obtained by STRATOS vs. the other 
possibilities.  
Figures 4.5 and 4.6 show the residence times for female and male patients 
obtained using each workstation for liver, spleen and kidneys. 
Regarding the S-values database for 177Lu, for beta, gamma emissions, for 
male and female models from OLINDA/EXM V1.0, OLINDA/EXM V2.0, for liver, 
spleen and kidneys, it can be seen that for the beta emission the S-value is two 
orders of magnitude higher than the S-value for the gamma emission. Then, only 
results related to the beta emissions are presented in the following sections. Spleen 
has the highest S-value value for all emissions for the two models.  
All mean absorbed doses results are presented after organ mass correction 
(S-value mass scaling), expecting to have almost same results for both OLINDAs 
version, because S-values are almost the same after mass scaling. 
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Figure 4.5: Residence times for liver, spleen and kidneys. Female patient, A: first treatment, B: second 
treatment. Own creation. 
 
 
 
Figure 4.6: Residence times for liver, spleen and kidneys. Male patient, A: first treatment, B: second 
treatment. Own creation. 
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Mean absorbed doses obtained with the different workstations/software can be 
seen in figures 4.7 and 4.8, for female and male patients, for both treatment cycle. It 
can be seen that the results are in general quite close among software/workstations, 
at least in the same order of magnitude, despite the range of absorbed dose 
calculation solutions/algorithms. Also, the observed difference follows those 
observed in residence time (Figures 4.5 and 4.6). 
Table 4.3 presents the mean absorbed doses obtained for the liver, spleen 
and kidneys and associated standard deviation. As compared to results from table 
4.2, the relative standard deviation between residence times obtained from different 
workstation is <22.9% for each cycle, and on average equal to 16.7% (all results 
pooled). However, in some situations the relative standard deviation can be quite 
high (i.e. MP, cycle 2 and kidneys: 41.7%), a variation largely induced by large 
discrepancies of the residence times obtained by STRATOS vs. the other 
possibilities. Our mean absorbed dose results for kidneys are in the same order of 
magnitude to the ones reported by Sundlöv (Sundlöv et al., 2017), for the median 
renal absorbed dose = 4.5Gy/fraction, for 51 patients (199 treatment cycles). 
 
Table 4.3. Results for mean absorbed dose (Gy) among all workstations. 
Mean absorbed 
dose (Gy) 
Treatment cycle for female patient Treatment cycle for male patient 
First Second First Second 
Liver 16.6±1.5 9.5±1.2 1.2±0.2 1.4±0.1 
Spleen 3.8±0.5 4.9±0.6 4.0±0.8 5.3±0.9 
Kidneys 3.3±0.6 3.8±0.5 2.3±0.4 2.3±1.0 
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Figure 4.7: Mean absorbed dose results among all software for liver, spleen and kidneys. Female 
patient. A: first treatment, B: second treatment. Own creation. 
 
 
 
Figure 4.8: Mean absorbed dose results among all software for liver, spleen and kidneys. Male patient. 
A: first treatment, B: second treatment. Own creation. 
 
A 
B 
A 
B 
Chapter	4:	Patient	data	evaluation	on	commercial	workstations	
173 
 
3.1.1. Absorbed dose estimation for red bone marrow results  
Table 4.4 shows the cumulated activities ratio between the two treatment 
cycles per patient. As it was described in the previous section, for both patients, in 
the second cycle of treatment the average absorbed dose was higher for the three 
organs, except for the liver, for female patient. The same effect can be seen for the 
red marrow and the remainder of the body.  
 
Table 4.4. Cumulated activity ratio between treatment cycles (ctx), for organs source and RB, per 
patient. 
Organs Female Male 
Ã
Marrowctx2
/Ã
Marrowctx1
 1.14 1.38 
Ã
R_Bodyctx2
/Ã
R_Bodyctx1
 1.12 1.18 
Organs 
Ã
Liverctx2
/Ã
Liverctx1
 0.52 1.12 
Ã
Kidneysctx2
/Ã
Kidneysctx1
 1.08 1.19 
Ã
Spleenctx2
/Ã
Spleenctx1
 1.37 1.40 
 
In table 4.5, mean absorbed dose results for the red bone marrow are 
presented, considered all contributions. Our results are similar to those presented by 
Forrer (Forrer et al., 2009). However, they used a different methodology for the same 
radiopharmaceutical. In the case of female patient, due to the high uptake of liver 
metastasis, the contribution to the red bone marrow due to all organs varies between 
5 and 10%. In the case of male patient, this contribution is less than 2%. In the case 
of self-irradiation, for both patients, for the second treatment cycle this contribution 
increase slightly. The contribution from the remainder of the body to the red bone 
marrow is important, varies from 50 to almost 60% for both patients.  
 
Table 4.5. Mean absorbed dose to RM and relative contributions from RM, organ sources (h) and RB. 
Patient/cycle of 
treatment 
D
RM
 (mGy) Relative contribution (%)* D
RM←RM
 D
RM←h
 D
RM←RB
 
Female/1
st
 475.6 34.0 9.3 56.2 
Female/2
nd
 515.6 36.5 5.1 58.4 
Male/1
st
 321.7 45.0 1.6 53.5 
Male/2
nd
 409.1 49.2 1.5 49.3 
*Similar results reported by Forrer (Forrer et al., 2009) in terms of relative contributions. 
 
4. Discussion  
One of the main challenges was to find a common parameter in order to be 
able to compare dosimetric results obtained from all workstations, since all of them 
have differences in the workflows. Each phase of the dosimetric workflow is a key 
factor that is going to affect the final result. Each step had been subject of multiple 
studies for several years and there are not meanings for assessing their performance 
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along the dosimetric chain. Each workstation provides different acquisition protocols 
that could be applied for clinical dosimetry. Having available 2D and 3D protocols 
could allow the user to correlate results depending on the studied organ. A drawback 
to implement this idea, is the final acquisition time, due to the clinical condition of 
some patients this is not an easy task.   
Having ways to assess the performance of each section of the dosimetric 
workflow, allow the user to clearly understand their connections and functioning; 
then, to try to estimate the uncertainties and to propagate them to the final result, as 
it is suggested by Gear (Gear et al., 2018). Unfortunately, none of the workstations 
evaluated provides this service, some of them provide tools to evaluate certain 
aspects, but none propose how to consider the uncertainties propagation. 
Residence time was one common aspect found among these workstations 
that can be compared as a final output of the dosimetric workflow, nevertheless, 
organ masses and mean absorbed doses were indexes for comparison.  
Therefore, in this section of the discussion aspects related to the comparison 
among the workstations are presented, them, further below, other features are 
considered for bone marrow dosimetry or the comparison of mean absorbed doses 
from different algorithms. 
4.1.1. Segmentation  
The final output of the segmentation process is the generation of a VOI, in 
which the organ mass can be associated. Using this parameter, the performance of 
the operators between the CRCT and the ICM was initially evaluated. In table 4.2 the 
organ masses were very close for the same patient data sets. We were interested in 
large organs to try to benchmark the evaluation among all workstations. Tumors and 
other small organs are more difficult to segment; then comparison could be more 
difficult. 
In three workstations manual segmentation (slice by slice) was carried out and 
in one workstation an automatic segmentation tool was used. Manual segmentation 
is user-dependent process (Mortensen et al., 2014) and should be validated. The 
segmentation of several structures occurred using the first SPECT/CT as a 
reference. Copying segmented structures, from the reference SPECT/CT to other 
SPECT/CT (also so-called propagation of the VOI), the propagation of the structure 
occurred. 
In this study we did not address the segmentation process itself, we were 
using the segmentation tools available in each workstation. The ideal situation would 
be to have patient data sets already segmented, in order to be uploaded in each 
workstation (for instance in DICOM RTStruct). However, this option was only 
available with PDOSE.  
The structure propagation process has a strong dependence on the 
registration stage. If there are errors in the registration procedure, the placement of 
the structure will change or may not fit from one time-point SPECT/CT to another. 
HDM and PDOSE allow moving or modifying the size of the propagated structure. In 
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our study displacement of structures occurred, but the size of the propagated 
structure remains constant. The idea was to keep constant the organ volume along 
the time-line to decrease the impact of the operator-dependence. 
An idea that will be consider as a future work is to vary the organ volume at 
each time point measurement, then, to estimate the residence time. 
4.1.2. Registration  
The registration process normally is carried out using the CT reconstructed 
image within the whole nuclear medicine field of view image (FOV). Rigid registration 
is available in most of workstations and it is the first proposed method to be 
performed. Nonetheless, some workstations also provide elastic/deformable 
registration. The rigid registration was performed taking as a reference bone 
structures within the patient, but this does not consider aspects such as variation in 
the positioning of the patient in a multi-SPECT/CT scenario, movement of the patient 
between CT and SPECT acquisitions, respiratory motion, patient tilt and organs 
movements (due to respiratory motion or different placement). Looking at figure 4.4 
(C, D), liquid can be seen in the stomach of the male patient, changing the position of 
the spleen and left kidney, comparing to other SPECT/CT time point measurements 
when the stomach was empty. All these aspects are sources of error, which 
negatively affect the registration process, therefore the accuracy of the image 
registration must be assessed and verified (Isambert, et al., 2008). Unfortunately, for 
the majority of the workstations, the user can assess this process visually. However, 
Dosisoft, proposed a method to optimize the registration process organ by organ, 
which might impact positively on the final result.  
Grassi et al. (Grassi et al., 2018) compare the rigid registration using the 
Siemens E-Soft workstation versus the deformable registration using Velocity (from 
Varian), in order to assess their impact on absorbed dose calculations. They applied 
the deformable registration to the whole image. They compared both registrations 
techniques by using the structural similarity index (SSIM) implemented in MATLAB. 
Finally, the registered images were uploaded into Raydose for absorbed dose 
estimations. Although they found mean absorbed doses by deformable registration 
higher than those estimated by rigid registration, the effect of the image registration 
algorithm might be negligible for relatively large segmented structures.        
Looking at the different tools used in radiotherapy to ensure the positioning of 
the patient during all sessions of therapy, one possible solution is to use the 
commercially available “Vac-lock” or similar devices, in which the patient can rest 
comfortably and the position of the patient on the table and its position on the 
SPECT/CT will be the same at all times. These devices must be evaluated prior to 
clinical implementation in Nuclear Medicine departments in order to evaluate their 
impact on images. Gosewisch et al. (Gosewisch et al., 2018) showed the impact of 
some patient movements on the absorbed dose estimations and techniques of 
correction to improve the final quantification. Finally, the effect of continuous 
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respiratory motion on kidneys or other organs within the pelvic region, could be 
studied to understand its impact on NM SPECT images. 
4.1.3. Time activity curve fitting and residence time determination  
Every workstation provides fitting models, for instance, the trapezoidal method 
and/or mono- or bi-exponential. Some of them consider the time between t = 0 and 
the first data point. Few options are available to the user to choose the best possible 
fitting. Most of the software considers mono-exponential decay after last time point 
measurement, which might be a “safe” overestimation in the cumulated activity 
estimation. Most of the software computed cumulated activity based-on organ 
approaches and only STRATOS is clinical validated for voxel-based cumulated 
activity estimations. PDOSE has a platform to perform this type of calculations but it 
was not clinical validated at the time of performing this study. In the case of 
STRATOS its results are close to the other software, for the majority of the organs, 
this was not expected, due to the behavior showed in the software validation section. 
Most probably the variations in organ patient position, from one time point to another, 
are compensated with counts from one organ into another one. Also for the same 
software, the fitting is performed by segments, using the trapezoid method and 
according to Guerriero et al. (Guerriero et al., 2013) an overestimation of time-
integrated activities has been observed compared to those generated by bi-
exponentials. However, from our few results, we have not observed the same effect 
on residence time results.  
In the case of DTK only mono-exponential fitting can be done. In the case of 
HDM, we applied bi-exponential fitting in almost most of the cases (for first treatment 
cycle of the male patient, mono-exponential fitting for kidneys). In the case of 
PDOSE, in order to assess the degree-of-goodness of the fitting, the Spearman 
coefficient was used for mono- or bi-exponential fitting, but sometimes best fitting 
was for a function such as 𝑓(𝑡) = 𝐴 ∗ 𝑡g ∗ 𝑒M∗PÙ . From these results comparison 
between workstations, only considering time activity curve fit, is practically 
impossible, because applying same fitting among all workstations, will also have an 
impact on cumulated activity.  NUKFIT (Kletting et al., 2013), is a software that it is 
interesting to compare with, therefore further investigation is planning using it. 
4.1.4. Absorbed dose calculation  
To estimate the mean absorbed dose (last section of dosimetric workflow) and 
following the MIRD formalism (Bolch, et al., 2009), two quantities are necessary, the 
cumulated activity (or the residence time) and the S-value. Until this point in the 
discussion, aspects related to the determination of the cumulated activity have been 
considered. For the second part of the equation, few aspects have to be considered 
in the case of reference dosimetry (because most of them have been discussed in 
chapter 2). In our study by using OLINDA/EXM V1.0 and V2.0 and considering 
patient organ mass adjustment, we can perform reference-adjusted dosimetry. 
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As it was previously mentioned, in the case of 177Lu, the S-value associate to 
the beta emission has a higher impact to the mean absorbed dose, up to two orders 
of magnitude higher than S-value associated to gamma emission.  
For same organ and model (male or female), S-values will change depending 
on the OLINDA version, this is due to the calculation of the Specific Absorbed 
Fractions (SAF) available in the two OLINDA/EXM versions. In version V1.0, for 
photons, SAF’s were estimated from the Cristy and Eckerman phantom series, 
developed in the Oak Ridge National Laboratory (ORNL) (Cristy & Eckerman, 1987). 
In version V2.0 models were based-on non-uniform rational B-splines (NURBS), with 
organ and body masses based on the references values from ICRP-89, and SAF’s 
were estimated using GEANT4 (Stabin, et al., 2008). The geometry of each organ 
and phantom has changed importantly since 1987 with the Cristy and Eckerman 
phantom series. Consequently, anatomical differences in organs-shapes and organs-
positions between the models may be one of the reasons to have these slightly 
differences in SAF values, as it has been shown by Ocampo et al. (Ocampo, et al., 
2013). Moreover, the adjustment of organ mass from the model to patient has a 
relation with the emission, as we have previously talked in chapter 2.  
In the case of the spleen for both patients, the standard deviation associated 
to the mean absorbed dose vary for each cycle of treatment. For this organ, the 
registration process was very difficult because at each time point measurement its 
position and organ size could change. Then for this organ it could be very helpful to 
consider the variation of organ mass per time point measurement, in order to 
estimate the residence time.  
For most of the organs, the mean absorbed doses computed are comparable 
and in the same order of magnitude among all workstations. Further studies will take 
place considering voxel-based cumulated activity calculations (at least for STRATOS 
and possibly for PDOSE). Then, absorbed dose volume histograms could be studies 
to see its variation within the VOI. 
The LDM from PDOSE considers b-particles as non-penetrating radiation 
(Pasciak, et al., 2014), then all energy deposition is with the voxel. Moreover, results 
from the two versions of OLINDA/EXM are close to each other. For most of the 
organs these results from both versions of OLINDA are close to the LDM from 
PDOSE. Therefore, both methods are comparable. Also because of the emission 
properties of 177Lu, in which b-emissions are more important, the approach 
implemented in PDOSE could be a good approximation for the estimation of the 
mean absorbed dose. 
In the case of mean absorbed doses from STRATOS, results are close to the 
others software (especially to those from PDOSE) for the majority of the organs, 
corresponding with the results from the residences times. Just in the case of the 
kidneys for male patient discrepancies can be seen. This software also considers 
that the irradiated volume was a uniform propagating medium. Also, the pre-
calculated DVK was estimated in water and most probably its gamma contribution is 
lower compared to the beta contribution.    
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Further improve/investigation can be done, if variation of organ mass is 
considered for the LDM implemented in PDOSE. 
4.1.5. Absorbed dose estimation for red bone marrow  
Following EANM recommendations (Hindorf, et al., 2010) for the estimation of 
absorbed dose to this organ, the cross- and the self- irradiation were considered. The 
cross-irradiation due to the whole body was challenging because in the clinical 
protocol no whole-body measurements were carried out. Our new proposed method 
allows estimating this contribution having measurement from the Whole-FOV. Some 
underestimations can occur if there are other uptake sources out of this region. 
Moreover, our approximation assumes a similar volume/mass between the patient 
and the reference model. This may not happen for some patients, then other 
phantom models available in the literature can be used to find the best approximation 
to the patient.  
On the other hand, no PVE corrections were considered to correct the 
cumulated activity from the VOI generate within the vertebras, because the three 
vertebras were considered as one whole entity, with volumes varying from 50 ml to 
70 ml for the female and male patient, respectively. One possible idea to improve 
further our results is to estimate the volume of each vertebra, then apply the 
appropriate recovery coefficient, to each vertebra, to correct the cumulated activity 
for this effect.  
Our approximation allows reducing the patient time in the department and 
further inconvenient to the patient, for instance, when blood samples are taken. Also, 
this approximation has to be validated with more patients and possible considering 
blood samples. Beykan et al. (Beykan et al., 2018) showed dosimetric results 
variations between blood-based vs image-based dosimetry for this type of treatment, 
three times lower for the blood-based, however this has to be validated in more 
patients. 
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5. Conclusions  
The dosimetric chain has been assessed on commercial workstations finding 
similar results, in terms of organ mass, residence times and mean absorbed doses, 
for patient data sets. The variations in residence times are in the same order of 
magnitude, regardless of the different processing modes in each section of the 
dosimetric chain. 
On patient data, organ placement varies in al multi-SPECT/CT scenario, 
especially in the abdominal/thoracic regions, where the rigid-registration cannot 
perform adequately. Nonetheless, a promising tool to carry out this type of 
registration can be based-on organ approaches, this might be important to take into 
account patient movements between sequential studies, poor patient positioning, 
patient tilt (especially in the pelvic region) and movement of an organ from one day to 
another. In general, the segmentation tools provided by the different workstations are 
good enough for this type of dosimetry.  
Options in terms of fitting are reduced for most of the workstations and it is 
generally not possible to perform an assessment of the goodness of the fitting.  
None of the workstations incorporate uncertainty analysis in each section of 
the dosimetric chain, so it is impossible to provide a mean absorbed dose results 
including term. 
On the other hand, we managed to see that the variations in terms of the 
calculation of the mean absorbed dose either using S values or using other 
approaches, in all cases generating results in the same order of magnitude.  
From our point of view, the assessed workstations are lacking of some 
phases/sections: 
• Diversity in processing clinical data, just two workstations allow to process 2D 
data and 3D patient data. 
• Some platforms do not allow import/export patient data in DICOM RTStruct 
format. 
• There is no possibility to incorporate the calibration data set from one gamma 
camera and to bind this data to a particular patient.  
• There is no possibility to incorporate information about the “QC” regarding the 
sensibility stability of the SPECT/CT. 
• There are no possibilities to have a “QC” assessment of patient data sets, to 
confirm if all-important DICOM tags (all important parameter) were 
acquire/process equally. For instance, acquisition time, number of projections, 
energy windows width and its positioning, radionuclide, reconstruction method, 
etc. 
• There is no possibility to incorporate information regarding the recovery 
coefficient curve, to correct for PVE the VOI’s cumulated activity and/or mean 
absorbed dose. 
• Few workstations allow the user to evaluate retrospectively the processing 
performed in each section of the dosimetric workflow. 
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• Uncertainty analysis must be included for each section of the dosimetry 
workflow. 
• Few platforms provide the possibility to assess mean absorbed dose (or 
residence times) based-on organ mass variation.  
Some of the previous points can be addressed in further evaluations that we 
are planning to develop as a future work. 
In terms of red bone marrow mean absorbed dose, a method for calculating 
this parameter without having whole-body information has been proposed. Further 
evaluations can be carry-out to confirm our initial results. Moreover, comparison 
between image-based approaches and blood-based should be perform in a cohort of 
patients in targeted radionuclide therapy. 
One possibility to study organ movements, for instance, due to respiratory 
motion, can be considering the possibility to incorporate 3D dynamic studies, but this 
is really depending on manufacturers interest.   
As a future work we would like to assess the impact on residence time 
estimation due to different registrations to the same organ, performed by the same 
user or by different users. Also, to compare results from different fittings against 
NUKFIT.  
Indeed, in this field of the nuclear medicine, optimization in several aspects 
can be considered in order to standardized the different sections of the dosimetric 
workflow, in this way, traceability of patient data can be processed allowing the user 
improve in patient-specific dosimetry. 
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Conclusion générale et perspectives futures (FR)  
 
Dans le cadre de ce travail de doctorat, la formulation MIRD a été analysée. 
Cette formulation peut être exprimée, dans sa forme la plus simple, par trois 
variables : La dose absorbée, l'activité cumulée et la valeur S. 
Chacune de ces variables pourrait être étudiée d'un point de vue préclinique 
et clinique. Dans chacun de ces deux domaines, il a été possible de comprendre le 
degré de complexité impliqué dans la détermination et l'utilisation de chacune d'elles. 
 Dans le deuxième chapitre de ce travail, l'estimation des doses absorbées et 
efficaces, qui peuvent être utilisées comme référence chez l'homme, a été réalisée, 
pour trois nouveaux produits radiopharmaceutiques, à partir de données au niveau 
préclinique. Dans ce cas, le calcul de l'activité cumulée a impliqué un défi particulier 
en fonction du type d'informations qui nous a été fourni. 
Par exemple, dans le cas du médicament radiopharmaceutique (MRP) étudié 
par imagerie TEP/TDM, huit volumes d'intérêt ont été étudiés, chacun avec 16 points 
de mesure, ce qui a permis de générer des courbes d'activité-temps permettant 
d'identifier avec une certaine facilité et pour certains organes, les phases de 
captation et d'excrétion. Pour plusieurs organes, il a été possible d'établir un modèle 
biocinétique décrivant ces deux phases, mais pour d'autres, et malgré un bon 
nombre de points de mesure, il n'a pas été possible d'établir un tel modèle. Dans ces 
cas, la méthode des trapèzes a été choisie. Cette méthode peut être considérée 
comme une méthode conservatrice puisqu'elle peut surestimer les activités cumulées 
au moment de l'intégration de la courbe activité-temps.  
Dans le cas des MRP pour lesquels on a utilisé la dissection d'organes, le 
nombre de points de mesure a été réduit, à trois ou quatre points, en raison du 
nombre d'animaux sacrifiés. Dans cette situation expérimentale, la méthode des 
trapèzes était préférable, car il n'y avait aucune possibilité d'établir un modèle 
biocinétique pour les organes à l'étude. On peut donc s'attendre à une surestimation 
des activités cumulées au moment de l'intégration de la courbe activité-temps. Pour 
ces deux cas, le nombre de volumes d'intérêts utilisés était de 13 et 14, si l'on 
considère les organes qui sont des moyens d'excrétion. Pour l'un des MRP, une 
étude a été développée considérant la vidange de l'urine présente dans la vessie. La 
même étude a montré d'importantes différences dans les résultats de dose absorbée 
lorsque cette considération n'était pas prise en compte. De ce point de vue, il a été 
montré que la prise en compte des activités cumulées provenant des organes qui 
sont des voies d'excrétion des MRP permet d’estimer les doses absorbées reçues 
par les organes environnants. 
Dans le cas de ces deux produits radiopharmaceutiques, aucun facteur 
d'étalonnage du détecteur n'a été utilisé pour effectuer les mesures des organes à 
l'étude. Donc une méthodologie a été mise au point pour estimer le comptage total 
des coups dans tous les organes et l'activité totale injectée. 
D'autre part, l'extrapolation des résultats précliniques à l'humain a été réalisée 
par pondération des masses des organes entre les deux espèces et cette méthode 
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peut créer des erreurs dans les temps de résidence, donc dans le calcul des doses 
absorbées et efficaces entre animaux et êtres humains. Cette méthode permet 
d'augmenter ou de diminuer significativement les valeurs de temps de résidence. 
En ce qui concerne l'utilisation de la valeur S fournie par plusieurs logiciels, on 
a pu constater que les différences sont principalement associées aux modèles 
anthropomorphiques et aux codes Monte-Carlo. Dans le cas des modèles 
anthropomorphiques, on constate des différences dans la position, les dimensions, la 
masse, le volume et la densité des organes. En outre, il a été possible de voir des 
différences entre les modèles en tant que tels, allant des modèles stylisés (qui ne 
reflètent pas l’anatomie des hommes et des femmes) aux modèles voxelizés (qui se 
rapprochent beaucoup de l’anatomie humaine). Dans le cas des codes Monte-Carlo, 
les différences peuvent être associées à l'interaction des particules chargées et non 
chargées avec la matière, c'est-à-dire les gammes d'énergie associées à ces 
particules, les spectres énergétiques utilisés, la manière dont ils ont été générés, etc. 
Cependant, il faut s'attendre à ce que dans les programmes les plus récents 
(OLINDA/EXM V2.0 et IDAC 2.1) les différences entre les codes Monte Carlo soient 
réduites. 
Il est prévu que dans un proche avenir IDAC 2.1 (ou ses nouvelles versions) 
et OLINDA/EXM V2.0 (comme son prédécesseur) seront utilisés comme référence 
pour les estimations de dose absorbée et efficace pour les nouveaux MRP. 
Toutefois, cela dépendra de la disponibilité des logiciels et de leur approche des 
recommandations de la CIPR. De ce point de vue, IDAC 2.1 montre la voie car il 
s'agit d'un logiciel conforme à toutes ces recommandations. Par contre, 
OLINDA/EXM V2.0 n'est pas conforme à plusieurs des recommandations de cette 
institution. L'attention est portée sur le fait que le facteur de poids du rayonnement, 
pour les émissions alpha, est de 5 au lieu de 20 et que les organes, tels que la peau 
ou les seins pour le modèle masculin ne sont pas disponibles. Le facteur de poids 
des tissus tels que les ovaires, les testicules, la prostate et les uretères est 
également différent. La définition du « remainder » dans la CIPR-133 comprend 14 
organes, mais dans OLINDA/EXM V2.0, on n'en trouve pas quatre : la région 
extrathoracique, le tissu lymphatique, le muscle et la muqueuse orale. Ces 
différences dans les deux programmes, en plus de celles mentionnées 
précédemment, génèrent des variations dans les doses absorbées qui peuvent 
atteindre jusqu’à 200 % pour les parois de certains organes, comme la vessie et le 
côlon gauche. 
Enfin, il a été possible de développer un calcul de dose efficace dans un MRP 
qui n'est utilisé que chez l'homme (puisque son but est de diagnostiquer le cancer de 
la prostate). Dans ces cas, des stratégies de calcul des doses efficaces doivent être 
élaborées en tenant compte de ce type de situation.  
Dans le chapitre 3, l'étalonnage d'un TEMP/TDM est effectué afin de 
déterminer le facteur d'étalonnage spécifique au 177Lu. Ce facteur est utilisé pour 
estimer l'activité des structures segmentées point à point. Par la suite, des courbes 
d'activité-temps peuvent être générées. 
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Selon le constructeur de l'équipement, disposant chacun de son propre 
programme de dosimétrie, l'étalonnage de la TEMP/TDM doit être développé en 
mode acquisition planaire. Cependant, il a également été décidé de faire un mode 
acquisition TEMP. 
Pour la sensibilité planaire, il est possible de conclure que sa variation, créant 
différentes régions d'intérêt, n'est pas significative entre 8 et 18 cm. La sensibilité est 
presque constante lorsque l'image entière est utilisée pour estimer le nombre de 
coups dans l'image. 
Deux configurations de sources radioactives ayant des activités différentes ont 
été utilisées dans l'étude de sensibilité TEMP. En ce qui concerne les paramètres du 
protocole d'acquisition, seuls les temps par projections étaient différents. Dans le cas 
de la reconstruction, la quantité d'itérations, de sous-ensembles, de post-filtration et 
de corrections varie selon les effets des corrections tels que l'atténuation, la diffusion 
et la réponse du collimateur. 
En ce qui concerne la géométrie de la source radioactive et du fantôme qui la 
contient, il a été conclu que pour deux configurations qui sont une source sphérique 
soit placée dans l'air, soit située au centre d'un fantôme rempli d'eau, le facteur de 
sensibilité ou d'étalonnage sera très similaire. En comparant ces résultats avec ceux 
obtenus avec une bouteille pleine d'eau (en essayant de simuler un rein), on peut 
dire que les différences de sensibilité ne sont pas significatives. Toutefois, dans les 
deux géométries, l'effet de volume partiel peut être présent, en particulier dans le cas 
de la source sphérique. Pour minimiser cet effet, une source radioactive de 
dimension plus importante peut être utilisée. Dans ce cas, les fantômes de volume 
supérieurs à 5 litres de volume peuvent être une bonne option. 
Dans le cas du protocole d'acquisition, on peut conclure que pour les postes 
de travail dosimétriques où le facteur d'étalonnage n'est pas directement dépendant 
du temps, la variation de ce paramètre a peu d'impact. Mais il est souhaitable que le 
temps d'acquisition par projection soit le même que celui qui sera utilisé pour les 
patients. Dans notre cas également, le protocole d'acquisition utilisé a été élaboré à 
partir de ceux trouvés dans la littérature pour le même modèle de TEMP/TDM. 
Toutefois, l'analyse documentaire permet de constater qu'il n'existe pas de protocole 
clinique unique pour l'acquisition d'images de patients traités par le 177Lu.   
Dans le cas de la reconstruction d'images, l'approche initiale consistait à 
utiliser deux postes de travail, chacun utilisant tous les outils possibles pour mettre 
en œuvre les corrections disponibles. L'objectif initiale était de mesurer les variations 
du facteur d'étalonnage, qui pouvaient devenir importantes entre les deux postes de 
travail, pour le même type de reconstruction. Ceci est dû à l'algorithme de 
reconstruction mis en œuvre et aux corrections associées dans chaque station. De 
ce fait, il a été conclu que les images reconstruites dans un poste de travail doivent 
avoir leur propre facteur d'étalonnage afin d'effectuer des estimations dosimétriques. 
 Un aspect important est la création de la courbe d'étalonnage du TDM pour 
les postes de travail. Cette courbe est importante car elle permet d'effectuer la 
correction d'atténuation de l'isotope utilisée pour la quantification des images. Dans 
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le cas du poste de travail d’Hermès, une courbe d'étalonnage bilinéaire a été établie, 
basée sur des nombres CT et des coefficients d'atténuation linéaire à 140 keV. 
En cas d'augmentation du nombre d'itérations et de sous-ensembles (mises à 
jour), on peut conclure qu'au fur et à mesure de leur augmentation, la sensibilité 
augmente, étant donné que le nombre de coups se trouvant dans le même volume 
d'intérêt augmente, atteignant éventuellement un niveau où la sensibilité n'augmente 
plus. Cependant, deux effets sont présents : lorsque les mises à jour augmentent, le 
temps de reconstruction augmente considérablement et un artefact connu sous le 
nom de « Gibbs-like » est présenté, qui est associé à l'utilisation de la correction de 
réponse de collimateur pour un grand nombre de mises à jour. En principe, ce 
dispositif n'affecte pas le nombre total de coups, mais leur répartition.  
Il a été possible de générer la courbe associée au coefficient de récupération, 
avec et sans activité de fond, avec et sans post-filtrage. Cette courbe a été générée 
pour caractériser la TEMP/TDM. Cependant, on constate que la gamme des volumes 
utilisés est réduite afin de pouvoir mieux étudier l'effet du volume partiel. Il serait 
souhaitable d'avoir une solution commerciale pour pouvoir étudier des volumes par 
exemple jusqu'à 100 ml. 
Il a également été possible de voir l'effet du post-filtrage sur l'estimation de la 
sensibilité. Sans post-filtrage ou avec un filtre gaussien de 0,11 cm, les sensibilités 
sont pratiquement les mêmes, mais en utilisant un filtre gaussien de 1,0 cm, on peut 
voir une diminution significative des coups. Pour cette raison, il a été conclu qu'une 
reconstruction utilisant l'algorithme de reconstruction OSEM, incluant des corrections 
pour l'atténuation, la dispersion et la réponse du collimateur, avec 6 ou 8 itérations, 
10 sous-ensembles et aucun post-filtrage, constitue un facteur d'étalonnage optimal 
pour la quantification. 
La conclusion ci-dessus a été étudiée dans trois postes de travail dotés de 
logiciels dosimétriques, à savoir HDM d’Hermès, STRATOS de Phillips et PDOSE de 
Dosisoft. Afin d'étudier et d'évaluer la conclusion ci-dessus, on a conçu une 
expérience dont l'objectif était de déterminer le temps de résidence, en tenant 
compte uniquement de la décroissance physique d'une source contenue dans une 
bouteille, dans un fantôme. L'ensemble fantôme-bouteille étant une structure fixe, les 
positions de deux des cinq points de mesure ont été modifiées afin d'évaluer le 
registre rigide automatique des postes de travail. En parallèle, il a été possible de 
déterminer les activités pour les points de mesure dans chaque poste de travail en 
utilisant le facteur d'étalonnage pour la reconstruction avec 60 mises à jour. Trois 
conclusions ont été tirées de cette expérience : a) STRATOS a des difficultés avec le 
recalage des images pour les points où il y a eu des variations dans les positions de 
l'ensemble fantôme-bouteille, b) Le recalage des images HDM et PDOSE est 
satisfaisant et permet de corriger les variations de position de la bouteille (source 
radioactive), c) Les estimations d'activité pour chaque point de mesure sont 
satisfaisantes pour HDM et PDOSE, mais pas pour STRATOS, où l'emplacement du 
fantôme varie. Par conséquent, le calcul du temps de résidence pour HDM et 
PDOSE présente des différences relatives assez faibles (%), tandis que pour 
STRATOS, il est assez élevé. Cette expérience a permis de conclure que les images 
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utilisées pour générer le facteur d'étalonnage doivent être traitées de la même 
manière que les images des patients, en termes d'acquisition et de reconstruction. 
Dans le quatrième chapitre, pour le calcul de la dose absorbée par les patients 
avec le groupe de travail de l'Institut de Cancérologie de Montpellier (ICM), il a été 
convenu d'utiliser la reconstruction OSEM, avec 60 mises à jour, toutes les 
corrections et une post-filtrage de 0,11 cm. Le groupe ICM, indépendant et utilisant le 
DTK de Xeleris, a pu déterminer un facteur d'étalonnage différent de celui trouvé au 
Centre de Recherches en Cancérologie de Toulouse (CRCT) avec HROD d’Hermès. 
Chaque centre a utilisé les données provenant de deux cycles de traitement 
de deux patients par 177Lu-DOTATATE qui avaient des tumeurs gastro-
entéropancréatiques. L'ICM a utilisé DTK pour effectuer l'analyse dosimétrique des 
données des deux patients. Le CRCT a utilisé les données reconstruites dans HROD 
pour effectuer des analyses dosimétriques dans HDM, STRATOS et PDOSE. De 
cette façon, il a été possible de comparer les résultats obtenus par chaque centre 
pour les quatre postes de travail. 
Les flux de travail pour les quatre postes de travail sont similaires. Le recalage 
de toutes les images TEMP/TDM sont réalisées entre une image TEMP/TDM de 
référence et toutes les autres images TEMP/TDM. Les structures d'étude sont 
segmentées, cela peut être automatique ou manuel. Une propagation des structures 
segmentées de la TEMP/TDM de référence est faite vers les autres. Le facteur 
d'étalonnage est utilisé pour déterminer l'activité présente dans chaque structure 
segmentée. Des courbes d'activité-temps sont créées. Ces courbes sont intégrées 
pour déterminer l'activité cumulée ou le temps de résidence, ce qui permet enfin 
d’aboutir aux doses absorbées. 
On peut conclure que tous les postes de travail peuvent effectuer un recalage 
rigide des images en utilisant l'ensemble du champ de vision. Il a été constaté que 
deux postes de travail fournissent à l'utilisateur des informations sur la matrice de 
transformation utilisée pour le recalage rigide. Peu d'entre eux peuvent développer 
un recalage élastique mais cette méthode n'a pas été utilisée. Chez DTK, STRATOS 
et HDM, le recalage rigide était automatique et les structures osseuses étaient 
généralement utilisées en tant que repères pour pouvoir effectuer cette étape. Dans 
le cas du PDOSE, le recalage rigide était également automatique, mais il pouvait être 
limité à un organe, ce qui permettait corriger les variations dans le positionnement 
des organes à chaque point de mesure. Aucun des postes de travail offre des 
outils pour le calcul de l'incertitude associée au processus du recalage. 
 Dans le cas de la segmentation automatique, les outils sur les postes de 
travail peuvent être suffisamment satisfaisants pour la dosimétrie. Certains postes de 
travail possèdent davantage d'outils que d'autres, cependant, déterminer quels outils 
sont plus importants et/ou nécessaires, dépend beaucoup de chaque utilisateur. La 
segmentation manuelle est en 2D et 3D c’est disponible et satisfaisant. Afin d'éviter 
l’utilisation de segmentations différents dans les différents postes de travail, l'idéal 
serait que tous permettent de charger des images de type « DICOM RTStruc ». 
Cependant, un seul d'entre eux permet l'importation et l'exportation de ce type 
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d'images. Aucun des postes de travail n'offre d'outils pour évaluer l'incertitude 
associée au processus de segmentation d'une structure. 
Le seul poste de travail qui permet d'abord la segmentation des structures et 
ensuite leur recalage est PDOSE. Il est probablement possible de réduire de cette 
façon les variations dans les positions des organes liés à un mauvais positionnement 
du patient ou par les mouvements des organes. 
La propagation des structures, consiste simplement à copier et coller les 
images de la TEMP/TDM de référence dans les autres TEMP/TDM. Lors de 
l’exécution de ce processus, il peut être vérifié que les structures copiées ne 
correspondent pas aux mêmes structures dans d'autres points de mesure, ceci est 
dû au mauvais positionnement du patient et/ou aux mouvements de certains 
organes. Dans ce travail, il a été entrepris un déplacement des structures dans 
chaque point de mesure, mais tout en conservant le même volume total, ce qui 
signifie que la masse totale de la structure n'a pas varié. Aucune des stations ne 
permet d’associer ce processus a un calcul des incertitudes. 
L'ajustement des courbes d'activité-temps était l'un des pas de la chaine 
dosimétrique qui diffère selon les postes de travail. DTK n'offre l'ajustement des 
données que par des moyens mono-exponentiels. STRATOS travaille uniquement 
selon la méthode des trapèzes, en considérant la décroissance physique (mono-
exponentielle) du dernier point de mesure à l'infini. HDM offre un ajustement mono- 
et bi-exponentiel des données. PDOSE offre tout ce qui précède et même le réglage 
tri-exponentiel. Seul PDOSE dispose d'un outil permettant d'évaluer l'ajustement des 
données. Aucune des stations n'offre un outil qui tient compte du calcul de 
l'incertitude qui peut être associé à l'ajustement des données. 
En ce qui concerne le calcul des doses absorbées, DTK et HDM effectuent le 
calcul dosimétrique au niveau de l'organe et exportent les résultats du temps de 
résidence vers OLINDA/EXM V1.0 et V2.0, respectivement. STRATOS calcule la 
dose absorbée, de voxel à voxel, en faisant un ajustement pour déterminer l'activité 
cumulée également de voxel à voxel. Enfin pour calculer la dose absorbée ce 
programme utilise un “kernel” qui a été calculé pour l'isotope étudié dans un milieu 
homogène infini (eau). Dans le cas du PDOSE, le calcul de la dose absorbée au 
niveau des organes est effectué en utilisant la méthode de dépôt local d'énergie, 
bien que d'autres outils soient disponibles. Dans le cas des données générées par 
PDOSE et STRATOS, les masses de chaque rein sont pondérées afin de pouvoir 
comparer les doses absorbées obtenues avec DTK et HDM. 
Il a été conclu que trois paramètres étaient communs à tous les postes de 
travail : la masse des organes générée par leur segmentation, les temps de 
résidence et les doses moyennes absorbées.  
Trois organes - le foie (y compris les métastases), la rate et les reins - ont été 
étudiés. Une correction de l'effet de volume partiel n'a pas été effectuée puisque 
pour ces trois organes, cet effet devrait être mineur en raison de la taille de chaque 
structure. 
Il a été conclu que les masses des organes segmentés étaient très similaires 
pour chaque centre, ce qui a permis d'évaluer le travail effectué par leurs opérateurs. 
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L'évaluation du flux du travail peut être évalué en utilisant les résultats des 
temps de résidence, qu’étaient très similaires et du même ordre de grandeur pour 
tous les postes de travail de chaque organe. On constate également que les temps 
de résidence pour le deuxième cycle de traitements sont plus longs pour les reins et 
la rate des deux patients. Dans le cas du foie pour le patient masculin, il est le même 
que pour les autres organes, mais pour le patient féminin, il est réduit de près de 
50%. On constate que pour STRATOS le calcul du temps de résidence des reins est 
beaucoup plus petit que celui obtenu avec les autres logiciels, pour le deuxième 
cycle de traitement, pour le patient masculin. 
La méthode de dépôt d'énergie local mise en œuvre dans PDOSE génère des 
résultats de dose absorbée qui sont très similaires à ceux générés par les deux 
versions d'OLINDA. Le même effet doit se produire avec le « kernel » déterminé 
dans STRATOS, la contribution bêta doit être beaucoup plus importante que la 
contribution gamma, donc les doses absorbées obtenues avec ce logiciel sont 
comparables aux autres. 
Dans le cas de la dose absorbée au niveau de la moelle osseuse, on obtient 
des résultats semblables à ceux d'autres études trouvées dans la littérature. Dans ce 
cas, il est possible de voir que la méthode développée fonctionne pour les deux 
patients, car ils peuvent avoir des similitudes avec les modèles de la CIPR en termes 
de masse et de volume. Ce qui est intéressant à propos de cette méthode, c'est 
qu'elle pourrait être mise en œuvre dans un service de médecine nucléaire où il n'y a 
pas de détecteur pour mesurer le corps entier du patient, comme c'est arrivé dans 
notre cas. Il est également conclu que près de 50% de la contribution à la dose 
absorbée dans la moelle osseuse est due au « remainder ». L'auto-irradiation est 
également importante, en fonction du patient, pouvant atteindre jusqu’à 50%. Notre 
méthodologie devrait être étudiée avec un plus grand nombre de patients et 
complétée par une dosimétrie sanguine afin d'établir une corrélation possible entre 
les deux méthodes. 
D'autre part, il a été possible de trouver dans la littérature qu'il n'y a pas de 
correspondance entre les doses absorbées dans la moelle osseuse par la méthode 
sanguine et la méthode d'imagerie L2 à L4. Cependant, ces résultats ont été obtenus 
dans un petit groupe de patients (Beykan et al., 2018). On devrait s'attendre à 
davantage de données probantes pour un plus grand groupe de patients. 
Dans le cadre de ce travail doctoral, certaines questions restent sans 
réponses, nous espérons donc pouvoir y donner suite par des études que nous 
développerons, par exemple :  
• Nous prévoyons effectuer la dosimétrie pour les volontaires sains et 
des patients pour les trois MRP étudiés. Actuellement, nous attendons 
l'approbation finale des comités d'éthique nationaux/locaux et la 
révision des protocoles cliniques proposés par chaque centre de 
recherche. 
• Nous espérons faire une publication où nous pourrons montrer les 
différences qui existent entre les deux versions d'OLINDA et IDAC 2.1, 
dans le cas de la dosimétrie de référence pour les nouveaux MRP. 
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• Nous espérons pouvoir estimer le facteur d'étalonnage à l'aide d'un 
mannequin de plus grand volume et comparer les résultats obtenus 
avec les autres géométries utilisées. 
• En raison de la variation de la position de certains organes, il peut 
parfois être nécessaire de considérer une variation du volume d’intérêt 
à chaque point de mesure. 
• En raison de la variation de la position de certains organes, l’utilisation 
du recalage d'image optimisé au niveau de chaque organe (disponible 
avec PDOSE) peut-être étudié en considérant deux cas : volume 
segmenté invariable, et volume segmenté variable, pour chaque point 
de mesure, donc, le calcul des temps de résidence doit être comparé 
pour les deux cas. A la suite des deux points précédents, les doses 
absorbées devraient être recalculées.  
• Des comparaisons devraient également être faites entre d’autres 
méthodes de calcul de la dose absorbée au niveau des organes, telle 
que la convolution, disponible chez Dosisoft.  
• De fait, certaines solutions dosimétriques (Dosisoft et STRATOS) 
permettent un calcul de la dose absorbée au niveau du voxel, par 
convolution ou en faisant l’hypothèse d’un dépôt local de l’énergie 
émise. On peut ainsi obtenir les histogrammes dose absorbée – volume 
(Dose Volume Histogrammes – DVH). De plus, ces résultats pourraient 
être comparés aux résultats obtenus à l'aide de simulations Monte-
Carlo. 
• Enfin, l'EANM a récemment soulevé la question de l'intégration du 
calcul d’incertitudes dans les protocoles cliniques. Cette question reste 
en suspens dans notre travail doctoral, étant donné qu'aucune des 
stations de travail étudiées ne permet d'évaluer l'incertitude dans les 
différentes étapes du protocole dosimétrique. Nous comptons toutefois 
orienter nos recherches en direction de l’estimation de la précision des 
résultats par propagation des incertitudes au long de la chaîne 
d’opérations qui mènent de la reconstruction des images à la 
détermination de la dose absorbée. 
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General conclusion and future perspectives 
 
In this doctoral work, the MIRD formulation was analyzed. This formulation can 
be expressed in its simplest form through three variables - absorbed dose, cumulated 
activity and S value. 
Each of these variables can be studied from a preclinical and clinical point of 
view. In each of these two areas, it was possible to understand the degree of 
complexity involved in the determination and its usage. 
In the second chapter of this work, the estimation of absorbed doses and 
effective doses that can be used as reference in human beings is presented. This 
estimation was done for three new radiopharmaceuticals using preclinical data. In 
this case, the calculation of the cumulated activity implied a particular challenge for 
the type of information we received. 
For example, in the case of the radiopharmaceutical studied with PET/CT 
images, eight volumes of interest, each with 16 measuring points were studied, which 
allowed to generate time-activity curves so as to identify easily the uptake and 
excretion phases of the radiopharmaceutical for certain organs. For several organs, it 
was possible to establish a biokinetic model, which described these two phases, but 
for others, despite having a good number of measurement points, it was not possible 
to establish a biokinetic model. In these cases, the trapezoid method was selected. 
This method can be considered as a conservative method since it can overestimate 
the cumulated activities at the time of the integration of the time-activity curve.  
In the case of radiopharmaceuticals in which organ dissection was used, the 
number of measuring points was reduced (between three and four points) due to the 
number of animals sacrificed. In this experimental situation, the trapezoid method 
was optimal since there was no possibility of establishing a biokinetic model for the 
organs under study. Therefore, it can be expected that there is an overestimation of 
the cumulated activities at the time of the integration of the time-activity curve. For 
these two cases, the amount of volumes of interest used was between 13 and 14, 
considering the organs in the way of excretion. For one of the radiopharmaceuticals, 
a study was developed considering the bladder-voiding. The same study showed 
important differences in the results of absorbed doses when this consideration was 
not taken into account. From this point of view, it is concluded that considering the 
cumulated activities coming from the organs used as excretion pathways of the 
radiopharmaceuticals helped to show the absorbed doses received by other organs 
close to them. 
In the case of these two radiopharmaceuticals, there was no calibration factor 
for the detector that was used to make the measurements of the studied organs. 
Hence, a methodology was developed to estimate the total number of counts in all 
the organs and the total activity injected. 
On the other hand, the extrapolation of preclinical results to humans was 
performed by weighting organ masses between the two species. This method can 
create errors in residence times thereby inducing errors in the calculation of 
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absorbed doses and effective doses between animals and humans. It can 
significantly increase or decrease the residence time values. 
Regarding the use of the S-value provided by several software, it could be 
seen that the differences are mainly associated with the anthropomorphic models 
and the Monte Carlo codes. In the case of anthropomorphic models, differences in 
organ positions, dimensions, mass, volume and density can be observed. 
Differences have also been seen from stylized to voxelized models i.e. from models, 
which do not reflect a human being to models very close to the anatomy of a man or 
a woman. In case of the usage of Monte Carlo codes, the differences may be 
associated with the interaction of charged and uncharged particles with matter, in 
other words, the energy ranges associated with these particles, the energy spectra 
used and how they were generated, and so on. However, it is expected that in the 
most recent software (OLINDA/EXM V2.0 and IDAC 2.1), the differences in the 
Monte Carlo codes are less important. 
It is expected that in the near future IDAC 2.1 (or its new versions) and 
OLINDA/EXM V2.0 (as its predecessor) will be used for absorbed and effective dose 
estimation as a reference for new radiopharmaceuticals. However, it will depend on 
the availability of the software and their approach to the ICRP recommendations. 
From this point of view, IDAC 2.1 takes the lead since it is a software that complies 
with all ICRP recommendations. On the other hand, OLINDA/EXM V2.0 does not 
comply with many of the recommendations of this institution. It is noteworthy that the 
weight radiation factor for alpha emissions is 5 instead of 20. In addition, organs such 
as skin, breasts are not available for the male model. Also, the weight factor for 
tissues such as ovaries, testes, prostate and ureters are different. The “remainder” 
definition in ICRP-133 is for 14 organs however in OLINDA/EXM V2.0, four organs 
namely the extrathoracic region, the lymphatic tissue, the muscle and the oral 
mucosa are not found. These differences in both software generate variations up to 
200% for the walls of some organs such as the bladder and left colon in absorbed 
doses. 
Finally, it was possible to develop an effective dose calculation in a 
radiopharmaceutical that is only used in men (since it is for prostate cancer). In these 
cases, effective dose calculation strategies must be developed considering this type 
of situation. 
In chapter three, the calibration of a SPECT/CT is performed in order to 
determine the calibration factor for the 177Lu. This factor is used to estimate the 
activity of the segmented structures point to point. Time-activity curves can then be 
generated. 
According to the manufacturer, for the equipment having its own dosimetry 
program, the calibration of the SPECT/CT must be developed in planar acquisition 
mode. However, it was also decided to make a SPECT acquisition mode.  
For planar sensitivity, it is possible to conclude that its variation creating 
different regions of interest is not significant between 8 and 18 cm. The sensitivity is 
almost constant when the whole image is used to estimate the number of counts. 
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Two configurations of radioactive sources with different activities were used in 
the SPECT sensitivity study. Regarding the parameters of the acquisition protocol, 
only the times per projection were different. In the case of reconstruction, the number 
of iterations, subsets, post-filtering and corrections for effects such as attenuation, 
scattering and collimator response were varied. 
With respect to the geometry of the radioactive source and the phantom 
containing this source, it was concluded that for a spherical source placed in air and 
located in the center of a phantom filled with water, the sensitivity or calibration factor 
will be very similar between the two configurations. Comparing these results with 
those obtained with a bottle full of water (trying to simulate a kidney), the differences 
in sensitivity are not significant. However, in both geometries the partial volume effect 
may be present especially in the case of the spherical source. Hence, to minimize 
this effect, a larger radioactive source may be used. In this case, phantoms with 
volumes higher than 5 liters of volume can be a good option. 
In the case of the acquisition protocol, it can be concluded that dosimetric 
workstations in which the calibration factor is not directly dependent on time, the 
variation of this parameter has little impact. However, it is desirable that the 
acquisition time per projection is the same as that to be used in patients. Also, in our 
case, the used acquisition protocol was developed based on literature for the same 
type of SPECT/CT. However, it can be observed from the literature review that there 
is no single clinical protocol for the acquisition of patient images who are treated with 
177Lu.   
In the case of image reconstruction, the initial approach was to use two 
workstations, each using all possible tools to implement the available corrections. 
The initial idea when using the two workstations was to see how significant the 
variations in the calibration factor could be for the same type of reconstruction. 
Immediately, it could be determined that the calibration factors were very different 
between the two workstations. This was due to the reconstruction algorithm 
implemented and the associated corrections at each station. Due to this, it was 
concluded that the images reconstructed in a workstation must have its calibration 
factor in order to make dosimetric estimations. 
An important aspect was the creation of the CT calibration curve for the 
workstations. This curve is important because it allows to make the attenuation 
correction for the isotope that is being used for the quantification of the images. In the 
case of the Hermes workstation, a bilinear calibration curve was established, based 
on CT numbers and linear attenuation coefficients at 140 keV. 
It can be concluded that with the increasing number of iterations and subsets, 
the sensitivity increases, given that the number of counts found in the same volume 
of interest grows, possibly reaching a level where the sensitivity will no longer 
increase. However, two effects are presented: as the updates increase, the time for 
reconstruction increases considerably and an artifact known as "Gibbs-like" 
appeared, which is associated with the use of collimator response correction for a 
high number of updates. In principle, this artifact does not affect the total number of 
counts, but it does affect its distribution. 
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It was possible to generate the curve associated to the recovery coefficient, 
with and without background activity, with and without post-filtering. This curve was 
generated to characterize the SPECT/CT. However, it was possible to see that the 
range of volumes used was not enough to better study the effect of the partial 
volume. It would be desirable to have a commercial solution to be able to study 
volumes up to 100 ml for example. 
It was also possible to see the effect of post-filtering on the estimation of 
sensitivity. Without post-filter and with a Gaussian post-filter set at 0.11 cm, the 
sensitivities are practically the same, but using a Gaussian filter of 1.0 cm decreases 
the number of counts significantly. Due to this, it was concluded that a reconstruction 
using the OSEM reconstruction algorithm, including corrections for attenuation, 
scattering and collimator response, with 6 or 8 iterations, 10 subsets and no post-
filter provides an optimal calibration factor for quantification. 
The above conclusion was studied in three workstations, namely HDM from 
Hermes, STRATOS from Phillips and PDOSE from Dosisoft. In order to study and 
evaluate the above conclusion, an experiment was designed in which the objective 
was the determination of the residence time, considering only the physical decay of a 
source contained in a bottle inside a phantom. As the phantom-bottle set was a fixed 
structure, the positions of two out of five measuring points were varied in order to 
evaluate the automatic rigid recording of the workstations. At the same time, it was 
possible to determine the activities for the measuring points in each workstation 
using the calibration factor for reconstruction with 60 updates. Three conclusions 
were generated from this experiments: a) STRATOS has difficulties in the registration 
of the images for the points where changes in the positions of the phantom-bottle set 
occurred, b) the registration of HDM and PDOSE images was satisfactory and the 
variations in the position of the bottle (radioactive source) could be corrected, c) the 
activity estimates for each measurement point are satisfactory for all three programs, 
except for STRATOS where there was a variation in phantom placement. Therefore, 
the residence time calculation for HDM and POSE have quite low relative differences 
(%), while for STRATOS it is quite high. From this experiment, it was possible to 
conclude that the images used to generate the calibration factor should be treated in 
the same way as the images of patients, in terms of acquisition and reconstruction. 
In the fourth chapter, with the group of the Institute of Cancerology of 
Montpellier (ICM), it was agreed to use OSEM reconstruction, with 60 updates, all 
corrections and a 0.11 cm post-filter for the calculation of absorbed dose in patients. 
The ICM using DTK from Xeleris were able to determine a calibration factor that was 
different to the one found at the Toulouse Cancer Research Center (CRCT) using 
HROD from Hermes. 
Each centre used information from two treatment cycles of two patients treated 
with 177Lu-DOTATATE who had gastroenteropancreatic tumors. ICM used DTK to 
perform dosimetric analysis of the data from the two patients. CRCT used the 
reconstructed data in HROD to perform the dosimetric analysis in HDM, STRATOS 
and PDOSE. In this way, it was possible to cross-check the results obtained by each 
center for the four workstations. 
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It was also possible to determine that the four workstations have fairly similar 
workflows - the registration of all SPECT/CT images was performed between a 
reference SPECT/CT and all other SPECT/CT images. The study structures are 
segmented which could be automatic or manual, generally done at the reference 
SPECT/CT point. The segmented structures of the reference SPECT/CT were 
propagated to the other images. The calibration factor was used to determine the 
activity present in each segmented structure. Time-activity curves were created. 
These curves were integrated to determine cumulated activity or residence time. 
Finally, the absorbed doses were obtained. 
It can be concluded that all workstations can perform a rigid registration of 
images using the entire field of view. It was found that two workstations provide 
information to the user about the transformation matrix used in the rigid registration. 
Few of them can develop an elastic registration but this method was not used. In 
DTK, STRATOS and HDM the rigid registration was automatic and generally the 
bone structures were used to be able to execute this work. In the case of PDOSE, 
the rigid registration was also automatic, but it could be restricted to an organ, which 
allowed the user to better correct the variations in the positioning of a patient's 
organs in each measuring point. None of the workstations offers two fundamental 
tools; one is associated with the calculation of uncertainty through the registration 
process and second is that it cannot analyze/correct retrospectively the registration 
that was used. 
For automatic segmentation, the available tools on the workstations can be 
sufficiently satisfactory for dosimetry. Some workstations have more tools than 
others, however, establishing which tools are more important and/or necessary than 
others, depends a lot on each user. Manual segmentation in 2D and 3D is also 
available and satisfactory. To avoid segmentation in different workstations, the ideal 
would be that all allowed loading “DICOM RTStruct” images. However, only one of 
them allowed the import and export of this type of images. None of the workstations 
offered tools to evaluate the uncertainty associated in the process of segmentation of 
a structure.  
The only workstation that allows first the segmentation of structures and then 
the registration of them is PDOSE. Probably in this way one can reduce the 
variations in the positions of the organs either by poor positioning of the patient or by 
movements of the organs. 
The propagation of structures is simply to copy and paste the images of the 
reference SPECT/CT to the other SPECT/CT's. When performing this process, it can 
be verified that the copied structures do not correspond to the same structures at 
other points of measurement, which could be due to poor positioning of the patient 
and/or movements of some organs. In this work, it was permitted to move structures 
in each measuring point but the total volume of the structure was not varied which 
meant that the total mass of the structure was not varied. Uncertainties cannot be 
estimate for the propagation of structures among all workstations.  
The fitting of the time-activity curves was one of the steps in the dosimetric 
chain which is different among the workstations. DTK only offers single-exponential 
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data fitting. STRATOS only works the trapezoidal method (at voxel level) considering 
physical decay (by means of a mono-exponential) from the last measurement point to 
infinity. HDM offers mono- and bi-exponential fitting. PDOSE offers all the above and 
even the tri-exponential fitting. Only in PDOSE there is a tool to evaluate the 
goodness of fitting. None of the stations offers a tool that considers the uncertainty 
calculation associated to the fitting of the data. 
Regarding the calculation of absorbed doses, DTK and HDM perform the 
dosimetric calculation at organ level followed by residence time results exportation to 
OLINDA/EXM V1.0 and V2.0, respectively. STRATOS calculates absorbed dose 
voxel to voxel, making a fitting to determine the cumulated activity voxel by voxel and 
further calculate the absorbed dose by using a voxel-kernel that was calculated for 
the isotope under study in a homogeneous medium (water). In the case of PDOSE, 
the calculation of absorbed dose is performed by using of the local energy deposition 
method at the level of the organ dosimetry, although other tools are available. In the 
case of the data generated by PDOSE and STRATOS, a weighting of the masses of 
each kidney is made in order to compare the absorbed doses obtained with DTK and 
HDM. 
It was concluded that among all the workstations, three parameters were 
common - the mass of the organs generated by their segmentation, the residence 
times and the mean absorbed doses.  
Three organs- the liver (including metastasis), the spleen and the kidneys 
were studied. A partial volume effect correction was not performed since for these 
three organs, this effect is expected to be minor due to the size of each structure. 
It was concluded that the masses of the segmented organs were very similar 
for each centre, which allowed to evaluate the work done by their operators. 
The evaluation of residence times begins to show results for the entire 
dosimetric workflow. They were very similar for all workstations for each organ. They 
were all in the same order of magnitude for all workstations. It can also be seen that 
the residence times for the second cycle of treatment was greater for the kidneys and 
spleen of both patients. In the case of the liver, for the male patient it was the same 
as for the other organs, but for the female patient it was reduced by almost 50%. It 
can be seen that for STRATOS, the calculation of kidney residence time was much 
smaller than that obtained with other software, for the second treatment cycle, for the 
male patient. 
The local energy deposition method implemented in PDOSE generated 
absorbed dose results that were very similar to those generated by the two versions 
of OLINDA. The same results are obtained by using the voxel-kernel determined in 
STRATOS. The beta contribution is more important than the gamma contribution in 
order to generated the voxel-kernel; therefore, the absorbed doses obtained using 
this software were comparable to the other. 
In the case of the absorbed dose at the level of the red bone marrow, our 
results are similar to other studies found in the literature. In this case, it was possible 
to see that the developed method works for both patients because there are 
similarities with the ICRP models in terms of mass and volume. This method that 
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could be implemented in a nuclear medicine service where there are no detectors to 
perform whole-body measurements of the patient, as happened in this case. It was 
also concluded that the greatest contribution to the absorbed dose in the bone 
marrow was due to the "remainder" with almost 50%. Self-irradiation is also 
important, depending on the patient it can be close to 50% as well. Our methodology 
should be studied with a larger number of patients and also by considering a blood 
dosimetry in order to establish a possible correlation between the two methods. 
Moreover, it has been found in the literature that there is no correspondence 
between the absorbed doses in bone marrow using a blood-sampling method and 
the L2 to L4 imaging method. However, these results were obtained in a small group 
of patients. More evidence should be expected in larger groups of patients (Beykan 
et al., 2018). 
In the context of this doctoral work, some questions still remain unanswered, 
so we hope to be able to follow them up with studies that we will develop. This 
includes the following: 
• As part of future work, we plan to perform dosimetry for healthy 
volunteers and patients for the three radiopharmaceuticals studied. 
Currently, we are waiting for the final approval from national/local ethics 
committees and the review of clinical protocols proposed by each 
research centre. 
• We hope to make a publication where we can show the differences 
between the two versions of OLINDA and IDAC 2.1, in the case of 
reference dosimetry for the new radiopharmaceuticals. 
• We hope to be able to estimate the calibration factor using a larger 
volume phantom and compare the results obtained with the other 
geometries used. 
• Due to the variation in the position of some organs, it may sometimes 
be necessary to consider a variation in the volume of interest at each 
measurement point. The calculation of residence time must be different 
from what is done today. 
• Due to the variation in the position of some organs, the use of optimized 
image registration at each organ (available with PDOSE) can be 
studied by considering two cases: invariable segmented volume, and 
variable segmented volume, for each measurement point. Therefore, 
the calculation of residence time must be compared for both cases. 
Following the two previous points, the absorbed doses should be 
recalculated. 
• Comparisons should also be made between other methods of 
calculating absorbed dose, such as convolution, available at Dosisoft. 
• In fact, some dosimetric solutions (Dosisoft and STRATOS) allow a 
calculation of the absorbed dose at the voxel level, by convolution or by 
assuming a local deposition of the emitted energy. This allows to obtain 
the absorbed dose - volume histograms (Dose Volume Histograms - 
DVH). In addition, these results could be compared to the results 
obtained using Monte Carlo simulations. 
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• Finally, EANM recently raised the issue of the integration of uncertainty 
calculation into clinical protocols. This question remains unresolved in 
our doctoral work, since none of the workstations studied allowed us to 
evaluate the uncertainty in the different stages of the dosimetry 
protocol. However, we intend to direct our research towards estimating 
the accuracy of the results by propagating uncertainties along the chain 
of operations that lead from image reconstruction to absorbed dose 
determination. 
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Organ masses for human and animals’ models  
 
Table A.1. Organ masses (in grams) according to different references. 
RADAR - OLINDA/EXM V2.0 ICRP 89 ICRP 23 OLINDA/EXM V2.0 
Organs Adult male 
Adult 
female 
Adult 
male 
Adult 
female 
Adult 
male 
Adult 
female 
Rat 
300g Mouse 35g 
Adren-glands 14 13 14 13 14 14   
Brain 1450 1300 1450 1300 1400 1200 5.4 0.7 
Eyes 15 15 15 15     
Breast  500 25 500 360 360   
GB-contents 58 48 58 48 62 50   
GB-wall 10 8 10 8 10 8   
Lcolon-contents 75 80 75 80 135 135 11.5 0.8 
Lcolon-wall 150 145 150 145 160 160   
Sintest-contents 350 280 350 280 400 375 15.5 2.5 
Sintest-wall 650 600 650 600 640 600   
Sto-contents 250 230 250 230 250 230 1.4 0.1 
Sto-wall 150 140 150 140 150 140   
Rcolon-contents 150 160 150 160 220 210   
Rcolon-wall 150 145 150 145 210 200   
Recto-contents 75 80 75 80     
Recto-wall 70 70 70 70     
Heart-contetns 510 370 510 370 500 410 2.6 0.3 
Heart-wall 330 250 330 250 330 240   
Kidneys 310 275.5 310 275 310 275 3.0 0.4 
Liver 1800 1400 1800 1400 1800 1400 1.2 2.6 
Lung 1200 950 1200 950 1000 800 0.9 0.1 
Lng-Cont   0 0 0 0   
Muscle   29000 17500 28000 17000   
Esophagus 40 35 40 35 - -   
Ovaries 1 11 0 11 11 11   
Prostate 17 1 17 0 - -   
Pancreas 140 120 140 120 100 85 0.5 0.4 
Skeleton 10500 7800 10450 7760 - -   
R_Marrow 1170 900 1170 900 1500 1300   
C_Bone-V 4400 3200 4400 3200 4000 3000 22.1 3.0 
T_Bone-V 1100 800 1100 800 1000 750   
Saliv-glands 85 70 85 70 - -   
Skin - - 3300 2300 2600 1790   
Spleen 150 130 150 130 180 150 0.9 0.2 
Testes 35 1 35 0 35 0 0.2 0.2 
Thymus 25 20 25 20 20 20   
Thyroid 20 17 20 17 20 17 0.3 0.0 
UB-contents 211 160 200 200 120 88,4 0.7 0.1 
UB-wall 50 40 50 40 45 35,9   
Uterus 1 80 0 80 80 80   
Body 73000 60000 73000 60000 68831 56912 326 35.3 
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Materials and methods used for estimations with 
OLINDA/EXM V1.0 
 
The residence times were used as input for OLINDA/EXM V1.0 according to 
the procedure described in Chapter 2 for this radiopharmaceutical.  
Results for [18F]FNM 
 
In table A.2, organ masses for male and female dosimetric models used for 
mass scaling can be seen, also residence times used in OLINDA/EXM V1.0 after 
mass scaling are exhibits. Organs with highest residence times are brain, kidney, 
liver and lungs. 
 
Table A.2. Organ masses for male dosimetric model and residence times (T) used in OLINDA/EXM 
V1.0 after mass scaling. 
Target organ Mmale (g) Mfemale (g) Tmale (h) Tfemale (h) 
Brain 1400 1200 2.12E-02 2.19E-02 
Heart contents 500 410 9.48E-03 9.41E-03 
Kidney 310 275 2.52E-02 2.70E-02 
Liver 1800 1400 5.66E-02 5.33E-02 
Lung 1000 800 3.48E-02 3.37E-02 
Spleen 180 150 7.15E-03 7.21E-03 
Stomach contents 250 230 6.41E-03 7.13E-03 
Remainder 63391 52447 6.25E-01 6.26E-01 
Total Body 68831 56912 - - 
 
Table A.3. shows results for the ADC and the CEDF per organ, for male and 
female dosimetric models from OLINDA/EXM V1.0. Organs with high ADC are 
stomach wall, kidneys, liver, lungs and spleen for both models. Mean effective dose 
was 4.65 x10-3 mSv/MBq and 5.73x10-3 mSv/MBq for the adult male and female 
models, respectively. This would correspond to effective dose of 1.63 mSv and 2.01 
mSv, respectively, for an administrated activity of 350 MBq. For gallbladder, heart 
wall and testes under ICRP-60 there is not weighting tissue factor, also they do not 
contribute to the remainder.  
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Table A.3. Absorbed dose coefficients (ADC) and contribution to the effective dose factor (CEDF) 
results for adult male model from OLINDA/EXM V1.0. 
 Male Female 
Organ ADC (mGy/MBq) 
CEDF 
(mSv/MBq) 
ADC 
(mGy/MBq) 
CEDF 
(mSv/MBq) 
Adrenals 4.66E-03 1.17E-05 5,91E-03 1,48E-05 
Brain 4.23E-03 1.06E-05 5,09E-03 1,27E-05 
Breasts 2.88E-03 1.44E-04 3,63E-03 1,81E-04 
Gallbladder Wall 4.88E-03 - 5,73E-03 - 
LLI Wall 3.72E-03 4.46E-04 4,68E-03 5,61E-04 
Small Intetine 4.01E-03 1.00E-05 4,63E-03 1,16E-05 
Stomach Wall 6.11E-03 7.33E-04 7,68E-03 9,21E-04 
ULI Wall 4.01E-03 1.00E-05 5,03E-03 1,26E-05 
Heart Wall 5.90E-03 - 7,15E-03 - 
Kidneys 1.76E-02 4.39E-05 2,05E-02 5,12E-05 
Liver 8.61E-03 4.30E-04 1,07E-02 5,36E-04 
Lungs 7.83E-03 9.39E-04 9,68E-03 1,16E-03 
Muscle 3.28E-03 8.19E-06 4,08E-03 1,02E-05 
Ovaries 3.87E-03 7.74E-04 4,76E-03 9,52E-04 
Pancreas 4.82E-03 1.20E-05 5,99E-03 1,50E-05 
Red Marrow 3.27E-03 3.92E-04 4,02E-03 4,82E-04 
Osteogenic Cells 5.01E-03 5.01E-05 6,55E-03 6,55E-05 
Skin 2.55E-03 2.55E-05 3,17E-03 3,17E-05 
Spleen 9.68E-03 2.42E-04 1,19E-02 2,96E-04 
Testes 3.04E-03 - - - 
Thymus 3.58E-03 8.96E-06 4,53E-03 1,13E-05 
Thyroid 3.30E-03 1.65E-04 3,84E-03 1,92E-04 
Urinary Bladder Wall 3.65E-03 1.83E-04 3,87E-03 1,94E-04 
Uterus 3.90E-03 9.74E-06 4,72E-03 1,18E-05 
Total Body 3.65E-03 - 4,55E-03 - 
Total effective dose (mSv/MBq) - 4.65E-03 - 5.73E-03 
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Results for [11C]SAM  
 
The mice remainder residence time was calculated as the sum of residence 
times for blood, muscles, bones and carcass. Therefore, the human remainder 
residence time considers same organs in OLINDA/EXM V1.0. Bladder contents with 
and without bladder voiding are also considered. 
Table A.4 shows the human and mouse organ mass used for the scaling 
process as well as the residence times used for OLINDA/EXM V1.0. On the other 
hand, S-factor values can be observed for different organs.  
The highest value for human residence time is for the bladder contents 
(without and without bladder voiding), also kidneys, liver + gallbladder contents, 
lungs, stomach contents exhibits high values. 
 
Table A.4. Organ masses for male dosimetric model and residence times (T) used in 
OLINDA/EXM V1.0 after mass scaling. 
Organ Mmale (g) S-factor
[a] 
(mGy/MBq-s) Mmouse (g) Tmale(h) 
Heart Wall 330 2.28E-04 0.1400 ± 0.010 5.33E-04 
Kidneys 310 2.46E-04 0.4746 ± 0.047 1.06E-02 
Liver + Gallbladder contents 1862  1.8355 ± 0.203 4.63E-03 
Liver 1800 4.65E-05  4.48E-03 
Gallbladder contents 62 6.39E-04[b]  1.54E-04 
Lungs 1000 7.01E-05 0.2018 ± 0.012 3.71E-03 
Spleen 180 4.08E-04 0.1109 ± 0.015 2.98E-04 
Stomach contents 250 1.47E-04[b] 0.100[d] 1.67E-03 
Intestines contents 755  3.300[d] 9.38E-04 
Left colon contents 
(LLI) 
135 2.43E-04[b]  1.68E-04 
Small intestine 
contents (SI) 
400 8.20E-05[b]  4.97E-04 
Right colon contents 
(ULI) 
220 1.57E-04[b]  2.73E-04 
Bladder contents without 
bladder voiding 
120[c] 1.87E-04[b] 0.1000[d] 1.52E-01 
Bladder contents with 
bladder voiding 
120 1.87E-04[b] 0.0900 6.10E-02 
Remainder 64024 --- 30.7023 1.11E-01[e] 
Whole Body 68831 1.62E-06 36.8650 ± 2.010 ----- 
[a] S-factor refers to self–irradiation; [b] S-factor for gallbladder wall, stomach wall, LLI, SI, 
ULI wall and urinary bladder wall, considering their contents as a source; [c] Urinary bladder 
contents and urinary bladder wall masses for human model ICRP-23; [d] Mouse Stomach, 
intestines and bladder contents masses from OLINDA/EXM V2.0; [e] Remainder takes into 
account blood, muscles, bones and carcass.  
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Table A.5 shows the ADC and the CEDF, with and without the bladder voiding 
consideration. Organs showing high ADC are, urinary bladder wall, kidneys and 
uterus. Organs showing differences between 1.7 and 2.5 times in ADC are LLI wall, 
ovaries, testes, uterus and urinary bladder wall. For gallbladder, heart wall and testes 
under ICRP-60, there is not weighting tissue factor, also they do not contribute to the 
remainder. 
The mean effective dose is 6.82x10-3 mSv/MBq and 3.32x10-3 mSv/MBq, 
without and with the bladder voiding consideration, respectively; corresponding to 2 
times difference between the two methods. Considering CUDIM protocols the mean 
effective dose range is between 1.99–2.99 mSv, without bladder voiding and with 
bladder voiding, the effective dose ranged from 0.97–1.45 mSv. 
 
Table A.5. Absorbed dose coefficient (ADC) and contribution to effective dose factor (CEDF) 
results for adult male model from OLINDA/EXM V1.0, with and without bladder voiding 
consideration. 
Target Organ 
Without bladder voiding With bladder voiding 
ADC 
(mGy/MBq) 
CED 
(mSv/MBq) 
ADC 
(mGy/MBq) 
CEDF 
(mSv/MBq) 
Adrenals 1.06E-03 5.31E-06 1.02E-03 5.11E-06 
Brain 6.22E-04 3.11E-06 6.22E-04 3.11E-06 
Breasts 6.25E-04 3.13E-05 6.18E-04 3.09E-05 
Gallbladder Wall 1.44E-03 - 1.34E-03 - 
LLI Wall 3.06E-03 3.67E-04 1.78E-03 2.13E-04 
Small Intestine 1.79E-03 8.97E-06 1.31E-03 6.54E-06 
Stomach Wall 1.78E-03 2.13E-04 1.71E-03 2.06E-04 
ULI Wall 1.58E-03 7.92E-06 1.21E-03 6.07E-06 
Heart Wall 8.68E-04 - 8.58E-04 - 
Kidneys 9.86E-03 4.93E-05 9.78E-03 4.89E-05 
Liver 1.16E-03 5.80E-05 1.11E-03 5.57E-05 
Lungs 1.27E-03 1.52E-04 1.26E-03 1.52E-04 
Muscle 1.24E-03 6.21E-06 9.22E-04 4.61E-06 
Ovaries 2.78E-03 5.55E-04 1.60E-03 3.21E-04 
Pancreas 1.08E-03 5.39E-06 1.03E-03 5.13E-06 
Red Marrow 1.02E-03 1.23E-04 8.17E-04 9.80E-05 
Osteogenic Cells 1.23E-03 1.23E-05 1.11E-03 1.11E-05 
Skin 7.65E-04 7.65E-06 6.52E-04 6.52E-06 
Spleen 1.04E-03 5.22E-06 1.00E-03 5.00E-06 
Testes 2.10E-03 - 1.24E-03 - 
Thymus 7.36E-04 3.68E-06 7.30E-04 3.65E-06 
Thyroid 7.08E-04 3.54E-05 7.07E-04 3.53E-05 
Urinary Bladder Wall 1.03E-01 5.15E-03 4.18E-02 2.09E-03 
Uterus 5.45E-03 2.73E-05 2.68E-03 1.34E-05 
Total Body 1.29E-03 - 9.82E-04 - 
Total Effective Dose (mSv/MBq) - 6.82E-03  3.32E-03 
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Results for [18F]SFR101 
 
The mice remainder residence time was calculated as the sum of residence 
times for blood, muscles, bones and carcass. Therefore, the human remainder 
residence time considers same organs in OLINDA/EXM V1.0. 
Table A.6 shows the mass values from ICRP-23 used for mass scaling for 
both the dosimetric models and the S-factors for several organs available in 
OLINDA/EXM V1.0.  
 
Table A.6. Mass values from ICRP-23 used for mass scaling for each organ in male/female dosimetric 
models and S-factors available in OLINDA/EXM V1.0. 
 Male Female 
Mmouse (g) Organ Mass (g) 
S-factor[a] 
(mGy/MBq-s) 
Mass 
(g) 
S-factora 
(mGy/MBq-s) 
Brain 1400 4.62E-05 1200 5.28E-05 0.4090 ± 0.0731 
Heart wall 330 1.54E-04 240 2.00E-04 0.1646 ± 0.0286 
Kidneys 310 1.69E-04 275 1.83E-04 0.4204 ± 0.0425 
Intestines contents 755  720  3.3000[c] 
Left colon contents 
(LLI) 
135 1.63E-04[b] 135 1.77E-04[b]  
Small Intestine 
Contents (SI) 
400 5.48E-05[b] 375 6.61E-05[b]  
Right colon contents 
(ULI) 
220 1.07E-04[b] 210 1.21E-04[b]  
Liver 1800 3.40E-05 1400 4.46E-05 1.8596 ± 0.2463 
Lungs 1000 4.69E-05 800 5.93E-05 0.2193 ± 0.0319 
Spleen 180 2.82E-04 150 3.39E-04 0.0963 ± 0.0285 
Stomach contents 250 1.03E-04[b] 230 1.19E-04[b] 0.1000[c] 
Bladder contents 120 1.31E-04[b] 88.4 1.85E-04[b] 0.1000[c] 
Remainder  62686 1.28E-06 51808.6 1.60E-06 28.2063[d] 
Whole body 68831 --- 56912 --- 34.8755 ± 3.4749 
[a] S-factor refers to self-irradiation; [b] S-factor for LLI wall, SI wall, ULI wall, stomach wall and 
urinary bladder wall considering their contents as a source; [c] Mouse Stomach, intestines and 
bladder contents masses from OLINDA/EXM V2.0; [d] Remainder takes into account blood, muscles, 
bones and carcass. 
 
 
Residence times used in OLINDA/EXM V1.0 are included in table A.7. Organs 
with highest values are intestines contents, liver and stomach contents.  
Absorbed and effective dose values for adult male and female dosimetric 
models from OLINDA/EXM V1.0 are listed in table A.8. In this case, LLI wall, SI wall 
and ULI wall show high ADC values, probably associated with the excretion path of 
the radiopharmaceutical. The mean effective dose obtained from OLINDA/EXM V1.0 
using the male and female dosimetric models is 6.55x10-3 µSv/MBq and 8.77x10-3 
µSv/MBq, respectively. Considering CUDIM protocols the mean effective dose is 
2.29 mSv and 3.07 mSv, for the male and female dosimetric models, respectively. 
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Table A.7. Residence times (T) used for dosimetric estimations in OLINDA/EXM V1.0. 
Organ Tmale(h) Tfemale(h) 
Brain 2.37E-04 2.46E-04 
Heart wall 9.67E-05 8.51E-05 
Kidneys 4.84E-03 5.19E-03 
Intestines contents 1.96E-01 2.27E-01 
Left colon contents (LLI) 3.50E-02 4.26E-02 
Small Intestine Contents 1.04E-01 1.18E-01 
Right colon contents (ULI) 5.71E-02 6.62E-02 
Liver 5.69E-02 5.35E-02 
Lungs 2.25E-03 2.18E-03 
Spleen 5.19E-05 5.23E-05 
Stomach contents 2.24E-02 2.49E-02 
Bladder contents 4.65E-03 4.15E-03 
Remainder 3.90E-02 3.90E-02 
 
 
 
Table A.8. Absorbed dose coefficient (ADC) and contribution to effective dose factor 
results (CEDF) for adult male model from OLINDA/EXM V1.0. 
Organ 
Male Female 
ADC 
(mGy/MBq) 
CEDF 
(mSv/MBq) 
ADC 
(mGy/MBq) 
CEDF 
(mSv/MBq) 
Adrenals 1.46E-03 3.65E-06 1.91E-03 4.78E-06 
Brain 8.92E-05 2.23E-07 1.13E-04 2.82E-07 
Breasts 3.96E-04 1.98E-05 5.17E-04 2.59E-05 
Gallbladder Wall 3.81E-03 - 5.24E-03 - 
LLI Wall 2.29E-02 2.74E-03 3.04E-02 3.65E-03 
Small Intestine 2.35E-02 5.87E-05 3.22E-02 8.04E-05 
Stomach Wall 9.85E-03 1.18E-03 1.28E-02 1.54E-03 
ULI Wall 2.65E-02 6.63E-04 3.50E-02 8.75E-04 
Heart Wall 7.97E-04 - 1.07E-03 - 
Kidneys 4.55E-03 1.14E-05 5.55E-03 1.39E-05 
Liver 7.80E-03 3.90E-04 9.78E-03 4.89E-04 
Lungs 9.26E-04 1.11E-04 1.22E-03 1.46E-04 
Muscle 9.66E-04 2.42E-06 1.32E-03 3.29E-06 
Ovaries 4.91E-03 9.83E-04 7.22E-03 1.44E-03 
Pancreas 2.13E-03 5.32E-06 2.84E-03 7.11E-06 
Red Marrow 1.33E-03 1.60E-04 1.75E-03 2.10E-04 
Osteogenic Cells 8.15E-04 8.15E-06 1.13E-03 1.13E-05 
Skin 4.47E-04 4.47E-06 5.92E-04 5.92E-06 
Spleen 1.27E-03 3.16E-06 1.70E-03 4.25E-06 
Testes 5.30E-04 - - - 
Thymus 3.80E-04 9.50E-07 4.98E-04 1.24E-06 
Thyroid 2.35E-04 1.17E-05 2.90E-04 1.45E-05 
Urinary Bladder Wall 3.63E-03 1.82E-04 4.76E-03 2.38E-04 
Uterus 3.43E-03 8.58E-06 4.92E-03 1.23E-05 
Total Body 1.48E-03 - 2.00E-03 - 
Total Effective Dose (mSv/MBq) - 6.55E-03  8.77E-03 
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Figure A.1 shows reconstructed images using all correction methods, without 
post-filter, for different updates (iterations*subsets), for a spherical source placed in 
the centre of a phantom filled with water and without background activity. All profiles 
are for the same position in the “y-axis” for each image on the second column of the 
figure. Gray values in these profiles are related to the number of counts present in 
each pixel of the line. 
As the number of updates increases, a discontinuity of the profile can be seen, 
which may be related to Gibbslike artifacts (for updates higher than 80). Moreover, as 
the number of updates increases, the spheres become clear and well defined. Also, 
the maximal number of counts remains constant as the number of updates increases. 
 
OSEM (4i, 5ss) 
+A+S+CR+non-GPF 
	 	
OSEM (4i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (6i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (8i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (16i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (32i, 10ss) 
+A+S+CR+non-GPF	
	 	
Figure A.1: OSEM reconstructed images of a source in the centre of a phantom filled with water 
without background activity using attenuation, collimator response and scatter corrections and non-
Gaussian post-filter. Also, line-profile across the sphere source. 
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Figure A. 2 is similar to figure A.1 but using the Gaussian post-filter set at 1.0 
cm, for different updates (iterations*subsets), for a spherical source placed in the 
centre of a phantom filled with water and without background activity is shown. As 
the number of update increases, the discontinuity in the profile starts to appear at 
320 updates. 
 
OSEM (4i, 5ss) 
+A+S+CR+GPF-1.0cm 
	 	
OSEM (4i, 10ss) 
+A+S+CR+ GPF-1.0cm	
	 	
OSEM (6i, 10ss) 
+A+S+CR+ GPF-1.0cm	
	 	
OSEM (8i, 10ss) 
+A+S+CR+ GPF-1.0cm	
	 	
OSEM (16i, 10ss) 
+A+S+CR+ GPF-1.0cm	
	 	
OSEM (32i, 10ss) 
+A+S+CR+ GPF-1.0cm	
	 	
Figure A.2: OSEM reconstructed images of a source in the centre of a phantom filled with water 
without background activity using attenuation, collimator response and scatter corrections and 
Gaussian post-filter set at 1.0 cm.  Also, line-profile across the sphere source. 
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Figure A.3 shows results for OSEM reconstructed images of a phantom 
without background activity, using all correction methods and non-Gaussian post-
filter. All images are for the same slice of the reconstructed phantom. Same figure 
shows profiles generated drawing a line across the biggest sphere source; all profiles 
are for the same position in the “y-axis” for each image, on the second column of the 
figure. Gray values in these profiles are related to the number of counts present in 
each pixel of the line. As the number of updates increases more clearly and well 
defined all spheres can be seen, also the maximal number of counts in the profile 
decreases as the number of updates increases. The same discontinuity showed in 
figure A.1 can be seen for updates higher than 80. 
 
OSEM (4i, 5ss) 
+A+S+CR+non-GPF 
	 	
OSEM (4i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (6i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (8i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (16i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (32i, 10ss) 
+A+S+CR+non-GPF	
	 	
Figure A.3: OSEM reconstructed images of phantom without background activity using attenuation, 
collimator response and scatter corrections and non-Gaussian post-filter. Also, line-profile across the 
biggest sphere source. 
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OSEM (4i, 5ss) 
+A+S+CR+non-GPF 
	 	
OSEM (4i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (6i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (8i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (16i, 10ss) 
+A+S+CR+non-GPF	
	 	
OSEM (32i, 10ss) 
+A+S+CR+non-GPF	
	 	
Figure A.4: OSEM reconstructed images of phantom with background activity using attenuation, 
collimator response and scatter corrections and non-Gaussian post-filter. Also, line-profile across the 
biggest sphere source. 
 
On the other hand, figure A.4 shows results for OSEM reconstructed images 
of a phantom with background activity, using all correction methods and non-
Gaussian post-filter. All images are for the same slice of the phantom reconstruction. 
Also, profiles were generated drawing a line across the biggest sphere source. Here 
as the number of updates increases all spheres can be seen more clearly and well 
defined, also contrast is improved and for 320 updates the image of the phantom 
looks “less smooth” comparing to the one at 20 updates.  
Looking at the generated profiles, which are coming from the same position in 
the “y-axis” for each image on the second column, as previously shown, gray values 
in these profiles are related to the number of counts present in each pixel of the line. 
Here one can see that as the number of updates increases the maximal number of 
counts in the profile decreases and the same discontinuity showed in figure A. 1 can 
be seen for updates higher than 80, however, the level of discontinuity with 
background activity is not as significant as it was shown without background activity. 
 
Appendix:	Chapter	3	
                                                                                                                              214 
 
	
	
Figure A.5: Recovery coefficient for OSEM reconstructed images of a phantom using attenuation, 
collimator response and scatter corrections with Gaussian post-filter 1.0 cm. A: without background 
activity. B: with background activity. 
 
Figure A.5, shows the recovery coefficient results using a phantom with and 
without background activity, with Gaussian post-filter set at 1.0 cm. In both cases, 
images were reconstructed using OSEM, applying all correction methods. For figure 
A.5.A, as the number of updates increase, the recovery coefficient increase, for 
updates equal to 60, the recovery coefficient reaches 65% for the 4 ml sphere and 
80% for the 16 ml sphere, for updates equal to 320 the recovery coefficient varies 
from 68% to 77% for the same sphere volumes. In the case of figure A.5.B, for the 2 
ml sphere the recovery variation varies between 16% and 42%, for the 4 ml sphere 
its variation is between 34% and 60%, for the 8ml sphere its variation is between 
43% and 58 %, for the 16 ml sphere its variation is between 59% and 67%. 
These values were generated just to benchmark the SPECT/CT system in the 
case of using a similar reconstruction method. 
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Table A.9. Organ mass (g) results for female patient for each workstation. 
Organ/Software 
First treatment cycle 
DTK HDM STRATOS PDOSE Mean (g) Standard deviation 
Liver 1643.0 1656.5 1560.3 1639.3 1624.8 43.6 
Spleen 109.2 103.0 112.4 99.0 105.9 6.0 
Kidneys 273.0 271.8 279.3 270.8 273.7 3.8 
Organ/Software 
Second treatment cycle 
DTK HDM STRATOS PDOSE Mean (g) Standard deviation 
Liver 1643.0 1551.3 1476.6 1540.6 1552.9 68.6 
Spleen 116.6 103.1 108.1 98.2 106.5 7.8 
Kidneys 281.0 260.6 294.0 266.1 275.4 15.1 
 
 
 
 
 
Figure A.6: Mass for liver, spleen and kidneys. Female patient, A: first treatment, B: second treatment. 
Own creation. 
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Table A.10. Residence times (h) results for female patient for each workstation. 
Organ/Software 
First treatment cycle 
DTK HDM STRATOS PDOSE Mean (h) Standard deviation 
Liver 39.0 45.7 41.7 45.2 42.9 3.2 
Spleen 0.6 0.8 0.6 0.7 0.7 0.1 
Kidneys 1.1 1.6 1.6 1.6 1.5 0.2 
Organ/Software 
Second treatment cycle 
DTK HDM STRATOS PDOSE Mean (h) Standard deviation 
Liver 21.0 24.3 24.7 24.8 23.7 1.8 
Spleen 0.9 0.9 0.9 0.9 0.9 0.1 
Kidneys 1.5 1.7 1.9 1.7 1.7 0.2 
 
 
 
Table A.11. Mean absorbed dose (Gy) results for female patient for each workstation. 
Organ/Software 
First treatment cycle 
DTK HDM STRATOS PDOSE Mean (Gy) Standard deviation 
Liver 14.5 17.8 17.5 16.9 16.6 1.5 
Spleen 3.6 4.5 3.4 4.3 3.8 0.5 
Kidneys 2.5 3.7 3.6 3.7 3.3 0.6 
Organ/Software 
Second treatment cycle 
DTK HDM STRATOS PDOSE Mean (Gy) Standard deviation 
Liver 7.8 10.0 10.7 10.0 9.5 1.2 
Spleen 4.6 5.1 5.0 5.9 4.9 0.6 
Kidneys 3.2 4.0 4.2 4.1 3.8 0.4 
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Table A.12. Organ mass (g) results for male patient for each workstation. 
Organ/Software 
First treatment cycle 
DTK HDM STRATOS PDOSE Mean (g) Standard deviation 
Liver 1208.4 1397.6 1383.3 1366.0 1338.8 87.9 
Spleen 244.9 239.6 254.4 234.0 243.2 8.7 
Kidneys 482.0 390.8 466.2 408.9 437.0 44.0 
Organ/Software 
Second treatment cycle 
DTK HDM STRATOS PDOSE Mean (g) Standard deviation 
Liver 1282.6 1303.9 1304.9 1306.3 1299.4 11.3 
Spleen 259.7 239.9 272.4 234.5 251.6 17.6 
Kidneys 483.0 402.7 473.6 410.2 442.3 41.8 
 
 
 
 
 
 
 
 
Figure A.7: Mass for liver, spleen and kidneys. Male patient, A: first treatment, B: second treatment. 
Own creation. 
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Table A.13. Residence times (h) results for male patient for each workstation. 
Organ/Software 
First treatment cycle 
DTK HDM STRATOS PDOSE Mean (h) Standard deviation 
Liver 1.9 2.8 3.2 2.7 2.7 0.6 
Spleen 1.2 1.6 1.7 1.5 1.5 0.2 
Kidneys 1.4 1.5 1.9 1.7 1.6 0.2 
Organ/Software 
Second treatment cycle 
DTK HDM STRATOS PDOSE Mean (h) Standard deviation 
Liver 2.6 3.2 3.1 3.0 3.0 0.3 
Spleen 2.1 2.2 1.9 2.1 2.1 0.1 
Kidneys 1.9 2.0 0.9 2.0 1.7 0.5 
 
 
 
Table A.14. Mean absorbed dose (Gy) results for male patient for each workstation. 
Organ/Software 
First treatment cycle 
DTK HDM STRATOS PDOSE Mean (Gy) Standard deviation 
Liver 1.0 1.1 1.5 1.2 1.2 0.2 
Spleen 2.9 4.7 4.3 4.0 4.0 0.8 
Kidneys 1.7 2.5 2.6 2.5 2.3 0.4 
Organ/Software 
Second treatment cycle 
DTK HDM STRATOS PDOSE Mean (Gy) Standard deviation 
Liver 1.2 1.3 1.5 1.4 1.4 0.1 
Spleen 4.9 6.6 4.4 5.6 5.3 0.9 
Kidneys 2.3 3.3 1.2 3.0 2.3 1.0 
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Dosimetría de radiofármacos en terapia dirigida con radionúclidos 
Resumen 
La medicina nuclear es una especialidad médica en la cual una de sus 
aplicaciones es estudiar la fisiología de los órganos y el metabolismo de diversos 
tipos de tumores. Productos farmacéuticos marcados con radio-nucleídos (radio-
fármacos) son estudiados a nivel pre-clínico antes de ser usados en seres humanos. 
Roedores son generalmente utilizados para estudiar la biocinética del trazador en un 
grupo de órganos predefinidos. La extrapolación de los resultados de estos estudios 
de animales a humanos provee una estimación del comportamiento de los radio-
fármacos y de la irradiación entregada clínicamente. Tres nuevos radiofármacos 
fueron desarrollados, uno en Francia (CHU-Hôpital Purpan) y dos en Uruguay 
(CUDIM). Dos con el objetivo de estudiar el cerebro y uno para el diagnóstico de 
cáncer de próstata. En este trabajo, la extrapolación de los resultados preclínicos es 
presentada, las dosis absorbidas y efectivas son estimadas utilizando los programas 
OLINDA/EXM V1.0, V2.0 e IDAC2.1. Las diferencias entre los resultados de cada 
programa son discutidas.   
A nivel clínico, los protocolos dosimétricos incluyen la determinación del factor 
de calibración, la segmentación, el registro, el ajuste de las curvas y el cálculo de 
dosis absorbida. En este trabajo, la calibración desarrollada a un SPECT/CT es 
presentada utilizando diferentes fuentes de calibración y diferentes geometrías. La 
influencia del método de reconstrucción en la determinación del factor de calibración 
y las curvas de factor de recuperación son mostradas.  
Por otro lado, se comparan cuatro programas comerciales basándonos en 
información clínica de dos pacientes con tumores gastro-entero-pancreáticos de 
origen neuroendocrino tratados con 177Lu-DOTATATE. Dos ciclos de tratamiento por 
cada paciente fueron usados para estimar tiempos de residencia para los riñones, 
hígado, bazo, médula ósea y cuerpo entero. El cálculo de las dosis absorbidas se 
desarrolló inicialmente utilizando OLINDA/EXM V1.0, V2.0, ajustando las masas de 
cada órgano/tejido. En el caso de la médula ósea, se presenta una novedosa 
metodología para estimar la dosis absorbida sin necesidad de contar con mediciones 
de cuerpo entero. Se logra ver que el registro de las imágenes tiene un impacto en la 
determinación de la dosis absorbida. Los resultados son calculados empleando una 
herramienta que permite el registro independientemente de cada órgano y no de 
toda la imagen del campo de visión. 
Diferentes algoritmos de cálculo fueron usados para determinar la dosis 
absorbida entregada a los pacientes, por ejemplo, el modelo de esferas de 
OLINDA/EXM V2.0, los métodos de convolución y depósito local de energía de 
PLANET®Onco Dose de Dosisoft. Los resultados encontrados con las diferentes 
herramientas son comparados y discutidos. 
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